<SEC-DOCUMENT>0001558370-22-002824.txt : 20220303
<SEC-HEADER>0001558370-22-002824.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303170157
ACCESSION NUMBER:		0001558370-22-002824
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38905
		FILM NUMBER:		22710036

	BUSINESS ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
		BUSINESS PHONE:		240-399-4900

	MAIL ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nxtc-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/3/2022 8:38:59 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 385c718d-a022-412c-bbd2-9cdd03d1abd9 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nxtc="http://www.nextcure.com/20211231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" name="us-gaap:TypeOfRevenueExtensibleList" id="Hidden_tTt21ZgtBk-W0pJEfxQKVQ">http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:TypeOfRevenueExtensibleList" id="Hidden_UtQtRmGb0EuPJna7GdernA">http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_oyydoO0AdkylL5JPTmIRgg">2.51</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_k3SONQVP20aoC7_plLOxow">1.33</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_BHSA1K7qf0y_675z_dMI4Q">27615977</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_-_keUW7NyU-mmVNN33QaCA">27532177</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" xs:nil="true" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" name="us-gaap:PreferredStockValue" id="Hidden_wTg-hQItxUW1i-lAprnTXA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" xs:nil="true" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" name="us-gaap:PreferredStockValue" id="Hidden_iUdxlbiBN0aOd-krv8nVQA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_DN8xdD6MRE6MMojBwaImsw">27680997</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityCentralIndexKey" id="Narr_7KcVcMJBiU69M_MlhSgwBA">0001661059</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:CurrentFiscalYearEndDate" id="Narr_nReG94DGwUmK5NIO-e3MYg">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentFiscalYearFocus" id="Narr_PKcQKiqbP0ahpUmPOG-2Tg">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentFiscalPeriodFocus" id="Narr_xla-VDeQNk2D_qJeMnwTPg">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:AmendmentFlag" id="Narr_Bir83qcYQE6XN50l4JUimg">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_hkoQ8GJUGEyIHnTAb-r26w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_NpCa8uFUzkmtHk3QJCc9mQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_E4lkwXOE3EWjcwZxsH94jw">27568802</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="0" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Hidden_VR5dWCt3C0Sh1B77yMPuHw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Hidden_uWLkBdDsz0GtDJO97s-CzA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_cpk3pttepkCkflUjT07eqQ">27680997</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_5_3_2019_To_5_3_2019_UUzyonDaOUCSPT8lhBhUag" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_sDmryUZLgEqm_48xdkZO4w">0.1245</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_X3VsFAQ5NEiHq5ECzPm1fA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_-cFdHJxdp0affo3bQWS-jg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_jNhHuhQk_UyO-tEfYC_Y8g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_-hqGGvF5CEGm7P86VQb_dw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_Q1KEPjTqhk6GA6gnGmG3gQ">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nxtc-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y7GXva2dbkWtJbsUzFBadQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2019_To_11_19_2019_YzRMsCVKvkGV2jcw4HTlxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-19</xbrli:startDate><xbrli:endDate>2019-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_UUzyonDaOUCSPT8lhBhUag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8gqQyeXsEa2baPiReBeLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wIP__71uMkOD1PkXsn-N0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ROd0_OVRAUibMHBnTwZzJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZINGtOppMEOQvolyBs2r2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3BA4U7O4vEq4IVDY7BQ4fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QqInZr8FSEKmnGZDc0UpLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g2SurcQldU2PCyhEWEYFNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7hwDq_hUlUOMlE_Q8n38kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qNbbMd7Kt06bhH7DHJgopQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_2_2019_WWMv6pgpRk2zjvig2oOTzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_19_2019_qoi0IG6E5ES_Szx_7icP0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRkd_wQNpE-PlILTjaNCPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_G_yj8-kGZEqKlKj7UfkTfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_G53rdmX140OTQJmbyiS6Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_w5P21kf0c0WRJYhRcmUNfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nxtc:ResearchAndDevelopmentCollaborativeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_GZR3kGJhT0eFCCICgDlBxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nxtc:ResearchAndDevelopmentCollaborativeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JJOGCiB-VUKIQzM08BXQzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_couFI7dtvE-qXjH-EmZFUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jUzYlFOGn0CwHbmMVEGKpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_oYnlwjc7HUGb5iWfCmq0fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_BSsHwW_jjUWkVvqBCbt48Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LFp27XQr4Uid6yEPdONaFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q2ALKasRH02YKQvydmMALQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_HwvSSMcY6EWFFgNhar4zeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xZ8jUscG3U-QIINlDwJ2ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_Qq_WJ4vpZkiMhOxoPOoNuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ytC6nbqJ5kebhS3ZyEI15A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_FRWWKvwUu0m7aWpFF9Q6iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qr9RYIPNZUOJJAf5Pj-l0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mtHwI-ED1USEa2VQIR0lwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_w26PQYiKDUS0odivM7VviQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Yan-j4dWbkS2KGt5iU5VRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_B9L06CbX5EGrB1JXLY5xsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E7waEgPyPkSn9Zcc1udIPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_hW36vSQqcEKgeJbxONrVSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qdi16EmCNUKD0BX_L5w1VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2019_ML94Z-Zsg0C5Id5hiZnfiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2016_dCCJWmRM8USlY0UQ6_FnFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_POQwOZH2fkaMcb9h4V0jNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_33XxS2bj4katgp19dilw6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_eNVV54RhUEqTl5x1mLRsMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_1Jdd-_wpikG_weZqBMb3Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oYhMcGirCE25Vip1ZFlDcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_kmwB305biUWLo3UjsSooUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_zGOjNpmC6EGr7pG_-L0KzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3BxpsJ2iNECPTNPjm8MqUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_e_s4q5Pn_Uu6ZKwpy8z4Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aAofUk9dFUCw9X561F27_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_ypDyfJrUqjGxvpjHQzEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aiYI6v5UyEeVRnXYUS5XLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HC8YQx8WSE68y6ph75dG7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eiLn54zwfEaRz2KZJSxGgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_pWUZUIh3IU2JNJgRAHr9Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-02</xbrli:startDate><xbrli:endDate>2019-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-13</xbrli:startDate><xbrli:endDate>2019-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1bJ_AHosZkOR2oPN_YnoLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vrV78_WLHUylRfRKRtNrFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mNncfD8YUC8da9cv5QKbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_SpiKMzSntkeJHGELywtLIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_JO8kC4Wv30ykMH8DL_H1Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_woD1OcCVU0i7W0uEaTV-eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NPmdibs4nkishMWIdyp4yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FJ9ZE9uoI0-WmaYGYBzHyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_XJYS-dihHU6jsGASXI2Dqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_2_2022_KjFy2haETEOXfvQdXHC5IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_w0Gf5YJwbUupsjwI1CCnAw"><xbrli:measure>nxtc:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_y2qUci353EOOoH7IWozW8A"><xbrli:measure>nxtc:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_4e5c6231_b274_4f69_bd9f_545433032111"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentType" id="Narr_zrqGWf8NSkSMy6CKDsPjOw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_5d2f0701_b0ce_4bad_a053_4d67aaabd2b1"></a><a id="Tc_d0fD_C7Q_Ue9rJDoS-Pcqw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentAnnualReport" id="Tc_rbpRueyt6UmCR2s7xQwiSA_1_0"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">ANNUAL Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentPeriodEndDate" id="Narr_G4_iZqKvw0iFDqIeC-zlKA"><b style="font-size:8pt;font-weight:bold;">December 31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_d5e1ee58_c4e0_4444_b6c4_4b35f78c6975"></a><a id="Tc_36EQ57kEF0igd8xg4sHAVg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:DocumentTransitionReport" id="Tc_LwNs8WpbQEOUcPBbQXNi7w_1_0"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from          to         &#160;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityFileNumber" id="Narr_Vjy9xtNjAE-erdirKxoOHw"><b style="font-size:7pt;font-weight:bold;">001-38905</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityRegistrantName" id="Narr_St7Kx_UdOUialkei9DTWtw"><b style="font-weight:bold;">NextCure, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:4pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_1da0343e_05ab_4528_811c_63ef7c2883ee"></a><a id="Tc_bAuuyjMs4UOHoRblEKdDnw_1_0"></a><a id="Tc_AeRKokb2q0m3UIOmhygZZw_1_1"></a><a id="Tc_XfHJ7RJ8k0CoFhLqINOzuw_3_0"></a><a id="Tc_u-vzQSsrUkWQLR59Iy0wDg_4_0"></a><a id="Tc_95ZfMOUEOUGzhrj0OFswlA_4_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_r0vAyNHnekip1U0EGNAsHQ_0_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityTaxIdentificationNumber" id="Tc_3TBw89D-1EKKQ9xUQ2-zcg_0_1"><b style="font-size:8pt;font-weight:bold;">47-5231247</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;">(State or other jurisdiction of</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> incorporation or organization)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;">(I.R.S. Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> Identification No.)</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityAddressAddressLine1" id="Narr_OLmWhBATu0yD3dUSKahCvQ"><b style="font-size:8pt;font-weight:bold;">9000 Virginia Manor Road, Suite 200</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityAddressCityOrTown" id="Narr_N-TE6qrITUCXDTQbXKJaNw"><b style="font-size:8pt;font-weight:bold;">Beltsville</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityAddressStateOrProvince" id="Narr_QW7LhqDa1EW4LtCtgTWSEg"><b style="font-size:8pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityAddressPostalZipCode" id="Tc_U2NBL_owJkOCQkC2nIczqQ_3_1"><b style="font-size:8pt;font-weight:bold;">20705</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code:</span><b style="font-size:8pt;font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:CityAreaCode" id="Narr_DGxBSD4_hk6Jz9a0LNER4Q"><b style="font-size:8pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:LocalPhoneNumber" id="Narr_-eeFLttoQkSEMOMP4VsjhQ"><b style="font-size:8pt;font-weight:bold;">399-4900</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_ab712d9a_5858_47a8_9bdc_27523d042820"></a><a id="Tc_-9u8dgIJX0GYZAbYIB4p0A_0_0"></a><a id="Tc_raEaIzWypU2TLhW7xNd1sQ_0_1"></a><a id="Tc_1drhBXpHtki0-grEp_ejfA_0_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.044857025%;padding-left:0pt;padding-right:0pt;width:100.08%;"><tr><td style="vertical-align:bottom;width:34.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:34.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</p></td></tr><tr><td style="vertical-align:top;width:34.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:Security12bTitle" id="Tc_Rdjk9W0nak22qpDqRK_MFg_1_0"><span style="font-size:8pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:TradingSymbol" id="Tc_pJFZueOvwUGTNtT0NpA_ZA_1_1"><span style="font-size:8pt;">NXTC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:34.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:SecurityExchangeName" id="Tc_MbpyGBYS-0GKgXrDeBmNTw_1_2"><span style="font-size:8pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_IE2hrjNbi0OA8Ihu0LLB0w"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityVoluntaryFilers" id="Narr_wa32Sz4HREyWSiv8kHybtw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityCurrentReportingStatus" id="Narr_CajEhy9w6U24s03qwC9nhg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityInteractiveDataCurrent" id="Narr_FVHfsRNeFkOQKsOLdnBJBw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.26;text-align:right;margin:0pt;">Accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityFilerCategory" id="Narr_bgL_vhTi3066CjwhIfz7Vg"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:right;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntitySmallBusiness" id="Narr_bDG7hl2N-0qp9aaY-C317g"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:right;margin:0pt;"><span style="font-size:8pt;">Emerging&#160;growth&#160;company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityEmergingGrowthCompany" id="Narr_foNhY7jfDk2vxPwWDY15Fg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityExTransitionPeriod" id="Narr_F_4vXQpUJkaKopNKvYf_Yg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_FZFprHNPx0-YwzOcimLVew"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:EntityShellCompany" id="Narr_x4N-hJlOJ0G8-WIiGF_tgw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates as of June 30, 2021 the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_XJYS-dihHU6jsGASXI2Dqg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_K4FAKrcEHE2Zmw-BoxjsmQ">209.0</ix:nonFraction> million, as computed by reference to the closing price of the common stock on the Nasdaq Global Select Market on that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt;">As of March 2, 2022, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_2_2022_KjFy2haETEOXfvQdXHC5IQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_wKCaYvVe_kehH2eU8f2oGw">27,724,303</ix:nonFraction> shares of common stock, par value $0.001 per share, issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Portions of the registrant&#8217;s definitive Proxy Statement for its 2022 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days after December 31, 2021, are incorporated by reference into Part III of this Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_de66a432_8ce0_4efe_af0f_ae2f6cc350d3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NextCure, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form 10-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the Year Ended December 31, 2021</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_73467"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ItemIBusiness_368398"><span style="font-style:normal;font-weight:normal;">Item&#160;1</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ItemIBusiness_368398"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_446956"><span style="font-style:normal;font-weight:normal;">Item&#160;1A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_446956"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_216361"><span style="font-style:normal;font-weight:normal;">Item&#160;1B</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_216361"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_180608"><span style="font-style:normal;font-weight:normal;">Item&#160;2</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_180608"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_9287"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_9287"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_549389"><span style="font-style:normal;font-weight:normal;">Item&#160;4</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_549389"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_356648"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquity"><span style="font-style:normal;font-weight:normal;">Item&#160;5</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquity"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_699531"><span style="font-style:normal;font-weight:normal;">Item&#160;6</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_699531"><span style="font-style:normal;font-weight:normal;">Selected Financial Data</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussion_693637"><span style="font-style:normal;font-weight:normal;">Item&#160;7</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussion_693637"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_728376"><span style="font-style:normal;font-weight:normal;">Item&#160;7A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_728376"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatements_538537"><span style="font-style:normal;font-weight:normal;">Item&#160;8</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatements_538537"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreements_266846"><span style="font-style:normal;font-weight:normal;">Item&#160;9</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreements_266846"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_609124"><span style="font-style:normal;font-weight:normal;">Item&#160;9A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_609124"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_9B._Other"><span style="font-style:normal;font-weight:normal;">Item&#160;9B</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_9B._Other"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_212520"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_124962"><span style="font-style:normal;font-weight:normal;">Item&#160;10</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_124962"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_11._Executive"><span style="font-style:normal;font-weight:normal;">Item&#160;11</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_11._Executive"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_12._Security"><span style="font-style:normal;font-weight:normal;">Item&#160;12</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_13._Certain"><span style="font-style:normal;font-weight:normal;">Item&#160;13</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_13._Certain"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_14._Principal"><span style="font-style:normal;font-weight:normal;">Item&#160;14</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_14._Principal"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_681968"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatement_2226"><span style="font-style:normal;font-weight:normal;">Item&#160;15</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatement_2226"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_16._Form"><span style="font-style:normal;font-weight:normal;">Item&#160;16</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_16._Form"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4807bc51_76e8_4a06_a63c_d9cbce3a87ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report contains forward-looking statements, including with respect to our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.&#160;Forward-looking&#160;statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the timing, progress and results of preclinical studies and clinical trials for NC318, NC410, NC762, NC525 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings for NC318, NC410, NC762, NC525 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;</span></td></tr></table><a id="_cp_blt_2_2"></a><a id="_cp_text_2_3"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the identification, analysis and use of biomarkers and biomarker data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continued impact of the COVID-19 pandemic on the initiation, progress or expected timing of our clinical trials and the timing of related data, our efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic, and other future impacts of the COVID-19 pandemic on the economy, our industry and our financial condition and results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of patient selection assays and companion or complimentary diagnostics for NC318, NC410, NC762 or any other product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the potential benefits, activity, effectiveness and safety of NC318, NC410, NC762, NC525 and any other product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intentions and ability to successfully commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the nature of the biological pathways we are targeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of and our ability to maintain our relationship with Yale University;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding our expenses, future revenues, capital requirements, our needs for or ability to obtain additional financing and the period over which we expect our current cash, cash equivalents and marketable securities to be sufficient to fund our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments and projections relating to our competitors and our industry, including competing therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of current and future laws and regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements, and other forward-looking statements, are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, such as the continued impact of the COVID-19 pandemic, and that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Forward-looking statements contained in this Annual Report should be considered in light of these factors and the factors set forth under &#8220;Risk Factor Summary&#8221; below and the&#160;factors described elsewhere in this Annual Report, including in the sections entitled &#8220;Risk Factors&#8221; and&#160;&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These&#160;factors, and the other cautionary statements made in this Annual Report, are applicable to all related forward-looking&#160;statements wherever they appear in this Annual Report. If one or more of these factors materialize, or if any&#160;underlying assumptions prove incorrect, our actual results, levels of activity, performance, or achievements may vary materially from any&#160;future results, activity, performance, or achievements expressed or implied by these forward-looking statements.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date of this Annual Report. We undertake no obligation to publicly update any forward-looking statements after the date of this Annual Report, whether as a result of new information, future events or otherwise, except as required by&#160;law.&#160;We qualify all of our forward-looking statements by the foregoing cautionary statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTOR SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risk factors that make an investment in our common stock speculative or risky. Before you invest in our securities, you should read the following summary together with the more detailed description of material risks described under &quot;Risk Factors&quot; in Item 1A of this Annual Report and the other information contained in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability. We have never generated revenue from product sales and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to the Discovery and Development of Our Product Candidates</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The impacts of the COVID-19 pandemic could continue to adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, marketing approval and ultimately commercialization, each of which is uncertain.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulatory approval processes are lengthy and inherently unpredictable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical development involves a lengthy and expensive process with uncertain outcomes, and as an organization we have limited experience designing and implementing clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, has resulted in delays in product development and could result in additional costs, delays or the inability to develop, obtain regulatory approval for or commercialize our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results may not be indicative of results obtained when the trial is completed or in later stage trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We, or our collaborators, could continue to encounter difficulties enrolling patients in our clinical trials due to the COVID-19 pandemic or otherwise.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because the numbers of subjects in our Phase 1/2 clinical trials of NC318, NC410 and NC762 are small, the results from each of these trials, once completed, may be less reliable than results achieved in larger clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our current or future product candidates may cause undesirable side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to the Regulatory Approval and Commercialization of Product Candidates and Other Legal Compliance Matters</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to obtain regulatory approval of our product candidates. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunities for any such product candidate may be limited.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Development of product candidates, in combination with other therapies, exposes us to additional regulatory risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on data and our information technology systems, and any failure of these systems or any related security breaches, loss of data, or other disruptions could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Manufacturing</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Given our limited operating history, our manufacturing experience, as an organization and with our manufacturing facility, is limited. We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing and, if approved, commercializing our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The loss of our third-party manufacturing partners or our, or our partners&#39;, failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on third-party suppliers for key materials used in our manufacturing process, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Intellectual Property</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have filed patent applications for our lead product candidates, but no patent has yet issued from these applications. If we are unable to obtain and maintain patent protection, or if the scope of the patent protection obtained is not sufficiently robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates. If we breach our obligations under this agreement, the agreement could be terminated, which would adversely affect our business and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to claims, or we may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful; our intellectual property could be found invalid or unenforceable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Reliance on Third Parties</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may depend on other third-party collaborators for the discovery, development and commercialization of certain of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Business</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to establish marketing, sales and distribution capabilities for any product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Common Stock</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our common stock has been and may in the future be volatile and fluctuate substantially.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are now and may in the future be subject to securities litigation, which can be expensive and could divert management&#39;s attention.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If securities analysts do not publish research or reports about our business or if they publish inaccurate or unfavorable research about our business, the price of our stock could decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_73467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I </p><a id="ItemIBusiness_368398"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1. Business</p><a id="_Toc18318196"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or &#8220;FIND-IO&#8221;, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, NC318, is a first-in-class immunomedicine against a novel immunomodulatory protein called Siglec-15, or &#8220;S15&#8221;. In October 2018, we initiated a Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors. We completed enrollment of the Phase 1 portion of this trial in August 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We began enrolling patients in the Phase 2 portion of the Phase 1/2 clinical trial of NC318 in October 2019. In this portion, we planned to enroll up to 100 patients with tumor types that have been shown to have elevated S15 expression, including non-small cell lung cancer, or &#8220;NSCLC&#8221;, ovarian cancer, head and neck squamous cell carcinoma, or &#8220;HNSCC&#8221;, and triple-negative breast cancer, or &#8220;TNBC&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have modified the Phase 2 portion of the trial for S15 selection, whereby clinical sites can select for S15-positive patients through screening biopsies in a Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;)-certified laboratory. In the second quarter of 2021, we revised the dosing regimen to 800 mg weekly to increase overall drug exposure to NC318. We provided a data update from our ongoing monotherapy trial of NC318 at the SITC Meeting in November 2021. Based on combined Phase 1 and Phase 2 data from the NC318 study, NC318 continued to show early evidence of possible clinical benefit in patients with HNSCC, lung and breast cancer and other advanced/metastatic solid tumors, with dosing once every two weeks during dose escalation and a dose of 400 mg selected for the Phase 2 studies. NC318 continued to be well-tolerated in the Phase 2 portion of the trial, with primarily mild or moderate treatment-related adverse events, or &#8220;TRAE&#8221;. We expect to provide further data from the Phase 2 portion of this trial in the fourth quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, Yale University commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC. Initial data are anticipated in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor, or &#8220;LAIR&#8221;, -1. In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. Interim data presented from the Phase 1 dose-escalation study show that NC410 appears to be safe and well-tolerated in patients with advanced tumors and shows evidence of immune modulation. We expect to provide further data from the Phase 1 portion of this trial in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our third product candidate, NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein, or &#8220;B7-H4&#8221;. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. We expect to announce initial data from the Phase 1 portion of this trial in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our fourth product candidate, NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or &#8220;AML&#8221;, blast cells and leukemic stem cells, or &#8220;LSCs&#8221;. Preclinical data show that NC525 kills AML blast </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:250.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cells and LSCs while sparing hematopoietic stem and progenitor cells, or &#8220;HSPCs&#8221;. Preclinical data were presented at the American Society for Hematology annual meeting, or the &#8220;ASH Meeting&#8221;, in December 2021. The data showed that NC525 (i) inhibits colony formation of AML LSCs <i style="font-style:italic;">in vitro</i>, (ii) inhibits AML growth in the MV4-11 derived xenografts, or &#8220;CDX&#8221;, animal model in vivo and (iii) restricts AML progression in patient-derived xenografts, or &#8220;PDX&#8221;, in vivo. An IND submission is planned for the fourth quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our approach to identifying targets for new immunomedicines is based on our FIND-IO platform. FIND-IO embodies a rational approach to the discovery of novel cell surface and secretory molecules that drive functional immune responses. We use our immunology knowledge, experience and capabilities and tools we have developed, including our FIND-IO platform, to support our discovery efforts. We are working to discover novel targets that play a key role in mediating immune dysfunctions that allow tumors to evade the immune system. We seek to identify and develop immunomedicines that counteract these outcomes and to further validate and advance our product candidates. We have identified multiple novel targets using our FIND-IO platform, including those for which certain of our research programs are being designed to target. The immunosuppressive properties of S15, the target of NC318, were discovered using a predecessor of our FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our understanding of biological pathways and our FIND-IO platform to discover, validate and build a proprietary pipeline of immunomedicine candidates. The figure below details our pipeline of product candidates and principal discovery and research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><img src="nxtc-20211231x10k005.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:250.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to use our fully integrated discovery and product development infrastructure to build a sustainable pipeline of product candidates to treat cancer patients who are not adequately served by currently available therapies. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advancing the clinical development of our lead product candidates, NC318, NC410 and NC762. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We began enrolling patients in the Phase 2 portion of the Phase 1/2 clinical trial evaluating NC318 in patients with advanced or metastatic tumors in October 2019. In addition, we believe scientific evidence supports a combination of NC318 with anti-PD-1 therapy, and Yale commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC. For NC410, we initiated the Phase 1 portion of a Phase 1/2 clinical trial in June 2020 and reported preclinical data demonstrating that </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NC410 promoted T-cell mediated anti-tumor immunity, enhanced infiltration and increased localized activity of T-cells in the TME. For NC762, we initiated a Phase 1/2 clinical trial in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types in July 2021. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Building an oncology pipeline of novel targets for new immunomedicines focused on non-responders</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We are continuing to leverage our immunological expertise and our FIND-IO platform to identify novel targets relevant to overcoming immune suppression.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leveraging our fully integrated development, quality systems and cGMP manufacturing capabilities. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our approach is to integrate key aspects of product development within our organization. We have assembled a team with extensive experience in identifying, characterizing and developing novel immunomedicines. We seek to couple discovery of important targets with the capability to rapidly streamline target validation and conduct key IND-enabling studies, leading to clinical development of lead candidates. Our purpose-built, dedicated, state-of-the-art cGMP manufacturing facility utilizes single-use technology to support development of our pipeline and advancement of our product candidates into and through clinical development. The facility has production capacity of 2,000 liters and is designed to operate as a multi-product facility. Compared to working with third-party manufacturers, we believe our facility provides better quality assurance, greater control in scheduling and prioritizing manufacturing activities and enhanced capital efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expanding our current focus and creating new opportunities outside of the oncology field</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. While our primary focus is oncology, the functional screening approach and proprietary technology of our FIND-IO platform are broadly applicable to the identification of positive and negative immune modulators, and therefore can be used and expanded to discover novel targets in other inflammatory diseases. Our goal is to enable next-generation immunomedicines for other serious inflammatory diseases with significant unmet medical needs in fields beyond oncology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Extending the reach of our product candidates through strategic partnerships and collaborations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We have exclusive worldwide rights to our current product candidates and our FIND-IO platform. We expect to explore a variety of market opportunities for our current and future product candidates and our platforms, including through the pursuit of strategic partnerships or other collaborations with regard to selected indications or geographical areas, such as Asia. We intend for our product candidates to be developed and commercialized globally, by us in key markets and in collaboration with other companies for other geographies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Immuno-Oncology Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The immune system has powerful biological mechanisms to defend and protect the body from pathogens, such as viruses, parasites and bacteria. It also provides surveillance against cancers by recognizing and responding to antigens that are uniquely or highly expressed on cancer cells. In cancer, complex interactions between immune cells and growing tumor cells can prevent an immune response by blocking cellular interactions, resulting in immunosuppression in the TME. This phenomenon, referred to as immune evasion, is a hallmark of cancer where the tumor can prevent tumor-specific immune cells called T-cells from functioning within the TME or gaining access to the tumor site, which allows the tumor to continue to grow, leading to disease progression. Tumors in advanced cancer have multiple mechanisms of evasion in the TME that can differ from tumor to tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Remodeling the TME and overcoming its immunosuppressive properties is a major focus of cancer research and drug development. Checkpoint inhibitors are a drug class designed to counteract certain tumor defenses against the immune system. Currently approved checkpoint inhibitors were developed based on the belief that an immune system inactivated by co-inhibitory proteins, known as checkpoints, could be reactivated to recognize and attack the tumor. Therapies against checkpoints, such as PD-L1, PD-1 and Cytotoxic T-Lymphocyte Antigen, or &#8220;CTLA&#8221;-4, have produced impressive results in the clinic across an array of cancers and have been approved for several malignancies. However, despite the recent success of these checkpoint inhibitors, it is estimated that up to 60% to 70% of cancer patients do not respond to single-agent therapy with checkpoint inhibitors. This limited efficacy highlights the importance of our effort to identify novel targets and molecular pathways responsible for tumor immune evasion mechanisms that we believe will work independently from current targets for cancer immunotherapy.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Approach to Developing Immunomedicines for Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our approach to identifying targets for new immunomedicines in cancer is based on the combination of our FIND-IO platform, our immunological expertise and our belief in the importance of understanding biological pathways and the normal function of the immune system in the TME. Rather than focusing on a specific type of immune cell, we are targeting molecules that modulate the immune system in ways that we believe may provide new treatment opportunities for patients that are differentiated from currently marketed targeted therapies as well as those in development. Our primary goal is to develop immunomedicines that increase response rates, efficacy and durable overall survival among patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types that are not adequately addressed by currently available therapies. We design our product candidates either to restore the normal effects of the immune system to promote elimination of the tumors or to counteract tumor immune evasion mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO platform applies a function-based screening approach to identify human proteins and to determine whether those proteins alter or stop an immune response resulting in immune evasion. The platform is designed to identify novel cell surface molecular interactions that drive functional immune responses. Our FIND-IO platform broadly and quantitatively evaluates interactions between relevant protein components and different T-cellular types over time in order to identify novel targets that either increase or decrease immune-related functional responses associated with desired immune responses against tumors. By identifying novel immune modulators through the FIND-IO platform, we aim to develop next-generation immunomedicines that restore normal immune function in the TME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To create our FIND-IO platform, we industrialized, expanded and optimized the T-cell Activity Array, or &#8220;TCAA&#8221;, a predecessor of the FIND-IO platform that Dr.&#160;Chen used to discover the immunosuppressive properties of S15. Our work in developing the FIND-IO platform beyond the TCAA includes using different and expanded gene libraries, adding biological pathways and reporters, expanding immune cell types and, most importantly, increasing the repertoire of functional assay readouts. We also broadened the platform to look at signaling within both the immune cell and the cell expressing the library gene. By transfecting cells with library genes, which encode membrane-bound or soluble proteins, FIND-IO is designed to determine whether the genes have signaling functions when interacting with an immune cell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO technology includes proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines from immune lineages, including T-cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines and cells isolated from diseased patients. This platform allows us to identify proteins that can be targeted with novel immunomedicines to repair and maintain anti-tumor immunity. By focusing on understanding the TME in oncology, we believe we can identify multiple new positive and negative modulators of immune cells, including T-cells, NK cells, macrophages and myeloid-derived suppressor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As shown in the figure below, our product candidates target a variety of cell types in the immune system. For example, NC318 targets macrophages and tumor cells and prevents suppressive myeloid cells from negatively regulating T-cells, and NC410 targets the negative signaling from dendritic cells, macrophages and T-cells mediated by the binding of LAIR-1 to its ligands collagen and C1q. We also have earlier stage discovery programs that are investigating the negative effects of NK cells and other immune cells in the TME on T-cells. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:303pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Expanding Targets Beyond T-Cells</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="nxtc-20211231x10k006.jpg" alt="Graphic" style="display:inline-block;height:302.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:351.36pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Our Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC318</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC318 is a monoclonal antibody that binds specifically to human S15 with high affinity. We have observed in preclinical studies that blocking S15 improved the immune response in multiple animal models. We believe that NC318 may help promote an effective anti-tumor immune response by targeting multiple cell types in the TME that express S15, including macrophages and S15-positive tumor cells. Based on the results of the Phase 1 portion of our Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors, we began enrolling patients in the Phase 2 portion of the trial in October 2019. The Phase 2 portion of the trial was designed as a Simon Two-Stage trial, a type of Phase 2 trial that is multi-stage and is conducted in two stages with the option to stop the trial after the first stage or after the second stage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have modified the Phase 2 portion of the trial for S15 selection, whereby clinical sites can select for S15-positive patients through screening biopsies in a CLIA-certified laboratory. In the second quarter of 2021, we revised the dosing regimen to 800 mg weekly to increase overall drug exposure to NC318. We provided a data update from our ongoing monotherapy trial of NC318 at the SITC Meeting in November 2021. Based on combined Phase 1 and Phase 2 data from the NC318 study, NC318 continued to show early evidence of possible clinical benefit in patients with HNSCC, lung and breast cancer and other advanced/metastatic solid tumors, with dosing once every two weeks during dose escalation and a dose of 400 mg selected for the Phase 2 studies. NC318 continued to be well-tolerated in the Phase 2 portion of the trial, with primarily mild or moderate TRAE. We have exclusive worldwide rights to NC318.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, Yale University commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">S15 Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">S15 is a member of the sialic acid-binding immunoglobulin lectins, or Siglec, family, a distinct subgroup of the immunoglobulin superfamily of proteins. Siglecs are expressed on most white blood cells of the immune system, except </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for T-cells. Siglecs recognize and bind to a sugar structure called sialic acid that coats proteins and fatty acids found on the surface of all mammalian cells. This binding can affect T-cell signaling on immune cells. Several Siglecs play key roles in helping immune cells distinguish between self, and non-self and modulating immune responses. S15 is expressed on tumor cells and, importantly, on M2 macrophages, which are highly immunosuppressive in the TME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">S15 molecules on M2 macrophages, as well as on tumors themselves, appear to interact with unidentified receptors on T-cells and inhibit T-cell proliferation and functions, leading to decreased anti-tumor immune response. It also appears that S15 interacts with myeloid cells to promote their survival and differentiation so that they contribute to the overall immunosuppressive tumor environment through production of cytokines, such as IL-6, IL-1&#946; and TNF-&#945;, that are tumor-promoting and immunosuppressive in the context of the TME. As shown in the figure below, the presence of S15 on either tumor cells or M2 macrophages can lead to an immunosuppressive TME, resulting in tumor growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">S15 is Highly Immunosuppressive in the TME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nxtc-20211231x10k007.jpg" alt="GRAPHIC" style="display:inline-block;height:280.8pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The mechanism of action of NC318 prevents immune suppression caused by S15 and promotes anti-tumor activity. As the figure below shows, by targeting M2 macrophages, S15-induced myeloid cells and S15-positive tumors, NC318 is engineered to decrease inflammatory cytokines associated with enhanced tumor growth, promote T-cell proliferation and restore T-cell function, which we believe will reduce and kill tumors.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:258.48pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">NC318 is Designed to Block Immunosuppressive Activity Induced by S15</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nxtc-20211231x10k008.jpg" alt="GRAPHIC" style="display:inline-block;height:258.48pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Phase 1/2 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, we initiated the Phase 1 portion of a Phase 1/2 clinical trial to evaluate NC318 as a monotherapy in patients with advanced or metastatic solid tumors. This ongoing trial is an open-label Phase 1/2 clinical trial designed to assess the safety and tolerability of NC318, to define the maximum tolerable dose and/or pharmacologically active dose and to assess preliminary efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Phase 1 portion was designed to determine the pharmacologically active dose, defined as the dose that provides a maximal biologic effect, such as an increase in biomarkers of immune activation or a reduction of biomarkers associated with immune suppression, and/or the maximum tolerable dose of NC318, including defining the optimal dose administration schedule and the maximum number of tolerated doses. We completed enrollment of the Phase 1 portion of the trial in August 2019 and dosed 49 patients across seven dose cohorts: 8 mg, 24 mg, 80 mg, 240 mg, 400 mg, 800 mg and 1,600 mg, the last of which was added to the trial because a maximum tolerated dose had not been reached through 800 mg. The most common tumors in the Phase 1 portion of the Phase 1/2 trial were NSCLC (13 patients), ovarian (7 patients), melanoma (7 patients), breast (4 patients) and colorectal (3 patients). Enrolled patients had all been subject to previous cancer treatments, with a median of three prior therapies, and all 13 NSCLC patients were PD-1 refractory and had been treated with a median of four prior therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preliminary data from the Phase 1 portion were presented in November 2019 at the SITC annual meeting and updated data were announced in December 2020. As of December 17, 2020, NC318 had been well-tolerated in the Phase 1 portion of the trial and only one dose-limiting toxicity, a grade 3 pneumonitis at the highest dose level, had been observed. Treatment-related adverse events experienced by more than 5% of patients as of that date were diarrhea, infusion reactions, fatigue, headaches, pruritis, elevated amylase and elevated lipase. Most treatment-related adverse events were easily manageable, asymptomatic or mild or moderate, with the exception of one case of grade 3 episcleritis/uveitis at the 400 mg dose level that resolved after steroid therapy and two cases of grade 3 pneumonitis (one at the 400 mg dose level and one at the 1,600 mg dose level). We also observed two grade 1 cases of vitiligo (one at the 80 mg dose level and one at the 400 mg dose level) that, along with other immune-related adverse events including diarrhea, elevated amylase and lipase, pruritis, episcleritis/uveitis and pneumonitis, indicate NC318&#8217;s activity as a modulator of the immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Data from the Phase 1 portion of the trial indicate activity in multiple tumor types, including durable stable disease in patients with NSCLC, endometrial cell cancer, ovarian cancer, squamous cell carcinoma, Merkel cell cancer, and head and neck cancer. As of December 17, 2020, durable responses observed include one complete response, which remained </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ongoing at 104 weeks, and one partial response, which remained ongoing at 78 weeks, both in NSCLC patients, as well as 10 patients with stable disease, which remained ongoing for six months or more. The patient with the complete response had multiple lesions prior to treatment with NC318, including two lesions that were at least 10 mm. Among the 10 patients with stable disease, four patients have NSCLC with stable disease for six months or more.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We began enrolling patients in the Phase 2 portion of the Phase 1/2 clinical trial of NC318 in October 2019. The Phase 2 portion of the trial is an open-label trial designed to detect a relevant efficacy signal, or response rate, for each tumor type at a 400 mg dose administered every two weeks. In this portion, we planned to enroll up to 100 patients with tumor types that have been shown to have elevated S15 expression, including NSCLC, ovarian cancer, HNSCC and TNBC. In the Phase 2 portion, patients were initially selected based on tumors with a PD-L1 TPS of less than 50%. S15 expression was analyzed retrospectively in all pretreatment biopsies successfully obtained from the Phase 2 patients. The primary endpoints for the Phase 2 portion of the trial are safety and tolerability, and secondary endpoints include response rate, progression-free survival, duration of response and overall survival. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2020, we reported a confirmed partial response in a HNSCC patient. In addition, we reported that at that time we would not progress the NSCLC and ovarian cancer cohorts to the second stage of the Simon 2-stage trial. In December 2020, we completed a retrospective analysis of S15 expression in biopsy samples collected from the Phase 2 patients at their initial screening. During initial screenings, we did not have an available screening assay to select for patients based on S15-positive biopsies. Therefore, inclusion criterion was based on a TPS PD-L1 score &lt;50%, given the non-overlapping expression of S15 and PD-L1. Of the evaluable biopsies collected, retrospective analysis showed that 13% of the patients enrolled had S15-positive tumors. These biopsies showed that the selection criterion, based on low PD-L1 expression, did not result in enough S15-positive patients for us to effectively evaluate the activity of NC318 in S15-positive tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have modified the Phase 2 portion of the trial for S15 selection, whereby clinical sites can select for S15-positive patients through screening biopsies in a CLIA-certified laboratory. In the second quarter of 2021, we resumed enrolling a NSCLC adenocarcinoma cohort in the Phase 2 trial, and we revised the dosing regimen to 800 mg weekly to increase overall drug exposure to NC318. We provided a data update from our NC318 monotherapy trial at the SITC meeting in November 2021. Based on combined Phase 1 and Phase 2 data from the NC318 study, NC318 continued to show early evidence of possible clinical benefit in patients with HNSCC, lung and breast cancer and other advanced/metastatic solid tumors, with dosing once every two weeks during dose escalation and a dose of 400mg selected for the Phase 2 studies. NC318 continued to be well-tolerated in the Phase 2 portion of the trial, with primarily mild or moderate TRAE. The only observed severe or higher-grade TRAE in the Phase 2 portion was a grade 3-4 infusion reaction in one patient. Pharmacokinetic and pharmacodynamic modeling using serum samples from the Phase1/2 trial, predicted that a dose of 800 mg once a week results in nearly ten times greater drug exposure which may impact drug activity and clinical outcomes. This led to the decision to revise the dosing regimen to 800 mg weekly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Phase 2 Combination Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, Yale University commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC410</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. Multiple preclinical studies support our understanding that eliminating or blocking the binding of LAIR-1 restores normal immune function in multiple immune cells. Our translational work has shown that NC410 blocks the interaction of LAIR-1 with its binding partners, thereby promoting T-cell function and dendritic cell activity to contribute to restoring anti-tumor immune activity. Consistent with our strategy, we believe NC410 has the potential to address the needs of patients who are not adequately addressed by currently available therapies. We have exclusive worldwide rights to NC410. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Background of LAIR Pathway in Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">LAIR-1 is a co-inhibitory receptor expressed on T-cells and several other immune cell subsets, including monocytes, macrophages and dendritic cells. Its binding partners include certain types of collagen and complement component 1q, or C1q.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:228.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under normal conditions, collagen forms a scaffold to provide strength and structure to tissues. C1q is part of the innate immune system to protect the host from infection and other foreign agents. Both collagen and C1q are highly upregulated and expressed under pathologic conditions, such as in the TME and in the immune organelles close to the tumor site known as lymph nodes, which are important sites for mounting immune responses to the tumor. However, binding of LAIR-1 to collagen or C1q leads to immune suppression. Our preclinical studies have shown that LAIR-1 and LAIR-2 bind to similar ligands, including collagen and C1q. LAIR-2, which is a secreted protein as opposed to a membrane-bound protein like LAIR-1, binds to the same regions of these ligands with stronger affinity than LAIR-1. However, because LAIR-2 does not induce immune suppression when binding to these ligands, LAIR-2 functions as an efficient decoy for LAIR-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the harsh conditions of the TME, collagen and C1q are overexpressed as a membrane protein on many types of tumor cells and in the ECM surrounding the tumor. This increased expression of collagen and C1q, combined with insufficient levels of natural LAIR-2, leads to increased binding of LAIR-1, resulting in immune suppression, tumor immune evasion and tumor growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC410 is a novel immunotherapeutic protein that was developed to block LAIR-1-mediated immune suppression by mimicking the natural decoy effects of LAIR-2. Our approach of using NC410 as a therapeutic is intended to take advantage of the natural LAIR-2 regulatory system in humans, which maintains human immune function under normal non-pathologic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The mechanism of action of NC410 prevents immune suppression caused by LAIR-1 binding to collagen or C1q and promotes anti-tumor immune activity. As the figure below shows, when LAIR-2 and NC410 are present in the TME, they bind to collagen or C1q preferentially compared to LAIR-1 given their higher binding affinity. This has the effect of blocking the collagen or C1q from binding to LAIR-1, which otherwise would have resulted in an immunosuppressive effect. By blocking this interaction with LAIR-1 and its binding partners, T-cell function and dendritic cell activity is promoted in order to restore anti-tumor immune activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NC410 is Designed to Prevent Immune Suppression Caused by LAIR-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nxtc-20211231x10k009.jpg" alt="GRAPHIC" style="display:inline-block;height:227.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Our Clinical Development Plan for NC410</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We and others have analyzed genomic and protein databases and observed that LAIR-1 expression levels negatively correlate with survival rates for several cancers, including brain, renal, colorectal, glioma, lung, urothelial and ovarian cancers. These analyses support possible targeting of these tumor types as primary indications for therapeutic treatment with NC410. We have conducted expansive screening efforts on tumor samples from different solid tumor types to identify tumors that express LAIR-1 on immune cells and varying levels of collagen in the TME, to guide our ultimate </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">selection of patients for the Phase 2 portion of the Phase 1/2 clinical trial. We plan to develop a CLIA-certified assay to select patients for the Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors after a temporary delay due to the COVID-19 pandemic. The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC410 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC410 will be evaluated in select tumor types. In May 2021, at the ASCO Meeting, we reported preclinical data demonstrating that NC410 promoted T-cell mediated anti-tumor immunity, enhanced infiltration and increased localized activity of T-cells in the TME. We provided a data update from the Phase 1 portion of this trial at the SITC Meeting in November 2021. Interim data presented from the Phase 1 dose-escalation study show that NC410 appears to be safe and well-tolerated in patients with advanced tumors and show evidence of immune modulation. Safety, tolerability, efficacy and biomarker analyses are ongoing in higher-dose cohort patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC762</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or &#8220;B7-H4&#8221;, a protein expressed on multiple tumor types. We believe NC762 acts by inhibiting tumor cell growth. While the inhibitory effect on tumor growth does not appear to be dependent upon T-cells, we believe NK cells may contribute to enhanced anti-tumor activity mediated by NC762. We have observed in preclinical studies that NC762 inhibits the growth of human melanoma tumors in mice, and we believe that NC762 has the potential to treat multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer, or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC762 will be evaluated in select tumor types. We have exclusive worldwide rights to NC762.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">B7-H4 Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">B7-H4 is a cell surface protein expressed on multiple tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer and hepatocellular carcinoma, and on tumor-associated macrophages, and shows limited expression in most normal tissues. B7-H4 was initially discovered in 2003 in the Mayo Clinic lab of our scientific co-founder Dr. Lieping Chen. It is a member of the same family of co-inhibitory checkpoint proteins as B7-H1, known as PD-L1, which was also discovered by Dr. Chen&#39;s laboratory (see &quot;Immuno-Oncology Background&quot;) B7-H4 has been shown in published articles to negatively regulate T-cell immune response, inhibit cytokine production, suppress antigen-presenting cells, promote immune escape and play a role in tumorigenesis and tumor development. Expression of B7-H4 in tumor cells has been shown in preclinical research and published articles to be correlated with reduced overall survival, and B7-H4 has generally non-overlapping expression with both PD-L1 and S15. Given the low expression of B7-H4 on healthy cells and the results of our preclinical cross-tissue reactivity studies, we believe that anti-B7-H4 treatment is unlikely to inadvertently cause adverse effects of tissues and pathways outside of B7-H4 positive tumors and tumor-associated macrophages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC762 is a novel immunotherapeutic protein that binds to B7-H4 on the cell surface of tumors. We believe NC762 acts by inhibiting tumor cell growth and killing tumor cells, including by enhancing immune response. Preclinical research indicates that the primary mechanism of action of NC762 inhibits tumor cell growth independently of immune cell infiltration into the TME. NC762 was also designed to enhance immune response by allowing for enhanced binding to CD16a/Fc&#947;RIIIa, a receptor found on the surface of natural killer, or NK cells, in order to increase antibody-dependent T-cell-mediated cytotoxicity, or &#8220;ADCC&#8221;, activity. ADCC is a process by which effector cells such as NK cells interact with and kill antibody-coated target T-cells such as tumor cells. Extensive in vivo modeling data using human melanoma in mouse models expressing B7-H4 indicate that NC762&#39;s anti-tumor effect may be enhanced in the presence of NK cells, but that it has an anti-tumor impact even in the absence of peripheral blood mononuclear cells (comprising several types of white blood cells including NK cells), and that the primary mechanism by which NC762 inhibits tumor growth is therefore ADCC-independent. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:153pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="nxtc-20211231x10k010.jpg" alt="Graphic" style="display:inline-block;height:153pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:320.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies did not raise any significant safety concerns with NC762. Specifically, dosage of cynomolgus monkeys at doses up to 100 mg/kg did not result in any observed adverse effects. A tissue cross-reactivity study of 37 tissues from three individuals found no signals that NC762 binds to tissues other than tumor tissue, which indicates that NC762 is not expected to bind off target and harm cells, tissues and pathways outside of B7-H4 positive tumors and tumor-associated macrophages. In addition, an analysis of changes in serum cytokines <i style="font-style:italic;">in vitro</i> leads us to believe that treatment with NC762 is unlikely to trigger overactive immune responses known as cytokine storms that can have harmful effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have developed an IHC assay using a commercially purchased antibody to test tumors for B7-H4 positivity and have performed screening of multiple tumor types. We intend to use this assay to select patients for treatment through patient biopsies, including in the Phase 1 dose expansion portion of our planned Phase 1/2 clinical trial, and have validated the assay for use in clinical trials. We also intend to retroactively use immunophenotyping and serum analysis as part of our clinical trials to determine the types of cells present after treatment in order to identify biomarkers, to look for signs of clinical activity, and to help determine the likelihood of responsiveness to treatment with NC762.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Our Clinical Development Plan for NC762</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and others have observed that B7-H4 is widely expressed on a number of cancers, including non-small cell lung cancer, ovarian cancer, breast cancer and hepatocellular carcinoma. These analyses support possible targeting of these tumor types as primary indications for therapeutic treatment with NC762. Using a B7-H4-specific antibody that we identified and optimized for IHC analyses, we are currently staining various cancer tissues to gain a more comprehensive and definitive understanding of B7-H4 prevalence in both primary and metastatic lesions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC762 will be evaluated in select tumor types. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC525</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our fourth product candidate NC525 is a novel LAIR-1 antibody that selectively targets AML, blast cells and LSCs. Preclinical data show that NC525 kills AML blast cells and LSCs while sparing HSPCs. Preclinical data were presented at the ASH Meeting in December 2021. The data showed that NC525 (i) inhibits colony formation of AML LSCs <i style="font-style:italic;">in vitro</i>, (ii) inhibits AML growth in the CDX, animal model <i style="font-style:italic;">in vivo</i> and (iii) restricts AML progression in PDX, <i style="font-style:italic;">in vivo</i>. We have exclusive worldwide rights to NC525. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Research Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to NC318, NC410, NC762 and NC525, we are also pursuing preclinical evaluation of other potential novel immunomodulatory molecules.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our FIND-IO Platform </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO platform uses proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines from immune lineages, including T-cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines, and cells isolated from diseased patients. This platform allows us to identify proteins that can be targeted with novel immunomedicines to repair and maintain anti-tumor immunity. We have identified multiple novel targets using our FIND-IO platform, including those for which certain of our research programs are being designed to target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The goal of our FIND-IO platform is to sustain a pipeline of novel immunomedicines that restore normal immune function to treat cancer and other immune-related diseases. While we are primarily focused on cancer treatment, we believe that our proprietary technology, our approach, our understanding of biological pathways and the convergence of immunology and inflammation provide us with opportunity to explore novel immunomedicines for other significant unmet medical needs. To maximize the full potential of our platform and expertise, we are expanding the functional screening approach of our FIND-IO platform to the identification of novel targets in autoimmunity and inflammation, as well as in neuro-inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with Yale University</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">License Agreement with Yale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into a license agreement with Yale, or the Yale Agreement, in December 2015 pursuant to which we obtained an exclusive, royalty-bearing, sublicensable worldwide license to products that either incorporate certain licensed patents used in the discovery of targets or arise out of research and development of Dr.&#160;Chen&#8217;s laboratory at Yale, including S15, and subsequently amended the Yale Agreement in January 2020 and October 2021. We are obligated to pay Yale low single-digit royalties on sales of products, including NC318, that are either covered by the patents licensed to us under the Yale Agreement or arise out of Dr.&#160;Chen&#8217;s laboratory as a result of research under the corporate sponsored research agreement described below, subject to minimum annual royalty payments in the low to mid hundreds of thousands of dollars. Until we are required to pay royalties under the Yale Agreement, we must pay an annual license maintenance fee to Yale in the mid to high tens of thousands of dollars. In addition, with respect to each product covered by licenses under the Yale Agreement, we are obligated to pay Yale milestone payments upon (i)&#160;the initiation of each of a Phase&#160;1 clinical trial, Phase&#160;2 clinical trial and Phase&#160;3 clinical trial or a pivotal trial, (ii)&#160;first commercial sale in the United States and (iii)&#160;first commercial sale in China, Japan or a major European country, in an aggregate amount of up to $2,975,000. The term of the license agreement with Yale runs, on a country-by-country basis, until the later of the expiration of all licensed patents or 10&#160;years from the first commercial sale in such country, unless Yale has cause to terminate earlier for our material breach of the license, bankruptcy or if we or any sublicensee bring a challenge against Yale in relation to the licensed patents. We have the right to terminate the Yale Agreement for Yale&#8217;s material breach or at any time during the term with six months&#8217; prior written notice to Yale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Sponsored Research Agreement with Yale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Yale Agreement, we also entered into a corporate sponsored research agreement, or &#8220;SRA&#8221;, with Yale, pursuant to which we had agreed to provide an aggregate of up to $15 million to fund a research program aimed at discovering new targets for immunomedicines. The SRA was subsequently amended in January 2020 and October 2021 and expired on December 31, 2021. We do not intend to renew the SRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Former Research and Development Collaboration with Lilly</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective March 3, 2020, Eli Lilly and Company, or Lilly, terminated the multi-year research and development collaboration agreement, or the Lilly Agreement, without cause that we had entered into with Lilly in November 2018 and that focused on the discovery and development of immunomedicines for oncology using our FIND-IO platform. Under the agreement, we had granted Lilly the exclusive option to obtain worldwide exclusive licenses to research, develop, manufacture and commercialize multiple compounds and products directed to oncology targets identified through our research collaboration.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Manufacturing</p><a id="_cp_text_1_134"></a><a id="_cp_text_1_136"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a purpose-built, dedicated, state-of-the-art cGMP manufacturing facility that utilizes single-use technology to support our pipeline and advance our product candidates into and through clinical development. The facility has a production capacity of 2,000 liters in order to support multiple product candidates. The investment in our manufacturing facility is a critical element of our ability to quickly identify whether a candidate is likely to be successful and to facilitate an efficient development path. While other companies may need to work with third parties for antibody production, we can do so in our own facility. Compared to working with third-party manufacturers, we believe our facility provides better quality assurance, greater control in scheduling and prioritizing manufacturing activities and enhanced capital efficiency. We are currently manufacturing all of the drug supply for our preclinical studies and our Phase 1/2 clinical trials of NC318, NC410, and NC762 and intend to provide the drug supply for future clinical trials of NC318, NC410, NC762 and NC525. As we advance the development of our growing pipeline of product candidates, we will continue to evaluate the merits of further expanding our internal manufacturing capabilities, including for the production of commercial drug supply, as compared to collaborating with third-party manufacturers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. We believe that our programs, platforms, technology, knowledge, experience and scientific resources provide us with competitive advantages, but we also face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our competitors include larger and better funded biopharmaceutical, biotechnology and therapeutics companies, including companies focused on cancer immunotherapies, such as Amgen,&#160;Inc., AstraZeneca&#160;plc, Bristol-Myers Squibb Company, or BMS, Genentech,&#160;Inc., GlaxoSmithKline&#160;PLC, Merck&#160;&amp;&#160;Co.,&#160;Inc., Novartis AG, Pfizer&#160;Inc., Roche Holding&#160;Ltd and Sanofi&#160;S.A. Moreover, we may also compete with smaller or earlier-stage companies, universities and other research institutions that have developed, are developing or may be developing current and future cancer therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product candidates that we successfully develop and commercialize will compete with a range of therapies that are currently approved and any new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&#160;Inc.&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217; Yervoy, and PD-1/PD-L1, such as BMS&#8217; Opdivo, Merck&#160;&amp;&#160;Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T-cell-engager immunotherapies, such as Amgen&#8217;s Blincyto. In addition to these marketed therapies, numerous compounds are in clinical development for the potential treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, methods and manufacturing processes, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. We rely on a combination of patent applications and trade secrets, as well as contractual protections, to establish and protect our intellectual property rights. We seek to protect our proprietary position by, among other things, filing patent applications in the United States and internationally. Our patent estate includes patent applications with claims relating to our product candidates, methods of use and manufacturing processes, and claims for potential future products and developments. As of December 31, 2021, our intellectual property portfolio includes, on a worldwide basis, 20 pending foreign patent applications relating to NC318, NC410, NC762 and NC525, two pending U.S. patent application relating to NC318, one pending U.S. patent application relating to NC410, two pending U.S. patent applications relating to NC762, one U.S. patent application relating to NC525 and additional pending patent applications for other discovery and research programs. Patents resulting from our patent applications for NC318, NC410 and NC525, if issued, are expected to expire beginning in 2037 absent any patent term adjustments or extensions and for NC762, if issued, are expected to expire beginning in 2039 absent any patent term adjustments or extensions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as described above, under the Yale Agreement, we have an exclusive, royalty-bearing, sublicensable worldwide license from Yale for an intellectual property portfolio, including among other things patent applications relating to methods of use for S15 that covers the use of NC318 and one allowed patent relating to FIND-IO. Any patents from these patent applications, if issued, are expected to expire no earlier than 2036 absent any patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For all patent applications, we determine strategy for claim scope on a case-by-case basis, taking into account advice of counsel and our business model and needs. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, based on our assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position, including with respect to our FIND-IO platform. We seek to protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. In addition, in the ordinary course of our business, we enter into agreements with other third parties for non-exclusive rights to intellectual property directed to other technologies that are ancillary to our business, including laboratory information management software and research and development tools. In addition, we have filed for trademark registration with the U.S. Patent and Trademark Office, or the USPTO, for &#8220;NextCure,&#8221; our logo and our FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation and Product Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The processes for obtaining regulatory approvals in the United States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government policies may change, and additional government regulations may be enacted, that could prevent or delay further development or regulatory approval of any product candidates, product or manufacturing changes, additional disease indications or label changes. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Review and Approval for Licensing Biologics in the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates our current product candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act, or &#8220;FDCA&#8221;, the Public Health Service Act and associated implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal, or microorganism) are complex in structure, and thus are usually not fully characterized. Biologics include immunomedicines for cancer and other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Biologics are also subject to other federal, state and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by the FDA, the FDA&#8217;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, Warning Letters or Untitled Letters, product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice, or the DOJ, or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of non-clinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s good laboratory practice, or &#8220;GLP&#8221;, regulations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, labeling and distribution of investigational drug in compliance with cGMP; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or &#8220;IRB&#8221;, or ethics committee at each clinical site before each clinical trial may be initiated; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current Good Clinical Practices requirements, or &#8220;cGCP&#8221;, to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a biologics license application, or &#8220;BLA&#8221;, after completion of all pivotal clinical trials requesting marketing approval for one or more proposed indications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain satisfactory completion of an FDA Advisory Committee review, where appropriate, as may be requested by the FDA to assist with its review; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or certain components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, safety, quality, purity and potency; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP requirements and the integrity of the clinical data; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees under the Prescription Drug User Fee Act for the relevant year; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with post-approval requirements, including the potential requirements to implement a Risk Evaluation and Mitigation Strategy, or &#8220;REMS&#8221;, adverse event and biological product deviation reporting and to complete any post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Before an applicant can begin testing the potential candidate in human subjects, the applicant must first conduct preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">establish a rationale for therapeutic use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations. The results of an applicant&#8217;s preclinical studies are submitted to the FDA as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment and administration of a biologic that is not subject of an approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA raises safety concerns or questions about the proposed clinical trial within the 30-day time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&#160;days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including cGCP regulations, including review and approval by an independent ethics committee and informed consent from subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or &#8220;DSMB&#8221;. DSMBs provide authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1: The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These trials may also yield early evidence of effectiveness. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2: The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3: The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to generate sufficient data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These phases may overlap or be combined. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials, after a product is approved, to gain more information about the product, referred to as Phase&#160;4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the biological characteristics of the product and treatment of patients in the intended therapeutic indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or <i style="font-style:italic;">in vitro</i> testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes, or &#8220;PROs&#8221;, and outcome reported outcomes, or &#8220;OROs&#8221;, the process typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO and ORO instruments during the clinical development process, the FDA usually reserves final judgment until it reviews the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, nonclinical studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture, controls and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee, currently exceeding $2.8 million for fiscal year 2021, and the manufacturer and sponsor under an approved BLA are also subject to annual program fees, currently $336,432 for each prescription product. These fees are typically increased annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA&#8217;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of the biologic in relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#8217;s request or by the agency&#8217;s initiative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and if the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate and requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety, efficacy and quality of its product or products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA performance goals generally provide for action on a BLA within 10 months of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by the FDA&#8217;s requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, the FDA may issue an approval letter or a Complete Response Letter, or &#8220;CRL&#8221;. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If the deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">condition for approval, including requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied and may require additional testing or information and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the BLA without a REMS that the agency has determined is acceptable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. Biologic manufacturers and their third-party contractors are required to register their facilities with the FDA and certain state agencies. These facilities are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, post-marketing safety reporting and data integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product. FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance and other aspects of regulatory compliance.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products or Import Alert; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug and biological products placed on the market. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#8217;s regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, or &#8220;HHS&#8221;, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil, administrative, and criminal fines, penalties, and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil, administrative, and criminal fines and penalties against companies for alleged improper promotion and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The distribution of prescription drug and biological products are subject to the Drug Supply Chain Security Act, or &#8220;DSCSA&#8221;, which requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension to restore a portion of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as one-half of the product&#8217;s testing phase, which is the time between IND and BLA </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The USPTO, in consultation with the FDA, reviews and approves the application for patent term restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which a BLA has not been submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Marketing Exclusivities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act, or &#8220;BPCIA&#8221;, created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. A biological product on which another biological product candidate&#8217;s BLA relies to establish biosimilarity is known as a reference product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form and strength, and no clinically meaningful differences between the biological product candidate and the reference product in terms of safety, purity and potency. Biosimilarity must be shown through analytical trials, animal trials and at least one clinical trial, unless the Secretary of HHS waives a required element. A biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the process by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biological product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&#160;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&#160;18&#160;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#160;18&#160;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#160;42&#160;months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42&#160;month period. At this time, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a biologic is designated and approved for an orphan indication, it will be granted seven years of orphan drug exclusivity. An orphan indication is granted to biological products and drugs designated and approved to treat diseases or conditions affecting fewer than 200,000 individuals in the United States, or if there is no reasonable expectation that the sponsor will be able to recover the costs of developing and marketing the drug or biological product in the United States. A biosimilar may not be licensed by FDA for the protected orphan indication until after the expiration of the seven-year orphan drug exclusivity period or the 12-year reference product exclusivity, whichever is later.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity adds an additional six-month exclusivity period to any marketing exclusivities and patents that a biological product has obtained. In order to obtain pediatric exclusivity, a BLA sponsor must conduct pediatric studies as requested by the FDA in a Written Request. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. While pediatric exclusivity is not an actual extension on a patent term, it effectively extends the preclusive effect of the patent on FDA&#8217;s authority to approve another application that relies on the product with pediatric exclusivity.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. On December 20, 2019, President Trump signed into law H.R. 1865, the Further Consolidated Appropriations Act of 2020. The law includes significant provisions related to the Trump Administration&#8217;s biosimilars policy framework and FDA&#8217;s implementation of the BPCIA, such as clarifying that &#8220;chemically synthesized polypeptides&#8221; are no longer excluded from being regulated as biologics, while &#8220;peptides&#8221; (polymers composed of 40 or fewer amino acids) will continue to be regulated as drugs unless they otherwise meet the statutory definition of biological products. In addition, the Further Consolidated Appropriations Act of 2020 clarifies exclusivity and procedural issues related to certain biologics approved as drugs pursuant to new drug applications, or &#8220;NDAs&#8221;, to be the subject of an approved BLA, or transition biological products. The law also incorporates provisions intended to reduce price and increase competitiveness in the pharmaceutical industry. The law amends the FDCA to create a private right of action against NDA or BLA holders that refuse to provide sufficient quantities of samples of an approved reference product to generic and biosimilar developers. In July 2018, the FDA released its Biosimilars Action Plan to improve the efficiency of the biosimilar and interchangeable product development and approval process. The Further Consolidated Appropriations Act of 2020 is consistent with FDA guidance documents issued in December 2018 that were intended to advance the agency&#8217;s biosimilars policy framework. The implementation of the Further Consolidated Appropriations Act of 2020 and the ultimate impact of the agency&#8217;s Biosimilars Action Plan are uncertain and may evolve over time through future laws and regulations and guidance provided by regulatory and governing bodies. In addition, other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have been the subject of recent litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulation of Companion Diagnostics and Laboratory Developed Tests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A companion diagnostic is an <i style="font-style:italic;">in vitro</i> diagnostic that can: identify the patients most likely to benefit from a particular therapeutic product; identify those likely to be at an increased risk for serious side effects; or monitor responses to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Under the FDCA, <i style="font-style:italic;">in vitro</i> companion diagnostics are generally regulated as medical devices. The FDA has generally classified <i style="font-style:italic;">in vitro</i> companion diagnostics as high-risk, Class&#160;III devices, which require FDA approval of a premarket approval application, or &#8220;PMA&#8221;, but recognizes the possibility of a moderate-risk IVD companion diagnostic (<i style="font-style:italic;">i.e</i>., Class&#160;II device), which would require clearance of a 510(k) premarket notification or grant of a <i style="font-style:italic;">de novo</i> request. Approval or clearance of the <i style="font-style:italic;">in vitro</i> companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For those <i style="font-style:italic;">in vitro</i> companion diagnostics that require PMA approval, the process involves gathering and submitting clinical and preclinical data on the device for review by the FDA. It involves a rigorous premarket review, during which the applicant must provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, as well as information regarding the device&#8217;s design, manufacturing and labeling. In addition, the FDA will typically inspect the device manufacturer&#8217;s facilities for compliance with the Quality System Regulation, which imposes testing, control, documentation and other quality assurance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has issued guidance on the approval of therapeutic products and <i style="font-style:italic;">in vitro</i> companion diagnostic devices. According to the FDA&#8217;s guidance, for novel therapeutic products including biologics, an <i style="font-style:italic;">in vitro</i> companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In some cases, information from a diagnostic test may be useful to a prescriber, but not necessary for the safe and effective administration of the therapeutic product. In those cases, health care providers may employ information derived from a complementary diagnostic test such as a laboratory developed test, or &#8220;LDT&#8221;, when administering a therapeutic product. An LDT is a type of <i style="font-style:italic;">in vitro</i> diagnostic test that is designed, manufactured and used within a single laboratory. LDTs can be used to measure or detect a wide variety of analytes (substances such as proteins, chemical compounds like glucose or cholesterol, or DNA), in a sample taken from a human body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Centers for Medicare and Medicaid Services, or &#8220;CMS&#8221;, regulates LDTs and the laboratories that develop them, and enforces the Clinical Laboratories Improvement Amendments, or &#8220;CLIA&#8221;. CMS evaluates whether there is clinical utility for each specific test, and also performs post-market oversight of laboratory operational processes. CMS&#8217;s oversight through the CLIA program is designed to confirm that a lab assesses analytical validity but does not confirm whether it had results from an analytical validity assessment that were sufficient to support the claimed intended use of the test.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, the FDA has generally not enforced premarket review and other FDA requirements on LDTs because LDTs were relatively simple lab tests and generally available on a limited basis. Due to advances in technology, however, some LDTs are now much more complex, have a nationwide reach and present higher risks, such as detection of risk for breast cancer and Alzheimer&#8217;s disease, which are similar to those of other IV <i style="font-style:italic;">in vitro</i> diagnostics that have undergone premarket review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has announced that in the future it intends to assert jurisdiction over LDTs and proposed increasing regulatory requirements for LDTs through a risk-based framework. The FDA received considerable resistance to its proposal, and to date generally exercises enforcement discretion with respect to LDTs, leaving responsibility to CMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New laws, regulations or changes to existing laws, regulations and policies may result in changes to the requirements for LDTs or <i style="font-style:italic;">in vitro</i> diagnostic devices and to the FDA&#8217;s compliance and enforcement policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Pharmaceutical Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully commercialize any of our product candidates for which we may receive regulatory approval will depend in significant part on the availability of coverage and reimbursement from third-party payors, including governmental healthcare programs such as the Medicare and Medicaid programs in the U.S.; private health insurers; managed care organizations; and other entities. Though we expect our initial product offering to be covered under Medicare Part B and thus not subject to Medicare Part D formulary requirements, private third-party payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory approval for commercial sale depends on those payors&#8217; coverage policies and reimbursement rates. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our product candidates. Third-party payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and related services, in addition to their cost-effectiveness, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary significantly from payor to payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. We cannot be certain that our product candidates will be considered cost-effective by third-party payors. This process could delay the market acceptance of any product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Other U.S. Healthcare Laws and Compliance Requirements</p><a id="_Hlk59959673"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to operate include but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback or bribe), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arranging for or recommending the purchase, lease, or order of any item or service for which payment may be made, in whole or in part, under federal healthcare programs like Medicare or Medicaid. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other, including, for example, consulting/speaking arrangements, discount and </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rebate offers, grants, charitable contributions, and patient support offerings, among others. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain discounts, or engaging such individuals as speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, the Anti-Kickback Statute safe harbors have been the subject of recent regulatory reforms. In late 2020, the U.S. Department of Health and Human Services Office of Inspector General issued two final rules finalizing significant safe harbor modifications related to (1) value-based and coordinated care arrangements and (2) certain point-of-sale discounts and the existing discount safe harbor, or the &#8220;Rebate Rule&#8221;. Implementation of the Rebate Rule is uncertain due, at least in part, to ongoing litigation and a Congress-passed moratorium on implementation before January 1, 2026. We cannot predict the future of the Rebate Rule, the full impact of the Rebate Rule, if implemented, or subsequent regulatory actions on our operations. As a general matter, however, any changes to the safe harbors may impact our future contractual and other arrangements with pharmacy benefit managers, group purchasing organizations, third-party payors, wholesalers and distributors, healthcare providers and prescribers, and other entities, as well as our future pricing strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or &#8220;FCA&#8221;, which prohibits, among other things: (i) knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent; (ii) knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim; (iii) knowingly making, using or causing to made or used a false record or statement material to an obligation to pay money to the government; or (iv) knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Private individuals, commonly known as &#8220;whistleblowers,&#8221; can bring FCA qui tam actions, on behalf of the government and may share in amounts paid by the entity to the government in recovery or settlement. Pharmaceutical companies have been investigated and/or subject to government enforcement actions asserting liability under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Moreover, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations. Such per-claim penalties are currently set at $11,665 to $23,331 per false claim or statement for penalties assessed after June 19, 2020, with respect to violations occurring after November 2, 2015. Criminal penalties, including imprisonment and criminal fines, are also possible for making or presenting a false, fictitious or fraudulent claim to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Health Insurance Portability and Accountability Act of 1996, or &#8220;HIPAA&#8221;, which, among other things, prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&#160;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation and (ii)&#160;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, the Health Information Technology for Economic and Clinical Health Act, or &#8220;HITECH Act&#8221;, and implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans, healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health information. HIPAA includes several tiers of civil monetary penalties as well as criminal penalties. In addition, state attorneys general have authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. Research institutions that we collaborate with and healthcare providers who may prescribe our products, once commercialized, are subject to privacy and security requirements under HIPAA. The Department of Health and Human Services Office for Civil Rights (OCR) has recently increased its enforcement efforts on compliance with HIPAA, including the security regulations (Security Rule), bringing actions against entities which have failed to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA; </span></td></tr></table><a id="_Hlk59952987"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Numerous other federal and state laws and regulations that also govern the privacy and security of individually identifiable health information, including state data breach notification laws, state health information or genetic privacy laws, and federal and state consumer protection laws such as Section 5 of the Federal Trade Commission, or &#8220;FTC&#8221;, Act and the California Consumer Privacy Act, or &#8220;CCPA&#8221;. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are certain exemptions for personal information subject to HIPAA and personal data collected in a clinical trial context, and the CCPA&#8217;s implementation standards and enforcement practices may increase our compliance costs and potential liability. Additionally, a California ballot initiative, the California Privacy Rights Act, or &#8220;CPRA&#8221;, passed in November 2020, and the majority of the provisions will take effect on January 1, 2023. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Laws similar to the California laws have passed in Virginia and Colorado, and comparable laws have been proposed in other states and at the federal level that may ultimately have conflicting requirements that would further complicate compliance. Meanwhile, the FTC has promulgated standards for fair information practices, which concern consumer notice, choice, security and access, and also require notice of certain health information breaches outside the HIPAA context. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating consumers&#8217; privacy rights, publishing untrue information about security practices, or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. Federal regulators, state attorneys general and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition, some countries are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of research activities. These laws and regulations, as well as any associated claims, inquiries, investigations or any other government actions may lead to unfavorable outcomes including increased compliance costs, delays or impediments in the development of new products, negative publicity, </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating costs, diversion of management time and attention and remedies that harm our business, including fines or demands or orders that we modify or cease existing business practices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Physician Payments Sunshine Act, implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Analogous U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States there have been and continue to be a number of healthcare-related legislative and regulatory initiatives and reforms that have significantly affected the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the &#8220;ACA&#8221;, was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacted the U.S. pharmaceutical industry. Among other things, the ACA: subjects biologics to potential competition by lower-cost biosimilars; addresses a methodology through which rebates owed by manufacturers under the Medicaid Drug Rebate Program, or &#8220;MDRP&#8221;, are calculated for covered outpatient drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the MDRP and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a Medicare Part D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part D, manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ACA and certain of its provisions have been subject to judicial challenges as well as legislative and regulatory efforts to repeal or replace them or to alter their interpretation or implementation. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the &#8220;Tax Act&#8221;, includes a provision that repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual mandate.&#8221; The Bipartisan Budget Act of 2018, among other things, amended the ACA to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. CMS rules issued in 2018 permit further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program. The Further Consolidated Appropriations Act of 2020 fully repealed the ACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high-cost employer-sponsored insurance plans and, effective in 2021, the annual fee imposed on certain health insurance providers based on market share. On January 28, 2021, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. Most recently, on March 11, 2021, Congress enacted the American Rescue Plan Act of 2021, which included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; MDRP rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in MDRP rebates than it receives on the sale of certain covered outpatient drugs. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the ACA for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. In the future, there may be additional challenges and/or amendments to the ACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it will have on the availability and cost of healthcare items and services, including drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the United States District Court for the Northern District of Texas ruled that the individual mandate is (i) unconstitutional as a result of the associated tax penalty being repealed by Congress as part of the Tax Act and (ii) not severable from the rest of the ACA, and that as a result the entire ACA is invalid. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court&#8217;s decision that the individual mandate is unconstitutional but remanded the case to the district court to reconsider the severability question. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020. On June 17, 2021, the Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, several recent U.S. Congressional inquiries and proposed and enacted pieces of federal and state legislation and regulation have been designed to, among other things: bring more transparency to drug pricing; reduce the cost of prescription drugs under government payor programs; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, included in the Consolidated Appropriations Act, 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the Departments of Health and Human Services, Labor and the Treasury. Policymakers have also indicated that they will continue to seek legislative and administrative measures to control drug costs. For example, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drugs, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, the Department of Health and Human Services issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, in May 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends upon our ability to retain and attract highly qualified management and technical personnel. As of December 31, 2021, we had 87 full-time employees, with 61% male and 39% female. Our workforce represents diverse racial and ethnic backgrounds with the following self-identified groups among our employees: 46% White, 25% Asian, 20% Black/African American and 9% Hispanic/Latino.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects. Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success, and competition for skilled personnel is intense and the turnover rate can be high in our industry. We have historically addressed the turnover we have encountered and grown our headcount in support of our expanding pipeline of research programs and product candidates, but we continue to monitor our turnover rate and the overall supply of skilled labor in the market. We also monitor our compensation programs closely and provide what we consider to be a competitive mix of compensation and benefits for our employees, as well as participation in our equity programs. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Corporate Information and Access to SEC Reports</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in September 2015. Our primary executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705 and our telephone number is (240) 399-4900. We make available, free of charge, on our website at <i style="font-style:italic;">www.nextcure.com</i>, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. The contents of our website are not incorporated into this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9897166e_a7f8_4648_80fa_5d4523af07ed"></a><a id="Item1ARiskFactors_446956"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all of the other information in this Annual Report, including our financial statements and the related notes and the information described in the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. If any of the events described below actually occurs, our business, results of operations, financial conditions, cash flows or prospects could be harmed. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history. Since our founding in 2015, we have incurred significant net losses. Our net losses were $69.4 million and $36.6 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $187.0 million. We have funded our operations to date primarily with proceeds from public offerings of our common stock, private placements of our preferred stock and upfront fees received under the Lilly Agreement, which was terminated effective March 2020. Since commencing operations, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and development activities for our product candidates, our discovery programs and our FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that it will be several years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from year to year. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to advance the preclinical and clinical development of our existing product candidates and our research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our FIND-IO platform to advance additional product candidates into preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our cGMP manufacturing capacity, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including to provide drug supply for future clinical trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory, scientific and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a marketing, sales, distribution and medical affairs infrastructure to commercialize any products for which we may obtain marketing approval and commercialize, whether on our own or jointly with a partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other technologies or engage in strategic partnerships; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting or other expenses in operating our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To become and remain profitable, we, whether on our own or jointly with any potential future collaborator, must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never generated revenue from product sales and may never be profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, or our potential future collaborators&#8217;, success in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing preclinical studies and clinical trials of our product candidates, including our ongoing Phase 1/2 clinical trials for NC318, NC410 and NC762;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining marketing approvals for any product candidates that we or our collaborators develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receiving acceptance of INDs for future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and developing new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing product candidates for which we obtain marketing approval by establishing a marketing, sales, distribution and medical affairs infrastructure or, alternatively, collaborating with a commercialization partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving coverage and adequate reimbursement by hospitals and third-party payors, including governmental authorities, such as Medicare and Medicaid, private insurers and managed care organizations, for product candidates, if approved, that we or our collaborators develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing cGMP supply of our product candidates for clinical trials and, if approved, commercial sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of product candidates, if approved, that we develop as viable treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defending against third-party interference or infringement claims, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate incurring significant costs associated with commercializing any product candidate that is approved for commercial sale. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. If we receive marketing approval for any product candidates, including NC318, NC410, NC762 or NC525, we will require significant additional amounts of cash in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and outcomes of our planned and anticipated clinical trials are highly uncertain, we </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cannot reasonably estimate the actual amounts necessary to successfully complete the development of and commercialize any product candidate we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, results and costs of researching and developing NC318, NC410, NC762, NC525 and our other product candidates, including targets identified through our FIND-IO platform, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining marketing approval for NC318, NC410, NC762, NC525 and any future product candidates we develop, if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing NC318, NC410, NC762, NC525 and any future product candidates for preclinical studies and clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including marketing, sales and distribution costs, for NC318, NC410, NC762, NC525 and any future product candidates we develop, whether alone or with a collaborator, if any of these product candidates are approved for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing therapies and other developments in the oncology market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. As of December 31, 2021, we had $219.6 million in cash, cash equivalents (excluding restricted cash) and marketable securities. Based on our research and development plans, we expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2024. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur that are within or beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates and changes in regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional capital through marketing, sales and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue streams, research programs or technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Discovery and Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As an organization, we have limited experience designing and implementing clinical trials, and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. For example, in December 2020, we announced that the initial selection criterion for our Phase 1/2 trial in NC318 did not result in enough S15-positive patients for us to effectively evaluate the activity of NC318 in S15-positive tumors, and that as a result we are modifying the Phase 2 portion of the trial for S15 selection. Also, in our NC318 trial, we are continuing to evaluate alternate doses and dose administration schedules depending on pharmacokinetics, pharmacodynamics, biomarker data, safety results and feedback from investigators. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. If we select an incorrect dose or dose administration schedule, that could negatively impact the results of the trial, including if we select doses that are too low to be effective or administer doses too infrequently based on the half-life of the active ingredient. We also expect to continue to rely on third parties to conduct our pivotal clinical trials (see &#8220;Risks Related to Reliance on Third Parties&#8221;). We rely, or will rely, on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for NC318, NC410, NC762, NC525 and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize NC318, NC410, NC762, NC525 and any future product candidates we develop, and our business could be materially harmed. Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for BLA submission and FDA approval of NC318, NC410, NC762, NC525 or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The impacts of the COVID-19 pandemic could continue to adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel, and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities, including clinical trial sites. The impacts of COVID-19 initially placed significant strain on our clinical trial sites, raised concerns around monitoring patient safety, slowed patient enrollment and caused delays in our clinical trials and issuance of results. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect our clinical trial going forward. We are continuing to work closely with our clinical partners and have taken steps as necessary to adjust our protocols and timelines due to the impact of the COVID-19 pandemic. The impacts of the COVID-19 pandemic could adversely affect our clinical trials and operations in other ways as well. For example, challenges may arise as a result of patients, members of the clinical team, or our employees becoming infected with COVID-19 or otherwise unable or unwilling to participate in trials or come to work, as applicable, as a result of COVID-19, interruptions to the supply chain or manufacturing, site closures, or difficulties in meeting protocol-specified procedures, including difficulties adhering to protocol-mandated visits and testing. The COVID-19 pandemic may also increase the likelihood and severity of other risks discussed in the &#8220;Risk Factors&#8221; section of this Annual Report, including but not limited to risks related to the conduct, progress and outcomes of clinical trials, risks related to reliance on third parties, risks related to our operations and dependence on key personnel, and risks related to our need to obtain additional capital.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic and its impacts continue to evolve, including the emergence of variant strains of the COVID-19 virus. Although vaccines are now available are being distributed globally, we cannot predict the full scope, duration and severity of disruptions resulting from COVID-19 or their impacts on us. Business disruptions for us or the third parties with whom we engage, including the collaborators, contract organizations, third-party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom we conduct business could materially and negatively impact our ability to conduct our business in the manner and on the timelines presently planned. The extent to which the COVID-19 pandemic may impact our business and financial performance will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope and duration of the pandemic and the extent and effectiveness of government restrictions, relief measures and other actions implemented to address the impact of the pandemic, and resulting economic impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts. We initiated our first clinical trial for NC318, our lead product candidate, in October 2018, our first clinical trial for our second product candidate, NC410, in June 2020, and our third product candidate, NC762, in July 2021. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of NC318, NC410, NC762 and any future product candidates we develop, which may never occur. Our current product candidates and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient cGMP manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical and commercial success of our current and future product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies and our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs for any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers, if needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our compliance with any post-approval requirements imposed on our products, such as post-marketing studies, a REMS or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost-prohibitive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing effectively with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify targets and immunomedicines, whether through our FIND-IO platform, through our relationship with Yale or otherwise; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that NC318, NC410, NC762, NC525 or any future product candidates we develop will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate. Neither we nor any future collaborator is permitted to market any biological product in the United States until we or the future collaborator receives regulatory approval of a BLA from the FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval from the FDA or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe, pure and potent for its proposed indication;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from current or future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we request, may grant approval contingent on the performance of costly clinical trials, development of an <i style="font-style:italic;">in vitro</i> companion diagnostic, or other post-marketing requirements, or may approve a product candidate with a label that does not include the labeling claims we believe are necessary or desirable for the successful commercialization of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities may change their policies, promulgate additional regulations, revise existing regulations or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take many years to complete, and its outcome is highly uncertain. Failure can occur at any time during the clinical trial process, and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing our planned clinical trials and development efforts. Additionally, we cannot be certain the ongoing and planned preclinical studies or clinical trials for NC318, NC410, NC762, NC525 or any future product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. For example, we have modified the Phase 2 portion of our ongoing Phase 1/2 clinical trial of NC318 for S15 selection, and clinical sites can select for S15-positive patients through screening biopsies in a Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;)-certified laboratory, which we anticipate will allow us to assess response rates in patients selected for S15. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results from preclinical studies or clinical trials may not be predictive of results from later clinical trials of any product candidate;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities, IRBs or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements on us, before permitting us to initiate a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or &#8220;CROs&#8221;, as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidate may fail to show safety, purity or potency, or may produce negative or inconclusive results, which may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials may be larger than we anticipate or we may have difficulty in recruiting and enrolling patients to participate in clinical trials, including as a result of the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease, competition from other clinical trial programs for similar indications and clinical trial subjects and the impact of public health emergencies, such as the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it may be difficult to enroll a sufficient number of patients, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of our product candidates could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical development or receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply, quality or timeliness of delivery of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or third parties on whom we are dependent, may suffer business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters and public health emergencies, such as the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We could encounter delays if a clinical trial is suspended or terminated by us, or by the IRBs of the institutions in which such trials are being conducted, ethics committees or the DSMB for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. The FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. In addition, factors outside our control, such as government shutdowns, natural disasters and public health emergencies such as the COVID-19 pandemic, could disrupt business at the FDA or other regulatory authorities, which could result in delays of reviews, approvals and communications with regulatory authorities related to our clinical trials and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. Any such events would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With the exception of NC318, NC410, and NC762, all of our product candidates are still in the preclinical stage, and the risk of failure for such product candidates is high. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain programs that are the responsibility of our potential future collaborators over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not limited to:</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to generate sufficient preclinical or other </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> data to support the initiation of clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on study design; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA not permitting the reliance on preclinical or other data from published scientific literature.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, notwithstanding the durable responses initially observed in our ongoing Phase 1/2 clinical trial of NC318 in NSCLC, we announced in July 2020 that based on additional clinical response data we would not be advancing the NSCLC cohort into the stage 2 portion of the Simon 2-stage trial. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because the numbers of subjects in our Phase 1/2 clinical trials of NC318, NC410 and NC762 are small, the results from each of these trials, once completed, may be less reliable than results achieved in larger clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A study design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes, such as our ongoing Phase 1/2 clinical trials of NC318, NC410 and NC762, can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the results across a broader community, thus making the study results less reliable than studies with a larger number of subjects and making it difficult to predict final results from preliminary results. As a result, there may be less certainty that NC318, NC410, and NC762 would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of NC318, NC410, or NC762, we may not achieve a statistically significant result or the same level of statistical significance seen, if any, in our Phase 1/2 clinical trials. Similarly, if we conduct a clinical trial of any other product candidate we develop with a small sample size, the results of any such trial may be less reliable than results achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects in any future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our approach to the discovery and development of product candidates using our FIND-IO platform is unproven and may not result in marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The success of our business depends in part upon our ability to identify targets based on our proprietary FIND-IO platform and to develop and commercialize immunomedicines. Our approach to the discovery of targets using the FIND-IO platform is novel. We have not yet initiated or completed a clinical trial of any product candidate developed for a target identified from the FIND-IO platform. The platform may fail to accurately identify targets that modulate the immune system and are appropriate for immunomedicines. Even if we are able to identify targets from the FIND-IO platform and to develop corresponding product candidates, we cannot assure that such product candidates will achieve marketing approval to safely and effectively treat cancer or other disease states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we uncover any previously unknown risks related to our FIND-IO platform, or if we experience unanticipated problems or delays in developing our FIND-IO product candidates, we may be unable to achieve our strategy of building an oncology pipeline of novel targets for new immunomedicines focused on non-responders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most biologics, use of our current or future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. There have been serious adverse side effects reported in response to immunotherapies in oncology. </p><a id="_Hlk60865746"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events experienced by more than 5% of patients in the Phase 1 portion of the Phase 1/2 clinical trial of NC318 as of December 17, 2020 were diarrhea, infusion reactions, fatigue, headaches, pruritis, elevated amylase and elevated lipase. Most treatment-related adverse events in the Phase 1/2 clinical trial were easily manageable, asymptomatic or mild or moderate, with the exception of one case of grade 3 episcleritis/uveitis that resolved after steroid therapy and two cases of grade 3 pneumonitis. In the Phase 2 portion of the trial, the only observed severe or higher-grade TRAE as of that date was a grade 3-4 infusion reaction in one patient. Immune-related adverse events that represent immune effects on normal tissue and can result from misdirected stimulation of the immune system are a common class of toxicity in immunomedicines such as NC318. Immune-related adverse events reported in the Phase 1 portion of the Phase 1/2 clinical trial of NC318 included diarrhea, elevated amylase and lipase, pruritis, episcleritis/uveitis, pneumonitis and vitiligo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Possible adverse side effects that could occur with treatment with immunomedicines include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. In addition to any potential side effects caused by the product or product candidate, the administration process or related procedures also can cause adverse side effects. If unacceptable adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although our current and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Immunomedicines and their method of action of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that NC318, NC410, NC762, NC525 or any other product candidate is safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are studying NC318 in combination with other therapies and may develop NC410, NC762, NC525 and future product candidates in combination with other therapies, which exposes us to additional risks relating to undesirable side effects or other properties. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for testing or commercial use with any of our approved products. The other therapies we may use in combination with our product candidates may also be supplanted in the market by newer, safer or more efficacious products or combinations of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we successfully advance one of our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS or create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues, which would materially harm our business. In addition, if one or more of our product candidates or our immunotherapeutic development approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would also materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If there are continued difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. For example, we experienced a slowdown of enrollment in our ongoing clinical trials as a result of the COVID-19 pandemic. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature and size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and location of participating clinical sites or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of competing commercially available therapies and other competing drug candidates&#8217; clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient informed consents for participation in our clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">factors outside of our control, including as a result of business interruptions resulting from natural disasters and public health emergencies, such as the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays from difficulties in patient enrollment in a clinical trial may result in increased costs or affect the timing, outcome or completion of the trial, which could delay or prevent our receipt of regulatory approval of the applicable product candidate or to abandon the trial altogether.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the FDA&#8217;s current cGCP or analogous requirements of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical committees at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or study protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the clinical trial operations or trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen adverse side effects or the emergence of undue risks to study subjects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the trial design necessary to demonstrate efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may not appear to offer benefits over current therapies; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality or stability of the product candidate may fall below acceptable standards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have chosen to prioritize development of NC318, NC410, NC762 and NC525. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on other candidates or indications for which there may be a greater likelihood of success or may be more profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited resources, we have strategically determined to prioritize development of NC318, NC410, NC762 and NC525 rather than other product candidates based, in part, on the significant resources required for developing and manufacturing immunomedicines. To date, no regulatory authority has granted approval for an immunomedicine targeting S15, the LAIR pathway or B7-H4. As a result, we may be foregoing other potentially more profitable immunomedicines or therapies or those with a greater likelihood of success. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties with respect to, certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our current or future product candidates or misread trends in the oncology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to develop, or enter into a collaboration or partnership to develop, complementary or companion diagnostics for our current or future product candidates. If we, or our future collaborators, are unable to successfully develop complementary or companion diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the key elements of our product development strategy is to identify cancer patient populations that may derive meaningful benefit from our current or future product candidates. Because predictive biomarkers are being and may be used to identify the right patients for current or future product candidates, we believe that our success may depend, in part, on our ability to develop complementary or companion diagnostics in collaboration with partners. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited experience in the development of diagnostics and, as such, we may rely in part on future collaborators in developing appropriate diagnostics to pair with our current or future product candidates. We have not yet begun substantial discussions with any potential partners with respect to the development of complementary or companion diagnostics and may be unsuccessful in entering into collaborations for the development of any such diagnostics for our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companion diagnostics are subject to regulation by the FDA and similar comparable foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization. Complementary diagnostics may be subject to regulation by CMS or the FDA and similar comparable foreign regulatory authorities and may require separate regulatory approval or clearance prior to commercialization. Gaining regulatory approval could be time consuming and costly and could delay regulatory approval of the related product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our collaborators may encounter difficulties in developing such tests, including issues relating to the selectivity or specificity of the diagnostic, analytical validation, reproducibility or clinical validation. If we, our collaborators, or any third parties that we engage to assist us, are unable to successfully develop complementary or companion diagnostics for our current or future product candidates or experience delays in doing so: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of our current or future product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not realize the commercial potential of our current or future product candidates if, among other reasons, we are unable to appropriately identify, or it takes us longer to identify, patients who are likely to benefit from therapy with our products, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of these events were to occur, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Regulatory Approval and Commercialization of Product Candidates and Other Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to obtain FDA approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To gain approval to market our product candidates in the United States, we must provide the FDA with clinical data that adequately demonstrate the safety, purity and potency, including efficacy, of the product candidate for the proposed indication or indications in a BLA submission. Product development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, marketing, sale and distribution of biological products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate to the satisfaction of the FDA or a comparable foreign regulatory authority that our product candidates are safe and effective for the requested indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s disagreement with our trial protocol or the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate that the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s requirement for additional preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s non-approval of the formulation, labeling, or specifications of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable regulatory authority&#8217;s failure to approve our manufacturing processes and facilities or the manufacturing processes and facilities of third-party manufacturers upon which we rely; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential for approval policies or regulations of the FDA or a comparable foreign regulatory authority to significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we eventually complete clinical testing and receive approval from the FDA or comparable foreign regulatory authorities for any of our product candidates, the FDA or comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or comparable foreign regulatory authorities also may approve any of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or comparable foreign regulatory authorities may not approve any of our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of any such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#8217; approval processes and are commercialized. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, current approved immunotherapies, and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. Our approach to targeting different components of the TME is novel and unproven. In addition, adverse events in clinical trials testing our product candidates or in clinical trials of others developing similar product candidates and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for our current or future product candidates. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our immunomedicines or our competitors&#8217; products, our products may not be accepted by the general public or the medical community. Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our current and any future product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our current and any future product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and potential advantages compared to alternative treatments, including those that are not yet approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our products, if approved, for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing, sales and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as a combination therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory approval and adoption of a companion or complementary diagnostic, if needed or advisable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the United States and any other jurisdiction for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We may initially seek approval for NC318, NC410, NC762, NC525 and any other product candidates we develop as second- or third-line therapies. If we do so, for those products that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The number of patients who have the types of cancer we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are studying NC318 in combination with other therapies and may develop NC410, NC762, NC525 and future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are studying NC318 in combination with pembrolizumab and may develop NC410, NC762, NC525 and future product candidates in combination with one or more currently approved cancer therapies. These combinations have not been tested before and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, or may fail to demonstrate sufficient safety </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any of these approved therapeutics. Therefore, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate NC318, NC410, NC762, NC525 or any future product candidate in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell NC318, NC410, NC762, NC525 or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the biologics we choose to evaluate in combination with NC318, NC410, NC762, NC525 or any product candidate we develop, we may be unable to obtain approval of or market any such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, adverse event and deviation reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and cGCP, for any clinical trials that we may conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers&#8217; manufacturing processes or facilities, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of, or imposition of restrictions on, the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warning Letters or Untitled Letters, or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved biologics licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent injunctions and consent decrees including the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials and other components required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in manufacturing our product or product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development and commercialization timelines and our business, financial condition, results of operations and prospects and could adversely affect our ability to meet our supply obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, an approved product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm&#8217;s product communication is consistent with the FDA-required labeling for that product, and those factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted, that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of our current and future product candidates in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on data and our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are dependent on our information technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, personal information, protected health information and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to maintain data security and data integrity of such information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. If we or our vendors fail to comply with applicable data privacy laws, or if the legal mechanisms we or our vendors rely upon for the transfer of personal data are ever deemed inadequate, or if we or our vendors experience a data breach resulting in exposure of personal data subject to the applicable laws, we could be subject to government enforcement actions and significant penalties against us, criminal and civil liability for us and our officers and directors, private litigation or adverse publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, phishing, persons inside our organization or persons with access to systems inside our organization. We and our third party service providers regularly defend against, respond to and mitigate risks from data security incidents. The risk of a security breach or disruption or data loss, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs, ransomware and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including HIPAA and its implementing regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. We may need to expend significant resources and make significant capital investment to protect against security breaches or to mitigate the impact of any such breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The availability of coverage and adequacy of reimbursement by third-party payors, including managed care plans, governmental healthcare programs, such as Medicare and Medicaid and private health insurers is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by third-party payors will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or not to separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully commercialize any product candidate, whether as a single agent or combination therapy, will also depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our current and future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, third-party payors are increasingly challenging prices charged for pharmaceutical and biological products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These third-party payors may deny or revoke the reimbursement status of our product candidates, if approved, or establish prices for our product candidates at levels that are too low to enable us to realize an appropriate return on our investment. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products, especially novel products like our immunomedicines. To date, no regulatory authority has granted approval for an immunomedicine targeting S15, the LAIR pathway or B7-H4. The Medicare and Medicaid programs are increasingly used as models in the United States for how private third-party payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exist among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement can change, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if we or our collaborators develop companion diagnostic tests for use with our product candidates, we, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. While we and our collaborators have not yet developed any companion diagnostic test for our product candidates, if we or our collaborators do, there is significant uncertainty regarding the ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Moreover, a primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts reimbursed for </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">medical products. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if coverage and reimbursement are available, we cannot be sure as to the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted healthcare legislation, changes in healthcare law and implementation of regulations, as well as changes in healthcare policy, may increase the difficulty and cost for us to commercialize our product candidates, may impact our business in ways that we cannot currently predict, could affect the prices we may set, and could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biologics to potential competition by lower-cost biosimilars, addresses a methodology by which rebates owed by manufacturers under the MDRP are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the MDRP and extends the rebate program to individuals enrolled in Medicaid managed care organizations, and establishes annual fees and taxes on manufacturers of certain branded prescription drugs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ACA and certain of its provisions have been subject to judicial challenges as well as legislative and regulatory efforts to repeal or replace them or to alter their interpretation or implementation. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Act included a provision that repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; The Bipartisan Budget Act of 2018, among other things, amended the ACA to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Also, in 2018, CMS issued final rules permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. The Further Consolidated Appropriations Act of 2020 fully repealed the ACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high cost employer-sponsored insurance plans and, effective in 2021, the annual fee imposed on certain health insurance providers based on market share. On January 28, 2021, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. Most recently, on March 11, 2021, Congress enacted the American Rescue Plan Act of 2021, which included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; MDRP rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in MDRP rebates than it receives on the sale of certain covered outpatient drugs. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the ACA for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. In the future, there may be additional challenges and/or amendments to the ACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it will have on the availability and cost of healthcare items and services, including drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2018, the United States District Court for the Northern District of Texas ruled that the individual mandate is (i) unconstitutional as a result of the associated tax penalty being repealed by Congress as part of the Tax Act </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and (ii) not severable from the rest of the ACA, and that as a result the entire ACA is invalid. In December 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court&#8217;s decision that the individual mandate is unconstitutional but remanded the case to the district court to reconsider the severability question. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020. On June 17, 2021, the Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other healthcare-related legislative and regulatory initiatives and reforms have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for automatic spending reductions under certain circumstances. A Joint Select Committee on Deficit Reduction tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021 was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reductions. In conjunction with the operation of subsequently enacted law, this has resulted in aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year into 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a subsequent reduction to 1% from April 1, 2022 until June 30, 2022, unless Congress takes additional action. The American Taxpayer Relief Act of 2012, which was signed into law in January 2013, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, beginning in 2018, CMS has maintained a reduced rate of payment under the Medicare outpatient prospective payment system and ambulatory surgical center payment system for certain separately payable drugs or biologics acquired under the 340B Drug Pricing Program, and a CMS indicated in a recent rule that it will continue to consider setting an even lower payment rate based on collected hospital survey data. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidate we develop or complementary or companion diagnostics or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation and regulation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, on November 20, 2020, CMS issued an interim final rule that implemented a mandatory &#8220;Most Favored Nation&#8221; demonstration model to test reimbursement of drugs or biologicals under Medicare Part B based on international reference prices, though the final rule is currently subject to a nationwide preliminary injunction. Additionally, included in the Consolidated Appropriations Act, 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the Departments of Health and Human Services, Labor and the Treasury. Policymakers have also indicated that they will continue to seek legislative and administrative measures to control drug costs. For example, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drugs, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, the Department of Health and Human Services issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which the U.S. federal government covers particular healthcare products and services and could limit the amounts that the U.S. federal government will pay for healthcare products and services. This could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment amounts by third-party payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, in May 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our relationships with customers, third-party payors and others may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal and state healthcare laws and regulations that may affect our ability to operate include, but are not limited to, those described in &#8220;Business&#8212;Government Regulation&#8212;Healthcare Regulation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our business arrangements with third parties comply with applicable healthcare laws, as well as responding to investigations by government authorities, can be time and resource consuming and can divert management&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil and administrative sanctions, including exclusion from government funded healthcare programs. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to operate our business and our financial results.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is heavily regulated and therefore involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or &#8220;FCPA&#8221;. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. In particular, our operations will be subject to FCPA, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could also result in prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Given our limited operating history, our manufacturing experience as an organization and with our manufacturing facility is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing is a critical component of our approach to developing immunomedicines and we have invested significantly in our manufacturing facility. We currently manufacture our product candidates for preclinical and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing drugs for clinical trials and for commercial sale is subject to oversight by the FDA to ensure compliance with cGMP and by other regulatory authorities under other laws, regulations and standards. We cannot assure you that we can successfully manufacture our products in compliance with cGMP and with any other applicable laws, regulations and standards in sufficient quantities for clinical trials or for commercial sale, or in a timely or economical manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facility requires specialized personnel and is expensive to operate and maintain. Validation is an ongoing process that must be maintained to allow us to manufacture under cGMP guidelines. We cannot guarantee that our facility will remain in compliance with cGMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing pharmaceutical products is a highly complex process in which a variety of difficulties may arise from time to time. We are currently the sole manufacturer of NC318, NC410, NC762 and NC525 and if anything were to interfere with our continuing manufacturing operations in our facility, it could materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to develop sufficient manufacturing capacity and experience, whether internally or with a third party, or fail to manufacture our product candidates economically or on reasonable scale or volumes, or in accordance with cGMP, our development programs and commercialization of any approved products will be materially adversely affected. This may result in delays in commencing or continuing our clinical trials for NC318, NC410, NC762 or NC525. Any such delays could materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing and, if approved, commercializing our product candidates<span style="font-style:normal;font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. Currently, our product candidates are manufactured in small quantities for use in various preclinical studies and our ongoing Phase 1/2 clinical trials of NC318, NC410 and NC762. We intend to expand our manufacturing capacity, including to provide drug supply of NC318 for future clinical trials, which will require us to incur significant expenses. If one or more of our product candidates progress to late-stage development, we may incur additional significant expenses in the further expansion or construction of manufacturing facilities and increases in personnel in order to manufacture product candidates in sufficient quantities. We cannot assure you that we will be able to successfully manufacture product candidates at a larger scale in a timely or economical manner, or at all. If we are unable to successfully increase our manufacturing scale or capacity, the development, testing and clinical trials of our current or future product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The loss of our third-party manufacturing partners or our, or our partners&#8217;, failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we currently manufacture our product candidates for preclinical and clinical trials, certain elements of manufacturing, including Master Cell Bank manufacturing and fill-finish services, take place at qualified third-party contract manufacturing organizations, or CMOs. If approved, commercial supply of NC318, NC410, NC762, NC525 and any future product candidates may be manufactured at a CMO or CMOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The facilities used by our CMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing process at our CMOs and are completely dependent on them for compliance with current regulatory </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">requirements. If we or our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for manufacturing elements of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for manufacturing our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, our CMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our CMOs were to encounter any of these difficulties, our ability to provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of manufacturing immunomedicines, including our product candidates, is complex, time-consuming, highly regulated and subject to several risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, including due to restrictions on the movement of people or goods, natural disasters, public health emergencies, power failures, other business disruptions and numerous other factors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are larger than we are. In addition, COVID-19 has disrupted global supply chains, including pharmaceutical and medical supply chains. We cannot be certain that our suppliers will continue to provide us with the quantities of the raw materials that we require or satisfy our anticipated specifications and quality requirements whether due to our size, COVID-19, or </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">otherwise. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have filed patent applications for our lead product candidates, but no patent has yet issued from these applications. If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and technology that are important to our business. No patent has yet issued from our patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates or that effectively prevent others from commercializing competitive technologies and product candidates. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file&#160;a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the USPTO, to determine who has the right to the claimed subject matter in the applications. Similarly, if our patent applications are challenged in a derivation proceeding, the USPTO may hold that a third-party is entitled to certain patent ownership rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products that do not infringe our patents.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates. If we breach our obligations under this agreement, the agreement could be terminated, which would adversely affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a party to a license agreement with Yale pursuant to which we in-license patents and technology for certain of our product candidates. This license imposes various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these and other obligations or otherwise materially breach this license agreement, Yale may have the right to terminate the license. If this agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates or products covered by the agreement, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents or applications and any patent rights we own or may own in the future. We rely, in part, on our outside counsel or our licensing partners to pay these fees due to the USPTO and to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are and could remain less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations and prospects may be adversely affected.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability were met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the &#8220;America Invents Act&#8221;, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&#160;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also included a number of significant changes that affected the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes</i> review and derivation proceedings. Additional changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or the patents of our licensors, or we may be required to defend against claims of infringement. Countering infringement or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop or license.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <i style="font-style:italic;">inter partes</i> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents, including portions of our FIND-IO platform. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including post grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of our, or our licensors&#8217;, patents or other proprietary or intellectual property rights. A third party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. We also seek to preserve the integrity and confidentiality of our trade secrets by other means, including maintaining physical security of our premises and physical and electronic security of our information technology systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. For example, in 2020, a lawsuit was filed against our Chief Executive Officer alleging that he breached contractual and fiduciary duties to a third party by, among other things, improperly utilizing confidential information to benefit the Company&#8217;s business, including with respect to our discovery efforts. While the original complaint was voluntarily dismissed by the plaintiffs, there can be no assurance that the same or similar claims may not be brought against our Chief Executive Officer or us. If we fail in defending claims of misappropriation and similar claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file&#160;a patent for certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for NC318, NC410, NC762, NC525 and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize NC318, NC410, NC762, NC525 and any future product candidates we develop, and our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently do not have the ability to independently conduct preclinical studies that comply with GLP requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, including cGCP, or requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and cGCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our cGCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and cGCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as 10&#160;days&#8217; prior written notice. Some of these agreements may also be terminated by such third parties under certain other circumstances. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, including as a result of natural disasters or public health emergencies such as the COVID-19 pandemic, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and cGCP, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may depend on Yale or other third-party collaborators for the discovery, development and commercialization of certain of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our collaborations pose, and potential future collaborations involving our product candidates may pose, the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other intellectual property proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective March 3, 2020, Lilly terminated the Lilly Agreement, which was focused on using our FIND-IO platform to identify novel oncology targets for additional research and drug discovery by ourselves and Lilly. The termination of the Lilly Agreement prevented us from receiving future research and development support payments, option exercise fees, development and regulatory milestone payments, sales milestone payments or royalties under the agreement. In the event a present or future collaborator terminates their agreement with us, we would be prevented from receiving the benefits of any such agreement, which could have a materially adverse effect on our results of operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees, and we do not have &#8220;key person&#8221; insurance on them. The loss of the services of one or more of our executive officers or of certain members of our SAB could impede the achievement of our research, development and commercialization objectives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success. We have observed an increasingly competitive labor market. Increased employee turnover and changes in the availability of our workers could result in increased costs. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our current or future product candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA or other regulatory approval or discovering, developing and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may obtain FDA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Our competitors may also develop drugs or discovery platforms that are more effective, more convenient, more widely used or less costly than our product candidates or our FIND-IO platform or, in the case of drugs, have a better safety profile than our product candidates. These competitors may also be more successful than us in manufacturing and marketing their products and have significantly greater financial resources and expertise in research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217; Yervoy, and PD-1/PD-L1, such as BMS&#8217; Opdivo, Merck&#160;&amp;&#160;Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T-cell-engager immunotherapies, such as Amgen&#8217;s Blincyto. Companies are also developing treatments targeting the Siglec family of proteins, such as Celldex Therapeutics and Palleon Pharmaceuticals, both of which are currently engaged in preclinical studies. In addition, numerous compounds are in clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience (see &#8220;Business&#8212;Competition&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our current and future product candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As our development plans and strategies develop, we expect to need additional managerial, operational, marketing, sales, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively, including the clinical and FDA review process for NC318, NC410, NC762 and any future product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance and our ability to advance development of and, if approved, commercialize NC318, NC410, NC762, NC525 and any future product candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize NC318, NC410, NC762, NC525 and any future product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish marketing, sales and distribution capabilities for NC318, NC410, NC762, NC525 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have sales or marketing infrastructure. To achieve commercial success for NC318, NC410, NC762, NC525 and any other product candidate for which we may obtain marketing approval, we will need to establish a sales and marketing organization. In the future, we expect to build a focused sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own marketing, sales and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to market our products on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians in order to educate physicians about our product candidates, once approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish our own marketing, sales and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we had developed such capabilities ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish marketing, sales and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidate we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of trial participants; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of clinical trial sites or entire trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial subjects or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidates that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><a id="_Hlk15053360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. As of December 31, 2021, we had federal and state net operating loss carryforwards of $160.9 million and $163.4 million, respectively. Certain federal and state net operating loss carryforwards will begin to expire, if not utilized, by 2036. Limitations imposed by the applicable jurisdictions on our ability to utilize net operating loss carryforwards could cause income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause such net operating loss carryforwards to expire unused, in each case reducing or eliminating the benefit of such net operating loss carryforwards. Furthermore, we may not be able to generate sufficient taxable income to utilize our net operating loss carryforwards before they expire. If any of these events occur, we may not derive some or all of the expected benefits from our net operating loss carryforwards. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other forms of severe hazards in the United States or in other countries in which we or our suppliers or manufacturers operate or are located could adversely affect our operations and financial performance. These types of unexpected events could result in physical damage to and complete or partial closure of one or more of the manufacturing facilities operated by our contract manufacturers, or the temporary or long-term disruption in the supply of products, and/or disruption of our ability to deliver products to customers. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations, our business, results of operations and stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to meet investor and stakeholder expectations regarding environmental, social and corporate governance, or &#8220;ESG&#8221; matters may damage our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, Board of Directors and employee diversity, human capital management, corporate governance and transparency, our reputation, brand, appeal to investors and employee retention may be negatively impacted, which could have a material adverse effect on our business or financial condition.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our common stock has been and may continue to be volatile and fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to remain volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance or prospects of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above a recently reported price, or at all. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment or results of our ongoing or future clinical trials, or changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated serious safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to our product candidates or our competitors&#8217; products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to our product candidates, including but not limited to clinical trial requirements for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or publications of research reports about us or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our annual or quarterly financial results or those of companies that are perceived by investors to be similar to us;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our directors, officers or their affiliated funds or our other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control, or unrelated to our operating performance or prospects.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, and Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and material adverse impact on the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish inaccurate or unfavorable research about our business, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We currently receive only limited coverage by equity research analysts. If additional analysts do not commence coverage of us, the trading price of our stock could decrease. In addition, if one or more of the analysts covering our business issue adverse reports about us or downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to publish reports on us regularly, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have filed registration statements on Form S-8 shares of common stock that are either subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. The number of shares available for issuance under the 2019 Omnibus Plan is subject to an automatic annual increase on January 1st of each year, continuing until the expiration of the 2019 Omnibus Plan, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year. The number of shares available for issuance under the 2019 Employee Stock Purchase Plan, or &#8220;ESPP&#8221;, is subject to an automatic annual increase on January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each year, continuing until the expiration of the ESPP, in an amount equal to the least of (i) one percent (1%) of the total number of shares of Common Stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year, (ii) 480,000 shares of Common Stock (subject to the capitalization adjustment provisions included in the ESPP) and (iii) a number of shares of Common Stock determined by the administrator of the ESPP. Shares registered under our registration statements on Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options and the restrictions of Rule 144 in the case of our affiliates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the holders of certain shares of our common stock outstanding as of December 31, 2021 are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of these securities, or the perception that they will be sold, could have a material adverse effect on the market price of our common stock. </p><a id="_Hlk59981324"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates exercise significant influence over our company, which limits your ability to influence corporate matters and could delay or prevent a change in corporate control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially own, in the aggregate, a majority of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership might adversely affect the market price of our common stock by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delaying, deferring or preventing a change of control of us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impeding a merger, consolidation, takeover or other business combination involving us; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are now and may in the future be subject to securities litigation, which can be expensive and could divert management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Exchange Act and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. For more information regarding these proceedings, please refer to Note 10 to the Company&#8217;s Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel, LLC, or &#8220;Immunaccel&#8221;, related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to vigorously defend these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management&#8217;s attention and resources from other business concerns, which could adversely affect our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. We maintain liability </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">insurance; however, if any costs or expenses associated with the Ye Zhou action, Liu action, or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could be substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. For example, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change of control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions also include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When we lose our status as an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes Oxley Act. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred and will continue to incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company we have incurred, and we expect, particularly after we are no longer an emerging growth company, to continue to incur significant legal, accounting, investor relations and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware or the United States District Court for the District of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction over the matter that is the subject of such action is vested exclusively in the federal courts, the United States District Court for the District of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv)&#160;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or the bylaws or (v)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery or the United&#160;States District Court for the District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery or the United States District Court for the District of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Court of Chancery or the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations.</p><a id="_fd297c4c_23e6_45e4_ae04_c9ba7eaed02b"></a><a id="Item1BUnresolvedStaffComments_216361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f0044bd7_8ee8_403e_a72a_4d080f91f8a1"></a><a id="Item2Properties_180608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our corporate headquarters are located in Beltsville, Maryland and consists of approximately 28,500 square feet of office, 20,600 square feet of laboratory and manufacturing and 4,400 square feet of warehouse space. In addition, we have approximately 15,800 square feet of space to be used for future office and laboratory space. The lease terms expire in March 2030. We believe that these facilities are adequate for our current needs and that suitable additional or substitute space will be available in the future if needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5f0e412a_c9c2_4856_ad6e_f7454d4aaf89"></a><a id="Item3LegalProceedings_9287"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 8, Commitments and Contingencies, in Notes to Financial Statements in Part II Item 8 of this Annual Report, is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dfcae2a8_89b5_41d7_b8f8_54dcaa8cf85f"></a><a id="Item4MineSafetyDisclosures_549389"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7ef66a09_5952_4a79_96f3_763488c99af3"></a><a id="PARTII_356648"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="Item5MarketForRegistrantsCommonEquity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information and Holders of Record</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades on the Nasdaq Global Select Market, or &#8220;Nasdaq&#8221;, under the symbol &#8220;NXTC.&#8221; As of March 2, 2022 we had 27,724,303 holders of record of our common stock. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include shareholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">Use of Proceeds from Initial Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, we closed our IPO pursuant to which we issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $86.3 million. The offer and sale of the shares was made pursuant to a registration statement on Form S-1 (File No. 333-230837) that the SEC declared effective on May 9, 2019. Morgan Stanley &amp; Co. LLC, Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated and Piper Jaffray &amp; Co. acted as joint book-running managers of our IPO. The net offering proceeds to us were approximately $76.9&#160;million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of approximately $3.4 million. During the period from the closing of our IPO on May 13, 2019 through December 31, 2021, $0.5 million of the net proceeds from our IPO have been used for payment to Yale University in connection with the closing of our IPO, and the remainder has been invested in temporary investments pending other uses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None of the offering expenses or net proceeds were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the final prospectus that forms a part of our Registration Statement on Form S-1 (Reg. No. 333-230837), as filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on May 9, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fdf19c77_4c4a_45cc_8498_945dd16a726f"></a><a id="Item6SelectedFinancialData_699531"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 6. [Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5dd9007b_5435_4414_91f8_41d0a7540525"></a><a id="Item7ManagementsDiscussion_693637"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and the related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that are based on management&#8217;s current expectations, estimates, and projections about our business and operations, and involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; and elsewhere in this Annual Report. The following discussion and analysis is expected to better allow investors to view the company from management&#8217;s perspective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or &#8220;FIND-IO&#8221;, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition, for these patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate NC318 is a first-in-class immunomedicine against a novel immunomodulatory protein called Siglec-15, or &#8220;S15&#8221;. In October 2018, we initiated a Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors. We completed enrollment of the Phase 1 portion of this trial in August 2019, and preliminary data from the Phase 1 portion were presented at the Society for Immunotherapy of Cancer annual meeting, or the &#8220;SITC Meeting&#8221;, in November 2019. Updated data were presented in December 2020 and November 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We began enrolling patients in the Phase 2 portion of the Phase 1/2 clinical trial of NC318 in October 2019. In this portion, we planned to enroll up to 100 patients with tumor types that have been shown to have elevated S15 expression, including non-small cell lung cancer, or &#8220;NSCLC&#8221;, ovarian cancer, head and neck squamous cell carcinoma, or &#8220;HNSCC&#8221;, and triple-negative breast cancer, or &#8220;TNBC&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have modified the Phase 2 portion of the trial for S15 selection, whereby clinical sites can select for S15-positive patients through screening biopsies in a Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;)-certified laboratory. In the second quarter of 2021, we revised the dosing regimen to 800 mg weekly to increase overall drug exposure to NC318. We provided a data update from our ongoing Phase 2 monotherapy trial of NC318 at the SITC Meeting in November 2021. &#160;Based on combined Phase 1 and Phase 2 data from the NC318 study, NC318 continued to show early evidence of possible clinical benefit in patients with HNSCC, lung and breast cancer and other advanced/metastatic solid tumors, with dosing once every two weeks during dose escalation and a dose of 400 mg selected for the Phase 2 studies. NC318 continued to be well-tolerated in the Phase 2 portion of the trial, with primarily mild or moderate treatment-related adverse events, or &#8220;TRAE&#8221;. We expect to provide further data from the Phase 2 portion of this trial in the fourth quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, Yale University commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC. Initial data are anticipated in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor, or &#8220;LAIR&#8221;, -1. In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. Interim data presented from the Phase 1 dose-escalation study shows that NC410 appears to be safe and well-tolerated in patients with advanced tumors and show evidence of immune modulation. We expect to provide further data from the Phase 1 portion of this trial in the second half of 2022.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our third product candidate, NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein, or &#8220;B7-H4&#8221;. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. We expect to announce initial data from the Phase 1 portion of this trial in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our fourth product candidate, NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or &#8220;AML&#8221;, blast cells and leukemic stem cells, or &#8220;LSCs&#8221;. Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells, or &#8220;HSPCs&#8221;. Preclinical data were presented at the American Society for Hematology annual meeting, or the &#8220;ASH Meeting&#8221;, in December 2021. The data showed that NC525 (i) inhibits colony formation of AML LSCs in vitro, (ii) inhibits AML growth in the MV4-11 derived xenografts, or &#8220;CDX&#8221;, animal model in vivo and (iii) restricts AML progression in patient-derived xenografts, or &#8220;PDX&#8221;, in vivo. An IND submission is planned for the fourth quarter of 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and development activities for our product candidates, discovery programs and FIND-IO platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue from product sales and only limited revenue from other sources. As a result, with the exception of the three months ended March 31, 2020, for which we reported a profit due to recognition of deferred revenue in connection with the termination of our former research and development collaboration agreement with Eli Lilly and Company, or &#8220;Lilly&#8221;, we have never been profitable and have incurred net losses since the commencement of our operations. Our net losses for the years ended December 31, 2021 and 2020 were $69.4 million and $36.6 million, respectively. As of December 31, 2021, we had an accumulated deficit of $187.0 million primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a product candidate, and we cannot assure you that we will ever generate significant revenue or profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations to date primarily with proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under our former research collaboration and development agreement with Lilly, or the &#8220;Lilly Agreement,&#8221; which was terminated in March 2020. From our inception through December 31, 2021, we received gross proceeds of $164.4 million through private placements of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, we entered into the Lilly Agreement, to use our FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by us and Lilly. We received an upfront payment of $25.0 million in cash and an equity investment of $15.0 million from Lilly upon entering into the Lilly Agreement, and we were eligible for quarterly research and development support payments during a portion of the term of the Lilly Agreement. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, we closed our initial public offering, or IPO, in which we sold 5,750,000 shares of common stock, at a public offering price of $15.00 per share, for aggregate gross proceeds of $86.3 million. The net offering proceeds to us were approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million. See Note 1 to our audited financial statements included elsewhere in this Annual Report for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2019, we completed an underwritten public offering, in which we issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to us of approximately $160.9 million after deducting underwriting discounts and commissions of approximately $10.3 million and offering expenses of approximately $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2021, we had cash, cash equivalents and marketable securities, excluding restricted cash, of $219.6 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">planned operations into the first quarter of 2024. We have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our available capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur substantial expenditures in the foreseeable future as we advance our product candidates through clinical development, the regulatory approval process and, if approved, commercialization, and as we expand our pipeline through research and development activities related to our FIND-IO platform and discovery programs. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing Phase 1/2 clinical trial and planned Phase 2 clinical trial of NC318, our ongoing Phase 1/2 clinical trial of NC410, our ongoing Phase 1/2 clinical trial for NC762, and other research and development activities. We expect to incur significantly increased costs as a result of operating as a public company, including significant legal, accounting, investor relations and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of public and private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year ended December 31, 2020, we recognized deferred revenue related to the terminated Lilly Agreement of $22.4 million. Through December 31, 2021, we have not generated any revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information about our revenue recognition policy, see Note 2 to our audited financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our discovery efforts, research activities, development and testing of our product candidates as well as for clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or clinical trials on our behalf, such as our license agreement with Yale University, or &#8220;Yale&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated costs are based on several factors, including patient enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">contracts are modified based on changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we advance our product candidates through development and expand the number of trials we are conducting and the patients enrolled in those trials, and as we utilize our current good manufacturing practice, or &#8220;cGMP&#8221;, manufacturing capacity, including to provide drug supply of NC318, NC410, NC762 and NC525 for future clinical trials, and as we expand our pipeline through research and development activities, including through our FIND-IO platform and discovery programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot determine with certainty the duration and costs of future clinical trials of NC318, NC410, NC762, NC525 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of NC318, NC410, NC762, NC525 and any other product candidate we may develop will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of clinical trials of NC318, NC410 and NC762, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the COVID-19 pandemic, including delays and slowdowns as a result of strain on our clinical trial sites and concerns about patient safety;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in selection of indications, clinical trial design and patient enrollment rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of manufacturing and commercial viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and receipt of any development or marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time to complete clinical development for any such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services, rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase substantially during the next few years, including as a result of expected staff expansion, additional occupancy costs, higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income, net consists primarily of interest income earned on marketable securities and payment of interest on our term loan with a commercial bank, or the &#8220;Term Loan&#8221;, which was paid in full and closed in August 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Years Ended December&#160;31, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the periods indicated (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue from former research and development arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,378</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,378)</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,638</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,573</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,049</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,524</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (70,765)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,225)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,540)</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,622</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,246)</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (69,389)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,603)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,786)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenue from Research and Development Arrangement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue was $0 and $22.4 million for the years ended December 31, 2021 and 2020, respectively. The 2020 revenue exclusively relates to the recognition of all of the remaining deferred revenue under the Lilly Agreement as of the Lilly Termination Date. Effective with the termination of the Lilly Agreement, no further quarterly research and development support payments are payable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses by product candidate for the periods indicated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">External research and development expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,455</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,852)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,847</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 686</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,399</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Programs in discovery and preclinical development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,063</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,487</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,576</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,909</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 809</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total internal research and development expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,283</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,454</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,829</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,638</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not allocate personnel-related costs, including stock-based compensation costs, or other indirect costs to specific programs, as they are deployed across multiple projects under development and discovery and, as such are separately classified as internal research and development expenses in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the year ended December 31, 2021 increased by $3.6 million to $50.2 million compared to $46.6 million for the year ending December 31, 2020. The increase was driven primarily by $2.3 million in clinical-related and $2.1 million in personnel-related expenses, offset by a $1.6 million decrease in contract manufacturing expenses. Another $0.8 million of increased expense was due to other items, primarily depreciation. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended December 31, 2021 increased by $3.5 million to $20.5 million as compared to $17.0 million for the year ending December 31, 2020. The increase was driven primarily by $2.7 million in personnel-related costs. Another $0.8 million of increased expense was due to other items, including professional services and insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income, net for the year ended December 31, 2021 decreased by $3.2 million to $1.4 million from $4.6 million for the year ended December 31, 2020 due to lower investment balances and a reduction in interest rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have financed our operations primarily with proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under the Lilly Agreement. On May 13, 2019, we closed our IPO in which we sold 5,750,000 shares of common stock, at a public offering price of $15.00 per share, for aggregate gross proceeds of $86.3 million. The net offering proceeds to us were approximately $77.0 million after deducting underwriting discounts and commissions and offering expenses. On November 19, 2019, we completed an underwritten public offering, in which we sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75 per share. The total gross proceeds to us were $172.2 million and the total net offering proceeds to us were approximately $160.9 million after deducting underwriting discounts and commissions and offering expenses. Since inception, we have received aggregate gross proceeds of $164.4 million from the sale and issuance of shares of our preferred stock. In addition, in November 2018, we received an upfront payment of $25.0 million in cash from Lilly pursuant to the Lilly Agreement. Our cash equivalents are held in money market funds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2021, the Company entered into a sales agreement, or the &#8220;Sales Agreement&#8221;, with SVB Leerink LLC, or the &#8220;Agent&#8221;, pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $75 million of its common stock through the Agent in negotiated transactions that are deemed to be an &#8220;at the market offering.&#8221; The Agent will be entitled to compensation equal to 3.0% of the gross proceeds from the sale of all shares of common stock sold through it as Agent under the Sales Agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among other things, market conditions, the trading price of the common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. We have not yet sold any shares of our common stock pursuant to the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had cash, cash equivalents and marketable securities, excluding restricted cash, of $219.6 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into the first quarter of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2016, we entered into the Term Loan to finance laboratory equipment purchases. In January 2019, we amended the Term Loan to increase our borrowing capacity from $1.0 million to $5.0 million. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all, including as a result of the impact of the COVID-19 pandemic. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates or delay our efforts to expand our pipeline of product candidates. Our need to raise additional capital will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing NC318, NC410, NC762, NC525 and our other programs, including targets identified through our FIND-IO platform, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining marketing approvals for NC318, NC410, NC762, NC525 and any future product candidates we develop, if clinical trials are successful;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing NC318, NC410, NC762, NC525 and any future product candidates we develop for preclinical studies and clinical trials in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including marketing, sales and distribution costs, for NC318, NC410, NC762, NC525 and any future product candidates we develop, whether alone or with a collaborator, if any such product candidates are approved for sale, including marketing, sales and distribution costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain additional collaborations, licenses or other arrangements on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing therapies and other adverse developments in the oncology market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through government or private grants, collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our future revenue streams, product candidates or research programs or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to retain for ourselves. See the section entitled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (57,244)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44,954)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,601</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,523</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,265)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,415)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,908)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,846)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_212"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Used in Operating Activities</p><a id="_cp_text_1_213"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $57.2 million for the year ended December 31, 2021, which was primarily due to our net loss of $69.4 million. Net cash used in operating activities was $45.0 million for the year ended December 31, 2020, which was primarily due to our net loss of $36.6 million, inclusive of our recognition of deferred revenue related to the terminated Lilly Agreement of $22.4 million.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_214"></a><a id="_cp_text_1_215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Provided by Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by investing activities for the year ended December 31, 2021 was $36.6 million, which was primarily due to net proceeds from marketable securities of $39.0 million, partially offset by purchases of property and equipment of $2.4 million. Cash provided by investing activities for the year ended December 31, 2020 was $43.5 million, which was primarily due to net proceeds from marketable securities of $50.6 million, partially offset by purchases of property and equipment of $7.1 million.</p><a id="_cp_text_1_216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Used in Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in financing activities was $3.3 million for the year ended December 31, 2021, which consisted primarily of payments related to the closure of the Term Loan. Cash used in financing activities was $1.4 million for the year ended December 31, 2020, which consisted primarily of payments related to the Term Loan.</p><a id="_cp_text_1_218"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Contractual Obligations and Commitments</p><a id="_cp_text_1_219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><a id="_cp_text_1_220"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, we entered into a non-cancelable facilities operating sublease, or the 2016 Sublease, for our current headquarters that expires in August 2025. The base rent under the 2016 Sublease is $32,254 per month, plus our prorated share of the sublandlord&#8217;s operating expense and is subject to annual rent increases of 3%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2019, we entered into a new lease to be used for office and laboratory space, or the 2019 Lease, that expires in March 2030. Upon expiration of the 2016 Sublease, the 2019 Lease will also cover the space we are currently subleasing under the 2016 Sublease. The base rent under the 2019 Lease is $37,824 per month, subject to annual rent increases of 3%. </p><a id="_cp_text_1_222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Term Loan</p><a id="_cp_text_1_223"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2016, we entered into a $1.0 million term loan, or the Term Loan. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal balance of $2.4 million of the Term Loan. Interest expense under the Term Loan was approximately $77,000 and $183,000 for the years ended December 31, 2021 and 2020, respectively. The outstanding balance on the Term Loan totaled $0 and $3.5 million as of December 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have potential contingent payment obligations upon the achievement by us of clinical, regulatory, and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed intellectual property, including our license agreement with Yale. The timing and amount (if any) of any such payments cannot be reasonably estimated at this time. See &#8220;Business&#8212;Our Collaboration Agreements&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, non-clinical studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. </p><a id="_cp_text_1_226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Policies, Significant Judgments and Use of Estimates</p><a id="_cp_text_1_227"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or &#8220;GAAP&#8221;. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. The most significant assumptions used in the financial statements are valuing share-based compensation, including the fair value of our common stock in periods before our IPO. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><a id="_cp_text_1_229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses, Including Clinical Trial Accruals</p><a id="_cp_text_1_230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as CROs, are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. For further discussion of research and development expenses, including clinical trial accruals, see Note 2 to our audited financial statements included elsewhere in this Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><a id="_cp_text_1_234"></a><a id="_cp_text_1_235"></a><a id="_cp_text_1_231"></a><a id="_cp_text_1_232"></a><a id="_cp_text_1_233"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect consideration to which we are entitled in exchange for the goods or services we transfer to the customer. For further discussion of revenue recognition, see Note 2 to our audited financial statements included elsewhere in this Annual Report.</p><a id="_cp_text_1_236"></a><a id="_cp_text_1_237"></a><a id="_cp_text_1_238"></a><a id="_cp_text_1_239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><a id="_cp_text_1_240"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for stock-based compensation, including stock options and restricted stock units, based on the fair value of the award as of the grant date. We utilize the Black-Scholes option-pricing model as the method for estimating the fair value of our stock option grants. The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, including the options&#8217; expected term and the price volatility of the underlying stock. The fair value of the portion of the award that is ultimately expected to vest is recognized as compensation expense over the award&#8217;s requisite service period. We recognize stock-based compensation to expense using the straight-line method and recognize forfeitures as they occur. If there are any modifications or cancelations of stock-based awards, we may be required to accelerate, increase, or decrease any remaining unrecognized stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before our IPO, there was no public market for our common stock to date and the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock, and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined by the American Institute of Certified Public Accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting and Valuation Guide, <i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>. Our common stock valuations were prepared using an option pricing method, or &#8220;OPM&#8221;, which used market approaches to estimate our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the closing of our IPO, we have determined the fair value of our common stock based on the closing price of our common stock on the Nasdaq Global Select Market as reported on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For further discussion of our accounting for stock-based compensation, see Note 2 to our audited financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">JOBS Act Accounting Election</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Jumpstart Our Business Startups Act of 2012, or &#8220;the JOBS Act&#8221;, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to take advantage of this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002. We will remain an emerging growth company until the earliest of (i)&#160;December&#160;31, 2024, (ii)&#160;the last day of the first fiscal year in which we have total annual gross revenues of at least $1.07&#160;billion, (iii)&#160;the last day of the first fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million on June&#160;30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> and (iv)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 2 to our audited financial statements included elsewhere in this Annual Report for a discussion of recent accounting pronouncements that have impacted or may impact our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7ab2c811_e37f_43f2_97f4_852a09d059cf"></a><a id="Item7AQuantitativeandQualitative_728376"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 7A. Quantitative and Qualitative Disclosure About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a smaller reporting company, we are not required to provide the information requested by this Item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb396a35_bb37_4056_982d_971faba1d15b"></a><a id="Item8FinancialStatements_538537"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:AuditorFirmId" id="Narr_mjV2hEL9MUuqHsIUCt2YAA">42</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:6.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_873817"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELO"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDER"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_298484"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">95</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS_913411"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">96</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_42e7c86d_9443_49a5_b7a9_a728beff3e6a"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of NextCure,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying balance sheets of NextCure,&#160;Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the&#160;years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the&#160;years then ended in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:AuditorName" id="Narr_tcZ1siYIlU-Yq6SbWrM1pw">Ernst&#160;&amp; Young LLP</ix:nonNumeric><br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2018.<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="dei:AuditorLocation" id="Narr_2IFDkryPW0GhGc0swy-PXg">Baltimore, MD</ix:nonNumeric><br />March 3, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_890be299_e2f0_49bc_8866_09ca5c5ec5c4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="BALANCESHEETS_873817"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share and per share amounts)</p><a id="_13f5efca_f111_4d2f_89e5_2b0952f0e94d"></a><a id="Tc_ahpQNmlU20qCccwDdnzAlg_1_2"></a><a id="Tc_nhnp5g_L8UaGwscW9X-_oA_2_2"></a><a id="Tc_v_dx1tVbKEex4z4pOmxfwg_2_5"></a><a id="Tc_Mr-nwMUe6kmN6wtfAXZktg_3_0"></a><a id="Tc_QkJccwHRDkiagddjuEQcQA_4_0"></a><a id="Tc_CXxAEp4yNESPVG8PXsZibg_5_0"></a><a id="Tc_VBGXwhoBlEyOiqT8TvGqCA_5_2"></a><a id="Tc_YeSZ5Zft5EioUUKf-8e5_Q_5_5"></a><a id="Tc_7v7uNTKo70-eDxl7gqNW6w_6_0"></a><a id="Tc_NVSfeYkEPk64fzBfA50n5A_7_0"></a><a id="Tc_w1XJLDqP3Eur8zcm8bDbJQ_8_0"></a><a id="Tc_7w7u9mDb7Uq6M8KK_gbT1Q_9_0"></a><a id="Tc_SZbVkNR4lkK08S8iar32bg_10_0"></a><a id="Tc_JbKGWdVvz02rTtEZSEtwug_11_0"></a><a id="Tc_hIkFMwvTPkKDScc4c6HJBw_12_0"></a><a id="Tc_Pm-1XsTdJkOn01OIjF12eg_12_2"></a><a id="Tc_bIVjFPqZx0ypg1oWeP5Cvg_12_5"></a><a id="Tc_7BRjc2xR7EOhrnrWCwZg5Q_13_0"></a><a id="Tc_oDgE-uMKUE-VmjcPhgde0Q_14_0"></a><a id="Tc_3qVGwiDxUkq0U86qCO7Fhg_15_0"></a><a id="Tc_dzD2F0A9jEyody5_Gshghw_15_2"></a><a id="Tc_iVmrHL-6Q06oKki3qbqSJg_15_5"></a><a id="Tc_I32EvayjVUS_IK1Qp9qFtw_16_0"></a><a id="Tc_sg65pxknr0K5IVuDk6sEAg_17_0"></a><a id="Tc_4x2NCLyDWE-_z0v2EnSEbA_18_0"></a><a id="Tc_zWagnR_NvUe79HFZuXaeKQ_18_3"></a><a id="Tc_iOutkPR29kmFQdKbxipYug_19_0"></a><a id="Tc_rAbkpKbosEqKchnYbiQpJQ_20_0"></a><a id="Tc_YgWbGz6_S0G8i7Jx8VRrTA_21_0"></a><a id="Tc_gHtP52dxvkGd6YOWe9gy1A_21_3"></a><a id="Tc_JeCDf7RlqEqXNfHvaBsVYA_22_0"></a><a id="Tc_2CgSJYLzwk6FzT_f3WOO6Q_23_0"></a><a id="Tc_u229WQjSBUG7l2GNmfZ1tQ_24_0"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d_2"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d_3"></a><a id="Tc_Y7VjD010PE6Jj-ssfLu7hA_25_0"></a><a id="Tc_LPHrU2kfDkiE4W31sS0yjw_26_0"></a><a id="Tc_Z-lkGaL_iUqYRqzuY_JYTg_27_0"></a><a id="Tc_2VbUs9qS9kuBsp6-sM6vdg_28_0"></a><a id="Tc_FFiqdqYZVEGiNzjT3qaHWA_29_0"></a><a id="Tc_kOWQ_5a34EeqfQ8tjwdoHg_30_0"></a><a id="Tc_RbM52CArdEe9pWFfMhdLpQ_30_2"></a><a id="Tc_Uf7zRQTCbkud4sksfy664Q_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_RYWJsm4ZkEuvouvtoVy36Q_5_3">12,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_rjvQPcf_BkeqMJ3KFo8z1Q_5_6">32,772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="3" id="Tc_-yKUpc1ZBUioMZwNwboLGg_6_3">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="3" id="Tc_L4NlIsWlREmKehnYaAcjUw_6_6">250,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_dl6Evgz8RkGF1VQpQ24TIg_7_3">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_0um09vOXhEOTQ-0ra0gAJQ_7_6">1,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_rTx5S5plgEqeUOyfjARgOA_8_3">8,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_01Mfs-nZL0GipE5hQZoMLg_8_6">2,824</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_D7HrXUt6akeHNfEtedDRug_9_3">227,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_k0fiHthUmEG2DPOfybVxSg_9_6">287,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_MKcyBHKJ806tpxgEq5EZJw_10_3">13,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_P5bvhJtiJ0y4QQgA1JKvjg_10_6">15,809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_sMF0opA4mkeHr1X-v9JKJg_11_3">577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_2hGsnZzYPUeEu2jd1GrKbA_11_6">2,857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_XhUQZ6OX1ECk8dNmBLyBog_12_3">242,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_OwhrkQTv3U-w55lQofC9KA_12_6">306,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_wUfHPYlUrkio2wRp9aOQZQ_15_3">1,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Zw39KuS7k0KezPgdyvTj1Q_15_6">3,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_6Zti3kTsPU2n3fvtWGxZ6A_16_3">4,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_YLj9AoDHMEWd5pLB8hq5OQ_16_6">4,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Deferred rent, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="Tc_tjmAiqzZu0OPmfPY0Nrvgg_17_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="Tc_GxOgnhB0zEao11LWyIm8Wg_17_6">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Term loan, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_wz5ztxF7YUe8M6DSWHX4AA_18_6">1,667</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_keq6tfcvrUukD2ZphXD8ew_19_3">6,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_SQEuYS94K0mHbm5vbleOhA_19_6">10,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Deferred rent, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_0rq8s40wyEOplWQKumBOJg_20_3">2,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_lckJOanckkGGhwRk2fYoKg_20_6">792</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Term loan, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_ZlNAu_yuW0mp7NT5bPi3fw_21_6">1,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_m1HXzzVUEUmjV4fObydI9w_22_3">9,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_upydhDMQqk2hD4A48A_SWg_22_6">12,923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hApKvNcjAkuP7H0czp1SrA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_JtT4KP5yz0eTkdz_v09I5w">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_OqBOERsaDkKdE7GXxtN92Q"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SK47j7HMe0K43kWLxBR4wA">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2021 and 2020. <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_-Mj5ReiVnky2aHZ-djwR3g"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ME3jicgyiEuWiJ6Q7JnUWA">No</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31,&#160;2021 and 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_wTg-hQItxUW1i-lAprnTXA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_iUdxlbiBN0aOd-krv8nVQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common stock, par value of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_drTeyeHY20KtixJdf77A0Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bXIvEggYSEyU6I1xp3BhrA">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_vKByLr6zIkCDQ-5M7EFTlA"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_E7g-125TvEqmJliWKaVlWw">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized at December 31,&#160;2021 and 2020. </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_0zNhKlf3L0mkCEEI1DeuoA">27,680,997</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_vKX98nVho0KzwJg4b6rFQw">27,568,802</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_E4lkwXOE3EWjcwZxsH94jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_DN8xdD6MRE6MMojBwaImsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at December 31,&#160;2021 and 2020, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_CRCmduRSGUOEb-Qu-zf3Ig_25_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_GrWsWuhi6Uiq_0s2-qGC3A_25_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_BWgY7QpVK0ahqdaHqYmAFg_26_3">421,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_MJ20h10qj06wxE-cWSGJFA_26_6">410,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_xaqq0eaqRku4dqhVxkDHkw_27_3">663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_AqLhD8w8dEe5RPZ52fOEIA_27_6">779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc__j9lLRj_UUqBy0A8SgX1wQ_28_3">187,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_KOVDrTC3-UGCgwP-LmHG5A_28_6">117,637</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0-S47vs5sUinhkIaBYrtQg_29_3">233,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FzsoMx6uskmSsYjpZ5Zlig_29_6">293,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_nAd6pDHqNU6xwD02V6XgvQ_30_3">242,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Rhdl9_u0PEyHe2mOl18c1w_30_6">306,644</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fbea856f_34fa_4b46_aa7e_ee3db275bb7d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFOPERATIONSANDCOMPREHENSIVELO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share and per share amounts)</p><a id="_e92848bc_e745_4610_b772_e5b0ed31bb13"></a><a id="Tc_PCTW4KnuTkCfuegX_I9FuQ_1_2"></a><a id="Tc_p6Auknk0F0utJSIBp9MNOg_2_2"></a><a id="Tc_u4h7pxtzUUmu1wrWcj1T0w_3_2"></a><a id="Tc_FlufSNz1AUexyYOHXBiC6A_3_5"></a><a id="Tc_Mg9uvDb0ikm4wkZ8xZDG9Q_4_0"></a><a id="Tc_360AIRDx20OptLFIlUKehA_5_2"></a><a id="Tc_0S2-YqltUUezOTBAt28x3A_5_3"></a><a id="Tc_Hc9cUb1WCUuNaiNpsMV8xw_5_5"></a><a id="Tc_nxPL5T7yZkaRVI_Bu9oEdA_6_0"></a><a id="Tc_Xdzr32DCgke20AuXYo4ljQ_7_0"></a><a id="Tc_8gO-3IZ0gEG3BpBqudK08A_8_0"></a><a id="Tc_hRde5PM7bU29eIk3co67Eg_9_0"></a><a id="Tc_NGfTwjy200uRRLnRhPO-jg_10_0"></a><a id="Tc_QNFs3S5h-EyG2uYr_-Bqdw_11_0"></a><a id="Tc_PWsaCuAH5Ei2FQADfOr7Lg_12_0"></a><a id="Tc_O84J6h782kupls7xpBTyEA_12_2"></a><a id="Tc_KW6IFFbufEi7RkPy_ANFOw_12_5"></a><a id="Tc_aUCHKWVkGkuiwdYO1uyv1w_14_0"></a><a id="Tc_i7eoRHg430KKIol-v8kiRA_15_0"></a><a id="Tc_lhtJih9s5025vuhms6KcMA_16_0"></a><a id="Tc_Z-oeU--pgECBjvpUdt_1OQ_17_0"></a><a id="Tc_kwEyNTNSVE2xBIhT6hBLCA_17_2"></a><a id="Tc_Kq-jsoFEHUmxiBbl6hb9-A_17_5"></a><a id="Tc_gZfCTr7XlkKoi48qMNXj_g_18_0"></a><a id="Tc_rJ1zFfxIwEGiOkLtWQQSjQ_19_0"></a><a id="Tc_UOzPs4JMRUi0lwudkuFEGA_19_2"></a><a id="Tc_pLQgxe1CdEu2yiSyu4qcXg_19_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.73%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_tTt21ZgtBk-W0pJEfxQKVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenue from former research and development arrangement</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_zRJUignyv0WEi42suKvh2g_5_6">22,378</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ndkIa5uz1kCb54j7Z3d7ag_7_3">50,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_n96MgJP8uEOROO-L1blFDg_7_6">46,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_dDx_9x0F70q0pYFSIv9A7g_8_3">20,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Pzuvyy2UEkawQS3K_9OVjA_8_6">17,049</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_s866e0MZfkqv63Lc6eFl6A_9_3">70,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_jPC16Cjg502-WrqnlUvwfQ_9_6">63,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_fGNXBPyruEyG6CQIMM3wrQ_10_3">70,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-xEu1kXC606pZpgCXbq0zw_10_6">41,225</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_3YQ6Pr-DJEawqLjBSPnVNg_11_3">1,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_f5rzpbdv6kSIha6bOuB3IQ_11_6">4,622</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2I8JVjQpt0SGTCOz2Nq6sQ_12_3">69,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mMxGYsi6HECkooXbLUGxIg_12_6">36,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_oyydoO0AdkylL5JPTmIRgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_DOuvgo1eSEawirQnsKhwSg_14_3">2.51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_k3SONQVP20aoC7_plLOxow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_fBtU6RmMq0CqG8zOIzAIoA_14_6">1.33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Ieg9O3TzDUSNHWbYGOMQHA_15_3">27,615,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_boOSB-aM0kaYBW2D5xaw3w_15_6">27,532,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dIyBc56qukCPOk7tGhiaVw_17_3">69,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XZUnfycio0Orqa1tWHyOHg_17_6">36,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized (loss) gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_Gbn5HrZHIEG7twuz80-WOw_18_3">1,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_Pm2VaBWNGkukYJyvse3fNw_18_6">779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Dw9PL9AMX0izUuhJ8p4u9Q_19_3">70,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_fIFBsTvdzEGuCyaGuT5_Rg_19_6">35,824</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c17ca972_2896_44c4_9292_66421f2d0e55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDER"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share data)</p><a id="_d831bdf9_a97f_4d1d_abb5_116529e56eb3"></a><a id="Tc_wvP7T8QmI0qkxc2XVARtDw_1_2"></a><a id="Tc_jmH68wkQF0O1sonmVgy6OA_2_7"></a><a id="Tc_wAbsoCoJHkWuEGWzKkzDbw_2_10"></a><a id="Tc_r9mezZopYkSwFklwjXdaRg_3_2"></a><a id="Tc_hJwJWD6lY0SEi0d_59UjWA_3_7"></a><a id="Tc_uRWsWP4syEesyy-hmovN7A_3_10"></a><a id="Tc_LqqyvvQX4ECnyMctVSKjmQ_3_13"></a><a id="Tc_xl140Ca7YEGfJr1utrvU0w_3_16"></a><a id="Tc__zYkE4dEkka-gwiUOnkbbw_4_2"></a><a id="Tc_U6Zk0IXfR0SwdPaGknx_pQ_4_4"></a><a id="Tc_ipYxOFMnQEWSKAMUQzkUZA_4_7"></a><a id="Tc_uY0iulRm50mRAW_p41ik3w_4_10"></a><a id="Tc_ejvHoZYQik68NHCXpXtAiA_4_13"></a><a id="Tc__QksDYP2tUmoSu6DPWfWkA_4_16"></a><a id="Tc_3nU832m7DkGgAQLnIR3wdg_5_0"></a><a id="Tc_FjyTphKkmU29XDT9cn094g_5_4"></a><a id="Tc_wROdAi3b-U6Rrvw2FfVmUg_5_7"></a><a id="Tc_B_xjp02iv0i47ff4tmJ1mw_5_10"></a><a id="Tc_wtYAqIZtn0S1C3d4rPsrug_5_13"></a><a id="Tc_ap_-og_-iE-nESvZFFFMEA_5_16"></a><a id="Tc_iD5wlsV-LkCeq4TUUqZTxQ_6_0"></a><a id="Tc_HavIjt8Q-EuSg0xEwwpVrw_6_2"></a><a id="Tc_y98Ux-jmRE6wtrpajEzReg_6_5"></a><a id="Tc_A-79W9Z6m067VMceE9eb2A_6_11"></a><a id="Tc_uG2CI2KIAEKg_2lGvHELxQ_6_14"></a><a id="Tc_SfnLDrQyTUO0UdSaVbw09g_7_0"></a><a id="Tc_rZvnJ78w7EW2qO3KPHBKVA_7_11"></a><a id="Tc_sMeqfr_tt0Kepvjt69f2-g_7_14"></a><a id="Tc_MFo3sYzZmEWhdliqZVZ9tw_8_0"></a><a id="Tc_G0S8UYR5I0W-EnkzIY4Xkg_8_2"></a><a id="Tc_H4UnWQiZvE-cCKCEFGMvqg_8_5"></a><a id="Tc_DaXVmsb8jEKzQaIl7yH3TQ_8_8"></a><a id="Tc_V1HhhXI7Z0ukdFcvyBNtWA_8_14"></a><a id="Tc_-8Xnbr8Ly0eyHsXofyHVLg_9_0"></a><a id="Tc_d6C7Jmjf20KhTKlRUnIguA_9_2"></a><a id="Tc_KjEI5SyNsUCfs8e92gfJxA_9_5"></a><a id="Tc_xea5bAWsckq2VhlFVFHbCw_9_8"></a><a id="Tc_AhfZuzES00qAu7AZ5Ux4uw_9_11"></a><a id="Tc_Jousx1R6ZU-APFzON19W-Q_10_0"></a><a id="Tc_LyMRJbCAXEeD_gbPORV0yQ_10_4"></a><a id="Tc_tN0feH-xAkCm_5PqhQBiNQ_10_7"></a><a id="Tc_AOIIYo7tHku43E6YeTKhWw_10_10"></a><a id="Tc_OnIQ5ptDmkKTdQjR6C1_8w_10_13"></a><a id="Tc_vrg2dBPJBkKCreyEFc02XA_10_16"></a><a id="Tc_fVz_xVi36EyLzNr31NB9ig_11_0"></a><a id="Tc_1tBq9Cud1Ea4mvwhwNb6-w_11_2"></a><a id="Tc_OYcu8RDQtkaT4pHMTs7jOg_11_5"></a><a id="Tc_K3jlrbMqUkeUyKAB4bKVjA_11_11"></a><a id="Tc_4ZNuaWuE3kuVDSbm1CElxA_11_14"></a><a id="Tc_xETEyMnWfE6iB8OcMkP2ow_12_0"></a><a id="Tc_2oGClsFAe0WQB5G9xy9aNQ_12_5"></a><a id="Tc_0jrGDoVGX0Sdoxat53ZL1Q_12_11"></a><a id="Tc_dqQCQ-ZLa0yz9oQYTkY8_w_12_14"></a><a id="Tc_bCSslax0OEakF93Tpc2F-w_13_0"></a><a id="Tc_zg5n-PgDkkaaBqXedyvP3w_13_2"></a><a id="Tc_340MHVo40k6G-Ci_Nu2JIg_13_5"></a><a id="Tc_4LPMl_NUM0S6ylX4HX3P0g_13_8"></a><a id="Tc_MkYTkqql-kGROcM2564Xng_13_14"></a><a id="Tc_IYcRxhxOwU6XYxUCzbd4VA_14_0"></a><a id="Tc_0RDtm_U5wUOVKpGUhkQYeA_14_2"></a><a id="Tc_xZUHSkkFmUKEfocjHq-ydA_14_5"></a><a id="Tc_W797RF7Wf0evhO_i0IZ1BA_14_8"></a><a id="Tc_0RIRoDhfM0SNcrI4VRW3QQ_14_11"></a><a id="Tc_z2NbwG4_zEOU-cROSYL6JQ_15_0"></a><a id="Tc_xfxZjeCfRUyjcqS8JXl3Qw_15_4"></a><a id="Tc_6b13Sht6AECZuy7qvVcfSw_15_7"></a><a id="Tc_3Vif2xhQC0uBO9GCzfi_Uw_15_10"></a><a id="Tc_-s0zjPbG3kSkcQukglGdsQ_15_13"></a><a id="Tc_MR5kpfoJ5EyFn0t4fs3tMw_15_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:66.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_p_FxqYQNMUiNv2dd02JVqg_5_2">27,499,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0tuliEgXz06zjL7kDQE1DA_5_5">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7hwDq_hUlUOMlE_Q8n38kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9T-YtzIPNUuDs2W_D2wcQA_5_8">402,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qNbbMd7Kt06bhH7DHJgopQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gQDIEGXSS06zBPJ7vIT5gQ_5_11">38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g2SurcQldU2PCyhEWEYFNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_84ZLguxhR0G-8f2IWdSHOw_5_14">81,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_o5DK1VR-yUyfyGdIQgWlbQ_5_17">321,484</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kxHLG-I0106mY9WC9-FhLQ_6_8">7,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ROuYzX5SbE64mvJwXm65hQ_6_17">7,911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Q5sARRX4N0axbwwH2CiaKw_7_2">69,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_geKUkmYAbkeKVQDmUZfK9A_7_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_KAHGzf7iAUCT11njv2aizg_7_8">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_NJzJcX2bZUi2aKP1fGNTGQ_7_17">112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain on marketable securities, net of tax $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="Narr_3RG216plPU-5i9AeajCfow">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vrV78_WLHUylRfRKRtNrFQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" scale="3" id="Tc_Hd2z0f3Bm0GWJ5MyLshMew_8_11">817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" scale="3" id="Tc_jbj7ZKsH7ECCMBkGTM_fnA_8_17">817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mtHwI-ED1USEa2VQIR0lwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ADyzzHoj4U6ACV_Nww6M1w_9_14">36,603</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_b6OBWs4I80CfRmYYMmg6tQ_9_17">36,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December 31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_ZbNyHXXUFES1xEW_ha-6RQ_10_2">27,568,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__8hiYY1thkqywguas813Yw_10_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3BA4U7O4vEq4IVDY7BQ4fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_am-VIeeSX0-XiGgpOwhV8Q_10_8">410,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QqInZr8FSEKmnGZDc0UpLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_60c5AdLU70uy0EmkEjNd1g_10_11">779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZINGtOppMEOQvolyBs2r2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_0Y3kiqRJRUK_X0SYm51mvg_10_14">117,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_m3M4LS5_JES8L9Ydsg0kVA_10_17">293,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0VL_E4m3q0aQjXxL1cRGsQ_11_8">10,288</ix:nonFraction></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_n60bsALA8UOxSVhIRHwh3w_11_17">10,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y7GXva2dbkWtJbsUzFBadQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Nfzgk7bVgE6a7b-ULo1DWA_12_2">112,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_SAQ9_b3qm0aqdmx-tT9iXA_12_8">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Q0h3XJ0zi06iO1nkyd_Ejw_12_17">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on marketable securities, net of tax $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="Narr_c5BCK8tfpkO-vPBEExoWng">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1bJ_AHosZkOR2oPN_YnoLQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_M7F3qpCVXki2evkxUKVE9w_13_11">1,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_tzGtDPTtu0mWkaj1Xz5gWA_13_17">1,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qr9RYIPNZUOJJAf5Pj-l0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bHCQ2Ku_eUuEdeggH0V1jA_14_14">69,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Gg1IMxdoZEGTy3da4pW0-Q_14_17">69,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December 31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_scCTlqQ_lk6vsPNP2vxIvA_15_2">27,680,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hAxBNVZ34k2eT-1sdMnvng_15_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wIP__71uMkOD1PkXsn-N0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1BKf-v_x2Eu6jUYYduU-Iw_15_8">421,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ROd0_OVRAUibMHBnTwZzJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jjbdFbi1LUeKLecU-esUkA_15_11">663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8gqQyeXsEa2baPiReBeLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kqyLOvzogkWYfCkRkLqRVQ_15_14">187,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Bk_v4Lgy4Ue7zcHHimQh7Q_15_17">233,386</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5d8b75f8_fb4f_4695_b0b3_9768585c22f1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFCASHFLOWS_298484"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8417c588_775b_4894_92c1_75bcebad939f"></a><a id="Tc_aYAyuaAPlk2RuKdBM_xVMg_1_2"></a><a id="Tc_5keToRRgz0yt3E2FplIA4g_2_2"></a><a id="Tc_RSYWahl1BUyG7I5DqIfUSQ_3_2"></a><a id="Tc_OD4NYdCv0U6PauGgFlSfvQ_3_5"></a><a id="Tc_p8ecFB2RtEWU-WsNX8-pgw_4_0"></a><a id="Tc_A_4NPMbPWEyB4h6y0pxzwg_5_0"></a><a id="Tc_j-MamaGl-kSX74WurnM7vA_5_2"></a><a id="Tc_5gMDNbVhdEeoxsapSgu6RQ_5_5"></a><a id="Tc_PSdIj3y-XEWqCoDK2Q5kdQ_6_0"></a><a id="Tc_oIQlMnh3z0SUyPEu60GQUw_7_0"></a><a id="Tc_vzKXv5Uzk0iU1SCt-RiVCA_8_0"></a><a id="Tc_PQXI8e7S9EGqSg6WeMi0Ug_9_0"></a><a id="Tc_K3_m-Cv0gkmoSRpbBu45uw_10_0"></a><a id="Tc_sTQqKQGnRkuN2OX_AjT63w_11_0"></a><a id="Tc_jOBntM_MSkOJVY_1qt579w_12_0"></a><a id="Tc_Z4mM9_LUf0aQURhQ6R8q7g_13_0"></a><a id="Tc_K-Ocml3KsUaO_EzB8ArxYg_14_0"></a><a id="Tc_ktWN7D_7lU6ArGHOlMRcUg_14_3"></a><a id="Tc_3q-1tybe3Eedr_nC04-hRA_15_0"></a><a id="Tc_ve98hh_1Lk-shXc96StVYg_16_0"></a><a id="Tc_Z8ZjjiBWuEq_Kxn_ldPwUw_17_0"></a><a id="Tc_bVyd0Uy3G0GA6k52A_q32A_18_0"></a><a id="Tc_WJK-Vgs3V0qsP8aal2wrOg_19_0"></a><a id="Tc_5_w84RGDxU2mCxWnrvMh7A_20_0"></a><a id="Tc_ahcpnQ2Tq0K7IWLjtGGgtA_21_0"></a><a id="Tc_nPL8ER5bl0yJUFsKpzQZPA_22_0"></a><a id="Tc_Y2rGFCN3BUuiMH9ZHJe4vw_23_0"></a><a id="Tc_mNpPNaYRjUCQjetSuH8ZmQ_24_0"></a><a id="Tc_deoLP_xNykir_gMjpNj9iw_25_0"></a><a id="Tc_z8zwkdhbR0GhSiQZZgo7PQ_26_0"></a><a id="Tc_6z1sDPHB40uVlmSaTcdDFg_27_0"></a><a id="Tc_cCzGt_I4Ok2lqMo6LVeZmA_27_2"></a><a id="Tc__4KomM4nEEqTlL4SlTuaZg_27_5"></a><a id="Tc_z3eO-hwdIk--Kn0Jju-fSQ_29_0"></a><a id="Tc_AehMpo6xMUm8DbdLWpOzsw_30_0"></a><a id="Tc_SEYzJwJgEkKbbeHrG6PxNQ_30_2"></a><a id="Tc_Oqk8fAa2gE6lWfQbaihVZQ_30_5"></a><a id="Tc_ZSItzqyryUes1Mrfh2-GfQ_31_0"></a><a id="Tc_akLGWAMjNEqK8Xw3pbNv7g_31_2"></a><a id="Tc_vaBaJymrJk2jI7IhbQLveg_31_3"></a><a id="Tc_55G2AmTSyEm1cQYFQrBJng_31_5"></a><a id="Tc_Es_RD3UhY0uaTODKENov-A_31_6"></a><a id="Tc_ckj6UImEGEOXD0tFbCABuA_33_0"></a><a id="Tc_yGpPlfOZp0i3-xfS6Arz4Q_34_0"></a><a id="Tc_mlLy0H1DUkuKfxZ8Ouik4Q_34_2"></a><a id="Tc_5kyFjiGBd0WsE3UMhBtbew_34_3"></a><a id="Tc_MTFQRAOMmEG1MmvplWjXGQ_34_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_3kc3d2Fje0qtpkHIBHyRPA_5_3">69,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_31826NnUjUuq3A_dX5qv_g_5_6">36,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation, amortization and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DepreciationDepletionAndAmortizationAndOther" scale="3" id="Tc_KM7vRZY5s0GQxM6zNo81SA_7_3">7,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DepreciationDepletionAndAmortizationAndOther" scale="3" id="Tc_3Y-evtYTLUq1V-VkaxIpOg_7_6">3,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_hO3R0pYChkmiwjaDwgO9iw_8_3">10,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_vVMnO-49V0-1KT4Fm0MsoQ_8_6">7,911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_WMiWZQGaJEaGzwcxup0YWw_10_3">4,889</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_M7VWVFGSNUKBM8rTFU58sg_10_6">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_EXTev06UCEKJ_8UmKwK_lA_11_3">1,959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_LvqfEDowXUW2fReDg3HWpg_11_6">2,040</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_HQkLhaKTvkanC43tNblZTQ_12_3">178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_SQzeY86M30GopeBBQfS36w_12_6">244</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:IncreaseDecreaseInDeferredRent" scale="3" id="Tc_Vmr-82K0UU2ZOCTRfdO6Zw_13_3">1,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:IncreaseDecreaseInDeferredRent" scale="3" id="Tc_C6p9U4A6lkyRXENaQMFEQA_13_6">348</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:IncreaseDecreaseInDeferredRevenueFromRelatedParty" sign="-" scale="3" id="Tc_YGaRRcg_nEi4moc-ndpP_A_14_6">22,378</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Aa9veJy91EyoMvNiovpckA_15_3">57,244</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Mz4rMJnWuUeoV0lr5D2Wpw_15_6">44,954</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_xgdEj60caUerMhKh8YtPOA_17_3">195,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_ZLMiBkRdg0mG6tFZGS1H4w_17_6">187,784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc__O7c36skFk2LHhuPHsTwHA_18_3">156,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_hMt6ej88O0C2xtsbZ_8X6w_18_6">137,129</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_vqlWPyBdh0eB4t5Xi4Hahw_19_3">2,360</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_xbdq0TJqd0uDr-70oKGbwQ_19_6">7,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_KisAOQUozk-LWlVD56MvYw_20_3">36,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_IKXglhNvyE-_LuNLNC8EVg_20_6">43,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_MOo1XDD4x0KOkC9d0-Y4Iw_22_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_pwMvQV3xzU-9CNUj7owi-w_22_6">112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments of the term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_4MMH1DM2ekSMQQPmXRnIuA_23_3">3,473</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_AGeZRHNa3UCk44H-xsFVZw_23_6">1,527</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_fECcZP8DFEeIArAjreEZyQ_24_3">3,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_ZOm7XgIMVUCX9P5EqET6_Q_24_6">1,415</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_nOYqhB4lUES74xiYqYvOsw_25_3">23,908</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_IV3UMCCu7kK2dW8Iow4IXw_25_6">2,846</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash &#8211; beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_g6i1UIP6-UiAnzoeIVclDw_26_3">36,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_4bzlzUOH1EKlpNro4M0GdA_26_6">39,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash &#8211; end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_aQrJids3hEqyEeIetcjWvw_27_3">12,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3aOhrIEeSUyJp-Jcj-tUeQ_27_6">36,284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_EkEmzk3-rUCulTwz7q48Hw_30_3">162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_VBJJsNPQOki3HV86F2qIvg_30_6">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosures of noncash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of property and equipment included in accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_g-Qwc5REdUWbC0nw4wgEBA_34_6">109</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTESTOFINANCIALSTATEMENTS_913411"></a><a id="_cp_text_1_1262"></a><a id="_cp_text_1_1266"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_syUFkIqMeEOeYXhop5-Mig" continuedAt="Tb_syUFkIqMeEOeYXhop5-Mig_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the Business and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NextCure,&#160;Inc. (&#8220;NextCure&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#8220;FIND-IO&#8221;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#8217;s product candidates, building and optimizing the Company&#8217;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#8217;s product candidates, discovery programs and its FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public Offerings of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, the Company closed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_g8krM8N_5USM6691c0jolg">5,750,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRkd_wQNpE-PlILTjaNCPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_xpawgYt3C0-jX8qgkF1BOQ">15.00</ix:nonFraction> per share, for net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_4uYI4vUpQkimPJsYIjWlBw">77.0</ix:nonFraction> million after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg" decimals="-5" format="ixt:numdotdecimal" name="nxtc:PaymentsOfUnderwritingDiscountsAndCommissions" scale="6" id="Narr_hZd4nnIJ0ECUVDBMcc8HHg">6.0</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_X0gfwbKyNEGGWnCp8JRTfg">3.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparation for the IPO, on May 3, 2019, the Company effected a <span style="-sec-ix-hidden:Hidden_sDmryUZLgEqm_48xdkZO4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s convertible preferred stock automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LkU-fd422ki69ghRU1oEDw">15,560,569</ix:nonFraction> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_yepjZJat-Ey_FyHvgA5ZLQ">no</ix:nonFraction> shares of preferred stock outstanding. Additionally, the Company&#8217;s certificate of incorporation was amended and restated to provide for <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JJEA5hw9EU2jJdrZf7C8OA">100,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_XyWMeT04y0qghKLrwuWYgA">0.001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_C8Oky10Dcku5qKbA8lCnGw">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_rdXyQUUE30KPkdxBuOREJA">0.001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_11_19_2019_To_11_19_2019_YzRMsCVKvkGV2jcw4HTlxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cwted_7ol0-0BEL2vsKcIQ">4,077,192</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_11_19_2019_qoi0IG6E5ES_Szx_7icP0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_OTIiTJBmEUKGXeCGMk9FKA">36.75</ix:nonFraction> per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_4iXtvlqCUU-rvXA6eny2Tg">611,578</ix:nonFraction> shares of common stock at the public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_2_2019_WWMv6pgpRk2zjvig2oOTzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr__lbo_d0O90SEF1A_J7NagQ">36.75</ix:nonFraction>, for total net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_VgAkSDVlWUG8_MciuyMu_g">160.9</ix:nonFraction> million after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA" decimals="-5" format="ixt:numdotdecimal" name="nxtc:PaymentsOfUnderwritingDiscountsAndCommissions" scale="6" id="Narr_UpGy1d24wESt0zGWJSsBiQ">10.3</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_Te4DrcShSECPWvVPgWsIgw">1.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#8217;s former agreement with Eli Lilly and Company (Note 7). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the issuance date of the financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_syUFkIqMeEOeYXhop5-Mig_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#8217;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#8217;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#8217;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#8217;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#8217;s planned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in <ix:nonFraction unitRef="Unit_Standard_segment_y2qUci353EOOoH7IWozW8A" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_NLNpsInQf0GHDpo2dQkTqA">one</ix:nonFraction> operating segment that operates exclusively in the United States.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_gDgAQDPUo06XOkLwwm-UFw" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_6kr33IK5D0yB83VJeQZpcA" continuedAt="Tb_6kr33IK5D0yB83VJeQZpcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_1298"></a><a id="_cp_text_1_1299"></a><a id="Tc_3iMOMmZQOUmJoUyezNUXNA_2_2"></a><a id="Tc_ZFWDxMQVH0ei2lqGCWDMBg_3_0"></a><a id="Tc_datvIgIudU-wE77RyrKunw_3_2"></a><a id="Tc_O_LjKYm0iUSM1xOkoA1j-Q_3_5"></a><a id="Tc_PdaZR-8ubke6PPtY1VID9A_4_0"></a><a id="Tc_h0QFegEnv0mSVT6YpD5p1A_4_2"></a><a id="Tc__OVsqFU5PUG3skwJDaB29Q_4_5"></a><a id="Tc_05r30SG-L0iiXZk8uoblgg_5_0"></a><a id="Tc_-2ly5d1WaEaAWc4DZWoeNQ_6_0"></a><a id="Tc_VcClBgZsdkKxWVJOXHuKeA_6_2"></a><a id="Tc_5DSaEAjW5U-vL7vKrLAJNQ_6_5"></a><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont1" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont2"><ix:continuation id="Tb_6kr33IK5D0yB83VJeQZpcA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:UseOfEstimates" id="Tb_XjmbwBAOhkymiVATF7K7-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_SHfNwqwJlkuelhz_VV8iZg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_vdAHLd2EN0i3Ea5sjdLThw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" sign="-" scale="6" id="Narr_QS2v41IwKkam_GVZx6v-XA">2.4</ix:nonFraction> million of its $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_O4xoeqJMI02sxslJymX3UA">5.0</ix:nonFraction> million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt-sec:numwordsen" name="nxtc:RequiredReserveRestrictedCashCurrent" scale="6" id="Narr_vi7nO8UYBE6Gw_LEDbqrBg">no</ix:nonFraction> restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" format="ixt:numdotdecimal" name="nxtc:RequiredReserveRestrictedCashCurrent" scale="0" id="Narr_9h4hUezve0KXnxByuMQS5w">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-5" format="ixt:numdotdecimal" name="nxtc:RequiredReserveRestrictedCashCurrent" scale="6" id="Narr_pWFMtRlcAEykOScQok28iA">3.5</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="Tb_Mr1RYPUQX02LLXHCfLVfrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HjJD777x30uhx-9uOl8DNA_4_3">12,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_c_MiorMZAECsKXlrUIpNFw_4_6">32,772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash (including $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:RestrictedCashOtherAssetsNonCurrent" scale="3" id="Narr_ktDXHuzmuE-Zr0ZJBs-dnQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:RestrictedCashOtherAssetsNonCurrent" scale="3" id="Narr_a1_1H3WNQ0K0WvzEDp5lGg">1,806</ix:nonFraction> in other assets as of December&#160;31,&#160;2021 and 2020, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:RestrictedCashAndOtherAssetsCurrent" scale="3" id="Tc_3wU3IaV_IEGsAgDzKVJV_A_5_3">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:RestrictedCashAndOtherAssetsCurrent" scale="3" id="Tc_3_oOuz11zUGdiCPd6ajEuA_5_6">3,512</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_BV8C2NjXA0KxwWNZZoC6ew_6_3">12,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tWr1rj9E5Euy4HlH70UAuw_6_6">36,284</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_Urqyqcap80-MmyBdjXtARw" continuedAt="Tb_Urqyqcap80-MmyBdjXtARw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security&#39;s relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont2" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont3"><ix:continuation id="Tb_Urqyqcap80-MmyBdjXtARw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_pB8b9-aVPky1zFZXb0MfVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#39;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_aL76DiFXm02K9ximrqQj1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_rwdxTbsVqkSi1W0rnpxsSQ" continuedAt="Tb_rwdxTbsVqkSi1W0rnpxsSQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk25829333"></a><a id="Tc_0R48IZerUkqiai-RkYSpfA_1_2"></a><a id="Tc_kvfum6Zm-UWc3CbWTpS5LA_2_0"></a><a id="Tc_zwf-BUTgKkOIEr1mUPxZYA_3_0"></a><a id="Tc_-axsNku5TkqXKne3cs9k5Q_4_0"></a><a id="Tc_8G1PFCSL1EWHt5injJnj7Q_5_0"></a><a id="Tc_j_8koQILw0KqMBoaeMPpIA_5_2"></a><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont3" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont4"><ix:continuation id="Tb_rwdxTbsVqkSi1W0rnpxsSQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="Tb_BVw7ve1sDk6zF5bStVj8jA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_JyGMiATq_0O2kc4XUS_1Ww_2_2">3&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_FRWWKvwUu0m7aWpFF9Q6iQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_i_4wX9gY00u8KDgfQxU6iQ_3_2">5&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ytC6nbqJ5kebhS3ZyEI15A" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_AMXJTCAzDUqjY3Me1BkpQA_4_2">7&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="Narr_QX33rRJqVEijVckpuYhgHQ"><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="Narr_XxmWNTK_uUWWcaVdqy5cZg">No</ix:nonFraction></ix:nonFraction> impairment losses were recognized during the years ended December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" id="Tb_zKXZQgOkEEaSOeD1thaNqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="Tb_i6rlyzjcekeP9PgoSTNqhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_EwrjcVqlxEyPGvd0HMVx_g"><ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_zHJLPBIChESAxtcZNUv9tQ">no</ix:nonFraction></ix:nonFraction>t have any outstanding preferred stock as of December 31, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_6rRszFsc7Eysv6Gn6qIiSQ" continuedAt="Tb_6rRszFsc7Eysv6Gn6qIiSQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont4" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont5"><ix:continuation id="Tb_6rRszFsc7Eysv6Gn6qIiSQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_iFoxBDAg6EeNl0smIsu_AQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_tltV-F9nZkC-TPk4IcGT_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_jnMcWsovKEGSJYgSEhOGBQ" continuedAt="Tb_jnMcWsovKEGSJYgSEhOGBQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont5" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont6"><ix:continuation id="Tb_jnMcWsovKEGSJYgSEhOGBQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_TIFWTuRGXkGAqKG8hQZSHQ">no</ix:nonFraction> interest or penalties related to uncertain income tax benefits.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_IEkYBWbQE06uEa2gxfpUsg" continuedAt="Tb_IEkYBWbQE06uEa2gxfpUsg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont6" continuedAt="Tb_gDgAQDPUo06XOkLwwm-UFw_cont7"><ix:continuation id="Tb_IEkYBWbQE06uEa2gxfpUsg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_lCPSqmSOy0mzcHs-zP7lHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_EmmKTsU6pEyz8iCIYJ0w8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#39;s stock option grants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_A9SIW9znT0GNwImI1XfNGw" continuedAt="Tb_A9SIW9znT0GNwImI1XfNGw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gDgAQDPUo06XOkLwwm-UFw_cont7"><ix:continuation id="Tb_A9SIW9znT0GNwImI1XfNGw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-02 (Topic 842), Leases (&#8220;ASC 842&#8221;). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_Tx03DgTslkmw9u8AH7LmjQ">5.8</ix:nonFraction> million of right-of-use assets and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_Go0OzEDsxk-KJCd21sqkHw">7.2</ix:nonFraction> million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. &#160;The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cd7d3b08_423d_489c_96c7_95d05ba43675"></a><a id="Tc_VXt0CQADdESeXGuWiOoU1A_1_2"></a><a id="Tc_HEDPc-qVA0e89ZYNPw0oXw_2_5"></a><a id="Tc_S6xhyFbv10m13gSqXzrt-A_2_8"></a><a id="Tc_KEeipKvHOkuFR1wM1np2Vw_3_2"></a><a id="Tc_kHs_O3oLw02dRpDRen-2gQ_3_5"></a><a id="Tc_JJGhaWFYhkWzpeTMF1eOuA_3_8"></a><a id="Tc_vQae8R4MWEiMYvj-5TQkxw_3_11"></a><a id="Tc_5rsnD8RRREmOyhVAm3lIyA_4_0"></a><a id="Tc_2AGS2aObz0m_i_evu8PrEA_4_2"></a><a id="Tc_6iMZa_h5vk6VpAp75rd2bw_4_5"></a><a id="Tc_NCa8gjA3s06Xo0y6G-vtgQ_4_8"></a><a id="Tc_4-bACiWMWUan34XpM9DXpw_4_11"></a><a id="Tc_nIpQJZ0mhUC8zeKh1XvSHQ_5_0"></a><a id="Tc_09rE1YdT6UaOVCg3ZOmJvw_5_2"></a><a id="Tc_0EKkR3owf0yqSEvi8tKlfg_5_5"></a><a id="Tc_wjzhXyIWE0Gs8pz0XZp3qA_5_8"></a><a id="Tc_56GGVA8gc0i3GDEVagGaeg_5_11"></a><a id="Tc_Kfp-cvOy6kGYqoOZvGFbrg_6_0"></a><a id="Tc_yFyq8U4aCESHg4HRYC5aZg_6_2"></a><a id="Tc_YcHFQKIFqE6MBC47Zv3vgw_6_5"></a><a id="Tc_F6c70NvRoEeGTez_EGvicQ_6_8"></a><a id="Tc_hHBguG5b6km9J7mmOew2AA_6_11"></a><a id="_2af83d82_9702_4d2e_a06b_a7a667e3e20b"></a><a id="Tc_bc8F1gx-CkOaUERV6j1e9Q_1_2"></a><a id="Tc_NPiGyr0Ay02_WSBjXUpfbQ_2_5"></a><a id="Tc_YproBtXcRUe6fuhxGEcktA_2_8"></a><a id="Tc_NwGQPnqofEGH2gp3LVwdiw_3_2"></a><a id="Tc_5RD5R4LXZkukjZS7FEQbEQ_3_5"></a><a id="Tc_6z1LOHXs0kSxNw-7SblATw_3_8"></a><a id="Tc_Wiu3MnTKbUWmarhfKNkYRA_3_11"></a><a id="Tc_O-XpW_gd5kmR3KTz04P2iQ_4_0"></a><a id="Tc_fGeVJnt3R0-uZnLn1v9l8w_4_2"></a><a id="Tc_9VKrDbvzo0iEk6r-JgOmhw_4_5"></a><a id="Tc_M2QFNc8ACEKCtXkHtG52iA_4_8"></a><a id="Tc_HRDCvWSZ50SSjuXu7vuKEQ_4_11"></a><a id="Tc_Psio3EfgLkqOOXkZWUUHQg_5_0"></a><a id="Tc_ECqFsV5U3Emu8NaMw5-vcw_5_2"></a><a id="Tc_6f-EhBXrTUGUjflfJVR7iw_5_5"></a><a id="Tc_MY7nNoXGY0GVswm8k7CEWg_5_8"></a><a id="Tc_0PZIP9Dv8EipoXXWRWpgEw_5_11"></a><a id="Tc_VjcNyNATbk2SVcXdUd30MQ_6_0"></a><a id="Tc_I1kw6bft4Emjy2zrij-rtA_6_6"></a><a id="Tc_sbkDTcEDPECQ0DEEFU5YMQ_6_9"></a><a id="Tc_2st0tWjihUueyHrXqWuLtg_7_0"></a><a id="Tc_S8caPEVOA0WP2cFci8hnqg_7_2"></a><a id="Tc_k8c-0MGAP02mmnPCYFsHGA_7_5"></a><a id="Tc_JeJviiECZEWSoNgyta8IZQ_7_8"></a><a id="Tc_5AxJJ-N0sEiCqaohBZ_6bQ_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_b1oMqMbk70-Nr2gOZlZRDQ" continuedAt="Tb_b1oMqMbk70-Nr2gOZlZRDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_5PrE-6176EKxLjlRByrJKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_r5cjIRr3zUexRW7DcMAK0Q_5_3">207,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_8yS6RFF7cUWnBpcdFfUiUg_5_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_wlOHj6NMXkO1ixllLImS8g_5_9">666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_oWwsVd5LyEWkFkq28cs-Fg_5_12">207,254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_f6FcGHiKmUS5vLvuRFhYxg_6_3">207,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_ZYnlxToLXkCKRSFwebaQrg_6_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_bpibasfy_Ue3fZ_9_ewtSQ_6_9">666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_LGJYrAt-o0q0_WvZ8lqYPg_6_12">207,254</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_uqmO2Ebp3EOSDYgHArSGpA_5_3">242,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_XZA0X6STW0qwZXBTrQHDlw_5_6">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_Sduq1JzU6kqbhSX2CzkPbQ_5_9">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_fb0lu5FkRESx-Br0VDgoOw_5_12">243,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_0QUjgYKmSkaYPag94pWyMQ_6_3">6,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_IkpfXt9qmk6EYcUI5yy2Zw_6_12">6,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_mRVoza8bNkG0xeG1TghynA_7_3">249,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_iteW9b8bIEqtcGeOzr0bmg_7_6">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_N0zhhenFM0ufyJkwk6al6A_7_9">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_xUwL3QQScU-LeD7yelb-cQ_7_12">250,676</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" scale="0" id="Narr_wwBHzKcx50idQyu-bEGVjw">no</ix:nonFraction> marketable securities are considered to be other-than-temporarily impaired. The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2021 and 2020, respectively, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="Narr_bueko-QyWkKIUMqIGZAV1w">57</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="Narr_3WtjcmjpsUOYPqs_2I8aiQ">70</ix:nonFraction> thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_pzGScgUnr0q6BC553qBuqw_1_2"></a><a id="Tc_lKTdE4AUDk6_rhF4gy_TJA_2_5"></a><a id="Tc_nx4m5I5QKEuXj_cKdZw_PQ_3_0"></a><a id="Tc_uTeDfw_8j0GpU7uCJ5bbhA_3_2"></a><a id="Tc_QJYtLY-J206ax3lK96BS8A_3_5"></a><a id="Tc_kHi2mPcv50C5GT_4JUbeqA_4_0"></a><a id="Tc_yJGOuYdOU0muVdegdvD4AQ_5_0"></a><a id="Tc_DD4wUSiL5Ee4t7LwTr3eqQ_5_2"></a><a id="Tc_Fa_pm9oMyka1WRi0Aku4Ng_5_5"></a><a id="Tc_U9YLP_Nu0k6wlRFE1JBLlA_6_0"></a><a id="Tc_vrj6y6tetECv8P8aUhhIVQ_7_0"></a><a id="Tc_EPnBfBmO1UeborrCC1CKMg_7_2"></a><a id="Tc_HiNrfSQXKkSEWoOfJqFuzA_7_5"></a><ix:continuation id="Tb_b1oMqMbk70-Nr2gOZlZRDQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturities of the Company&#8217;s investments available-for-sale as of December 31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" id="Tb_zf46_FJWpkC5A0C1tuIWJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_IPdoIfofwUK4yoPiv28nyQ_5_3">104,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="Tc_7mvWCl6J30OlMtVJyM1vKw_5_6">104,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" scale="3" id="Tc_EuZT8PyoLUCZU7en4HsySg_6_3">102,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" scale="3" id="Tc_IJT_88W1TUaPhBkmEHqDxw_6_6">102,479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total investments available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="3" id="Tc_m6NRgXV6DU6AOQthVaeJ-Q_7_3">207,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="3" id="Tc_UP3P7jn_hkuI9Q1gU12YEw_7_6">207,254</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_95c0780f_3787_4751_9683_cc9253a0c181"></a><a id="Tc_ZFQbTXI7dUW8JzRar3fpeg_1_2"></a><a id="Tc_Ja32d8tYIkiD7I7A8mFjoA_2_8"></a><a id="Tc_bJhJAXP9I0ye4HijS00jxQ_3_5"></a><a id="Tc_yvV3DqA-8UyP2DougKfRlw_3_8"></a><a id="Tc_YGoyXQN4o0e9PB7ZEnWv0g_4_5"></a><a id="Tc_Ls8YvPL8B0OFaI79ZfWgQQ_4_8"></a><a id="Tc_WwuLs1W4Bk6eR5pad6vKHA_4_11"></a><a id="Tc_0G6zyDZeskWQGmT_Ll07Xg_5_5"></a><a id="Tc_4SobNQdMIEuWnm71uPiXEQ_5_8"></a><a id="Tc_-B6EbhWTS0i4x-14A9T0CA_5_11"></a><a id="Tc_iIiu_jFg9Eikg-FrbHUdog_6_0"></a><a id="Tc_t935bSQdykyw8squcXL-0A_6_2"></a><a id="Tc_EMXKQojQMkGSadAVJzS4dQ_6_5"></a><a id="Tc_5Yw648qdMUeIGJgYoj0YvA_6_8"></a><a id="Tc_oDMx9HhDvESrsP9xv3cWxQ_6_11"></a><a id="Tc_tUfL2TRPV0WRShSqEU0J7A_7_0"></a><a id="Tc_9xmPZQUYQUSSHeCHAhUKwA_8_0"></a><a id="Tc_fhcikND_dky5fARSICLUxQ_8_2"></a><a id="Tc_KK525aDRNU-e8B9IBOPmNQ_8_5"></a><a id="Tc__Ow7XpH0FEyx1ZNoHOP4og_8_8"></a><a id="Tc_k2UZZbpYIUCmLZDV80xLdA_8_9"></a><a id="Tc_ZVpPzsffsEKPD3S3R8ktHg_8_11"></a><a id="Tc_kgLIrZNFoEiikJxQ3oIdqA_8_12"></a><a id="Tc_zqPOHxIQrkiSaWgxZjpJYg_9_0"></a><a id="Tc_UnFsc8pBREuEmjpVMxm_Qw_10_0"></a><a id="Tc_fElfWrUlCEamDCFoYmKfVg_10_6"></a><a id="Tc_hvzps2b4iUqgKR-EPHHL3w_10_12"></a><a id="Tc_cCAC1aTzWk2ZCuCZvDPudQ_11_0"></a><a id="Tc_lop9GloWkU2br3w3h1ibcQ_11_2"></a><a id="Tc_Jpa9ikRI0UGhfzLMwecjSQ_11_5"></a><a id="Tc_UzBMWwysLk2A-XiQnKmzlg_11_8"></a><a id="Tc_zib5Ehp15UyMP4cGqQEsgw_11_11"></a><a id="Tc_pyCM9H7S1UCHa-FFxFFYJQ_11_12"></a><a id="_57c0a96f_0c82_4f4e_91eb_1ae91e80cbb6"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_lR80szm2C0WAed6H5lvHug" continuedAt="Tb_lR80szm2C0WAed6H5lvHug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy as of December 31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_ZgqV2bxlA0CzWJb910J57g" continuedAt="Tb_ZgqV2bxlA0CzWJb910J57g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_kmwB305biUWLo3UjsSooUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_4dcnmquowUOjl8J7pQYD3g_8_3">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oYhMcGirCE25Vip1ZFlDcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_8dYFTdzUbE6KyRW4jqCkfw_8_6">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Yan-j4dWbkS2KGt5iU5VRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_2QHogolw6kWWBmO-226dqg_10_3">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_w26PQYiKDUS0odivM7VviQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_Tz9X8QP-S0ay56DHKRAdxQ_10_9">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_JO8kC4Wv30ykMH8DL_H1Ww" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_qmNfIuY9YU2P8LBWfTJgeQ_11_3">209,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_SpiKMzSntkeJHGELywtLIQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_sHsOpOyumEybceEkAv86nw_11_6">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mNncfD8YUC8da9cv5QKbA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_z4omeXM25UakmfYiSybrjw_11_9">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_PB4sGeQPnkyENg9Vbq8dSw_1_2"></a><a id="Tc_wqAHN-JcNUi5ytAfgrGCTg_2_8"></a><a id="Tc_5pvKf4OxOUCQzK7dvasP3g_3_5"></a><a id="Tc_fuobdHXNpkCm9P9S_V71HA_3_8"></a><a id="Tc_UdP_hRkqwE2p9CB-79fZTg_4_5"></a><a id="Tc_V_dWFhtTC0GQt3AlQP20KA_4_8"></a><a id="Tc_Ga_EALwYlkauqQE5Vpj8KA_4_11"></a><a id="Tc_lnFVSF9KFECd8-sD_2P5rw_5_5"></a><a id="Tc_smur6zVjxkyMXdWSg-ox0w_5_8"></a><a id="Tc_beqDOkG3uEqAU_cRxEZl7g_5_11"></a><a id="Tc_ps2ZJWbJg0S2UESudr5vRQ_6_0"></a><a id="Tc_MzMMFZaCbUy49pqyhIiHAg_6_2"></a><a id="Tc_ZvGbkk38I0axZbeopahWFg_6_5"></a><a id="Tc_cCjUKmVUjkCqh0IrrvMlfA_6_8"></a><a id="Tc_gky-iSiKTUSiyoutEburrA_6_11"></a><a id="Tc_uCRsLxJmBUiLWpzHSSX5OA_7_0"></a><a id="Tc_lreqqpxrlUqVf1p3xpSRHA_8_0"></a><a id="Tc_nSw805ojNEqzOKx-Rucxcg_8_2"></a><a id="Tc_-wdm9PmFAk-_gwfJQSQWRA_8_5"></a><a id="Tc_eLVvJ9ZRskG1pl760QYeSw_8_8"></a><a id="Tc_5KNOzGctGkeaDa5QuVy7hg_8_9"></a><a id="Tc_hNCkS6jcqUeaW25qpZeU0g_8_11"></a><a id="Tc_jz4TrKjeBkiaWWPEGkixZA_8_12"></a><a id="Tc_yRCke9vBCEaGUkLoweBxsQ_9_0"></a><a id="Tc_zVd0kvWkdUim6wmejl-Y7w_10_0"></a><a id="Tc_EyzKX2Bl40G4Y8KmiidwrA_10_6"></a><a id="Tc_GqOodbWK8k2n3DBI5C-w9Q_10_12"></a><a id="Tc_jetyTVHPz06G26Ll9AwuGA_11_0"></a><a id="Tc_TBOdKNjJuUGTkXWIazXCkA_11_6"></a><a id="Tc_SL6ctg6k9EC2a9C6qRtc6Q_11_12"></a><a id="Tc_in_ExuXntU2yl-ECqXUasw_12_0"></a><a id="Tc_xKr0zix0WEiIBZaSCGFaIA_12_2"></a><a id="Tc_dzMNIY9-7EGAo1POxiAWrg_12_5"></a><a id="Tc_gxDwMiqLOEy50wHIQquBug_12_8"></a><a id="Tc_jYvRmaGb6Uuof_dkfxAaEQ_12_11"></a><a id="Tc_7mPG-6q5kUCyjNzqnVC3Yg_12_12"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48_2"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48_3"></a><a id="Narr_gpQqRb0xtUSdh3rSd0p7aA"></a><a id="Narr_2x4_xi392USgFs-7VoiuHw"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4_2"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4_3"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078_2"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078_3"></a><ix:continuation id="Tb_lR80szm2C0WAed6H5lvHug_cont1"><ix:continuation id="Tb_ZgqV2bxlA0CzWJb910J57g_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3BxpsJ2iNECPTNPjm8MqUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_xLHaFMTP_E231P0w3fcjKw_8_3">11,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_zGOjNpmC6EGr7pG_-L0KzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_HhCh6sqibEefqqasnM0qtA_8_6">11,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_hW36vSQqcEKgeJbxONrVSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_KhbGquBOSkmcO5fj-7rmsA_10_3">243,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_B9L06CbX5EGrB1JXLY5xsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_8VQPrsv7UU6w8KjAWQJmrQ_10_9">243,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qdi16EmCNUKD0BX_L5w1VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_tRZL9PAVaEKYfEzfA7s07w_11_3">6,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E7waEgPyPkSn9Zcc1udIPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_k1RKHKtHKk-tOYMQFQswlg_11_9">6,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FJ9ZE9uoI0-WmaYGYBzHyg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_BY2JOvRCJUOS8Zbosc54VA_12_3">261,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NPmdibs4nkishMWIdyp4yw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_GRQKLSdXCkmGFq7-jiI65g_12_6">11,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_woD1OcCVU0i7W0uEaTV-eA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_nb5HsTjN406PQzhyX8r2qQ_12_9">250,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_FEhKRq9ls0-fot3cS42Tag_1_2"></a><a id="Tc_FZteLUloWEqAS8Gp8UqYIw_2_0"></a><a id="Tc_QO3WOxu--UahVjKhJknQyw_2_2"></a><a id="Tc_9DBgneAwFU-goRSWJ9dDjA_2_5"></a><a id="Tc_t_VUxme7AUCs8PLneeoj-w_3_0"></a><a id="Tc_-_Sfw9TwnkeYdKK8GdKx1g_3_2"></a><a id="Tc_EUWFhMId5E2q5wAK8GkdQw_3_5"></a><a id="Tc_Xy1tXewPHEOm3fSeLhY8tQ_4_0"></a><a id="Tc_tCKPmtMIY0qXdEwiKhCwjQ_5_0"></a><a id="Tc_7GWFM2vpjUqXKRwIAauCNg_6_0"></a><a id="Tc_LfWl-IjXWkaW253YGKIODw_7_0"></a><a id="Tc__3gXA19-9E2S3k6-PBJ6HQ_8_0"></a><a id="Tc_6bTj11r0nEqO8klq7Hc4zw_9_0"></a><a id="Tc_IXiu7hDgcUKInEfIFr9wDA_10_0"></a><a id="Tc_VYiDv1Ixv0-nsNGNgflV4w_10_2"></a><a id="Tc_djdm-xFTXESXBuvQS_SP1w_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_75Hht7571Ee3UmJMUUsRAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_pOCMR_lzi0mrnzkJvjpGFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_BSsHwW_jjUWkVvqBCbt48Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_j1nSlmovrkKJgUJhdYEOtg_3_3">16,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_Qq_WJ4vpZkiMhOxoPOoNuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_9UYZFgnkd0CQtLNZu06N9Q_3_6">13,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JJOGCiB-VUKIQzM08BXQzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_uJ-oW1t4tUSH5ztOKr4ntQ_4_3">8,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LFp27XQr4Uid6yEPdONaFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Yt8avdDwcUm_KIK_yVAG0A_4_6">8,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_oYnlwjc7HUGb5iWfCmq0fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_mLAnM5_MhkWA9jmQJI1WtQ_5_3">1,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xZ8jUscG3U-QIINlDwJ2ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ao28GxI4_EiZPj6vJv8C7g_5_6">1,010</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_couFI7dtvE-qXjH-EmZFUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ZoUtcuuv7EO2cBxI7QPBIg_6_3">167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q2ALKasRH02YKQvydmMALQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Pz1a8dEAmEOLIRB8ngSk5A_6_6">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jUzYlFOGn0CwHbmMVEGKpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_M41p3sjqLU2i6hJQo8Ratg_7_3">371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_HwvSSMcY6EWFFgNhar4zeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_wc2uZSSlZ0qXsIKvt2icJQ_7_6">1,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_d7zLTP82uUWVMfN_FwI-zA_8_3">26,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cN0BSvUIdUmDYPe2qWxPqw_8_6">24,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_hrk9HhkbmUaT_z0mi4jBBw_9_3">12,737</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_QNwqpXxiOECW5jumu2Wi0A_9_6">8,560</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_CemFNOvtUE2fVqh10afyMw_10_3">13,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_tmDw2rhGwUOzC6PtvXq1wQ_10_6">15,809</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress at December&#160;31, 2021 and 2020 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_2Ym-1sDxz0Oo7juXDs_4vw">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_AfLsCbvNHUeMohYyejiM3w">3.4</ix:nonFraction> million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_a7YwohC2v0epTVtE_j5qHw_1_2"></a><a id="Tc_V52hg7inOESwNwwnuwzByg_2_0"></a><a id="Tc_GIc0Vmsyy0yMfyFcvnOQ-w_2_2"></a><a id="Tc_2H0iv3EZrE6KNjYkGyfllA_2_5"></a><a id="Tc_vkzYjf2Z_kyvpjP3-WvRPw_3_0"></a><a id="Tc_tziPpM75zEKylS5fzRpJYg_3_2"></a><a id="Tc_Rs2IYugpMUayOAH4LvTOpQ_3_3"></a><a id="Tc_K3g5p19zB0KIP76Oya0MVQ_3_5"></a><a id="Tc_TPLifv5bWEOjT8NrvbG2yA_4_0"></a><a id="Tc_2Uwoh8XRAU2eLyk2yvKm9w_5_0"></a><a id="Tc_X4F7DgKVXUykM34mpgqMmQ_6_0"></a><a id="Tc_YoobVJvKw0unlY9Y1p1peA_7_0"></a><a id="Tc_14YyMeyJsUOoLRuTpk_3mQ_8_0"></a><a id="Tc_jibPETIbiUWHaZn-JcacXA_8_3"></a><a id="Tc_fwp7IpKE_0qrkyePHQAQng_9_0"></a><a id="Tc_hFJW3oEZYUeUuruDX9ao4w_9_2"></a><a id="Tc_lInW7hyF4EqbzfJI6TmCXg_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_Z4hXJIGNHkONwL0ME6MJXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_jjjBhlrdL0CFSyUUxUvy6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedConstructionInProgressCurrent" scale="3" id="Tc_cKcV_W-Io0-194p_HTacKg_3_6">109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_MdudHo5Yak2aL9yE9MfN4w_4_3">1,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_U9vjW_VLj0KZ7DkcHoR9QQ_4_6">973</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedClinicalTrialCostsCurrent" scale="3" id="Tc_kCVQXO_YxECV3NZurBWPbg_5_3">727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedClinicalTrialCostsCurrent" scale="3" id="Tc_FDiqVn6K9E2Em3oe_X1pAA_5_6">1,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedSponsoredResearchExpenseCurrent" scale="3" id="Tc_rKiMJ6p0kUW7io06Jg5xmw_6_3">1,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedSponsoredResearchExpenseCurrent" scale="3" id="Tc_2F2DbmQeb0SLA-HekBHxRA_6_6">472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedOperatingExpensesCurrent" scale="3" id="Tc_D4FkrPpjkEGOP8q4K4F68A_7_3">656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedOperatingExpensesCurrent" scale="3" id="Tc_TmZFbaP1F0yFnQPT-9co5Q_7_6">1,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_vCOgig9KqU6NbttODv2WJg_8_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_kZ7Axq-FwkG52z42SP0ApQ_9_3">4,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_1eak_EfxxEGneJeH--Nurw_9_6">4,627</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_doG9nBhP0kqczIbVtQO-dg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Former Agreement with Eli Lilly and Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the &#8220;Lilly Agreement&#8221;) with Eli Lilly and Company (&#8220;Lilly&#8221;), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly, terminated the Lilly Agreement without cause. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized revenue under the Lilly Agreement of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_w5P21kf0c0WRJYhRcmUNfw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_GwMVG96FdUG2WUhKnhvngQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_GZR3kGJhT0eFCCICgDlBxA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_9LU-GZeyCUu-RRZOc0SCuw">22.4</ix:nonFraction> million for the years ended December 31, 2021 and December 31, 2020, respectively. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5327feb0_80e6_4eaa_955d_2e33b23d8dce"></a><a id="Tc_yoNloAjp_EC7_NJM_idMHg_1_0"></a><a id="Tc_AkiYP3Jw2kaT877QncSXGg_2_0"></a><a id="Tc__fmrPaQpGkKRDZT1bqQy0w_3_0"></a><a id="Tc_gh2PYdPTr0WO-4KILBSl8Q_3_2"></a><a id="Tc_nb6LQYGfAUyIOTYfzkOqdw_4_0"></a><a id="Tc_Xg-JxMkTskuhSNSrT9H6Dw_5_0"></a><a id="Tc_63CObuPTS0u-WKotUSMKXQ_6_0"></a><a id="Tc_dApMMd6zmUyL2C_NSeYZ7g_7_0"></a><a id="Tc_4zHhJVQ2RUqofcsHHInWkg_8_0"></a><a id="Tc_53eFegcI3Ee9Uk-AloT5Hg_8_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_eR3epGnM7EeFT4zOzoN68w" continuedAt="Tb_eR3epGnM7EeFT4zOzoN68w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s leases primarily comprise real estate for office and manufacturing space. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="Tb_upN1zaYMCk6v7vAyOTT3gg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company&#8217;s minimum obligations under non-cancelable operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="Tc_mspO-HFqRUCApxgYYMqoyw_3_3">1,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="Tc_8eSWNjRTCEKugKatPZ9SKw_4_3">1,171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="Tc_vsPPO_5dHkau1yKcC-F27A_5_3">1,231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="Tc_emfO8CAg9EKgTOR4kj8e7A_6_3">1,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="Tc_eTCgMzbV9kSCm2Mn0CN2gA_7_3">6,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="Tc_tDoeoqAjeke9_UyqFsI7QQ_8_3">11,427</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense incurred under operating leases was $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="Narr_r9xPdIWQuUOyDD0hFXGD-A">1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="Narr_R6fpHEE7rEeAQZ---9Q65A">0.9</ix:nonFraction> million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#8217;s management, are likely to have a material adverse effect on the Company&#8217;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eR3epGnM7EeFT4zOzoN68w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#8217; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#8217;s motion to dismiss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#8217;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_f6ruOnqxVEKzfOfccViKcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_4_30_2016_dCCJWmRM8USlY0UQ6_FnFg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_TQ83WWOvoUObW9mLPCbsNg">1.0</ix:nonFraction>&#160;million term loan, or the &#8220;Term Loan&#8221;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_1_31_2019_ML94Z-Zsg0C5Id5hiZnfiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_mB9QpLf5iEeQGXswMQ6KXg">5.0</ix:nonFraction> million, which amount remains secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="0" id="Narr_DRjMmv6B8ka9_AYazrR8kA">no</ix:nonFraction> outstanding payments due from us. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:PreferredStockTextBlock" id="Tb_MrmZaHLxfUSL65t4kigbWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_a7zRTz_TY0G44I86TksWBA">10,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_K8jZ8z478keRGqe470Suhw">0.001</ix:nonFraction> par value preferred stock, and there were <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_7r2CSHviJUeYHbYhA1kS7w">no</ix:nonFraction> shares of preferred stock <span style="-sec-ix-hidden:Hidden_Q1KEPjTqhk6GA6gnGmG3gQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.</p></ix:nonNumeric><a id="_cp_text_1_1369"></a><a id="_cp_text_1_1372"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="nxtc:CommonStockTextBlock" id="Tb_u9pKnr5J0kKB6VbwA9-qsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_nSAeDaZlt0-GtUJN41Xqdw">100,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TQhlReRec0KzzYommSSN1w">0.001</ix:nonFraction> par value common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_nTE20PZJAEqIOpUXdH0Xiw">27,680,997</ix:nonFraction> were issued and <span style="-sec-ix-hidden:Hidden_cpk3pttepkCkflUjT07eqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to <ix:nonFraction unitRef="Unit_Standard_Vote_w0Gf5YJwbUupsjwI1CCnAw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="INF" format="ixt-sec:numwordsen" name="nxtc:NumberOfVotesPerShare" scale="0" id="Narr_S9lk7sEHf0e6tlOtbHMKuw">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="Narr_rzHRgMLW1E2Z4LOXOkWiSQ">No</ix:nonFraction> dividends have been declared or paid by the Company through December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_RyBTQBhCdUuoZr3TD5y-Qg" continuedAt="Tb_RyBTQBhCdUuoZr3TD5y-Qg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_7a02f31d_493c_4457_918f_ec14c8c9032d"></a><a id="Tc_obNz09qXME67UrZEAcxp3A_1_2"></a><a id="Tc_ZEPSaSORGkCiK0zN5hYVDg_2_7"></a><a id="Tc_DAN2LGwp2Uy5gp_ezIcPog_3_4"></a><a id="Tc_xFBOc8xNDUCE3K9f6ZfMyg_3_7"></a><a id="Tc_rKkpHSjJtka4pHHCmQwAqg_3_9"></a><a id="Tc_XLknLtDcrEG8ENi9ODFvCA_4_4"></a><a id="Tc_B3Pxma-CHESv-urljlmKiQ_4_7"></a><a id="Tc_xew__uxVKUCX0s4dyF3L_w_4_9"></a><a id="Tc_WmaK-Ti8kkSxQ7FnefKc2w_5_2"></a><a id="Tc_AVZgcL704Ua1FE5i3I-Tvg_5_4"></a><a id="Tc_BXWoXk1SjkyyuWUDkD7NgA_5_7"></a><a id="Tc_AnYAEK5GhUK8r9cQg-VqhQ_5_9"></a><a id="Tc_TjLYSKYdckaYo6-GNU98Yw_6_2"></a><a id="Tc_pkuhk7O22UWQD1D42sbLJQ_6_4"></a><a id="Tc_k3eVI_vdo02u17p6Mt8q1w_6_7"></a><a id="Tc_LxV1UA8hL0aGWoaAaCkULA_6_9"></a><a id="Tc_LThmfGV800iYdNJsfjnMYQ_7_0"></a><a id="Tc_yyFjC6jMGE6rU2GhlQ-srw_7_4"></a><a id="Tc_kfzwYV_HsU-Qn6WZY-ZZQA_7_9"></a><a id="Tc__hSHkBEY-USn725f5GJBag_8_0"></a><a id="Tc_x1zxCXY3NEmPFYDec2xdiQ_8_4"></a><a id="Tc_clzAjg3IpkqZv_8lzHRwvQ_8_7"></a><a id="Tc_PKii3CgDNE2VFHpFrWNIoA_8_10"></a><a id="Tc_vmbsXT_cnUyxdb_PaTdpwQ_9_0"></a><a id="Tc_76pxgjO1fU-_WtoO8QfNCw_9_4"></a><a id="Tc_OVwXUsLURkaJ78hHcJfkfg_9_7"></a><a id="Tc_YR_n-PP6u0idto-7oaHcAQ_9_10"></a><a id="Tc_N00TCcsqqE6Eg9X7a2UFQw_10_0"></a><a id="Tc_rK6AUmPaikeqHi0A_Xpitg_10_4"></a><a id="Tc_921wHrsTLUKN0emYzti3nw_10_7"></a><a id="Tc_08uOxJaDmky3G3_BRFu6ow_10_10"></a><a id="Tc_WctWV-v5KU-ydThwhDy_GA_11_0"></a><a id="Tc_bu5FpOTSNkGc20liZscCUg_11_4"></a><a id="Tc_R-Az74SHnE-4ESrPyEu5Ww_11_9"></a><a id="Tc_EllxFY91xUKNo3wbg8bOGg_12_0"></a><a id="Tc_lERm543wQUKl6nUglz9SWQ_12_4"></a><a id="Tc_3_L0U7V_SkGD0jyRBOSXdA_12_7"></a><a id="Tc_diweDT77bkmFQVw_PFL_pg_12_10"></a><a id="Tc_aaZk6bNIP0CF2bpKW21X6A_13_0"></a><a id="Tc_O6BBdXRBg0Kd-PFxczlzYA_13_4"></a><a id="Tc_t0TRtcfvk06iTfb2llbppQ_13_7"></a><a id="Tc_XlUisa9AakWmDqnGQ2EkGQ_13_10"></a><a id="Tc_AIyaPHSW7kiEIxRLekfdaw_14_0"></a><a id="Tc_VuhxaliLqkutlb3vxzS-mA_14_4"></a><a id="Tc_K5Mi7u1hnkSVwQHnJ96ijg_14_7"></a><a id="Tc__54BKAPm3EiHT9BfqDXCBw_14_10"></a><a id="Tc_tkyt9ylAxU2b7S1oDA37ZQ_15_0"></a><a id="Tc_WHx22VRE2UesjnGJwjaLgA_15_4"></a><a id="Tc_1JQCccdzE0mV9PSaZ9AMbQ_15_9"></a><a id="Tc_KKP-RQfok0GhNMP7hcvW3Q_16_0"></a><a id="Tc_gkisgb04qEmdzAotrjL8qw_16_4"></a><a id="Tc_bnOfMPFnhEO55Tql1KmP7A_16_9"></a><ix:continuation id="Tb_RyBTQBhCdUuoZr3TD5y-Qg_cont1" continuedAt="Tb_RyBTQBhCdUuoZr3TD5y-Qg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#8220;2019 Plan&#8221;), which became effective on May 8, 2019, the date on which the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#8220;Effective Date&#8221;). The Company&#8217;s board of directors (the &#8220;Board&#8221;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company&#8217;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_eNVV54RhUEqTl5x1mLRsMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_RYihVZiJtEqnYOqy1fhYiw">2,900,000</ix:nonFraction> plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> during the term of the 2019 Plan by <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_pWUZUIh3IU2JNJgRAHr9Ig" decimals="2" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" scale="-2" id="Narr_vfWR6wtpNECXozPYsNKPNg">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year or such lesser number of shares determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_POQwOZH2fkaMcb9h4V0jNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_wnCjeeL0FEaRAiJaQtp2zA">2,313,433</ix:nonFraction> shares were reserved for future issuance under the 2019 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options granted under the 2015 Plan and 2019 Plan (together, the &#8220;Plans&#8221;) to employees generally vest over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Cz0-jmFaUEuCMMJbTQQLQg">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw" format="ixt-sec:durwordsen" name="nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="Narr_jyghYh75g0qOTVZ0G2fs_g">10 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity for awards under the Plans is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_VwM1iBcLHk-yX20Wi7gjfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_6WKZ69gc50i5PREOsI_e_A_7_2">2,170,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_FTR7NpF-wEW42mZhfjA1SA_7_5">6.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_G53rdmX140OTQJmbyiS6Jw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_xgvIFAtRtk69_n492cHuZA_7_7"> 8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_aIazqnpYm0CeF1b8y7K2-A_7_10">113,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_8H62AbLQBkOC8AlqON61CQ_8_2">1,115,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8D0dVaBKLEGdRcmFk2pU4g_8_5">37.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_L_K068e050OUubMn2V23nQ_9_2">69,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_SUU0VcOFfkG1-Dxm_e4OuQ_9_5">1.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_VPieaV0rdEafcLBrcf6IMw_10_2">104,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_0mQ3n1FeRkGLhZl4aU4Wmw_10_5">25.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc__suFsxaOa0aObafqdOrnzQ_11_2">3,112,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yGi6vDCjS0WcNevIep743Q_11_5">16.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_4A4mnIoPuEG9LWTUOXe8nw_11_7"> 8.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_16f_hnCmckK7vwVMID4KTw_11_10">10,810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_BUh-C-DwYEuPIMzXFtdL2A_12_2">2,020,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_uB1dCGhleEiMUuVrdO0ZVg_12_5">10.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_LSP5RckOVkSu9YBrht_dhQ_13_2">105,731</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_DWTAFHZ-RU6uzeQ1aWqP2A_13_5">1.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_ZYnHHAJmrka25xq5XZ_g9A_14_2">481,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_oY1KWVwYXE2ITVfZxmwatQ_14_5">21.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HJcOGaqIo0yQdemDBjpEmQ_15_2">4,545,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_FS2votmF6kuBmEjCBAfXCQ_15_5">14.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_cXg3HahHrEi4JR29ea92nw_15_7"> 8.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_QCRTy-a05k6Eo0BHRXEciQ_15_10">2,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_kJ_bjFUZEky-_YaX3XFyHQ_16_2">1,915,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_zwzFXX_i5E21KQVm5fZmyQ_16_5">12.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Mzk8XhWkckmZ4BakCkAWGg_16_7"> 7.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_cHCINdAM8U-QjSPmSxeLEQ_16_10">2,783</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_LW0FH5CFrUWOpbOIEEWNSg">7.47</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_6e9Z2k1KBU2L7WBkCv0ToA">23.25</ix:nonFraction>, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_3ehMVWt-jkiNvDIcv_DTPA">469,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_WCreSwh_B0SkOouRlmyAVw">633,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2021 and 2020 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_VdtP6BVgdUCi5PnxXFx7vw">13,398,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_83lITadgH0mA3-it8usA2A">2,389,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the Internal Revenue Code. A total of <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_1Jdd-_wpikG_weZqBMb3Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_EmwaNgNzL0OSBQmxEei7Xw">240,000</ix:nonFraction> shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> until expiration of the ESPP, in an amount equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ" decimals="2" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" scale="-2" id="Narr_5gRQzC0AFEetAzST9ZJF9g">1</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ" decimals="0" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" scale="0" id="Narr_xwoyfveQeUOkPoaT5d52uQ">480,000</ix:nonFraction> shares of common stock and (iii) a number of shares of common stock determined by the administrator </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_X4SWu9iVt0GZoQD0QY7MCA_1_2"></a><a id="Tc_2qMXwXARjUyjNujDtwQO7A_2_2"></a><a id="Tc_jI-npdXlOUKRNW6tC8vOpA_3_0"></a><a id="Tc_Vsp5RZZ4UUSLfzU1AlcSmw_3_2"></a><a id="Tc_vEwJGiN_vked8W8-P0e4nA_3_5"></a><a id="Tc_MXdcO4IoPkWZomm3JRTG7A_4_0"></a><a id="Tc_TewyBCyBGkSIqT-Awp8SCg_4_2"></a><a id="Tc_r_ZdNzgelU-JnVzHXr_h_w_4_5"></a><a id="Tc_LwtE-Dqqlk-dgWN58GBuTA_5_0"></a><a id="Tc_NWo4KamiAkCr9qHW5Yjo4A_6_0"></a><a id="Tc_lBnphpd8MUKWAkBA-x5u3g_6_2"></a><a id="Tc_9OT1Z56Ud0G5LNKFUeRNpA_6_5"></a><a id="Tc_ijPyp54l9k2WPqGeGQDV_A_1_2"></a><a id="Tc_PJzVhV8MDEm2FWvTwOvX4Q_2_2"></a><a id="Tc_xUBhLc1FjUWSfGB0_RDwfg_3_2"></a><a id="Tc_JUNgLZiZn0uPFSlOKiSBRQ_3_5"></a><a id="Tc_aBXAsgYfEE2OGAE4HWSPVQ_4_0"></a><a id="Tc__kVqrvHss0mR9rb05ff3JQ_4_2"></a><a id="Tc_c-xBUAZqmU-AaC_lwt1bKA_4_3"></a><a id="Tc_2ilOF3N0HUWDcnsLHyXPcg_4_5"></a><a id="Tc_xLPW3Xb8dUG-ij20arHQ2w_4_6"></a><a id="Tc_FsfMpEGUoEekycbHcIVJ3g_5_0"></a><a id="Tc_2kgARicLZUqaBaL1UZ_TtQ_5_3"></a><a id="Tc_Zx3kV97C6Eq9hPwbCpuhTQ_5_5"></a><a id="Tc_yuwjrifiWUSS4oVLA_Sucw_5_6"></a><a id="Tc_ybSv61vot0uhS9rYxQ8pmQ_6_0"></a><a id="Tc_l8VEvvO_E0Ck6yc2EH_-Xw_6_2"></a><a id="Tc_MvKODx3ML0ml9xR4P_mEXw_6_3"></a><a id="Tc_WC9fvrINiEewVnbIkmFoAw_6_5"></a><a id="Tc_Hc116JXNkkS2SaSwrhnjdA_6_6"></a><a id="Tc_rii0o7Iu8UuImTp45o6GWg_7_0"></a><a id="Tc_N5PpxCu50kyYRc4h-GQoLQ_7_2"></a><a id="Tc_r5EvJ_MQKU21mG0eghwWQQ_7_3"></a><a id="Tc_W2zhOiyvKk2ET3vbO4yFmw_7_5"></a><a id="Tc_Jh3-jfl200CxRKKvn-jLPQ_7_6"></a><ix:continuation id="Tb_RyBTQBhCdUuoZr3TD5y-Qg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the ESPP. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_G_yj8-kGZEqKlKj7UfkTfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_9ojBYBwiH0iTV9yg9QrU0Q">6,464</ix:nonFraction> shares of common stock had been issued pursuant to the ESPP and <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_33XxS2bj4katgp19dilw6A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_IE6kLDLFdku-nLohQ2jzrg">784,216</ix:nonFraction> shares were reserved for future issuance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_IKDxg_Uy00SPXe-IbK6XwQ">10.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_fc0uSizHbUebyk8MFI2X3g">7.9</ix:nonFraction> million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_TcVHblcGuEe2b70AUgRwKQ">23.3</ix:nonFraction> million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_9R_fCOnFX0ynbTlku3ncSw">three years</ix:nonNumeric> as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_qkJ48ZEOFkGpX3Mmiw0AFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_ypDyfJrUqjGxvpjHQzEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HANgt6MtnkWLFhKVeRHKXQ_4_3">4,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HC8YQx8WSE68y6ph75dG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HBXTeLvaqUubPep8fxcbkw_4_6">3,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aiYI6v5UyEeVRnXYUS5XLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Jj4ir4tK-EKAaEGO9_tSjA_5_3">6,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eiLn54zwfEaRz2KZJSxGgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tzpq66seukejEZ_UuN6M9A_5_6">4,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_5HeMB_3KaEi7vRRliJ47gQ_6_3">10,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_O8BxxaI5-USmAEJ6FX1fpQ_6_6">7,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_ocdp-WXrZEmYFnv1rzUSUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_EVrIdedkiEaxDueScGxyoA">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_WZxifzsQjESjxsQy3nPF1A">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_JVn9hR-AtkKEjJmLWRpFXg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Tc_fhw5-OuHwUaYFHOcUbkPxA_5_2">79.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_yL9NnkYYNkivsjq4F79mIg">69.7</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_2CydXJWG1kmX2YFSY_hTEQ">81.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_fPnH8ZC3Vkaz3b6v1I__fg">0.8</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_VflD86XATEOnDkLEC9wuyg">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_Dq_cLRPxfkC6B42Tv5-U9A">0.3</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_07Kg4VxzF06Z-3j-jQuq6w">1.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_NpKVcmfjv0O0cwlraJGzhQ_1_2"></a><a id="Tc_p5oE7gJCpUW2P0CNHf1x5w_2_2"></a><a id="Tc_x3mKFVc2HUqaF7UNF1Vchg_2_5"></a><a id="Tc_qd37WhnYpketlNPncQAN9g_3_0"></a><a id="Tc_ulJyFaWJ3Ui2_zTVKQl7LQ_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_iog4UuCtWE6GAxrrbFks2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_iXbW33CWcUK0lPjI-SNsYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_e_s4q5Pn_Uu6ZKwpy8z4Pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dzuRxnRkLEK4xhb1_7zP8Q_3_3">4,545,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aAofUk9dFUCw9X561F27_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LP5NbPlGIUC5p5in9zt-7g_3_5">3,112,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_PxbC6Sobx0SQASMU3Oz7ug_4_3">4,545,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KcHwAQQmDEGiZVtw89qvlA_4_5">3,112,376</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_05cXx79nRUaNmBm6_7J2ug_1_2"></a><a id="Tc_xqMDeLC4JUqXPKe5R5lf5Q_2_2"></a><a id="Tc_62yQwBVOgUyhZd2GAGZzQw_2_4"></a><a id="Tc_ZDSG9DPwP02TwuEqww5Pww_3_0"></a><a id="Tc_94deri-lYU6dbScGNqysxw_3_3"></a><a id="Tc_eWLffmXxxkuw2W9HMZZDDg_3_5"></a><a id="Tc_cZpe8gzds0OUOzzqHsnTvA_4_0"></a><a id="Tc_EMSlWMv5GkuOKpdcm6a8FA_5_0"></a><a id="Tc_ZqFt1KCaPkybUykP7Q8EGQ_6_0"></a><a id="Tc_k9L9__KnRkmu7KW0ThOUMQ_7_0"></a><a id="Tc_NqSuxsXpI0WjyUuJmjGaKg_8_0"></a><a id="Tc_wUGQdg3_qECItcJEwcLN2w_9_0"></a><a id="Tc_Ulr-v8aAL0mfsPXvg16svw_9_2"></a><a id="Tc_myfMCgdB-0yhlEDMPogQew_9_3"></a><a id="Tc_rXQArpWYzEmWkqS6OjNTlw_9_4"></a><a id="Tc_H0RZfwkvCUuMUJ-y-CwkJA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_77sBmoxUOkiCKiNkPKEL7w" continuedAt="Tb_77sBmoxUOkiCKiNkPKEL7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_ppU4t1gBWEir_pz9g4X8ZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_dxS6cXI4MEupRiW9MWYegg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_HktW3HhafUCbYssQD4nETA_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_G-zE5Dj0LEeKDrwi5qzQQQ_4_2">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_4joGK_hDYEGMA6WlWxGvYw_4_4">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_T_4U7EHQX0qyNEI88iM2_g_5_2">3.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_BUIlBiul_kaLneuI6rUAAQ_5_4">7.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_gZzM2_hUh0CHmQUN8p06_w_6_2">1.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_HWDDLZrLNEy4utvAIuXa7g_6_4">2.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" sign="-" scale="-2" id="Tc_25QFCgmz1kyr_ooeIOHVvg_7_2">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="Tc_nlYQnKTC00WCpjrn1hEjwQ_7_4">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_DayPibu_mEOH8KlvaHft9Q_8_2">28.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_gZtYYJ9ekEiFe8o4L0FBgg_8_4">32.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk25830017"></a><a id="Tc_BQCvVVyTVUioDGgRWn5rAw_1_2"></a><a id="Tc_Zi7fFL-A10GT9e7Q63NuSA_2_0"></a><a id="Tc_0ObXlT97VkKtH3gPLgxEbQ_2_3"></a><a id="Tc_BJ4nMqtoX0mT8zuTDxr1GA_2_6"></a><a id="Tc_2N1Y9HX6hU-tcmlr9XfR6Q_3_0"></a><a id="Tc_rI3u1EGyhECmbn6X1ymFgg_4_0"></a><a id="Tc_BcFWoZGvIUGHJPwzyvHPNg_4_2"></a><a id="Tc_BgMGNQTkpU22Kh1U9ESRWw_4_5"></a><a id="Tc_qqRXKRi7oEi0PPgC6PmsCw_5_0"></a><a id="Tc_HgL8Hvi3tkuRjpZlM0D4gw_6_0"></a><a id="Tc_K5Zf9k5A5kO1--g2DUhW0w_7_0"></a><a id="Tc_acNbK-EJfk-gKLelibm5Jw_8_0"></a><a id="Tc_OqZpZAm_xUCaA1AjoiCX8Q_9_0"></a><a id="Tc_MfyQK9in40a0mj0Vojo2Lw_10_0"></a><a id="Tc_PsrnT6vkV0mhwL11_GZ_Mg_11_0"></a><a id="Tc_j1ePHHiWLUyOuYFJTTinow_11_2"></a><a id="Tc_s3Ug1UuSGEenexYqaePF_A_11_5"></a><a id="Tc_JVETTtsGskSWWvFE5ZMG4Q_12_0"></a><a id="Tc_s8xZgHlEXEuPDVhXV8UAEQ_13_0"></a><a id="Tc_oJQRo9mEdk6c-uMuph8XCw_13_2"></a><a id="Tc_qBv-TcOG5EuBQkZv6TdF8w_13_5"></a><a id="Tc_4d3dBUwCdEqbWfZHID_RVg_14_0"></a><a id="Tc_DX6UK7oCUUKItRB-az-Sew_14_3"></a><a id="Tc_EcCOLyVdb0CcC8LFTdbBEA_15_0"></a><a id="Tc_s8uszzfMVk-LPhOhuXSJVA_15_2"></a><a id="Tc_e7I6bhuiu0m57Jw3PanfEg_15_5"></a><a id="Tc_gz-EFGRssEGtxPtzq0hEyw_16_0"></a><a id="Tc_2AbKBxj24UC93_KYTB6YBg_16_2"></a><a id="Tc_zUsq9cZVrUmIQQvqIcltAA_16_3"></a><a id="Tc_rN6q4llZHkWYhyAu-grT3Q_16_5"></a><a id="Tc_vsh_d8GlH06TZIc1xBp4zg_16_6"></a><ix:continuation id="Tb_77sBmoxUOkiCKiNkPKEL7w_cont1" continuedAt="Tb_77sBmoxUOkiCKiNkPKEL7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_Bm6CfzZPNkyt0S8Xx7NkUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_qlKIagCKRUiKhHR-VT-eQA_4_3">44,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_KTMK2KtMDk2RPpKpkhEZcg_4_6">28,511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_DHwFV1In_0CV1GZ-qvEmJg_5_3">8,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_lI-AOlA2i0Kd2PIhM7fiHQ_5_6">6,874</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charitable contribution carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" id="Tc_lk7OAC0gzkqgmkVI_EqSTg_6_3">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" id="Tc_n8MUDZyW6kKjA6BHegqIDw_6_6">306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_doy5M20-PEC1ztJ8sBi67g_7_3">3,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_2yN9acVGS026tTmHZzcoeA_7_6">1,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_mn0krQyEbkyJXXDoe17eVw_8_3">1,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_AnXmVyj9Dk6JOE4S5NVnew_8_6">635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_eB44cyE_PkGfzmhGbeYiKQ_9_3">57,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_78KQEXZC-Ee4Tvaw6aVmmQ_9_6">38,109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Vkh01yjtGE-IDbPIc2fLqA_10_3">57,705</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_YeGvuyB4sUCRfijvNT8VAw_10_6">37,552</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_XgInd3HopUSrCSczAlcCgw_11_3">83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_2elx-MUV3E6Mp-Qj2lI1Ug_11_6">557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization" scale="3" id="Tc_y3fYBkD4-USGGf_94g1STg_13_3">83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization" scale="3" id="Tc_sRD9meFTTE-QIjcWgb5hUA_13_6">342</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" scale="3" id="Tc_olP6YLajfUSVTQXQCb6baA_14_6">215</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_lW3D5oF0J0SIsoipN72EUg_15_3">83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_FdnbMJT18U-AFcOw-4oKrA_15_6">557</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021. The Company increased its valuation allowance by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_Lf7_bEnw30um-wDIZSYX3A">20.2</ix:nonFraction> million for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company had federal and state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_sKVImdQFiU-VtcBZKjk20Q">160.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_se03hqRzk0eJpMD7U1kUgA">163.4</ix:nonFraction>&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_hqk5DU_YiUCgS7KttJFTjQ">138.2</ix:nonFraction> million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" scale="6" id="Narr_Om4kYNF1WkiK-IPHMYxg4A">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="-5" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" scale="6" id="Narr_ngAYFsm2I0qpruY4V-zoNg">0.1</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2021. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#8220;IRC&#8221;), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2017 to 2020 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_59f7dYum3ESxAYEm3pnTlQ">no</ix:nonFraction> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Coronavirus Aid, Relief, and Economic Security Act, or &#8220;CARES Act&#8221;, and the Consolidated Appropriations Act, 2021, or &#8220;Stimulus Bill&#8221;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_77sBmoxUOkiCKiNkPKEL7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_ZQMQTVB8JEmc7Ebh4s0_eg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the years ended December 31, 2021 and 2020 the Company did <ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_lxqL8wlvJ0q8NzLxZv2vxA"><ix:nonFraction unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ" contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_REm_x9uud0axiL3do5AFLw">no</ix:nonFraction></ix:nonFraction>t provide any contributions to this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Vg1UCy50dUyjDCvyT0MDlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">16. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 4, 2022, the Company entered into a Third Amendment to its original Lease Agreement, dated January 30, 2019, whereby the Company has expanded its leased property by approximately <ix:nonFraction unitRef="Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ" contextRef="As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_QQrBjKt75UO2BbWan09Khg">5,700</ix:nonFraction> square feet.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8136cac_ca78_4491_b546_33ea9eaf9185"></a><a id="Item9ChangesinandDisagreements_266846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e3c65828_d57b_4f40_89f1_09394c9e5715"></a><a id="Item9AControlsandProcedures_609124"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2021. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Report of Management on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and Principal Financial Officer, our management assessed the effectiveness of our internal control over financial report as of December 31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &quot;Internal Control-Integrated Framework&quot; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This Annual Report does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &quot;emerging growth companies.&quot;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c9442a19_8f47_454b_b9d5_8f6bd2945d28"></a><a id="_Item_9B._Other"></a><a id="Item9BOtherInformation_632493"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8fb66380_ee56_4e27_9b5d_b7a63ce9d5dc"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e806abfb_f87d_483e_ba1b_8f549aa9fb2a"></a><a id="PARTIII_212520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><a id="_Item_10._Directors"></a><a id="Item10DirectorsExecutiveOfficers_124962"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 10. Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained under the headings &#8220;Proposal No. 1: Election of Class III Directors,&#8221; &#8220;Corporate Governance and our Board of Directors,&#8221; and &#8220;Executive Officers&#8221; in our definitive proxy statement for our 2022 annual meeting of stockholders, or our &#8220;Proxy Statement&#8221;, to be filed with the SEC within 120 days of December 31, 2021 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_43e704dc_d246_45a9_9b02_48c8fdd586c6"></a><a id="_Item_11._Executive"></a><a id="Item11ExecutiveCompensation_378389"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and is incorporated herein by reference.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b165002b_272c_4484_b2ad_9701364b541c"></a><a id="_Item_12._Security"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Ownership of our Common Stock&#8221; and &#8220;Equity Compensation Plan Information&#8221; and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8ab8c4af_cd8a_4294_aa1f_ac188af68b61"></a><a id="_Item_13._Certain"></a><a id="Item13CertainRelationships_29705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Board Leadership and Governance Structure&#8221; and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0e733280_5546_421d_a086_e62e4703c355"></a><a id="_Item_14._Principal"></a><a id="Item14PrincipalAccountantFees_216711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 14. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item will be contained in the Proxy Statement under the heading &#8220;Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c54536d6_5ccb_41c6_a51d_302d00055e70"></a><a id="PARTIV_681968"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART IV</p><a id="Item15ExhibitsandFinancialStatement_2226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following documents are filed as part of this report:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statements</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">See Index to Financial Statements in Part II Item 8 of this Annual Report.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statement Schedules</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">All schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibits</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">The documents listed in the following Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:12.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;width:2.27%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.67%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description </b></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919003060/a2238817zex-3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&#160;3.1 filed with Company&#8217;s Current Report on 8-K filed with the Commission on May&#160;13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919003060/a2238817zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;3.2 filed with Company&#8217;s Current Report on 8-K filed with the Commission on May&#160;13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investors&#8217; Rights Agreement, dated as of November&#160;5, 2018, by and among the Company and the investors party thereto (incorporated by reference to Exhibit&#160;4.1 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000155837020002566/nxtc-20191231ex42d841f91.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registered Securities (incorporated by reference to Exhibit 4.2 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 12, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of December&#160;29, 2015, by and between the Company and Yale University (incorporated by reference to Exhibit&#160;10.1 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Corporate Sponsored Research Agreement, dated as of December&#160;29, 2015, by and between the Company and Yale University (incorporated by reference to Exhibit&#160;10.2 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001661059/000155837021002384/nxtc-20201231ex10322e166.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to License Agreement and SRA, dated as of April 25, 2020, by and between the Company and Yale University (incorporated by reference to Exhibit 10.3 filed with the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2015 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit&#160;10.6 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement under the NextCure,&#160;Inc. 2015 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.7 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.8 filed with Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Forms of Stock Option Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.9 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.10 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.11 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.12 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920104856/tm2030788d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Program (incorporated by reference to Exhibit&#160;10.1 filed with the Company&#8217;s Current Report on Form&#160;8-K filed with the Commission on September 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.5 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Michael Richman (incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Steven P. Cobourn (incorporated by reference to Exhibit 10.2 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Solomon Langermann, Ph.D. (incorporated by reference to Exhibit 10.3 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of January&#160;30, 2019, by and between the Company and ARE-8000/9000/10000 Virginia Manor,&#160;LLC (incorporated by reference to Exhibit&#160;10.14 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000155837019010701/nxtc-20190930ex101b27cfe.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease Agreement, dated August&#160;2, 2019, by and between the Company and ARE-8000/9000/10000 Virginia Manor,&#160;LLC (incorporated by reference to Exhibit&#160;10.1 filed with Company&#8217;s Quarterly Report on Form 10-Q filed on November&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000155837021014632/nxtc-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the NextCure, Inc. 2015 Omnibus Incentive Plan dated September 30, 2021 (incorporated by reference to Exhibit 10.1 filed with Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Sublease Agreement, dated as of March&#160;15, 2019, by and between the Company and Lupin,&#160;Inc. (incorporated by reference to Exhibit&#160;10.4 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex10d23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to License Agreement and SRA, dated as of October 20, 2021, by and between the Company and Yale University. (**Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.**).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex10d24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of January 11, 2021, by and between the Company and Han Myint, M.D. (**Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex10d25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease Agreement, dated February 19, 2020, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (**Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex10d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease Agreement, dated February 4, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (**Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young&#160;LLP, independent registered public accounting firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature page of this Annual Report on Form 10-K).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.INS</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.SCH</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.CAL</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.DEF</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.LAB</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.PRE</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Coverage Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">*  &#160;Filed herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">+  &#160;Indicates a management contract or compensatory plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">&#8224;  &#160;Portions of this exhibit have been omitted in compliance with Item&#160;601 of Regulation&#160;S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_157"></a><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_61c671d9_99c6_497a_b792_84f45b1612ca"></a><a id="_Item_16._Form"></a><a id="Item16Form10KSummary_696187"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 16. Form 10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_88b8d036_773c_48e5_a340_d97585408ef2"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEXTCURE, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person whose signature appears below constitutes and appoints Michael Richman and Steven P. Cobourn and each of them, jointly and severally, his or her attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 60pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Kabakoff</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of the Board</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Kabakoff, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anne Borgman</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anne Borgman, M.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ellen G. Feigal</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ellen G. Feigal, M.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John G. Houston</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John G. Houston, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Elaine V. Jones</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elaine V. Jones, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chau Q. Khuong</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chau Q. Khuong</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Garry Nicholson</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Garry Nicholson</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stephen Webster</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stephen Webster</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>nxtc-20211231xex10d23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:39 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.23</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECOND AMENDMENT TO LICENSE AGREEMENT AND SRA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">THIS SECOND AMENDMENT TO LICENSE AGREEMENT AND SRA (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">AMENDMENT</font><font style="font-size:12pt;">&#8221;) is made and entered into, and effective, as of this 20</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> day of October 2021 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">AMENDMENT EFFECTIVE DATE</font><font style="font-size:12pt;">&#8221;) by and between Yale University, a nonprofit corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">YALE</font><font style="font-size:12pt;">&#8221;), and NextCure, Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">LICENSEE</font><font style="font-size:12pt;">&#8221;). &#160;YALE and LICENSEE are each referred to herein, individually, as a &#8220;party&#8221; and, collectively, as the &#8220;parties.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">WHEREAS, the parties entered into that certain License Agreement effective as of December 29, 2015, as amended by the Amendment to License Agreement and SRA (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">First Amendment</font><font style="font-size:12pt;">&#8221;) made and entered into as of April 25, 2020 and effective as of January 31, 2020 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Existing License Agreement</font><font style="font-size:12pt;">&#8221; and, as amended by this AMENDMENT, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">License Agreement</font><font style="font-size:12pt;">&#8221;) and the parties entered into that certain Corporate Sponsored Research Agreement effective as of December 29, 2015, as amended by the First Amendment (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Existing SRA</font><font style="font-size:12pt;">&#8221; and, as amended by this AMENDMENT the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SRA</font><font style="font-size:12pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">WHEREAS, the Parties desire to amend the Existing License Agreement and the Existing SRA as more particularly set forth in this AMENDMENT, or as the context of this AMENDMENT may require.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the mutual promises, representations, warranties and covenants set forth in this AMENDMENT, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">I. AMENDMENTS TO DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions and Phrases</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.1</font></font><font style="font-size:12pt;">The following terms used in this AMENDMENT shall be defined as set forth below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGET COPYRIGHTS</b><font style="font-size:12pt;">&#8221; means all copyrights and copyrightable materials, including data and software, created in performance of the RESEARCH to the extent directed to the RELINQUISHED TARGETS or the RELINQUISHED TARGET INVENTIONS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGET INFORMATION</b><font style="font-size:12pt;">&#8221; means all data, know-how and information, in any form, whether or not patentable, including all RESEARCH RESULTS, in each case, to the extent directed to the RELINQUISHED TARGETS or the RELINQUISHED TARGET INVENTIONS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGET INVENTIONS</b><font style="font-size:12pt;">&#8221; means all INVENTIONS (as defined in the Existing SRA) to the extent directed to the RELINQUISHED TARGETS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGET MATERIALS</b><font style="font-size:12pt;">&#8221; means all materials, including TANGIBLE RESEARCH PROPERTY, to the extent directed &#160;to the RELINQUISHED TARGETS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGETS</b><font style="font-size:12pt;">&#8221; means </font>[***]<font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.2</font></font><font style="font-size:12pt;">The term &#8220;</font><b style="font-size:12pt;font-weight:bold;">to the extent directed to</b><font style="font-size:12pt;">&#8221; means, with respect to any RELINQUISHED TARGET INFORMATION, RELINQUISHED TARGET INVENTIONS or RELINQUISHED TARGET MATERIALS, such information, inventions or materials applicable to the RELINQUISHED TARGET, but not information, inventions or materials applicable to any other target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.3</font></font><font style="font-size:12pt;">Capitalized terms used, but not defined, in this AMENDMENT shall have the respective meanings ascribed to such terms in the Existing License Agreement, or the Existing SRA, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.4</font></font><font style="font-size:12pt;">Any reference to &#8220;</font><b style="font-size:12pt;font-weight:bold;">the AGREEMENT</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">this AGREEMENT</b><font style="font-size:12pt;">&#8221; with respect to the Existing License Agreement shall mean the Existing License Agreement, as amended by this AMENDMENT. Any reference to &#8220;the Agreement&#8221; or &#8220;this Agreement&#8221; with respect to the SRA shall mean the Existing SRA, as amended by this AMENDMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">II.  AMENDMENTS TO EXISTING SRA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment to Exhibit A of the Existing SRA</u><font style="font-size:12pt;">. &#160;Exhibit A of the Existing SRA is hereby deleted in its entirety and replaced with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;"> attached to this AMENDMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">III.  AMENDMENTS TO LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment of Appendix C to the Existing License Agreement</u><font style="font-size:12pt;">. &#160;Appendix C of the Existing License Agreement is hereby deleted in its entirety and replaced with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix C</u><font style="font-size:12pt;"> attached to this AMENDMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment of Appendix D to the Existing License Agreement</u><font style="font-size:12pt;">. &#160;Appendix D of the Existing License Agreement is hereby deleted in its entirety and replaced with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix D</u><font style="font-size:12pt;"> attached to this AMENDMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">IV.  OTHER AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.1</font></font><font style="font-size:12pt;">Notwithstanding any other provision of the Existing License Agreement or the Existing SRA, as amended by this AMENDMENT, or otherwise, as of and after the AMENDMENT EFFECTIVE DATE, the Parties hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">LICENSEE and YALE hereby acknowledge and agree that (i) all RELINQUISHED TARGET INVENTIONS were created solely by YALE employees, students or agents and constitute UNIVERSITY INVENTIONS (as defined under the SRA) and none of such RELINQUISHED TARGET INVENTIONS are SPONSOR INVENTIONS or JOINT INVENTIONS except as set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 1</b><font style="font-size:12pt;"> (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">SPONSOR INVENTIONS</b><font style="font-size:12pt;">&#8221;), (ii) LICENSEE does not have any right, title or interest in or to any of the RELINQUISHED TARGET INVENTIONS except for the SPONSOR INVENTIONS (in each case, whether or not a deliverable under the SRA), (iii) LICENSEE unconditionally and irrevocably waives, relinquishes and terminates all options, rights, titles and interests in and to all RELINQUISHED TARGET INFORMATION and RELINQUISHED TARGET INVENTIONS including the SPONSOR INVENTIONS (which LICENSEE hereby assigns and transfers to YALE), including under Section 8(c) and Section 8(e) of the SRA and Section 3.5 of the License Agreement and (iv) neither Party shall have any disclosure obligations with respect to the RELINQUISHED TARGET INVENTIONS under Section 8(e) of the SRA;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">LICENSEE hereby assigns and transfers to YALE all of SPONSOR&#8217;s right, title and interest in and to all SPONSOR INVENTIONS and SPONSOR INFORMATION and, within thirty (30) days of the AMENDMENT EFFECTIVE DATE, LICENSEE shall deliver a copy of all SPONSOR INFORMATION to YALE;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">LICENSEE and YALE hereby acknowledge and agree that (i) LICENSEE does not have any right, title or interest in or to any of the RELINQUISHED TARGET INFORMATION (whether or not a deliverable under the SRA), (ii) all RELINQUISHED TARGET INFORMATION and all SPONSOR INFORMATION constitutes YALE&#8217;s CONFIDENTIAL INFORMATION, (ii) LICENSEE shall keep all RELINQUISHED TARGET INFORMATION confidential, (iii) LICENSEE shall not disclose any RELINQUISHED TARGET INFORMATION to any third party, (iv) LICENSEE shall not use any RELINQUISHED TARGET INFORMATION for any purpose and (v) within thirty (30) days hereof, LICENSEE shall destroy all RELINQUISHED TARGET INFORMATION and all SPONSOR INFORMATION, except that LICENSEE may retain one copy of RELINQUISHED TARGET INFORMATION solely to assure compliance with the terms of this AMENDMENT, and shall not be required to remove any RELINQUISHED TARGET INFORMATION from its electronic records;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">LICENSEE and YALE hereby acknowledge and agree that (i) all RELINQUISHED TARGET INFORMATION shall be excluded from LICENSED INFORMATION, (ii) LICENSEE will not, after the AMENDMENT EFFECTIVE DATE, be entitled to have access to the RELINQUISHED TARGET INFORMATION under Section 8(d) of the SRA or otherwise, and will not have any other license, right, title or interest in or to any RELINQUISHED TARGET INFORMATION, including under Section 3.1 and 3.5 of the License Agreement and (iii) LICENSEE may not use any RELINQUISHED TARGET INFORMATION in connection with its research and product development efforts or otherwise;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">LICENSEE acknowledges and agrees that from and after the AMENDMENT EFFECTIVE DATE, (i) LICENSEE shall cease to have any right to receive any RELINQUISHED TARGET MATERIALS including under Section 8(f) or 8(g) of the SRA, (ii) LICENSEE does not have any right, title or interest in or to any of the RELINQUISHED TARGET MATERIALS (whether or not a deliverable under the SRA) and (iii) LICENSEE unconditionally and irrevocably waives, relinquishes and terminates all options, rights, titles and interests in and to all RELINQUISHED TARGET MATERIALS including under Section 8(c) and Section 8(e) of the SRA and Section 3.5 of the License Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:12pt;">LICENSEE AND YALE hereby acknowledge and agree that (i) all RELINQUISHED TARGET COPYRIGHTS were created solely by YALE employees, students or agents and constitute UNIVERSITY COPYRIGHTS, (ii) none of such RELINQUISHED TARGET COPYRIGHTS are SPONSOR COPYRIGHTS or JOINT COPYRIGHTS, (iii) LICENSEE does not have any right, title or interest in or to any of the RELINQUISHED COPYRIGHTS (whether or not a deliverable under the SRA) and (iv) LICENSEE unconditionally and irrevocably waives, relinquishes and terminates all options, rights, titles and interests in and to all RELINQUISHED COPYRIGHTS including under Section 8(c) and Section 8(e) of the SRA and Section 3.5 of the License Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:12pt;">LICENSEE (i) unconditionally and irrevocably waives, relinquishes and terminates all rights, titles and interests (including access rights) in and to all EXISTING MATERIAL AND UNPUBLISHED INFORMATION to the extent directed to any of the RELINQUISHED TARGETS, RELINQUISHED TARGET INVENTIONS or RELINQUISHED TARGET INFORMATION and (ii) acknowledges and agrees that no EXISTING MATERIAL AND UNPUBLISHED INFORMATION to the extent directed to any of the RELINQUISHED TARGETS, RELINQUISHED TARGET INVENTIONS or RELINQUISHED TARGET INFORMATION shall be licensed to LICENSEE under the License Agreement or otherwise constitute LICENSED INFORMATION;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:12pt;">LICENSEE acknowledges and agrees that LICENSEE does not have any rights under Section 8(k) of the SRA with respect to the RELINQUISHED TARGET INVENTIONS, RELINQUISHED TARGET INFORMATION, &#160;RELINQUISHED TARGET MATERIALS or RELINQUISHED TARGET COPYRIGHTS or any other information or technology owned or controlled by YALE to the extent directed to the RELINQUISHED TARGETS;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:12pt;">LICENSEE and YALE hereby acknowledge and agree that LICENSEE shall have no ongoing obligations to YALE with respect to the RELINQUISHED TARGETS or any RELINQUISHED TARGET INVENTIONS or RELINQUISHED TARGET INFORMATION, including under Section 10 of the License Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:12pt;">LICENSEE hereby unconditionally and irrevocably consents to YALE&#8217;s right to license to Normunity AccelCo, Inc. and/or any other person or entity any and all rights to the RELINQUISHED TARGETS, RELINQUISHED TARGET INVENTIONS,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">RELINQUISHED TARGET MATERIALS, RELINQUISHED TARGET COPYRIGHTS and RELINQUISHED TARGET INFORMATION, without any restriction or encumbrance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2</font></font><font style="font-size:12pt;">In consideration the rights granted to YALE by LICENSEE hereunder, including the relinquishment of rights to the RELINQUISHED TARGETS, RELINQUISHED TARGET INVENTIONS and RELINQUISHED TARGET INFORMATION, YALE or its designee shall pay NEXTCURE </font>[***]<font style="font-size:12pt;">percent (</font>[***]<font style="font-size:12pt;">%) of NET SALES &#160;of any RELINQUISHED TARGET PRODUCT (as defined below). &#160;Such obligation shall expire [***] after the first NET SALE of such RELINQUISHED TARGET PRODUCT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">RELINQUISHED TARGET PRODUCT</b><font style="font-size:12pt;">&#8221; means any product (including apparatus or kit) or component of a product that binds to or is a modulator of a RELINQUISHED TARGET, or is comprised of a RELINQUISHED TARGET INVENTION or used &#160;RELINQUISHED TARGET INFORMATION for its discovery or development.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">For the purposes of this AMENDMENT, the term NET SALES shall have the meaning set forth in the LICENSE AGREEMENT except that LICENSED PRODUCT as used therein shall mean a RELINQUISHED TARGET PRODUCT, and LICENSEE therein shall refer to YALE, its licensees and their affiliates, with such other modifications as the context requires.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">V.  GENERAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Acknowledgement</u><font style="font-size:12pt;">. &#160;Except as expressly provided herein: (a) no terms or provisions of the Existing License Agreement or the Existing SRA are modified or changed by this AMENDMENT and (b) the terms and provisions of the Existing License Agreement and the Existing SRA shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.2.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date</u><font style="font-size:12pt;">. &#160;This AMENDMENT shall be effective from and after the AMENDMENT EFFECTIVE DATE.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.3.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts; Facsimile Signatures</u><font style="font-size:12pt;">. &#160;This AMENDMENT may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. &#160;This AMENDMENT may be executed by facsimile or electronic transmission signatures (including .pdf copies).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[</font><i style="font-size:12pt;font-style:italic;">signature page follows</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties hereto have executed this AMENDMENT as of the AMENDMENT EFFECTIVE DATE.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">YALE UNIVERSITY</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NEXTCURE, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Lisa D. D&#8217;Angelo, Ph.D.</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Tim Mayer, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Lisa D. D&#8217;Angelo, Ph.D.</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Tim Mayer, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Interim Managing Director</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Operating Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Yale University</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Office of Cooperative Research</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[Signature Page to Second Amendment to License Agreement and SRA]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">RESEARCH PLAN/STATEMENT OF WORK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Appendix C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXCLUDED TARGETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Appendix D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">RESTRICTED TARGETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SPONSOR INVENTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[***]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[Signature Page to Second Amendment to License Agreement and SRA]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>nxtc-20211231xex10d24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nxtc-20211231xex10d24001.jpg" alt="Graphic" style="display:inline-block;height:38.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:215.97pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">May 11, 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Via Email Only</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Han Myint, M.D.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">RE:</b></font><b style="font-size:12pt;font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Dear Dr. Myint:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">On behalf of NextCure, Inc. (&#8220;</font><b style="font-size:12pt;font-weight:bold;">NextCure</b><font style="font-size:12pt;">&#8221;, or the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Company</b><font style="font-size:12pt;">&#8221;), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Board</b><font style="font-size:12pt;">&#8221;) and you have agreed that you will continue your employment with the Company, serving as the Company&#8217;s Chief Medical Officer, reporting to the Company&#8217;s Chief Executive Officer, effective as of January 11, 2021 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Start Date</b><font style="font-size:12pt;">&#8221;). &#160;During your employment with NextCure, you will devote substantially all of your professional efforts to the business of NextCure, except that you may engage in the business activities described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix A</u><font style="font-size:12pt;"> of this employment agreement (this &#8220;</font><b style="font-size:12pt;font-weight:bold;">Agreement</b><font style="font-size:12pt;">&#8221;), and other activities that may be approved in advance by the Company&#8217;s Chief Executive Officer, with advice from the Board (which may include the for-profit board membership(s) described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix A</u><font style="font-size:12pt;">), in each case, so long as these activities do not interfere or conflict with your obligations to the Company. &#160;Your employment under the terms of this Agreement shall continue until it terminates in accordance with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5</u><font style="font-size:12pt;"> below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Agreement is intended to summarize some of the terms and conditions of your employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Location</u><font style="font-size:12pt;">. &#160;Your place of employment will be at NextCure&#8217;s principal offices, currently located in Beltsville, Maryland.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compensation</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><i style="font-size:12pt;font-style:italic;">Base Salary</i><font style="font-size:12pt;">. &#160;Your initial annualized base salary rate will be $425,000, less standard deductions and withholding and payable bi-weekly in accordance with NextCure&#8217;s regular payroll practices. &#160;Your salary shall be reviewed annually and may be adjusted in connection with any such review.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><i style="font-size:12pt;font-style:italic;">Housing Allowance</i><font style="font-size:12pt;">. &#160;Upon your Start Date, you were provided with a special, one-time bonus in the amount of $75,000 to cover relocation and housing expenses resulting from your move from New Jersey to Maryland, to be used at your discretion. If you should voluntarily terminate your employment prior to the 24-month anniversary of your Start</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Date, then you will pay NextCure a ratable portion of this bonus based on the number of months remaining in this 24-month period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><i style="font-size:12pt;font-style:italic;">Bonus Program</i><font style="font-size:12pt;">. &#160;You will be eligible for an annual target bonus of 40% of your annual base salary as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones. &#160;Any annual bonus, if earned, shall be paid no later than March 15</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> of the year immediately following the year to which the applicable annual bonus relates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><i style="font-size:12pt;font-style:italic;">Option Grants. &#160;</i><font style="font-size:12pt;">As of your Start Date, you were granted an option to purchase 200,000 shares of NextCure&#8217;s common stock, vesting 25% on the first anniversary of your Start Date, and thereafter in 36 equal, monthly installments until fully-vested, on the fourth anniversary of your Start Date. &#160;The option grant is subject to the terms of NextCure&#8217;s equity incentive arrangements, including its customary Incentive Stock Option (ISO) Grant Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">e.</font></font><i style="font-size:12pt;font-style:italic;">Withholding. &#160;</i><font style="font-size:12pt;">NextCure shall withhold from any compensation or benefits payable to you by NextCure any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Benefits</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><i style="font-size:12pt;font-style:italic;">Vacation and Holidays</i><font style="font-size:12pt;">. &#160;You will be eligible each year for 10 paid vacation days (excluding federal holidays), 2 paid personal days and 8 paid days of sick time, as well as paid time off from December 28 through December 30.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><i style="font-size:12pt;font-style:italic;">Other</i><font style="font-size:12pt;">. &#160;You will be eligible to participate in the benefits to be offered by NextCure on the same terms and conditions as it will make such benefits available to employees in positions similar to your position. &#160;The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><i style="font-size:12pt;font-style:italic;">Expenses</i><font style="font-size:12pt;">. &#160;NextCure shall reimburse you for all reasonable expenses of the type authorized by NextCure and incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#8217;s reimbursement policies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable NextCure plans or policies, which are subject to change or discontinuation at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severance</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><i style="font-size:12pt;font-style:italic;">Definitions.</i><font style="font-size:12pt;"> &#160;For purposes of this Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">i.</font><font style="display:inline-block;width:29.67pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Accrued Benefits</b><font style="font-size:12pt;">&#8221; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with NextCure&#8217;s reimbursement policy, (iv) accrued but unused vacation (if applicable), earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by NextCure or this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ii.</font><font style="display:inline-block;width:26.33pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Cause</b><font style="font-size:12pt;">&#8221; means conduct involving one or more of the following by you: (i) failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Agreement and your position, which failure continues for, or is not permanently cured within, a period of 60 days after written notice given to you by NextCure except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures NextCure or breach of fiduciary duty to NextCure; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude, or fraud; (iv) the commission of an act of embezzlement or fraud; or (v) the material breach of any agreement between NextCure and you.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iii.</font><font style="display:inline-block;width:23pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Good Reason</b><font style="font-size:12pt;">&#8221; means, without your express written consent, (i) any reduction in your annual base salary other than a reduction which is proportional to general reductions affecting other senior executive officers of NextCure generally, (ii) any material reduction in your title or scope of responsibilities without your consent (other than your removal from the Board); or (iii) a requirement that the location of the office in which you perform your principal duties for NextCure be changed to a new location that is outside a radius of 50 miles from the Company&#8217;s corporate headquarters in Beltsville, Maryland.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><i style="font-size:12pt;font-style:italic;">Severance Benefits and Payment</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">i.</font><font style="display:inline-block;width:29.67pt;"></font><i style="font-size:12pt;font-style:italic;">Generally</i><font style="font-size:12pt;">. &#160;If your employment with NextCure is terminated by NextCure for any reason other than Cause or by you for Good Reason, NextCure will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4(c)</u><font style="font-size:12pt;"> below, after the execution and delivery of the Separation Agreement and General Release in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix B</u><font style="font-size:12pt;"> (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Separation Agreement and General Release</b><font style="font-size:12pt;">&#8221;) and the expiration of any revocation period without the release being revoked, 9 months&#8217; base salary, less standard deductions, payable in a single lump sum on the 60</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> day following the termination of your employment; and (3) if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><b style="font-size:12pt;font-weight:bold;">COBRA</b><font style="font-size:12pt;">&#8221;), following the termination of your employment, your monthly premium under COBRA on a monthly basis until the earlier of (x) 9 months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by NextCure). &#160;A termination of your employment by NextCure due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause. &#160;The term &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-size:12pt;">&#8221; shall mean that you have not been able to materially engage in your duties and responsibilities by reason of any medically determinable physical or mental impairment for a period of not less than 120 consecutive days or not less than 180 days during any one-year period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ii.</font><font style="display:inline-block;width:26.33pt;"></font><i style="font-size:12pt;font-style:italic;">In connection with the Change in Control Period. &#160;</i><font style="font-size:12pt;">If your employment with NextCure is terminated by NextCure for any reason other than Cause or by you for Good Reason during the Change in Control Period, NextCure will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4(c)</u><font style="font-size:12pt;"> below, after the execution</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">and delivery of the Separation Agreement and General Release and the expiration of any revocation period without the release being revoked, 12 months&#8217; base salary plus your annual target bonus, less standard deductions, payable in a single lump sum on the 60</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> day following the termination of your employment; and (3) if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">employment</u><font style="font-size:12pt;">, your monthly premium under COBRA on a monthly basis until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by NextCure). &#160;A termination of your employment by NextCure due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><i style="font-size:12pt;font-style:italic;">Eligibility for Severance</i><font style="font-size:12pt;">. &#160;Eligibility for receipt of the items in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4(b)(ii)</u><font style="font-size:12pt;"> &#160;above shall be conditioned on your (i) returning to NextCure promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and (ii) signing and not revoking the Separation Agreement and General Release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><i style="font-size:12pt;font-style:italic;">Accrued Benefits</i><font style="font-size:12pt;">. &#160;The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">At Will Employment</u><font style="font-size:12pt;">. &#160;Your employment with NextCure is at will, meaning it may be terminated by you or NextCure at any time, subject to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4</u><font style="font-size:12pt;"> above, for any reason with or without Cause. You understand that this Agreement is not a contract for employment for a definite term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality and Proprietary Rights Agreement</u><font style="font-size:12pt;">. &#160;This offer of employment is subject to the Confidentiality and Proprietary Rights Agreement attached as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Appendix C</u><font style="font-size:12pt;">, which shall be effective as of the date set forth therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Inconsistent Obligations</u><font style="font-size:12pt;">. &#160;By accepting this offer of employment, you represent and warrant to NextCure that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Agreement or that would be violated by your employment by NextCure. &#160;You agree that you will not take any action on behalf of NextCure or cause NextCure to take any action that will violate any agreement that you have with a prior employer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Delayed Commencement Date for Payments and Benefits</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><font style="font-size:12pt;">The intent of the parties hereto is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#8220;</font><b style="font-size:12pt;font-weight:bold;">Code Section 409A</b><font style="font-size:12pt;">&#8221;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or exempt therefrom. &#160;If you notify NextCure (with specificity as to the reason therefor) that you believe that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause you to incur</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">any additional tax or interest under Code Section 409A and NextCure concurs with such belief or NextCure independently makes such determination, NextCure shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and NextCure of the applicable provision without violating the provisions of Code Section 409A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><font style="font-size:12pt;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; Notwithstanding any provision to the contrary in this Agreement, no payments or benefits that are considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A to which you otherwise become entitled under this Agreement in connection with your termination of employment, shall be made or provided to you prior to the earlier of (i) the expiration of the 6 month period measured from the date of your &#8220;separation from service&#8221; with NextCure (as such term is defined in Code Section 409A) or (ii) the date of your death, if you are deemed at the time of such separation from service to be a &#8220;specified employee&#8221; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8(b)</u><font style="font-size:12pt;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><font style="font-size:12pt;">For purposes of Code Section 409A, your right to receive any installment<br>payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. &#160;Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><i style="font-size:12pt;font-style:italic;">e.g.</i><font style="font-size:12pt;">, &#8220;payment shall be made within 30 days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of NextCure. &#160;Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><font style="font-size:12pt;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by NextCure or incurred by you during the time periods set forth in this Agreement. &#160;All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. &#160;The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">to be provided or the expenses eligible for reimbursement in any other taxable year. &#160;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">e.</font></font><font style="font-size:12pt;">If under this Agreement an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">280G</u><i style="font-size:12pt;font-style:italic;">. &#160;</i><font style="font-size:12pt;">In the event that the amount of any compensation, payment or distribution by NextCure or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Aggregate Payments</b><font style="font-size:12pt;">&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction. &#160;In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c). &#160;For purposes of this Section 9, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">After Tax Amount</b><font style="font-size:12pt;">&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments. &#160;For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. &#160;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by NextCure, which shall provide detailed supporting calculations both to NextCure and you. &#160;The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by NextCure. &#160;Notwithstanding the foregoing, if (i) NextCure is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that NextCure seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#8220;base amount&#8221; (as such term is defined in Section 280G) in order that, upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">under Sections 280G and 4999 of the Code, NextCure shall use its reasonable best efforts to obtain such approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><font style="font-size:12pt;">This offer of employment is made subject to you having the legal right to work in the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><font style="font-size:12pt;">Your employment with NextCure is subject to all Company policies and procedures, and NextCure retains the right to change its policies or procedures at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><font style="font-size:12pt;">This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><font style="font-size:12pt;">Neither this Agreement nor any of your rights or obligations hereunder shall be assignable by you. &#160;NextCure may assign this Agreement or any of its obligations hereunder to any subsidiary of NextCure, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of NextCure. &#160;This Agreement is intended to bind and inure to the benefit of and be enforceable to you and NextCure and NextCure&#8217;s permitted successors and assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">e.</font></font><font style="font-size:12pt;">No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board. &#160;No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">f.</font></font><font style="font-size:12pt;">The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Maryland without regard to the choice of law principles thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[</font><i style="font-size:12pt;font-style:italic;">remainder of page intentionally left blank</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If the foregoing is acceptable, please indicate your agreement by signing below and returning the original signed Agreement (keeping a copy for your own records) to me on or before []. &#160;If you have any further questions or require additional information, please feel free to contact me.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sincerely,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NEXTCURE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Michael Richman</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Michael Richman</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">President and Chief Executive Officer</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ACCEPTED AND AGREED:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Han Myint</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Han Myint, M.D.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">May 24, 2021</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Appendices:</font></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Appendix A &#8212; Approved Activities</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Appendix B &#8212; Separation Agreement and General Release</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Appendix C &#8212; Confidentiality and Proprietary Rights Agreement</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>nxtc-20211231xex10d25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="color:#0a0a0a;font-weight:bold;">Exhibit&#160;10.25</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0a0a0a;font-weight:bold;">SECOND AMENDMENT TO LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#0a0a0a;font-weight:bold;">THIS SECOND AMENDMENT TO LEASE AGREEMENT (&#8220;this Second Amendment&#8221;) </b><font style="color:#0a0a0a;">is dated as of </font><font style="color:#0a0a0a;font-size:10.5pt;">February 19, 2020 </font><b style="color:#0a0a0a;font-weight:bold;">(&#8220;Effective Date&#8221;), </b><font style="color:#0a0a0a;">by and between </font><b style="color:#0a0a0a;font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC, </b><font style="color:#0a0a0a;">a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 </font><b style="color:#0a0a0a;font-weight:bold;">(&#8220;Landlord&#8221;), </b><font style="color:#0a0a0a;">and </font><b style="color:#0a0a0a;font-weight:bold;">NEXTCURE, INC., </b><font style="color:#0a0a0a;">a Delaware corporation, having an address at Suite 140, 8000 Virginia Manor Road, Beltsville, Maryland 20705 </font><b style="color:#0a0a0a;font-weight:bold;">(&#39;&#39;Tenant&#39;&#39;).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0a0a0a;font-weight:bold;text-decoration:underline;text-decoration-color:#0a0a0a;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;text-align:justify;">A.</font></font><font style="color:#0a0a0a;font-size:10pt;">Landlord and Tenant have entered into that certain Lease Agreement dated as of January 30, 2019 </font><b style="color:#0a0a0a;font-size:10pt;font-weight:bold;">(&#8220;Original Lease&#8221;), </b><font style="color:#0a0a0a;font-size:10pt;">as amended by that certain First Amendment to Lease Agreement dated as of August 2, 2019 </font><b style="color:#0a0a0a;font-size:10pt;font-weight:bold;">(&#8220;First Amendment&#39;&#39;; </b><font style="color:#0a0a0a;font-size:10pt;">together with the Original Lease, the </font><b style="color:#0a0a0a;font-size:10pt;font-weight:bold;">&#8220;Lease&#8221;), </b><font style="color:#0a0a0a;font-size:10pt;">wherein Landlord leased to Tenant certain premises located at Suite 140, 8000 Virginia Manor Road, Beltsville, Maryland 20705, as more particularly described in the Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">B.</font></font><font style="color:#0a0a0a;">Landlord and Tenant desire to (i) update references to lease expiration dates in a table set forth in </font><u style="color:#0a0a0a;text-decoration:underline;text-decoration-color:#0a0a0a;">Section 39(a)</u><font style="color:#0a0a0a;"> of the Lease, and (ii) correct a reference to a suite number in the Basic Lease Provisions and on </font><u style="color:#0a0a0a;text-decoration:underline;text-decoration-color:#0a0a0a;">Exhibit A</u><font style="color:#0a0a0a;"> of the First Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0a0a0a;font-weight:bold;text-decoration:underline;text-decoration-color:#0a0a0a;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#0a0a0a;">Now, therefore, the parties hereto agree that the Lease is amended as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><font style="color:#0a0a0a;">Definitions; Recitals. Terms used in this Second Amendment but not otherwise defined shall have the meanings set forth in the Lease. The Recitals form an integral part of this Second Amendment and are hereby incorporated by reference.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><b style="color:#0a0a0a;font-weight:bold;">Amendment to Section 39(a). </b><font style="color:#0a0a0a;">The table set forth in </font><u style="color:#0a0a0a;text-decoration:underline;text-decoration-color:#0a0a0a;">Section 39(a)</u><font style="color:#0a0a0a;"> of the Lease, as amended by the First Amendment, is hereby further amended by (a) changing the lease expiration date for Suite 207 in the 9000 VMR Building from &#8220;May 31, 2022&#8221; to &#8220;December 31, 2029,&#8221; and (b) changing the lease expiration date for Suite 21</font><font style="color:#0a0a0a;font-size:9.5pt;">O </font><font style="color:#0a0a0a;">in the 9000 VMR Building from</font> <font style="color:#0a0a0a;">&#8220;May 31, 2020&#8221; to &#8220;May 31, 2022.&#8221; As </font><font style="color:#0a0a0a;font-size:12.5pt;">a </font><font style="color:#0a0a0a;">result, such table is hereby deleted in its entirety and replaced with the following table:</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.95%;" align="center"><tr style="height:11.25pt;"><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#0a0a0a;font-size:9.5pt;font-weight:bold;">Suite</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#0a0a0a;font-size:9.5pt;font-weight:bold;">Lease Expiration Date </b><font style="color:#0a0a0a;font-size:12pt;">t</font></p></td></tr><tr style="height:17.85pt;"><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">170 </font><i style="color:#0a0a0a;font-style:italic;">(</i><font style="color:#0a0a0a;">8000 VMR Building)</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">March 31, 2024</font></p></td></tr><tr style="height:17.45pt;"><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">207 (9000 VMR Building)</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">December 31, 2029</font></p></td></tr><tr style="height:13.4pt;"><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">210 (9000 VMR Building)</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">Mav 31, 2022</font></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">230 (9000 VMR Building)</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;">Januarv 31, 2021</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><font style="color:#0a0a0a;">The table above identifies the expiration date for the lease agreement with the existing tenant subject to rights of renewal or extension in favor of the existing tenants</font><font style="color:#464646;">.</font><font style="display:inline-block;width:3.93pt;"></font><font style="display:inline-block;width:18pt;"></font><font style="display:inline-block;width:18pt;"></font><font style="color:#0a0a0a;">&#39;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><b style="color:#0a0a0a;font-weight:bold;">Amendment to Definition of &#8220;Premises (before 9000 </b><b style="color:#0a0a0a;font-size:11pt;font-weight:bold;">VMR </b><b style="color:#0a0a0a;font-weight:bold;">Date).&#8221;</b><font style="display:inline-block;width:4.59pt;"></font><font style="color:#0a0a0a;">The</font><font style="font-size:11pt;"> </font><font style="color:#0a0a0a;">definition of Premises (before 9000 VMR Date)&#8221; in the Basic Lease Provisions is hereby amended by deleting the reference to &#8220;Suite 170&#8221; and replacing it with &#8220;Suite 180.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><b style="color:#0a0a0a;font-weight:bold;">Amendment to Exhibit A of First Amendment. </b><u style="color:#0a0a0a;text-decoration:underline;text-decoration-color:#0a0a0a;">Exhibit A</u><font style="color:#0a0a0a;"> of the First Amendment references &#8220;Suite 170&#8221; when it should have referenced &#8220;Suite 180.&#8221; As a result, </font><u style="color:#0a0a0a;text-decoration:underline;text-decoration-color:#0a0a0a;">Exhibit A</u><font style="color:#0a0a0a;"> of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nxtc-20211231xex10d25001.jpg" alt="Graphic" style="display:inline-block;height:21.74pt;width:60.74pt;"></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright <font style="font-family:'Arial','Helvetica','sans-serif';">&#169;</font> 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 6.95pt;">I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Second Amendment to Lease Agreement -NextCure, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 54pt;"><b style="font-weight:bold;">Page-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">First Amendment is hereby deleted in its entirety and replaced with <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit </u><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">A</b> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><b style="font-weight:bold;">Miscellaneous.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><b style="font-weight:bold;">Entire Agreement. </b>The Lease, as amended by this Second Amendment, is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. The Lease, as so amended by this Second Amendment, may be amended only by an agreement in writing, signed by the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><b style="font-weight:bold;">Binding Effect. </b>This Second Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><b style="font-weight:bold;">Broker. </b>Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, <b style="font-weight:bold;">&#8220;Broker&#8221;</b>) in connection with this Second Amendment and that no Broker brought about this Second Amendment. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Second Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><b style="font-weight:bold;">Counterparts. </b>This Second Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Second Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">e.</font></font><b style="font-weight:bold;">Ratification; Conflicts. </b>Except as amended and/or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment. In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment shall prevail. Regardless of whether specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[SIGNATURES APPEAR ON NEXT PAGE]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nxtc-20211231xex10d25001.jpg" alt="Graphic" style="display:inline-block;height:21.74pt;width:60.74pt;"></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright <font style="font-family:'Arial','Helvetica','sans-serif';">&#169;</font> 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#0c0c0c;font-weight:bold;">Second Amendment to Lease Agreement -NextCure, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="color:#0c0c0c;font-weight:bold;">Page- </b><font style="color:#0c0c0c;">3</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#0c0c0c;">IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment under seal as of the day and year first above written.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:51.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TENANT:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:51.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:51.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEXTCURE, INC.,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:51.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware corporation</p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:51.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy Mayer</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(SEAL)</p></td></tr><tr><td style="vertical-align:bottom;width:48.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LANDLORD:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a<font style="color:#b5b5b5;">.</font>Delaware limited liability company</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alexandria Real Estate Equities, L.P.,</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited partnership,</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">managing member</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARE-ORS CORP.,</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Maryland corporation,</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">general partner</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[(SEAL)]</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allison Grochola</p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President, Legal Affairs</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nxtc-20211231xex10d25001.jpg" alt="Graphic" style="display:inline-block;height:21.74pt;width:60.74pt;"></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright <font style="font-family:'Arial','Helvetica','sans-serif';">&#169;</font> 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT A<br>EXPANSION PREMISES</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>nxtc-20211231xex10d26.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;10.26</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THIRD AMENDMENT TO LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">THIS THIRD AMENDMENT TO LEASE AGREEMENT</b> (&#8220;<b style="font-weight:bold;">this Third Amendment</b>&#8221;) is dated as of February 4, 2022 (&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and between <b style="font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b>, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and <b style="font-weight:bold;">NEXTCURE, INC</b>., a Delaware corporation, having an address at Suite 140, 8000 Virginia Manor Road, Beltsville, Maryland 20705 (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">A.</font></font>Landlord and Tenant have entered into that certain Lease Agreement dated as of January&#160;30, 2019 (&#8220;<b style="font-weight:bold;">Original Lease</b>&#8221;), as amended by that certain First Amendment to Lease Agreement dated as of August 2, 2019 (&#8220;<b style="font-weight:bold;">First Amendment</b>&#8221;) and that certain Second Amendment to Lease Agreement dated as of February 19, 2020 (&#8220;<b style="font-weight:bold;">Second Amendment</b>&#8221;; together with the Original Lease and the First Amendment, the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;), wherein Landlord leased to Tenant approximately 63,576 rentable square feet (&#8220;<b style="font-weight:bold;">Existing Premises</b>&#8221;) located at Suite&#160;140, 8000 Virginia Manor Road, Beltsville, Maryland 20705, as more particularly described in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">B.</font></font>Landlord and Tenant desire to amend the Lease, among other things, to expand the Existing Premises by an additional 5,720 rentable square feet located adjacent to and between the Existing Premises (&#8220;<b style="font-weight:bold;">2022 Expansion Premises</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Now, therefore, in consideration of the foregoing Recitals, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree that the Lease is amended as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><b style="font-weight:bold;">Definitions; Recitals</b>. Terms used in this Third Amendment but not otherwise defined shall have the meanings set forth in the Lease. The Recitals form an integral part of this Third Amendment and are hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><b style="font-weight:bold;">Summary of Premises/Suite Numbers</b>. To facilitate the review of this Third Amendment, set forth below is a summary of the various areas comprising the Premises from time to time along with the assigned suite number:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr><td style="background-color:#d9d9d9;vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Suite Number</b></p></td><td style="background-color:#d9d9d9;vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rentable Square Feet</b></p></td><td style="background-color:#d9d9d9;vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Defined Term</b></p></td><td style="background-color:#d9d9d9;vertical-align:top;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></td></tr><tr><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">140</p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14,075</p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Existing Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td rowspan="2" style="vertical-align:middle;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">8000 VMR Premises</p></td></tr><tr><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">180</p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,069</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">4,377</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14,446</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expansion Premises #1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Expansion Premises #2</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expansion Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:top;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">130</p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;"> 5,720</font></p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2022 Expansion Premises</p></td><td style="vertical-align:middle;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Former [***] space</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:28.9pt;"><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">200</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">201</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">201A</p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24,846</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7,300</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">2,909</u></p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9000 VMR Premises</p></td><td style="vertical-align:top;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Former Lupin space</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">2</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0046310425%;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35,055</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.47%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TOTAL</b></p></td><td style="vertical-align:top;width:26.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">69,296</b></p></td><td colspan="2" style="vertical-align:top;width:55.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><b style="font-weight:bold;">2022 Expansion Premises</b>. Effective as of the 2022 Expansion Premises Commencement Date (as defined below), (a) the Existing Premises shall be expanded to include the 2022 Expansion Premises, and (b)&#160;<b style="font-weight:bold;">Exhibit A</b> to this Third Amendment, which depicts the 2022 Expansion Premises as the hatched area, is hereby added to <b style="font-weight:bold;">Exhibit A</b> to the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><b style="font-weight:bold;">Changes to Defined Terms</b>. Effective as of the 2022 Expansion Premises Commencement Date, the following amendments are hereby made to the definitions contained on pages&#160;1 and 2 of the Lease in the Basic Lease Provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term &#8220;<b style="font-weight:bold;">Premises (before 9000 VMR Effective Date)</b>&#8221; shall be deleted in its entirety and replaced with the following definitions:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#8220;<b style="font-weight:bold;">Premises (before 2022 Expansion Premises Commencement Date)</b>: That portion of the Project, containing approximately 28,521 rentable square feet, which consists of the following: (a)&#160;approximately 14,075 rentable square feet, as shown as the hatched area on <b style="font-weight:bold;">Exhibit A</b> attached to this Lease (&#8220;<b style="font-weight:bold;">Existing Premises</b>&#8221;), and (b)&#160;approximately 14,446 rentable square feet of space shown as the hatched area on <b style="font-weight:bold;">Exhibit A</b> attached to the First Amendment to Lease Agreement between Landlord and Tenant (&#8220;<b style="font-weight:bold;">Expansion Premises</b>&#8221;). The Expansion Premises consists of (i)&#160;approximately 10,069 rentable square feet (&#8220;<b style="font-weight:bold;">Expansion Premises #1</b>&#8221;) identified as &#8220;Suite 110&#8221; on <b style="font-weight:bold;">Exhibit A </b>attached to the First Amendment to Lease Agreement between Landlord and Tenant, and (ii)&#160;approximately 4,377 rentable square feet (&#8220;<b style="font-weight:bold;">Expansion Premises #2</b>&#8221;) identified as &#8220;Suite 170&#8221; on <b style="font-weight:bold;">Exhibit A </b>attached to the First Amendment to Lease Agreement between Landlord and Tenant. Ewing Cole, Landlord&#8217;s architect, has measured the area of the Premises pursuant to the BOMA 2017 for Office Buildings: Standard Methods of Measurement as adopted by the Building Owners and Managers Association International (ANSI/BOMA Z65.1-2017). Tenant acknowledges receipt of such measurement and confirms that (A) Tenant has had an opportunity to confirm such measurement with an architect of its selection before the Commencement Date (with respect to the Existing Premises), and the Expansion Premises Commencement Date (with respect to the Expansion Premises), and (B)&#160;such measurement shall be conclusive as to the area of the Premises.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#8220;<b style="font-weight:bold;">Premises (from and after 2022 Expansion Premises Commencement Date but before 9000 VMR Effective Date)</b>: That portion of the Project, containing approximately 34,241 rentable square feet, which consists of the following: (a)&#160;approximately 14,075 rentable square feet, as shown as the hatched area on <b style="font-weight:bold;">Exhibit A</b> attached to this Lease (&#8220;<b style="font-weight:bold;">Existing Premises</b>&#8221;), (b)&#160;approximately 14,446 rentable square feet of space shown as the hatched area on <b style="font-weight:bold;">Exhibit A</b> attached to the First Amendment to Lease Agreement between Landlord and Tenant (&#8220;<b style="font-weight:bold;">Expansion Premises</b>&#8221;), and (c)&#160;approximately 5,720 rentable square feet of space shown as the hatched area on <b style="font-weight:bold;">Exhibit A</b> attached to the Third Amendment to Lease Agreement between Landlord and Tenant and known as Suite 130 in the 8000 VMR Building (&#8220;<b style="font-weight:bold;">2022 Expansion Premises</b>&#8221;). The Expansion Premises consists of (i)&#160;approximately 10,069 rentable square feet (&#8220;<b style="font-weight:bold;">Expansion Premises</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">3</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><b style="font-weight:bold;">#1</b>&#8221;) identified as &#8220;Suite 110&#8221; on <b style="font-weight:bold;">Exhibit A </b>attached to the First Amendment to Lease Agreement between Landlord and Tenant, and (ii)&#160;approximately 4,377 rentable square feet (&#8220;<b style="font-weight:bold;">Expansion Premises #2</b>&#8221;) identified as &#8220;Suite 170&#8221; on <b style="font-weight:bold;">Exhibit A </b>attached to the First Amendment to Lease Agreement between Landlord and Tenant. Ewing Cole, Landlord&#8217;s architect, has measured the area of the Premises pursuant to the BOMA 2017 for Office Buildings: Standard Methods of Measurement as adopted by the Building Owners and Managers Association International (ANSI/BOMA Z65.1-2017). Tenant acknowledges receipt of such measurement and confirms that (A) Tenant has had an opportunity to confirm such measurement with an architect of its selection before the Commencement Date (with respect to the Existing Premises), the Expansion Premises Commencement Date (with respect to the Expansion Premises), and the 2022 Expansion Premises Commencement Date (with respect to the 2022 Expansion Premises), and (B)&#160;such measurement shall be conclusive as to the area of the Premises.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term &#8220;<b style="font-weight:bold;">Premises (from and after 9000 VMR Effective Date)</b>&#8221; shall be deleted in its entirety and replaced with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#8220;<b style="font-weight:bold;">Premises (from and after 9000 VMR Effective Date)</b>: That portion of the Project, containing approximately 69,296 rentable square feet, which consists of the following: (a) approximately 28,521 rentable square feet (&#8220;<b style="font-weight:bold;">8000 VMR Premises</b>&#8221;) located in the 8000 VMR Building (as defined below) as shown as the hatched areas on <b style="font-weight:bold;">Exhibit A</b> attached to this Lease, (b)&#160;approximately 35,055 rentable square feet (&#8220;<b style="font-weight:bold;">9000 VMR Premises</b>&#8221;) located in the 9000 VMR Building (as defined below) as shown as the hatched areas on <b style="font-weight:bold;">Exhibits&#160;A-1</b> and <b style="font-weight:bold;">A-2</b> attached to this Lease, and (c) approximately 5,720 rentable square feet (&#8220;<b style="font-weight:bold;">2022 Expansion Premises</b>&#8221;) located in the premises known as Suite 130 in the 8000 VMR Building as shown as the hatched area on <b style="font-weight:bold;">Exhibit&#160;A-3</b> attached to this Lease. Ewing Cole, Landlord&#8217;s architect, has measured the area of the Premises pursuant to the BOMA 2017 for Office Buildings: Standard Methods of Measurement as adopted by the Building Owners and Managers Association International (ANSI/BOMA Z65.1-2017). Tenant acknowledges receipt of such measurement and confirms that (i) Tenant has had an opportunity to confirm such measurement with an architect of its selection before the Commencement Date (with respect to the 8000 VMR Premises and the 9000 VMR Premises) and the 2022 Expansion Premises Commencement Date (with respect to the 2022 Expansion Premises), and (ii)&#160;such measurement shall be conclusive as to the area of the Premises.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Rentable Area of Premises (before 9000 VMR Effective Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall be deleted in its entirety and replaced with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Rentable Area of Premises (before 2022 Expansion Premises Commencement Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> mean approximately 28,521 rentable square feet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Rentable Area of Premises (from and after 2022 Expansion Premises Commencement Date but before 9000 VMR Effective Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall mean approximately 34,241 rentable square feet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Rentable Area of Premises (from and after 9000 VMR Effective</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">4</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall mean approximately 69,296 rentable square feet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">e.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Base Rent (Commencement Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall be deleted in its entirety and replaced with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Base Rent (before 2022 Expansion Premises Commencement Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall mean (i) as of December 1, 2021, $[***] per month, with respect to the Existing Premises, and (ii) as of the Expansion Premises Commencement Date, $[***] per month, with respect to the Expansion Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Base Rent (from and after 2022 Expansion Premises Commencement Date)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall mean (i) as of December 1, 2021, $[***] per month, with respect to the Existing Premises, (ii) as of the Expansion Premises Commencement Date, $[***]per month, with respect to the Expansion Premises, and (iii)<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>as of the 2022 Expansion Premises Commencement Date, $[***], per month, with respect to the 2022 Expansion Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Base Rent (effective as of September 1, 2025)</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> shall mean the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;">$[***], per month (8000 VMR Premises)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;">$[***], per month (9000 VMR Premises)<b style="font-weight:bold;">&#8224;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;">$[***], per month (2022 Expansion Premises)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><b style="font-weight:bold;">&#8224; </b>If the 9000 VMR Effective Date occurs before September 1, 2025, the Base Rent for the 9000 VMR Premises shall be an amount (based on an annual per rentable square foot basis) that is then being paid by Tenant for the 8000 VMR Premises as of the 9000 VMR Effective Date, and the Base Rent for the 9000 VMR Premises shall be increased in the same manner and amount, and at the same time, as the Base Rent for the 8000 VMR Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">g.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term &#8220;<b style="font-weight:bold;">Tenant&#8217;s Share of Operating Expenses (before 9000 VMR Effective Date)</b>&#8221; shall be deleted in its entirety and replaced with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term &#8220;<b style="font-weight:bold;">Tenant&#8217;s Share of Operating Expenses (before 2022 Expansion Premises Commencement Date)</b>&#8221; shall mean (i) with respect to the Existing Premises, [***] %, and (ii)&#160;with respect to the Expansion Premises, [***] %. From the Expansion Premises Commencement Date to the day before the 2022 Expansion Premises Commencement Date, the aggregate amount of Tenant&#8217;s Share of Operating Expenses shall be [***] %.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The defined term &#8220;<b style="font-weight:bold;">Tenant&#8217;s Share of Operating Expenses (from and after 2022 Expansion Premises Commencement Date but before 9000 VMR Effective Date)</b>&#8221; shall mean (i) with respect to the Existing Premises, [***] %, (ii)&#160;with respect to the Expansion Premises, [***]%, and (iii) with respect to the 2022 Expansion Premises, [***]%. From the 2022 Expansion Premises Commencement Date to the day before the 9000 VMR Effective Date, the aggregate amount of Tenant&#8217;s Share of Operating Expenses shall be [***] %.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">h.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The defined term &#8220;<b style="font-weight:bold;">Tenant&#8217;s Share of Operating Expenses (from and after 9000 VMR Effective Date)</b>&#8221; shall mean [***] %.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">5</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><b style="font-weight:bold;">Delivery of 2022 Expansion Premises</b>. Landlord shall use reasonable efforts to deliver the 2022 Expansion Premises to Tenant on July 1, 2022 in their vacant, &#8220;as is&#8221; (but broom clean) condition as more fully described in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 4.a.(i)</u> below (&#8220;<b style="font-weight:bold;">Delivery</b>&#8221; or &#8220;<b style="font-weight:bold;">Deliver</b>&#8221;). The date on which Landlord Delivers the 2022 Expansion Premises to Tenant is referred to as the &#8220;<b style="font-weight:bold;">2022 Expansion Premises Commencement Date</b>.&#8221; Upon request of Landlord, Tenant shall execute and deliver a written acknowledgement of the 2022 Expansion Premises Commencement Date when it is established in the form attached hereto as <b style="font-weight:bold;">Exhibit&#160;B</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that Tenant&#8217;s failure to execute and deliver such acknowledgement shall not affect Landlord&#8217;s rights under this Third Amendment or the Lease. If Landlord fails to Deliver timely the 2022 Expansion Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Third Amendment and the Lease with respect to the 2022 Expansion Premises shall not be void or voidable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Except as set forth in this Third Amendment, if applicable: (i) Landlord shall, at its expense, Deliver the 2022 Expansion Premises to Tenant with the interior of the 2022 Expansion Premises demolished to the exterior walls leaving in place only the main HVAC trunk lines and the 2 rooftop HVAC units serving the 2022 Expansion Premises (collectively, &#8220;<b style="font-weight:bold;">Demolition Work</b>&#8221;), (ii) Tenant shall accept the 2022 Expansion Premises in such condition as of the 2022 Expansion Premises Commencement Date, (iii)&#160;Landlord shall have no obligation for any defects in the 2022 Expansion Premises, and (iv)&#160;Tenant&#8217;s taking possession of the 2022 Expansion Premises shall be conclusive evidence that Tenant accepts the 2022 Expansion Premises and that the 2022 Expansion Premises were in good condition at the time possession was taken.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Neither Landlord nor any of its agents has made any representation or warranty with respect to the condition of all or any portion of the 2022 Expansion Premises, and/or the suitability of the 2022 Expansion Premises for the conduct of Tenant&#8217;s business, and Tenant waives any implied warranty that the 2022 Expansion Premises are suitable for the Permitted Use. Tenant shall use the 2022 Expansion Premises only for the Permitted Use under the Lease in compliance with the provisions of Section 7 of the Lease.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Except for Landlord&#8217;s performance of the Demolition Work and as set forth in this Section 5, Landlord shall have no obligation to perform any work at the Building in connection with Tenant&#8217;s occupancy of the 2022 Expansion Premises or obtain any permits, approvals, or entitlements related to Tenant&#8217;s specific use of the 2022 Expansion Premises or Tenant&#8217;s business operations therein.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of the Effective Date, Landlord is leasing the 2022 Expansion Premises to [***] LLC, a Maryland limited liability company (&#8220;<b style="font-weight:bold;">[***]</b>&#8221;), and the lease agreement (&#8220;<b style="font-weight:bold;">[***] Lease</b>&#8221;) between Landlord and [***] is scheduled to expire on October 31, 2023. This Third Amendment is contingent on Landlord and [***] agreeing in writing to terminate the [***] Lease and [***] vacating the 2022 Expansion Premises on or before May&#160;31, 2022 (&#8220;<b style="font-weight:bold;">Termination Agreement</b>&#8221;), which Termination Agreement shall be on terms and conditions acceptable to Landlord in its sole and absolute discretion (&#8220;<b style="font-weight:bold;">Contingency</b>&#8221;). Landlord will notify Tenant promptly of the execution and delivery of the Termination Agreement. Tenant acknowledges that Landlord makes no promise, guaranty, or assurance that it will be able to enter into the Termination Agreement and, as a result, Landlord makes no guaranty, representation, or assurance that Landlord will be able to Deliver the 2022 Expansion Premises to Tenant by the 2022 Expansion Premises Commencement Date and that Landlord shall have no obligation or duty to seek the vacation or removal of [***] from the 2022 Expansion Premises. If Landlord is unable to</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">6</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Deliver the 2022 Expansion Premises on or before August 31, 2022, Tenant shall have the right to terminate this Third Amendment by sending written notice thereof to Landlord by no later than September 15, 2022, whereupon neither Landlord nor Tenant shall have any further rights, duties, or obligations under this Third Amendment. If Tenant does not elect to so terminate this Third Amendment by September 15, 2022, such right to terminate this Third Amendment shall be waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">e.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Tenant, at its sole expense, shall make any alterations or modifications to the interior of the 2022 Expansion Premises that are required by Legal Requirements (including, without limitation, compliance of the 2022 Expansion Premises with the ADA).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Notwithstanding any contrary provision contained in this Section 5, Tenant shall have a period of 60 days after Landlord&#8217;s Delivery of the 2022 Expansion Premises to Tenant to reasonably identify in writing any latent defects in the mechanical, electrical, and plumbing systems and the structural components serving the 2022 Expansion Premises. For purposes of this paragraph, &#8220;<b style="font-weight:bold;">latent defects</b>&#8221; means those material defects in such systems and/or components that could not have been identified or discovered through a reasonable inspection of such systems or components conducted by a qualified technician. Landlord will promptly repair such identified latent defects (subject to Landlord&#8217;s reasonable confirmation that such defects are, in fact, latent defects).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><b style="font-weight:bold;">Base Rent for 2022 Expansion Premises</b>. (a) Tenant shall continue to pay Base Rent with respect to the Existing Premises and the Expansion Premises at the rates set forth in the Lease, (b)&#160;commencing on the 2022 Expansion Premises Commencement Date (but subject to the 2022 Expansion Premises Base Rent Abatement [as defined below]), Base Rent for the 2022 Expansion Premises shall be payable at the rate of $ [***] per month, and (c) commencing on the 2022 Expansion Premises Commencement Date, Base Rent for the 2022 Expansion Premises shall be increased as of the date or dates on which Tenant uses the Additional 2022 Expansion Premises TI Allowance (as defined in the 2022 Expansion Premises Work Letter attached hereto as a part hereof as <b style="font-weight:bold;">Exhibit C</b>) (such increase to be calculated based on the amount of the Additional 2022 Expansion Premises TI Allowance used by Tenant, such amount to be amortized over the Base Term based on an interest rate of [***] % per annum; the resulting amount so amortized shall be added to the monthly installments of Base Rent for the 2022 Expansion Premises). Notwithstanding any contrary provision contained in the Lease, the Base Rent for the 2022 Expansion Premises shall thereafter be increased on each anniversary of the 2022 Expansion Premises Commencement Date by multiplying the Base Rent payable for the 2022 Expansion Premises immediately before such date by the Rent Adjustment Percentage (i.e., [***]%) and adding the resulting amount to the Base Rent payable for the 2022 Expansion Premises immediately before such date; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that as more fully set forth in Section 5(b)2 of the Work Letter, the Rent Adjustment Percentage shall not apply to the 2022 Expansion Premises TI Allowance. Base Rent for the 2022 Expansion Premises, as so adjusted, shall thereafter be due as provided in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><b style="font-weight:bold;">2022 Expansion Premises Base Rent Abatement</b>. Notwithstanding anything to the contrary contained in this Third Amendment, but provided Tenant is not in Default hereunder or under the Lease, Landlord hereby grants Tenant an abatement of the Base Rent payable for the 2022 Expansion Premises during the period beginning on the 2022 Expansion Premises Commencement Date and ending <font style="font-size:12pt;">[***] </font>after the 2022 Expansion Premises Commencement Date (&#8220;<b style="font-weight:bold;">2022 Expansion Premises Base Rent Abatement</b>&#8221;). For the avoidance of doubt, if the 2022 Expansion Premises Commencement Date occurs on the first day of a month, the 2022 Expansion Premises Base Rent Abatement will be measured from that date. If the 2022 Expansion Premises Commencement Date occurs on a day other than the first day of a month, the 2022 Expansion Premises Base Rent Abatement will be measured from the first day of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">7</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">following month. Except as provided in the preceding sentences, Tenant shall pay the full amount of Base Rent due for the 2022 Expansion Premises in accordance with the provisions of this Third Amendment and the Lease. The administration rent set forth in Section 5 of the Lease shall not be abated and shall be based on the amount of Base Rent with respect to the 2022 Expansion Premises that would have been payable but for the 2022 Expansion Premises Base Rent Abatement. Notwithstanding anything to the contrary in this <u style="text-decoration:underline;text-decoration-color:#000000;">Section</u><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration:underline;text-decoration-color:#000000;">&#160;</u><u style="text-decoration:underline;text-decoration-color:#000000;">6(a)</u>, the adjustment in the Base Rent as set forth in this <u style="text-decoration:underline;text-decoration-color:#000000;">Section</u><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration:underline;text-decoration-color:#000000;">&#160;</u><u style="text-decoration:underline;text-decoration-color:#000000;">6</u> shall be based on the full and unabated amount of Base Rent payable with respect to the 2022 Expansion Premises for the first <font style="font-size:12pt;">[***] </font>period from and after the 2022 Expansion Premises Commencement Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><b style="font-weight:bold;">Extension Right</b>. The Extension Right set forth in Section 40 of the Lease applies to, and shall be exercised (if at all) only with respect to, the entire Premises. The Extension Term shall be for the period beginning on April 1, 2030 and ending, unless earlier terminated in accordance with the terms and conditions of the Lease, on March 31, 2035. For the avoidance of doubt, the Market Rate shall not include the adjustments for the TI Allowance as described in Section 4 of the Lease, the Expansion Premises TI Allowance as described in the First Amendment, and the 2022 Expansion Premises TI Allowance as described in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> of the Work Letter attached to this Third Amendment, but may include build-out allowances to the extent they are then provided as market concessions in the Market Area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><b style="font-weight:bold;">Amendment to Section 20(h)</b>. Section 20(h) of the Lease, captioned &#8220;Work Letter and 9000 VMR Work Letter,&#8221; is hereby deleted and replaced with the following new Section 20(h):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><b style="font-weight:bold;">Work Letter, Expansion Premises Work Letter, 2022 Expansion Premises Work Letter, and 9000 VMR Work Letter</b>. Tenant fails to perform any obligation imposed on it under the terms and conditions of the Work Letter, the Expansion Premises Work Letter, the 2022 Expansion Premises Work Letter, or the 9000 VMR Work Letter (as applicable), which failure is not cured within any applicable notice and cure period specifically set forth in the Work Letter, the Expansion Premises Work Letter, the 2022 Expansion Premises Work Letter, or the 9000 VMR Work Letter, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><b style="font-weight:bold;">Amendment to Section 21(f)</b>. Section 21(f) of the Lease, captioned &#8220;Suspension of Funding,&#8221; is hereby deleted and replaced with the following new Section 21(f):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><b style="font-weight:bold;">Suspension of Funding</b>. Upon a Default by Tenant hereunder and during the continuance thereof, Landlord shall have the right to suspend funding of any TI Allowance, the Expansion Premises TI Allowance, and the 2022 Expansion Premises TI Allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><b style="font-weight:bold;">Amendment to Section 30(a)</b>. Section 30(a) of the Lease, captioned &#8220;Prohibition/Compliance/Indemnity,&#8221; is hereby amended by deleting the proviso and replacing it with the following new proviso:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that Tenant shall have no indemnification, remediation, or other obligation or responsibility under this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 30</u> for any contamination or Environmental Claim if Tenant proves by a preponderance of the evidence that such contamination or Environmental Claim arises from any Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from the Premises by Landlord or another tenant unrelated or unaffiliated with Tenant or that existed in the Existing Premises as of the Commencement Date, in the Expansion Premises as of the Expansion Premises Commencement Date, or in the 2022 Expansion Premises as of the 2022 Expansion Premises Commencement Date, and were not brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">8</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Premises by Tenant or any Tenant Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><b style="font-weight:bold;">Miscellaneous</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a.</font></font><b style="font-weight:bold;">Entire Agreement</b>. The Lease, as amended by this Third Amendment, is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. The Lease, as so amended by this Third Amendment, may be amended only by an agreement in writing, signed by the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">b.</font></font><b style="font-weight:bold;">Binding Effect</b>. This Third Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">c.</font></font><b style="font-weight:bold;">Broker</b>. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;<b style="font-weight:bold;">Broker</b>&#8221;) in connection with this Third Amendment and that no Broker brought about this Third Amendment, other than [***] (&#8220;[***]&#8221;). [***] shall be paid by Landlord pursuant to a separate agreement between Landlord and [***]. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than the brokers named in this Section, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Third Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">d.</font></font><b style="font-weight:bold;">Counterparts</b>. This Third Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000, including DocuSign) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Third Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">e.</font></font><b style="font-weight:bold;">Ratification; Conflicts</b>. Except as amended and/or modified by this Third Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment. In the event of any conflict between the provisions of this Third Amendment and the provisions of the Lease, the provisions of this Third Amendment shall prevail. Regardless of whether specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Third Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 21pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[SIGNATURES APPEAR ON NEXT PAGE]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">9</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment under seal as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TENANT:</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEXTCURE, INC</b>.,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware corporation</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="3" style="vertical-align:bottom;width:23.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(SEAL)</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td colspan="3" style="vertical-align:bottom;width:23.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">X<font style="font-family:'Segoe UI Symbol';">&#9744;</font> I hereby certify that the signature, name, and title above are my signature, name, and title.</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LANDLORD:</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b>,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited liability company</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alexandria Real Estate Equities, L.P.,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited partnership,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">managing member</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARE-QRS CORP.,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Maryland corporation,</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">general partner</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:38.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[(SEAL)]</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:bottom;width:38.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gregory Kay</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td colspan="2" style="vertical-align:bottom;width:38.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVP- Real Estate Legal Affairs</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Third Amendment to Lease Agreement &#8211;-NextCure, Inc.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page - </b><font style="font-weight:bold;">10</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Suite 140, 8000 Virginia Manor Road</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022 EXPANSION PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACKNOWLEDGMENT OF 2022 EXPANSION PREMISES COMMENCEMENT DATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022 EXPANSION PREMISES WORK LETTER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">2022 Expansion Premises Tenant Improvement Progress Report</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:44.5pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a name="_Hlk96953106"></a><img src="nxtc-20211231xex10d26001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:62.24pt;"></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Copyright &#169; 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>nxtc-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><font style="font-size:11pt;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.43;text-align:left;">Registration Statement (Form S-8 No. 333-231438) pertaining to the NextCure, Inc. 2019 Employee Stock Purchase Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.43;text-align:left;">Registration Statement (Form S-8 No. 333-231436) pertaining to the NextCure, Inc.&#160;2015 Omnibus Incentive Plan and the NextCure, Inc. 2019 Omnibus Incentive Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.43;text-align:left;">Registration Statement (Form S-8 No. 333-260776) pertaining to the NextCure, Inc. 2019 Employee Stock Purchase Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.43;text-align:left;">Registration Statement (Form S-8 No. 333-260779) pertaining to the NextCure, Inc. 2019 Omnibus Incentive Plan, and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.43;text-align:left;">Registration Statement (Form S-3 No. 333-241706) of NextCure, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;">of our report dated March 3, 2022, with respect to the financial statements of NextCure, Inc. included in this Annual Report (Form 10-K) of NextCure, Inc. for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Ernst &amp; Young LLP</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Baltimore, Maryland</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">March 3, 2022</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>nxtc-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:54 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Michael Richman, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of NextCure, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Michael Richman</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>nxtc-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:39:57 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Steven P. Cobourn, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of NextCure, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>nxtc-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 08:40:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form 10-K of NextCure, Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned each hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge, on the date hereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(1)&#160;&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(2)&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 3, 2022</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 3, 2022</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven P. Cobourn</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nxtc-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'V \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC(]:,CUH *
MKWY*Z==$$@B)R".W!JQD>M,E1)HGB?E74J1[&A >'^%VU&]MM(ETN75WU/[1
M_I$LDC& QYYZ\=*CUF_DCU/Q&\DFJ><EYY=K/#<%8H6)XW<U[1I&DV>AZ='8
M6*%+>,DJI8GK[FJG_"*Z.8M2B:VW)J3;[D,Q.X^H]/PKL^L1YF[?U<P]D[6.
M0U*74;[7?#_AZ_U.6*WEM!)<36\FPSN!TW"J\>JZAX;U/Q/IEC>37MK9V!N8
M#,WF-"_'&>_4\>U=E-X/T6XTNWT^:!GBMO\ 4L9#O3Z-UJSI7AS2M%MYH;.V
M51-_K6<[FD^I/6H]K"UOZWW*Y'<\TAFM[+3](U*\O]<GN[UD8W<-Q^Z5R?N%
M<_I5#Q'?M'XH\3-<-JLB0K&(&MIRJ0LPX+<]"<5Z0OP_\-I=+.MF1M?>L?FM
ML#>H7.*T!X9TD76HW!M]SZB@2Y#,2' Z<=JKV\$[_P!;D^SE:QQ7B/5[JQ\!
MZ-I]UJ@6]ORB27:R?=3J6R/;%4].UZ6[^%6MVHO7EN].+1"=7.YE)RK9Z^H_
M"NXM?!>AVDMJZV[2?95985ED+J@/7@T^3P?HDDFH/]EV?;XQ'<*C%58#IP.G
M2I56G:UNM_Z^0^26YY/JNK>(3X/73'EN(S8*L\EV&(,J-C8,_B:Z3Q##K5Q>
MV4P6\OM*2RCW6UG=>7(LF.6;')KOKW0-.O\ 1O[)N(MUIL5-H8@X7ISUJE?^
M"]$U&9)IH95D5%CW13,A*@8 .#SQ5*O'MW#V;(? E[;7WAT-:W%Y,B2LI%XV
MZ1#_ '<]\5T]5--TVSTFS2TL85AA7HJ^OJ:MY'K7--IR;1K%65F%%&1ZT9'K
M4C"BC(]:,CUH **,CUHR/6@#SKXEZ6D%G%JD-W>Q7$MS%$PCN&5-IX. *=XS
M:#PKX432K.^N(GO[@()IIV9D!QN.>H&!79ZOH]EK=JEM?(7B219  Q'S#ITI
ME]H.G:EJ5M?W<(EFM@1&&.5&>O'0UO&JK13Z?TC-PU=CS?3==EG^&/B"R%^\
M]SIV52X5SN9"PPP/6J_@^YN)/$VDQ6LNHV["T\V[2\N"RW (&"@/K7HLW@_1
M)I;Z0VNS[=$(IU1BH91R.!TZ4^7PII$KZ<YA99-/4);NKD,JCH">X^M7[:%F
MK;_Y$\DM/(\YCO#JEEJFMZQ<ZM.\%R\7V:QG\O[,@YW$9_6C6[FXU"\\*QVL
MFHW<5Q:.VP7!BDDYX+$'&:[[4/ V@:E=R74]H5DE_P!9Y4C()/\ > /-+?\
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MR/6C(]:Q- HHR/6C(]: "BC(]:,CUH KWQ*Z?<D$@B)B"/H:\>M8IK+X??\
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M_P#%4?\ "":'_=O/_ V7_P"*KI:*.>7<.5'-?\()H?\ =O/_  -E_P#BJ/\
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MYY=PY4<U_P ()H?]V\_\#9?_ (JC_A!-#_NWG_@;+_\ %5TM%'/+N'*CFO\
MA!-#_NWG_@;+_P#%4?\ "":'_=O/_ V7_P"*KI:*.>7<.5'-?\()H?\ =O/_
M  -E_P#BJ/\ A!-#_NWG_@;+_P#%5TM%'/+N'*CFO^$$T/\ NWG_ (&R_P#Q
M5'_"":'_ ';S_P #9?\ XJNEHHYY=PY4<U_P@FA_W;S_ ,#9?_BJ/^$$T/\
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M?\()H?\ =O/_  -E_P#BJ/\ A!-#_NWG_@;+_P#%5TM%'/+N'*CFO^$$T/\
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M_P#%4?\ "":'_=O/_ V7_P"*KI:*.>7<.5'-?\()H?\ =O/_  -E_P#BJ/\
MA!-#_NWG_@;+_P#%5TM%'/+N'*CFO^$$T/\ NWG_ (&R_P#Q5'_"":'_ ';S
M_P #9?\ XJNEHHYY=PY4<U_P@FA_W;S_ ,#9?_BJ/^$$T/\ NWG_ (&R_P#Q
M5=+11SR[ARHYK_A!-#_NWG_@;+_\56[96<-A9Q6L&_RHQM7>Y8X]R>35B@=*
M3DWN"20444&D,*\3\.?#35=9&O6VL:A?Z?I5QJ;2/8HB@7*Y!#;NH' _*O:]
MP]11N'J* /%/$7@'6]3\?:PVDRWNFVRZ2D-K/"VU)"HQY9/IBFGPYK5QX3\*
M7UCX?DM[[PY>;YM.<X\\9!+J3U)QG\:]MW#U%&X>HH \J2PUOQCX_L_$,^BW
M&E6.G6LD:K<D>9,[#I@=JYC2+'Q0/AW?^"H_"UX+F^GDS=3X6&-&?.[.<Y K
MWS</44;AZB@#R6YT+6/!OB[1-9M=+N-7M+;2EL)5MB-X8#K@]JQ_^%>>(-5^
M'^OLUJ+:_O\ 5AJ4%G*PR57^%CTR<G\J]RW#U%&X>HH Y#PWXFUG5;JWL[KP
MM>:='''B>>=E"A@, +CJ*I^"=*O[#QOXUN[JUDBM[N[C>WD8<2 !LD5W>X>H
MHW#U% 'G_P 3/#VJ:A<:%K6DVWVR;2;KSGM<X,B^WO5?7?$GB;6O".L1V'A:
M_LYI(5@@\XC>SN<,0!T"CG->D;AZBC</44 >(^&O"'BSP=XP\/WDEG;2V;6_
MV*X^P@_*O4-)GOGO5%OA[KDO@W5K^SLY;77K;5+J2W!&&N+>0*&7W!Y(KWS<
M/44;AZB@#PZ?1]=TNS^'MXNAWMTVEQN;F&%070G/'/UK=TJRUN3Q+XB\<WVB
M7%N)[);6UT]"#-(!CYF'3/%>J;AZBC</44 >"6NCZ_<_!36/#[:!?0WPN/-C
M1U'[P-(#\O/85NM9:[XSU'PO%)H%UI=EH;K/-/=8#R,J@;4 ['%>O;AZBC</
M44 ?/FK>"?&OB"'Q!K8LK>&6>[$\$<P/VE1$?D"8X&:[CQQ::SXE^'VA.FFS
MB_-S;2W%OCYHR/O9^AKTO</44;E]1^= 'E'Q:T._U/4O#$\&FW][;6LKM<BR
M;;(HP.A[&JUUI,%[X(%F?".OW-NM[O:*ZNLW49V_ZR,D].V/K7L&Y?4?G1N7
MU'YT >6_#+2?$=AKM[),VK1>'S"%AM]5E#RB3/4>@ZUZG2;E]1^=&Y?4?G0
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MR+'_ )X'_OXW^-']D6/_ #P/_?QO\:NT478612_LBQ_YX'_OXW^-']D6/_/
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M/_BJ@_X6%X-_Z&C2O_ @4?\ "PO!O_0T:5_X$"CGEW"R)_\ A#=!_P"?)_\
MP(D_^*H_X0W0?^?)_P#P(D_^*J#_ (6%X-_Z&C2O_ @4?\+"\&_]#1I7_@0*
M.>7<+(G_ .$-T'_GR?\ \")/_BJ/^$-T'_GR?_P(D_\ BJ@_X6%X-_Z&C2O_
M  (%'_"PO!O_ $-&E?\ @0*.>7<+(G_X0W0?^?)__ B3_P"*H_X0W0?^?)__
M  (D_P#BJ@_X6%X-_P"AHTK_ ,"!1_PL+P;_ -#1I7_@0*.>7<+(G_X0W0?^
M?)__  (D_P#BJ/\ A#=!_P"?)_\ P(D_^*J#_A87@W_H:-*_\"!1_P +"\&_
M]#1I7_@0*.>7<+(G_P"$-T'_ )\G_P# B3_XJC_A#=!_Y\G_ / B3_XJH/\
MA87@W_H:-*_\"!1_PL+P;_T-&E?^! HYY=PLB?\ X0W0?^?)_P#P(D_^*IP\
M&:!Y9/V)\Y_Y^)/_ (JJW_"PO!O_ $-&E?\ @0*=_P +#\&>61_PE&E]?^?@
M4<\NX<J)?^$-T'_GR?\ \")/_BJ/^$-T'_GR?_P(D_\ BJ@_X6%X-_Z&C2O_
M  (%'_"PO!O_ $-&E?\ @0*.>7<+(G_X0W0?^?)__ B3_P"*H_X0W0?^?)__
M  (D_P#BJ@_X6%X-_P"AHTK_ ,"!1_PL+P;_ -#1I7_@0*.>7<+(G_X0W0?^
M?)__  (D_P#BJ/\ A#=!_P"?)_\ P(D_^*J#_A87@W_H:-*_\"!1_P +"\&_
M]#1I7_@0*.>7<+(G_P"$-T'_ )\G_P# B3_XJC_A#=!_Y\G_ / B3_XJH/\
MA87@W_H:-*_\"!1_PL+P;_T-&E?^! HYY=PLB?\ X0W0?^?)_P#P(D_^*H_X
M0W0?^?)__ B3_P"*J#_A87@W_H:-*_\  @4?\+"\&_\ 0T:5_P"! HYY=PLB
M?_A#=!_Y\G_\")/_ (JG+X,T HQ^Q/Q_T\2?_%56_P"%A>#?^AHTK_P(%.'Q
M$\&!&'_"4:7S_P!/ HYY=PY42_\ "&Z#_P ^3_\ @1)_\51_PAN@_P#/D_\
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M5<DX&?4U'5J/[GXG^=%V]PLA]4=8_P"03<?[H_F*O51UC_D$W'^Z/YBL*_\
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M":ZO;8WNN->Q*IEM-7P'C4]&4#@@^H)H ZJBBB@ HHHH *<?N#ZTVG'[@^M
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M6WD1?*M_*<'G#D@C\:@J&VGN4DGT*?\ 9.F?] VS_P"_"?X4?V3IG_0-L_\
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MGL$FDC+(58R3;\>61T&*CT^SB\ZX2_C91'&&QG!7.,']:OV5337<GVD-=-C
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MSQ\5A73?-'8]#HHHKT3C"BBB@![?ZI?K3*>W^J7ZTR@ HHHH **** "BBB@
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M*Y%L,!!_"5SS]:?HVA36.H76IZA??;=0N$6(R"/RT2-<D*J_4YK;HH ****
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M+<8+*2/D)]NE '3H2R*6&"0"1G.#2U%;0):VL-M'N\N&-8UW')PHP,G\*EH
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MP]VXZ'/4*/UI=%TB?X@W8NIUD@\+0/\ (#E6U!AW]HQ^M>K111P0I#"BQQH
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MK'_/U9?]^6_QH\O6/^?JR_[\M_C1RKN@YW_*_P"OF:%%9_EZQ_S]67_?EO\
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M_GZLO^_+?XT>7K'_ #]67_?EO\:/J]/LOZ^0>WJ>?]?,Y'_A5EM_T,NO?^!
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M]BO(/^$'\/?\^#?]_P!_\:/^$'\/?\^#?]_W_P :/[6I=G^'^8?V?4[H]?\
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MU+L_P_S#^SZG='K_ -H@_P">\7_?8H^T0?\ />+_ +[%>0?\(/X>_P"?!O\
MO^_^-'_"#^'O^?!O^_[_ .-']K4NS_#_ ##^SZG='K_VB#_GO%_WV*/M$'_/
M>+_OL5Y!_P (/X>_Y\&_[_O_ (T?\(/X>_Y\&_[_ +_XT?VM2[/\/\P_L^IW
M1Z_]H@_Y[Q?]]BC[1!_SWB_[[%>0?\(/X>_Y\&_[_O\ XT?\(/X>_P"?!O\
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M5<&Q2">YDC%K,\8R!Y"@;3Z!O3TK&T?3KAYO#5C#HDUE=Z7*6O;MXPJL-I!
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MU_+[_P#@!]?I>9/14'_""^-/^ANT[_P6?_94O_"">-=N[_A+M.QT_P"09_\
M94?V77\OO_X ?7Z7F345!_P@OC3_ *&[3O\ P6?_ &5'_""^-/\ H;M._P#!
M9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\ P6?_ &5'_""^-/\ H;M.
M_P#!9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\ P6?_ &5'_""^-/\
MH;M._P#!9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\ P6?_ &5'_""^
M-/\ H;M._P#!9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\ P6?_ &5'
M_""^-/\ H;M._P#!9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\ P6?_
M &5'_""^-/\ H;M._P#!9_\ 94?V77\OO_X ?7Z7F3T5!_P@OC3_ *&[3O\
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MTO,GHJ#_ (07QI_T-VG?^"S_ .RH_P"$%\:?]#=IW_@L_P#LJ/[+K^7W_P#
M#Z_2\R>BH/\ A!?&G_0W:=_X+/\ [*E'@3QJ03_PEVG8'_4,_P#LJ/[+K^7W
M_P# #Z_2\R:BH/\ A!?&G_0W:=_X+/\ [*C_ (07QI_T-VG?^"S_ .RH_LNO
MY??_ , /K]+S)Z*@_P"$%\:?]#=IW_@L_P#LJ/\ A!?&G_0W:=_X+/\ [*C^
MRZ_E]_\ P ^OTO,G) !)( '))[5B6=E=>/;Y[.TD>W\/PMMNKM>&N".L:'T]
M36F?ASXBORMOJ_BJ"73V8>?%:V7E/(O]T-GC->A6-C:Z;90V=E D-O"H5(T&
M !79A,N]G+GJZOH<V(QO.N6F%C8VNFV,-E90)!;0J$CC08"BK%%%>L>>%%%%
M !1110 ]O]4OUIE/;_5+]:90 4444 %%%% !1110 4444 %%%% !5J/[GXG^
M=5:M1_<_$_SIB8^L_7'6/1;IV.%"Y/YBM"LKQ)_R+U[_ +G]125-5/<>ST^\
M4ZCIQ=1;K7[CSO\ M&V_OG_OFD_M"U_O'_OFLBBM/]6L)_-+[U_D>9_K/B_Y
M8_<_\S7_ +0M?[Q_[YH_M"U_O'_OFLBBC_5K"?S2^]?Y!_K/B_Y8_C_F:_\
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M_P $R_[:MO\ GE=?]^&H_MJV_P">5U_WX:M&BB\>WXARS[_A_P $SO[:MO\
MGE=?]^&H_MJV_P">5U_WX:M&BB\>WXARS[_A_P $SO[:MO\ GE=?]^&H_MJV
M_P">5U_WX:M&BB\>WXARS[_A_P $SO[:MO\ GE=?]^&H_MJV_P">5U_WX:M&
MBB\>WXARS[_A_P $SO[:MO\ GE=?]^&H_MJV_P">5U_WX:M&BB\>WXARS[_A
M_P $SO[:MO\ GE=?]^&H_MJV_P">5U_WX:M&BB\>WXARS[_A_P $SO[:MO\
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M47CV_$.6??\ #_@F7_;5M_SRNO\ OPU']M6W_/*Z_P"_#5HT47CV_$.6??\
M#_@F=_;5M_SRNO\ OPU']M6W_/*Z_P"_#5HT47CV_$.6??\ #_@F=_;5M_SR
MNO\ OPU']M6W_/*Z_P"_#5HT47CV_$.6??\ #_@F=_;5M_SRNO\ OPU']M6W
M_/*Z_P"_#5HT47CV_$.6??\ #_@F=_;5M_SRNO\ OPU']M6W_/*Z_P"_#5HT
M47CV_$.6??\ #_@F=_;5M_SRNO\ OPU']M6W_/*Z_P"_#5HT47CV_$.6??\
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MN2>!["M"XT^SN].;3Y[=)+-D"&%A\I4=!^E $T7^HC_W%_E3Z    . !@44
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MHHH **** "BBB@ HHHH **** .T\!_ZN]_WE_E785Q_@3_5WO^\M=A7AXO\
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M)_W];_&C^Q+'^Y)_W];_ !K0HKF]I/N9^RAV1G_V)8_W)/\ OZW^-']B6/\
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MC1_8EC_<D_[^M_C53PMXIT[Q;I"W]@^"/EF@;[\+]U85MUE[2?<CV4.R,_\
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M88>Q&#356\N4.?6QRE%%%;%A1110 4444 %%%% $NEZGJ/AK6%U?1WVS#B>
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M8^';K4I[2*)3>3F0;$V[%P,)].,UO444 %%%% !3C]P?6FTX_<'UH ;1110
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MUG^]8?\ ?+T<GF@]IY,L_8K3_GTM_P#OTO\ A1]BM/\ GTM_^_2_X56QK/\
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MH/:>3+U%9^-9_O6'_?+T8UG^]8?]\O1R>:#VGDS0HK/QK/\ >L/^^7HQK/\
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M %^BJ.HZI#86]TP9'N(+9KGR-V&91W^F>,TEEJMO=6]D7DCCN+J!9U@W9;!
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M'URGV8?ZN8O^:/WO_(^O\>X_.C'N/SKY ^RI_P ];C_O^_\ C1]E3_GK<?\
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M.QC7R'%4:;J:.W:]_P CZ9HJIIFIV>L:=#?V$ZSVTR[D=3_GFK==)XH4444
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M@=&8C*CDJ0W;N*S?%37WB"WTR_@L=4@L;6Y8RHUJ&E8%<!Q$>H![8S7H%&:
M/.-,TEXTT^:U34I4DUR.XD^TVGD; (R"P0#A>F3@<U7FTPQ:38SW-MJ45U!=
M7+1&*Q^TIAG_ (T]QT->GY-&3ZT 9'A9KUO#-B=0LH[*ZVG?!&NT+\QQ\O;(
MP<=LUKT44 %%%% !1110 5X'\:/^2AVO_8-7_P!#->^5YQ\0?AGJ'BWQ'!JM
MEJ=M:A+80E)HV8GDG/'UK.K%R@XHZ\!7C0Q,*L]DSPVBO2/^%'Z__P!!_3O^
M_#T?\*/U_P#Z#^G?]^'K@^J5#Z[_ %AP?G]W_!/-Z*](_P"%'Z__ -!_3O\
MOP]'_"C]?_Z#^G?]^'H^J5 _UAP?G]W_  3S>BO2/^%'Z_\ ]!_3O^_#T?\
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MX?\ !,+^V+;_ )Y7?_@,_P#A1_;%M_SRN_\ P&?_  K=HHO#M^/_   M/O\
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M^'_!,+^V+;_GE=_^ S_X4?VQ;?\ /*[_ / 9_P#"MVBB\.WX_P# "T^_X?\
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M=OQ_X 6GW_#_ ()A?VQ;?\\KO_P&?_"C^V+;_GE=_P#@,_\ A6[11>';\?\
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M]M7^ZOY5:TC5M0\-:Q'J^CR>7<*-LL1^Y.G=6']:F>"DE=.Y4:Z;LT?5=/\
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M,IZ_ZMZ &4444 %%%% !1110 4444 %%%% !1110 ]O]4OUIE/;_ %2_6F4
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M5I2GR34B9QYHV/GK!]*,'TKV[_A27A+_ )Z:K_X%_P#UJ/\ A27A+_GIJO\
MX%__ %J[?KT>QS_5WW/$<'THP?2O;O\ A27A+_GIJO\ X%__ %J/^%)>$O\
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MJ/UH 91110 4444 %%%% !1110 4444 %/7_ %;TRGK_ *MZ &4444 %%%%
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M_?\ 3_&C[3J?_0&E_P"_Z?XUMT4<R_E7X_YAR2_F?X?Y&)]IU/\ Z TO_?\
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MJ?\ T!I?^_Z?XT?:=3_Z TO_ '_3_&MNBCF7\J_'_,.27\S_  _R,3[3J?\
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MEG=6#HE_8SB:'?\ =8=&4_4$_I1+X;MY_$L.O/=7JW447E+$LW[H*>HVX[D
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M_2DU/Q%K%M::Y8:O;6;36]HMS&UI(ZJ5+8VDDYR/48K<B\%Z4FE7EA(UU/\
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>nxtc-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )= K\# 2(  A$! Q$!_\0
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M $V:,U!YP]:3SQZT 6,T9JOYX]:/.'K0!8S2YJOYP]:7S1ZT 3T5#Y@IPD%
M$E%,W"EW4 .HI,TN: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHI,T +1FFEJ89 * ),TA:J[3@=ZKO= =Z +ID J-I@*S9+T 'FLJ[\1
M6-L2);N,,/X5.X_I1:XFTMSHVN .]1-=@=ZXBZ\;6J9$,4LI[$X452'B36KT
MXLM.)ST*QL__ -:K4)$.K%'?M>@=ZC:]P,\X]:X=;+Q?>_>+0*?[SJG\N:<O
M@W6)_P#CYU., ]1N9Z?L_,GVW9'72:I#']^:)?\ ><#^=57\06"'YKV ?]M
M?Y5AQ_#^+_EMJ,A/^Q&!_,FK*> ]-'W[BZ?_ ($!_2GR+N+VLNQ<?Q1IJ_\
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M^G/ZUU-%5<BW<H6NBZ99X\BQ@4C^(KD_F:O]L=O2BBD,**** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HI":8SXH <6J)Y .]12SA>]9MU?K&C,SA5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5'Y=33663;MS"E1Y5=LY&C(]:],\.^%[:QTU3?6T4UU+\SB1 VST49_6M?\
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MWCCH:EOH7YD;.9'RRC;D9(%=EX(L)3J41*;E#9SCH/>N5T^P:YGRH<J3\N,
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MG\#^5<WX8N8+;X[^+6GGBB4VR &1PH/W/6M;QOX/T[Q7J<6I:5XACTWQ!8Q
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MS UGP?I.NSZ9+=QRJ=-</;K"^Q0?0C'2LGQ#\+O#OB;6WU>^-\EVZ!&-O<[
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M3@G//4]:[2BBP79GZ-H>F^'].2PTJSCM;9#D(@ZGU)/)/N:T,444P#%&***
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ML;K2[=0C6T=GM8J!@ -C^M8EA\.O&N@ZEJ4^A>*K"U@OK@SNCVF\\GW!]>U
M!I7_ "</J_\ UXK_ "J3XF^&]>D\1Z3XJT6PBU7^SE(DL)1G(SG('?\ #FI=
M3^'WBL^,I?$FB^)+*SNIK=(9#);%\D#!.,$<FM"Y\/?$01VTUIXQL_M0CV7"
M36F8G.>&4 <'\* +/P[\5Z/XIL[R2PTH:7?12 7MMY84[_7( S^(S7:XKD/
MO@E_":7US>W_ -OU34)/-N9PFQ<^BCTKKZ:)88HQ113 ,48IDL@BB>0C(4$U
MY[=>+))-3DCDN9(@IQMC.,4XQ<MC6E1G5=HGHN*,5B:+JS7)%O.X=R-R/C&X
M>_O6W2::(E%Q?*PQ1BBB@D,48HHH ,48HHH :R!U*L,J1@@]Q7F_EMX8\6-
M21:SGY3['I^5>E5ROCG2_MFE"\C7][;')(Z[>]-=B)=UT-ZTER!S6FAR*X[P
MQJ7VW38V)^=/D?ZBNK@?(%9M6=C=.ZN6J*04M(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2&EICGB@"O.^ :Y#Q5J/V33)=K8DD_=K^/7]*Z
M:[DPIKSW60^M^)[72XR=JL%;VSRQ_ 54%=D5':)TW@C3/L.A+<.N);H^8?\
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M^%=,M;D7"1EF'(W8KF=1+1HXJF,:3A..IKP%FMXV;[Q4$U)2T5SGEB48I:*
M/./%:?9/&MK<#@2!2?Y5V=FV0*Y3XBQ[+K3KD#IE<_0YKI--??$C#NH-.6R(
MAI)HVTZ5)449XJ6H-0HHHH **** "BBB@ HHHH **** "BBB@ IC]*?4;]*
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M?X:+=UE4U#X7?=H]J<_P8JG\)$?C9UD1XJ:J\/058%0:A1110 4444 %%%%
M!1110 4444 %%%% !4;]*DJ-^E &5>G@UQOA;YO']T?19/Z5V-[]TUQ_@[YO
M'-\?1)?_ $(5<=F9U-T>D4445)84444 <[XITR6Z@2ZMU+21=5'<5R(U$1C;
M(I5AU!%>H54ETNQF??):1,WKMKEJX?G?,G8]##8U4X\DU='G+7B-SL;Z[34L
M5TC#@UZ*+&T"[?LL.,8QL%9&I^%;.\C9K=1!-V*]#6;PTDM'<Z(YA2D[25CE
MC%%<#+KSZCK4+Z<#]V4CZBA(Y[&\:TNAM=3U]:OA":PU.N26Z,X:< ,M(3]!
M4EO;*&^1?QJ>[;RHO<U5LUN9Y-EO&\C_ .S1Y EI<T/*(4G' JK>.(X&/M3[
MBUU>(9DMI<=LYJLFEZC?R!9$,4>>2:'?:P1<%JY(T?#-LJVKW!7YW/6MVHK6
MW2TMDA3HHJ6J2/.JSYYN0AHHI*M&(4AI:2J0@I#0:2K1+"DI3252)8UC5:9\
M U.YXJC<O@&K1+,/7+WR+9@I^=^!71^"=&%AI0NY%_TBY&[GLO8?UKD5MVUG
MQ/;V8Y0,-WL.IKU=45%"J,*!@ =A73%<L;'*WS3;[#<48I^VC;1<=C#\3'Q$
MNFJ?#(T\WF\;A>ABFWVQWKS6/Q?\3I/%LOAH0^'?MT< G),<FS:??/6O9MM>
M66P_XR&O?^P8O\Z3&CMO#<^M/8&+Q$=/&I!B2EFQV[>QP3FM?S(_-\KS$\S&
M=FX;L>N.M>:Z>3_PT!J@SUTY*DN\CX^V@!_YAA_F:+A8]#>ZMHT=WN(56,X=
MFD4!3[\\4&ZMQ;?:3<0B#&?-\P;/^^LXKQCP]X1L/%?Q'\6+JQDGL[>[W"UW
MD1LQ'WB!U-0>$?!-AJGC/Q!X>O)KF;0]+N-T%@\I\L%AU(]J+ARGN4<D<T8D
MB=)$;HR,"#^(J.>[MK4J+BY@A+=!)(JY^F37EWP]'_".>*O&&A6CN=-L6\VW
MA=BVSY<D"J?@+P?I?CVQO?$GB:)M0NKJ=U02NV(D!X51GC%%PL>Q;E*;]R[<
M9W9XQ]:A-Y:AHU-U #+_ *L>:N7^G//X5Y/X4:;19_&OA-9Y9K"QB9[7S&+&
M-2OW<_C5?X2^ =*U3PY8Z]J7FW-VK9MRSD"$*> HHN%CV?%8/BS1EU72'*+_
M *1 "\9]?45T.WBC;33):NK'EFA7ADA\IS\\?'/I72POD"N9U6U_L7Q;+&!B
M&4[E^A_^O6];/D"F]S2E*\;/H: HIJGBGTT:B44452&%,=ML;'T%/J*XXMY/
M]TU2&>6Z_,7NYF[EJM^$6\NSNI.[OC\!67K61<3?]=#4_AZ<1V>W/5R#7M5%
M^Z214=SH;B?GK6>X4R;SG/<#O3Y9,U69LUS<J:U.E#VQ&=P!^;G)ZU(LY,(4
ML<9Z>E5I&^4 ]J19!LVG%%K"EL*\BB8 G <;"3V]*(88X9/,D7;@[G+#@"JL
MSK@YP?:J,KY 4LQ4=%+$@?A6<HZW+IUG"-D+-,)9I)<8#L6Q6=?\I$XZ@XJ:
M22JMPVZW [[Q54W:2.>9<TRY,5^D@."""*^E-/F^TZ=;S8^_&IY^E?,%F?\
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M_-*[J['RFN!G86_Q#L)#P&>/]?EJX=3.IT?F>HT445!H%%%% !1110 4444
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M27-K-"DUT&C:1"H<8Z@GK3/#NFWB?%CQ;++:S1PW$:B*5T(5^.Q[UZ?BC'-
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M6A 4444 :7A]@OB32V8@*+N(DDX ^<5U-QX@30_BMJEXQ$MC-<O#<H.5DB;
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MTY]-F;]]:_<SU*'_  /'Y5;UC<R7NRMW.RHHHJ#4**** "BBB@ HHHH \?\
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M%5+6+ %7U&!4&B5API:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4D.,X/H>*Y?:KC*D&G)<2PD!LN@[$\CZ&LI8==#&IEL;7IO[SL5<&GUB6.H
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M*** *]R^V,FO.M>NC/?; <A:[W47VP.?:O,[A@^H.6/&X _2@[<#&\W+L6[
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M** "BBB@ HHHH **** "BBB@ HHI"0!DG % "T5F7>OZ=:.(VG$DAZ)'R?\
M"N>G\:37*77V"WVB!"69UW$?7T_6K5.3'9G1:K:HT1G!"LHY). 17+7.KVEL
M0I?<QZ 5@7E_?:CIRRS7)\YI<;"3D#';L:+B$3&T=0W[J,<A\@D>G<&MHT>Y
MT0JRC&Q?DUF:74ULXPJ GE@^.WJ1P:S[*6XFO)C<EF3!7U;V]C5HQ2W=Y)=
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M*N*?4&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/\ \_%K_P" P_QH_P"%G^)_^?BU_P# 8?XT?59A]>I>9[I17A?_  M#Q/\
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M    .@Q5Z.$#M4JQ@=J>!4&@BKBG 4M% !1110 4444 %%%% !1110 4444
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MAKR*XL5NK.\39+#O*'&<C![57L_=V_(CVOO+7OW-3PSK:O=ZE)>ZG]DU.[C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nxtc-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( HL# 2(  A$! Q$!_\0
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MX$5MA:***T, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,,+#H/[S#U]!V^M;Y8#O1.2V08>DX^\Q:,4@(/2EK,Z0HHHH **** "BBB@
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MC#JV,Y/>BS-:$))*+>Q4L(TC)B<Y+G&#VK<\-:R+"2[L47S+J5U,:>IV[3^
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M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!*,4M% !28I:* $Q1BEHH
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MD!5F'0G]:SY]96(+%.IE'9LU)?:F\ZD':Y/<<5FVE@NHZI:6[$HLLZ19';+
M<?G0W979T6Y5S,W+(/J:B-2T4!&!CUKI+2TM-(T)8H%*K+GYSU+'^(_7^E4(
M].CT[6(;*&X+VN#*)V7[JH6WY^A4_I4VH7$,5_/IUW-<-%#M:-HD7<V]03G/
M^]TK)S3..=>$I*QR]SIK23$NHW<C-%TXTC39;DD%LB.)>[2'I^ Z_A6O<VDM
MKJ5U9^>&6"3:6/ / /\ 6L_Q/90ZEI$$<$F)K6;S5_V^,'_ZWTK5.ZT-Y3YD
MK=2*UTVW.E6\$<OERE0&8*&8^M6)+32M&A$D8\R?O(_+?G_A6'/+);Q*(V93
MM&[ZU'!%=Z@/WC?NP><T[.YIR=V3WVO7%P#!!\L9XXJ&*RGNKD80[!C.>],G
MN;+3IA"R-/,>D2=1[L>P_6NIT@Z-+;H]_<M@X/DK&RJ#[]S^)I/0YZ^*5)62
MN/\ "&G2_P!L+*GS1Q,S,Z_=&1@*#W/K]!7I%8$'B/0K6,1Q3+&B\ !" /TK
M6M-1M+]-]K<1RKZJV:RDVW<^?KSE4FYR5BSBC%+14F(E&*6B@!,48I:* $Q1
MBEHH 3%%+10 4F*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* );3_C\7_</]
M*TJS;7_C\7_</]*TJREN=-/X1&^XWTK(C_U:_2M=_N-]*R$_U:_2J@35V'44
M459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444!8PO%<!DT
MD2C/[B19&Q_='7]":R-(NEC!C8C!XKL)HEFA>-QE6&"#WKSJYBETN\>W;/[H
M_*?[R?PG^GX5Q8R#LIKH>SE-1/FH2Z['53'(JE+TJO8Z@)T"DU8F[5Q7N>MR
M.#LQ8A@5GRW(AFOU*,QGMG@7;V)*XS[<&M%#Q61<#_2Y,^M.+L[D3@IJS'K+
M;FP^SW"3'9<_:%\O'S@J%*G/3IUJ:?5(96GQ%*-^J+>#('W H'KUR.E5XX&N
M9/*0JN$:1G?[J*HR2:CAM&F2>1908(F5#*(7.2PR %'/XUO"4VM$<E2G14KR
M9/=7XG?46BC<M<7\%S'O QM1LG/-6;J[M2NJ30&=YM0B>/RW4 1;NN3WZ<54
MDL!!;WR7$2_:(;RWB)] V<X]B"*6YB2&_O8XU"QI<R*JCH!GI52E**NS.G3I
M3GRK^MA-2N4OK\W"(X BC1=XY&%P?US4VF-\LB^AS5$UH::O[N1O4XKFD^9W
M9WP@H1Y43RC(-,MXE8D$<5++P*=;C"YJ.ILG:)GW]FJ L%^4]1ZUT?AN\DNM
M/,<K%Y(7,98_Q#L?Q!%8>I3J(RO>M+PE&1;W4AZ-+M'_  %0#^H-=F#D^9KH
M>7FT$Z49O>YT=%%%>@>#8**"<#)KE]6\5&*:2VTZ+SI4X>0_<0_UH2;*C"4W
M:*.F9U49) K/NM>TVS.V6[CW_P!T')_(5YQJFJWDX)N[URIXV X&?8#^M0Z?
M?VL<RA82^.[<#\JM0/0IY94DKR9UNJ>)WO[=[33H74R*1Y\@VA1Z@=2:QK)S
M96[PV\#2KN )&!C QU_"GM>VPEX0++/(L8/]W) S^M<GJVJW#7CQHSQQ1$JJ
M+QTJXQ.^AA8T4['4RI/'*TK:=)&AC 78H;ZG -1BUNM5>1XK>:&+9@R3+M^N
M!UK1M[34;2-E:_M3):PK/*AW<1L!S^'I_C5B6\FANHH7E0^;$)D9%9@R$9'R
MCGU_*IYT.->$?A.*G6&WF=2K,6)VX/ J;2[J.VU.SFD!VP7"2MCK@,#6E=>&
M;JZU&Z$LT4%M'&MTUPP. C=/EZYR#Q[53'AN3^SKC4CJ=N+6"5HE<J09& !
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M]*J326IEBJE%0:D>FVLOGVL4O3>H;\Q4U-C01HJ*, #%.KF/G@HHHH ****
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M![CWK4M_%4E_&5D!BD'!5NF?8U+IEO#+8O3Z\(_-6ZM UO+:):O$KG<0A)#
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ML"",T &*,4M&* $Q1BEHH 3%&*6B@!,48I:* 'VO_'XO^X?Z5HUG6W_'XO\
MNG^E:-92W.B'PB/]QOI65'_JU^E:K_<;Z5EQ_P"K7Z4XBJ;"T4M%68A24M%
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MF>-I-\KMNF8'@MZ#V'0?B:UHTW.5BX0N]2OJ6JM*S*C-LW;LL?F8_P!YO?\
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M^E0MJ< ]:+#46^A<HJD-5MSZU,E] _1\?6BP.+70GHH#!AE2#]*6@0E%+10
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MZB@!N*7%+10 W%&*=10 W%&*=10 W%+BEHH 3%&*6B@!,4F*=10 W%&*=10
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MKR3^%4I9\YILC@1'DY'0^M1B-I&''&":1:5AI#2'"GFGF,!5"GGTH+;0$7
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M285N;A%^T%<!1TC'H/\ &L<3B%!66Y<8J*-3PSH::+IB1<&9OFD;U;O6W29
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M"V-M)/<VP6=I"REAR!4M]!+5W.BL[&WLK:.&&-55% &!5FBBI+"BBB@!J_\
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M:R2)*H:-PRGN#FAJP6%Q1BEHI )BC%+10 F*,4M% "8HQ2T4 &*3%+03CDT
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M<\MLD$<!:031CYD*]CTJ=?B%HK:VNF_Z0,W0LOM'E'RA<$?ZO=Z]OKQ5'3/
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MIT<H>[<23O+*TC.P&,DGO5-? FA&]O;N>&>ZFNX)+=S<SM)MB<Y95R?E!]J
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M7^Z*E?[C?2H[?_CVC_W10)DE%%%,!**6B@ Q1110 F**6B@ I,4M% "44M%
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MDG'X>M=$%"C & *6BL&V]SDE-R=V)12T4B1*6BB@!*6BB@!*,4M% "8HI:*
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M7NF-PXY 884?11Q7345E*I*6YC*K.6[&1Q)$@5%"@=@*?114&84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '-^-/"S>+-*M[1+M;=K>Z2Y42Q>;
M%*5S\DB9&Y>>F>H%8&C_  O&E75E/_:BR?9M7EU,JEJ(U8O$(R@4'"@8R,?3
MWKT.B@#SQOAI/;R)>:=K7V?4H=7NM2@F>WWHHG #QLNX9&!US6_X,\+/X3TR
M\M9+]KZ2ZO9;QYFC"$L^,\ GN/UKI** /.'^&=X-.GLH=<5(XM575=.+6N3!
M+O9B'^;YP=V.W2I8/AI,)%GN];:YN#KD6LR2?9PNYD3;L !X!['L/6O0J* .
M%'PZ4$'^T3QXD.O?ZKO_ ,\NOZ_I5:U^&<MO/96;:V[Z!8ZA_:-O8_9P'$FX
MN%,F>5#$GIGFO0Z* ,#PCX:_X171I-/^U?:=]S-<;]FW[[EL8R>F:\OU/POJ
M[Z]-H.DPZPNG3:ZFH.LUFJVZ#>&=Q-N.Y>.%P#FO;Z* .*N?AW;7N@:]I4]Y
M)C5=2?44F1,-!(2I7'/."OXYJ!?AW+J"ZU/XAU4:A?:I8BP,L=N(DBB&2,+D
MY.[YLY[5WE% 'FG_  J.&2UT*.XU:2:2QGDEOI#" ;\/*LI5N>!N1?6M'7?A
M_<:MJ?B&>'5A!;:[9);W$36^\JZ#:CJV1QCJ*[JB@#F;#PD++Q?'KPNRQ328
M]-\G9CA7W;\Y_#%=-110 4444 0/_P ?D7^ZW]*GJ!_^/R+_ '6_I4] "$9!
M%16S8C\L_>C^4C^535%)"';<K%''\0H EHJ#%R. T9]R#1_I7K%^1H GHJ#_
M $KUB_(T?Z5ZQ?D: )Z*@_TKUB_(T?Z5ZQ?D: )Z*@_TKUB_(T?Z5ZQ?D: )
MZ*@_TKUB_(T?Z5ZQ?D: )Z*@_P!*]8OR-'^E>L7Y&@">BH/]*]8OR-'^E>L7
MY&@">BH/]*]8OR-+_I/K%^1H FHJ#_2O6+\C1_I7K%^1H GHJ#_2O6+\C1_I
M7K%^1H GHJ#_ $KUB_(T?Z5ZP_D: )Z*A_TGUB_(TG^E>L7Y&@">BH?])]8O
MR-)_I7K%^1H GHJ#_2O6+\C1_I7K%^1H GHJ#_2O6+\C1_I7K%^1H GHJ#_2
MO6+\C2_Z3ZQ?D: )J*@_TKUB_(T?Z5ZQ?D: )Z*@_P!*]8OR-'^E>L7Y&@">
MBH/]*]8OR-'^E>L7Y&@">BH/]*]8OR-'^E>L7Y&@">BH/]*]8OR-'^E>L7Y&
M@">BH/\ 2O6+\C1_I7K%^1H GHJ'_2?6+\C2?Z5ZQ?D: )Z*@_TKUB_(TO\
MI/K%^1H FHJ#_2O6+\C1_I7K%^1H GHJ#_2O6+\C1_I7K%^1H GHJ#_2O6+\
MC1_I7K%^1H GHJ#_ $KUB_(T?Z5ZQ?D: )Z*@_TKUB_(T?Z5ZQ?D: )Z*@_T
MKUB_(T?Z5ZQ?D: )Z*A_TGUB_(TG^E>L7Y&@">BH/]*]8OR-'^E>L7Y&@">B
MH/\ 2O6+\C1_I7K%^1H GHJ#_2O6+\C1_I7K%^1H GHJ#_2O6+\C2_Z3ZQ?D
M: )J*@_TKUB_(T?Z5ZQ?D: )Z*@_TKUB_(TO^D^L7Y&@":BH/]*]8OR-'^E>
ML7Y&@">BH/\ 2O6+\C08YWX>0*.^P<G\: !3YET6'*QC;^)ZU/3418U"J, 4
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nxtc-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G HL# 2(  A$! Q$!_\0
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MF@RT8C@D(P9';SIG_(X'Y_A73WVE17-NY0!7/'/;%<4L<[3R6XC6-E.TRL<
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M]!6+<W4L3%8S@'KQUJ')W-H4URFN9XR-I89J%MN>]9UM<[N' 'HP[?6K$KL
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M=2T18D'!HM5QDT3'(P*;]H2"++&D6DVK(BU+:JAA]X'(JSX3)%FR?PI(ZK]
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M GAE8L.OW@3T;OFJ.N:!):$3*[M$G*7"_>C]F]1[_GZUX&*PU:A4=:F[GUF
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MZO8JEJP_XES_ .\O\Z;V%'<-.^Z*V%^Z*Q].^Z*V%^Z*@V92O/N&LO2O^/\
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MD;D^G>M(RMJB)1N<]!/GH>#UK:TJ]:.18/,V9;?"_P#<?L?H>A]C[5B7UO\
M8[H%/]5)ROMZBIH6\R,@'YAR*UDE.)BM'9GO_A+7!JNGKO\ EF3Y9$/56'!%
M=+BO$_"&M&UU2WE+$+<_NY1G_EHHZ_BN/RKVF!Q+$KCH17E2CRRL3*-F/Q1B
MEQ67K6N6VBP*TH,DS_ZN%3RWO[#WI)-NR)-/%&*X6U\4ZQ>ZO;Q(L(#N ;>.
M/<2.^6/(P._%=WCFJG!PT8E9B8HQ2XHQ4#L)BC%+BC% 6$Q1BEQ1B@+"8HQ2
MXHQ0%A,48I<48H"PF*,4N*,4!83%&*7%&* L)BC%+BC% 6$Q1BEQ1B@+"8JC
M=Z18WLGFS0_O?^>B,48_4CK5_%&*+B:3W*UK96]E&8[>((I.3W+'U)/)JQBE
MQ1BBX[)"8HQ2XHQ0%A,48I<48H"PVC%.Q28I7"PVD-*:8QJ7(I1 FFEJ:SXJ
M!Y0*QG52-HTVR5GJ)Y0.]5I)\55DN*X:N,4>IU4\.V6WN/>JTMTJ#+, /4FJ
MKS'!/-4G\V0G))&<X->=4Q]WHSI]BHHO/>J)A'R21UK-FO)IEVMM*D@].G^-
M.%LQ[&GBR<CIBL8XQ7,JL)25EH4!-.BA4E=0,X . *B#8.[&<#\/:KTELRD@
MU \&.@KHACX7.26#J-;C$E97#ARK YW UHP:M+&096WI@YX (_QK-\H@<BDR
M5(.!QVQ77'$4ZAR\E6B]-CK;>\CF!,;AL=<5>CESWKB(KN: EU<KG@XQTK:T
M_5EF 64A7. ".C5O&<H>:.B%6%31Z,Z56S4@JE%)5I&R*[J=121$Z=B2EQ0*
M7%;&-AH4#H *7%+BC% "8HQ2XHQ0%CA?$WCRY\*Z_P#8[O3%N+.2,212Q2%7
MP>""#P2"#Z=JFT_XI>%+XA9;Y[*0D#;=QE!_WT,C]:@^*FBB_P##:Z@BYFL7
MW$C_ )YMPWY'!KPV)H+74+>:]L_M5LKAI(&8KYB=QD<COS2+44T?4UM=6U["
M)K6YAGB/1XI X/XBJ^K_ /(.?_>7^=4O#.G>'(=,@OO#UA9P6US&&62"(*S#
MT8]<@]03U%7M7'_$M?\ WE_G0]B4M1NG?=%;"_=%8^G?=%;"_=%2:,I7GW#6
M9I'_ !_W/^X/YUIWGW#6;H__ !_W7^XO\Z.H=#8JO?7 M+&>=ND:%OR%6L5A
M^+'VZ%+'G'G,L7_?1 JB4CRC6IW:<"0Y:-<M_OM\Q_GC\*YB1O-N43KN8"MK
M6)M\LS=RY8_4G_#%8VE@3>(;)#]WS03]!S_2O9@N6!3WL>JJ!:6<-N/X$ /U
M[U0GEY/-23S[CG-9L\O)%<<4="%DF]#4,K J&'XU/IEHFHZE':RS&%&5F9P,
MX"J6Z?A5UM'E>SU#SI!&]F2D8 _UQ&,G/IAE.?>FY).P[I&-YP!&*ORLHB1H
M\B-AW/>J(TS4#+)$+5]R2F)LD *P&2"2<< 9)Z"K\.ES"PN#(DGVE&A$<:$,
M'$A(!!&0>G&#0VA-HHR2GH#DU6DF(S[5HOI=Q"[_ &F&0*(9)%:)D<90<Y(.
M.._?VJM-H]S;Z3?WEW&T31+$47>I.7;&& .1P<@'%/F0KF/<2[L'K5*1Q3I9
M/EJL[U0,@OHA<V<B#ET^=?J*S]/;>X7LP(K25P)AZ'@UD6[>1=NN/N.16M-[
MHQGO<WM.28J1&RB1F5T)'1U/]037I5KXLUFUMUB6WM6VC&XAO\:\PTO4MEY"
M%A!(E7 8\<Y'->B^&H;SQ)!YJ26ML,D%3$7(P?PK&I[-.\C*:D]BT_BOQ#(?
MEFMHA_LP@_SK+E:>6:6[NIGGG*DEG.>@)Q]*[)?!<A'[S5#G_IG !_,UE:KX
M<OM-7S<B[M^[HF&3_>7N/<4H5*2>ADXRMJ0_#:2.YU"_F/,BPJ ?8L<_R%>B
MUY#X=>?PSKC7MOMN+&5"DD0;#!<Y!!Z'!%>NPR)/#'+&<I(H93[$9%88I>_=
M;,JE\-A:*=BC%<YH-HIV*,4 -HIV*,4 -HIV*,4 -HIV*,4 -HIV*,"@+#:1
MW5!EF JO<7BQ95.6]:S9)V<DDU2C<M0ON:$E\HX1"WN:@:_F[;5JE^\?H":/
M(G/2,U7*C111:^VSY^^*<NH2CKM-4C#,.J&F$.O52*=D/E1KQZ@C??4CZ5:2
M19!E6!KG@Y]:ECG9#E3@TG AP1O453M;]9,+)P?6KV*S:L9N+0VBG8HQ0(;1
M3L48H'88:0TXTQC4-E)#&.*A=\4LCXJG-+C-<E:LHHZ*=.XLDV*IR3^]1RS9
M-5;FZM;.-9;VYC@1C@%SC)]J\6OBY2?+#5G=&G&"O(E+LYP*J:C>KIR0YA>X
MEE)"QHP'09)R3CI61>>*B]I=_P!DV?VJ/#PQSQS+DN.,A3V!/KV-9@TR".2.
M5(Q]HCCV^8&8YR,,3SR3SS6^$RNI6?-7T78\W&YM"DN6EJS0NO% DE+:=Y3Q
M0P":2*13O;YB&7@_*1CWYIMSXH%S<++I3H]JK11C*9\]W/*@]L CIW^E0P6L
M$5P[)$@:3 D<*-SXZ9/>B:SBNH/*N(]Z @J"<;2.0?:O364T$MCR7F]9O7R+
MM_K%XVH7*65Q'!#;R>4H,0?S& RQ)[ $@<<]:Q[F\NM8>6ZO()+5QMC@7S,>
M60/F<8/=NA/85:MK6&TACBC0A5).&.<DG)))Y)]S4AC#\]\\<5T4<OHTTK1U
M1SULQK5&TGHRS;^++>.QADUFSEM-J!99V967?CT4D@$]#4UIKEI<W:V][$EB
M)D+P-)*/F''!]&P0<>]9,EL!G?RQZYY!HEACD'[V(.A.2K ,&_ URSR;#RO;
M1LZ89U65KHWX;K2KV:2*VOX7=!DC=@$>H/<?2FS6V!N4@J>A!R#7.S117.Q9
MXHF6(_(C1@A>. .P_E6AX=U6U@TN.PU3987.&E7S)%V-ELD*<XXR!BO-Q>5R
MP\>>DVST<)F4<3+DFK#Y5VY!ID<S1$,#PI&,_P"%:=S;#:&&&4C((Z&LJ:+;
MG]*RPV*O[LC:OAK>]$ZG2K\W"LKN"X/ [XK<A?-<%IMR;:Y0L. <_ATKLK6=
M)%#(P93WKTJ<^66FPZ;]I#7=&LIS3ZR=2UNQT2T6YOWF2)FV@Q6\DISC/(12
M0,#J>*30?$^D^)8WDTJ>::-%5B[VTD2D-G!4NH#=#TS7I1=T825F:]%.VGT-
M&*LFPVBGX]C1B@17NK6*]M)K6==T4R&-QZ@C!KS'QCX!5?A]9O#&K:CI,'SL
MG_+6/)+CW(SN'X^M>JXI&164JPRI&"#W% T>+_!?Q(8;RY\-W#?)+FXM23T8
M??7\1AOP->LZQ_R#9/\ >7^=?.ETLO@?XC;XQQIU]E1_>B)Z?BC8KZ,UC!TM
MR.1N7'YTAM:D>G?=%;"_=%8^G?=%;"_=%(;*5Y]PUG:/_P ?]U_N+_.M&\^X
M:SM'_P"/^Z_W%_G1U#H;5<UXT)&FVP'>ZC_G72USOC)<Z,LG:*:-S] PJUN)
M;GB^I'(G/_37%9VBG&O1'T5R/^^36EJR[);M/23=6+I\GE:S;L>A;;^8Q7LK
MX&#^)'H/VC?$K9ZBJLKU3MKG;F-C]*?))[US6L=*+-E?FPNQ.L8<A'3:3C[R
ME?ZU;?Q!<3PI!*JE1:&TSGKDKES[X4#\*Q&?FE#90GN*3BGJ/0Z.^\2&VU&S
M:!TN!#;E)W3<@F=E"LP)&<X50#CM4:^)YBS31QG<7A9/-E+D>62<9XSG)],=
MJSK#3X;C3KB]GBNY_+E2$16N-PW G<<@\<8^M7)M%M(-"CO&N9/M!MX[@8!*
M'<P&SA,#TSNZC&*S:BM"'8B?7D@@:WM+!8(#',NPRESND4*6R1V &!5/4O$,
M=U;7JK8)%<7QC-Q,)2=Q4@Y"XXR>W-:OC1MJ@@ ?\3"['3_<KAI9.22:<4FK
M@ALDG.*KN_6D=_FZU!(]6,7S#YB_6J,QQ?SX_O5.IS(![U6SYDEQ+_M?UK2G
MN8S+=@^+I,==Z?\ H5>N_#)ODF7L)GQ_WT:\@TT;M0@!Z>8"?H.:]?\ A<A:
MR\T_QL6_,YKEQ70.AZ>.E%%%<I!0ET32YI#))I]N7;[QV 9^N.M7@H50J@
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MR]MS);Q1B)B/+9]P/&TD\\?K5V[MMI((KC;BZ+Q7,4447F2PE00J@N<<#/\
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M]Y?YU?JAK/\ R#)/]Y?YT^@NI%IWW16POW16/IWW16POW12&RE>?<-9VC_\
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MT^]!.>!3E4G '4F@HOZ5%NE,G9:T)CUI;6#[/;JO\74TV:N2L[D1=Y&'J\T
MMGAD!=W4[$49.?7V^M9"Y7:&P6 Y([GUK1U> J6N5D4?*%96[XZ8QWYJA'\T
M =E(<]58\K7/ATK.QPX]RYE=:%FW0J/,V@YZ'THG.>:6*4"(1 ?-G.344S@"
MN7'*\67@VDR*XLQJ5BUOYODN&61),9"LIR"1W%<>ID^WS@SV\]JB_P#'Q"K
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MPUG:/_Q_W7^XO\ZT;S[AK.T?_C_NO]Q?YT=0Z&U1115$A1110 4444 %%%%
M!1110 4444 (RAEPP!![$9H50HPJ@#T Q2UA>,FNU\'ZI]AL'O[EH=JVR.RE
MP2 <%"&X!)P""<8[T ;@C48 0<'(^7I]*"BD,I08;J,=?KZUX?9>'==_X1GQ
M%86UAJ,-G/?:?)9QQV\MM\N\><R(SNR=,GYNV>*U-3\+:GI=AKNEZ78ZD^@C
M6+69K2&5FDGM#&IG6(D[CE^H!YP12&>C:?K%K>:[JFBQ6S1R:2(=S$ *?,4L
M-H'3 %:IB0R+*8U+J,!]O('L:\^^'.D?V=KWB:XMM(O]-TNY-K]BCO596*JC
M!L!B2!GL>F>W2L"\T+4W\9^(&L=-U*YFOX;Z,WEW#)%Y&Z$B-8Y1)LDC+ !5
MV@KG- 'L.Q>/D'!S]WO_ (TT0QJ[.(D#L<EM@R3]:\7U.W\1:WI=VUIHVM0-
M'X7BL0)H6C9[E9D+!1GDX!Y[X-:WB+PCJF@W$=OX0MKG[/K=L=/OV\UW-NQ<
M$W!+$\[6D!/'.* /2+*[M[NZODBMI8Y+:;RY'DMR@=MH.Y21\PP<9%6EAC5V
M=8D#,<E@HR3ZYKS6[\/ZM;6>NW.GVMS]HTO6(+W2X=S?OXXX(D9%]0RAU^M8
M.K:#K5UI5@FHZ%=7,^IR7.H74GERS^1.^!'#Y:2(%P@4!V. 0>.30!ZK_:]F
MOB[^Q/L["]:Q^V&;:,>6'V;<]<Y_"M78O'RKP<CCOZUYWX/T[6U\2Z)?ZK;7
M0=/"Z6UQ-,O(G$P)5C_>P,UZ+3$%%%% !6%J*[;G\*W:RM7BX60#V-5'<J+U
M,-JMA^A]155^N:DB?*8[K_*MF:HL9S6)+K-[)KTVEZ=IJ7/V5(GN99;D1!/,
MSM"C:=W"DGI6N&K-O="TV_OXM0FM4-["H$<VYE(P<KN"D;@#S@YJ; <EJOQ#
MNVT&:XT?3@+RWA1[L3RC%HYG\KRR,?,Q(;TXP:V=4\6W6F27Y;1]\.EQ0RZB
MPNQF+S.=L8V_O,#G)VY[5-I_A6VCL-4AU5;>]EU:<SWI2(QHYXPJC)( QGKG
M))JQ<>%=#NIH);C3HY9($2-"[N<JIRH?GY\'D;LTK,-3D8_&$J:3XAM0;R26
MQ>[N)KE)Q')%'YY6-8]RG=P,9QA0,=>*W$\8R'6C:/IA6R6_?3C=_: 6\U8S
M)GR]O0@=<]:T[GPSHETFV?3HG!,I/S,,^:=TF<'D,>2.F:F&CZ<DOFK:1AQ=
M&\W<_P"N*[=_7KCCTH28:G+V?Q!DO[2XN(-!NY%%M]IMQ'O8R+N"X;]V #AM
MWR[^ >I%='I&HIK6D1W;) 1)N5DCD\U 02",E0>W0@$=#59/"NAPQ7,4>GJD
M=RH215D<#;NWX7YOD&[G"XYJ[8V-KIEHMK9PB*%26"@DY).2222223DDFFK@
MKEDFDS@$^U(336/ 'K3&*.$%:.C*&OE)[5G'H*V]%M<C[0W\)( ]2:4GH2]C
M9)S1116)B)44@XJ6F.*F2T*BS&U-)6M7$.=V1D*<$COCWKFV#Q2"-XC& NX
MXZ9].U=C,M<OJ=K+%*9-R$22=P<D>GT S7'&7).Q.+I\\.;L-MW1'P6ZCK22
MXR?K5<;<DCG XJ3S-R<XSWK:K&Z/+IRL0_=<'L:BU:PN[]K6>S5)3"K+Y3.%
MP3CYE)!&1C'XU(YX'M4MO.4<5\[7Y\/656'0]ZARUZ3IR.0OK6\M=1-O>Q1*
MWE"4E)BY7G #< <\XQZ&LV:0?O,*>F%]!76Z_HMW*M_JMK+;N-@E:.4-N^5<
M8!!Z<?J:Y"5U#\-E" P([@C.:^DP6*5>DI7N^I\[C<*Z%6UK+H-2[D9]K=AU
M%2EBS8)(Z54"*F[+@$'@&CS<*1N]\GO7:I'&T6;V!-K$#8V< CO6+<?:$&2N
MY?45HY,@9V8+M'.3VJG<.@7(8D9PHJD5$SI)7=0I5OR--+.(R!$Q7D8(ZG%7
MRZ^26W@$?P]ZJB0RS*O=B *"T54M7?8KG;ST!ZTZ;;'F, 8!YYZT]FD\[)'W
M"1@CWJ>XMF\I97Q\QY_G2O89':2A-P!Y(/Y59G,<-L&0Y=C\PJBNQ&X.6-6#
M^Z/(+!UR >W;FI;'8BV)(@"YW[OTKIM \/75^Y6"U:1XU#R,9A&$ST'(.2>O
MTQ6;H]JK7=NS!AER<"-FX&,] ?45ZGHD/]E^&[6W\HQ2D%I-WWF))Y;_ &B,
M9KS,QQOU:G>.[._ X3ZQ/WMD%C;/IFEM;RL@=Y&D*(<JFXYP#W_Q)JA<2'?^
M-6+F<G/-9LCEG&/6O!P\)5:CJ2W9[M:4:<.2.R'G .?TJ1@WECTJON8$\<U*
M7)X]J]^G&R/'F[L51A\GL<<5U>B2Y1X\<YW@_7_#%<M!@..<@_>KK-%">2>/
MWO&\^OICVI5MC7"_Q#>AZ"K0Z56A' JP.E=%/8Z9[CJ***U,@JAK/_(,D_WE
M_G5^J&L_\@R3_>7^=)C1%IWW16POW16/IWW16POW12&RE>?<-9VC_P#'_=?[
MB_SK1O/N&L[1_P#C_NO]Q?YT=0Z&U1115$A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4-S")X&3U'%344 CDI4*L
M0PY'!J$,8WW#\:V]5L^?.0<'[U8K+6\7=&R9-D$ @\&C=5='*<'E:?NXR.13
M&3;J-U0[J-U("4M3":86II:@!Q--)I"::32&+GUI!R<TGWJ>@Y^E-"'HADE5
M!U-=;;0BWMTB'8<_6LS1[''^DR#_ '<^M;%9S=]#.;Z!1114$!2$<4M)28T5
MY4K'U*R:Y1=C!74G&>A!&"*W77(JK*E<M:'5&T;27*SBFC>"25'VL4<K\HQQ
M@?XU#N"-ECVS6SK4,8DA(0"4G.__ &1U'OUK#?:\C 'WQ3ISYH:GE8BE[.HU
M'8&D#\BFK)AJKR$@<9![D5&DA[\UQ8JASHVPU;D9K74<M]HEW:0L!)*FT G
M/J,^_3\:Y#4]+O+::.>>Q\F&9F"AW!<$ MT7C;@8ZYKI(;DQG@U=E^S:C;I#
M=AF"MN1D8JRGU!'2O.PN+G@Y<K7NGH8G#0Q<>;J>:W"F5S\C*"<D'K4)0NRH
MQ("G KT;_A%=,E<>5>WL2]U,@?\ (L"17*ZCH-[IK1++;32QB80K<F08().U
MLGDG'4>W6O>P^94*[Y8O4\2OEU>BN9JZ,-P8S@XSZ&H5"L_3.>PJQ,K--\TB
M^<07"%AN(]<53>25F)^Z<]0,5WW.)(9-$C':&X]*K[4C9B,MMJPA1)#O!9?0
M'&*8XR6V_P 7447*1'\[1@QJ N,G\^?Z4R8%BJ;]WOG@5;A@E>%]N?*!&?2M
M;1O#T^K7'DVL*RR>7YAWR;%5<D#G!))(/%1.HH1YI;%PBYRY8J[,$6X0MD$D
MCL>AK2TC33>7*1(5#RR)"ID&Y06/4CV /Z5=DTJ33[UHYR+:95;]W*>0<'&W
MLXSCI^5=?I?A9[46EU=W<9P(Y718-KEA@@$@XZ^@%<F)QE.E3YK[['3A\)4J
MSM;;<L:-X;GT/5$N9)K<I$K@>5N&[<!V/3IZFKUW<EF))IUW=;F)S67++N/7
M%?,WJ8JISU#Z-1IX:'+ CGES4*CC<>,]*0 R$'M3G4J<8KV\/044>96J\S)E
MB+8(/+4LBJLFULCUID3L.?3I3VY^\,L>0?6NU(Y66+"W,DP5>K':..?<_E7:
M6=LD PF>>I)R37-Z/ TDR[<#9M?<3^>!^E=="M83]Z=CNPT4H<S19C&!4U,0
M5)77%602>H44459(50UG_D&2?[R_SJ_5#6?^09)_O+_.DQHBT[[HK87[HK'T
M[[HK87[HI#92O/N&L[1_^/\ NO\ <7^=:-Y]PUG:/_Q_W7^XO\Z.H=#:HHHJ
MB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#C_NO]Q?YT=0Z&U1115$A1110 4444 %%%% !1110 4444 %%%% !1110
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M'_+K%_WT:7^UKO\ Y]8O^^C6L811#FV:ZK3\8K&_M>[_ .?6+_OHT?VO=_\
M/K%_WT:T5B-3:HK%_M>[_P"?6+_OHT?VO=_\^L7_ 'T:=T*QM45B_P!KW?\
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M+A]C7T%'V-?0444!</L:^E'V-?2BB@+A]C7T%'V-?2BB@+A]C7TH^QKZ444
M'V-?2C[&OI110%P^QKZ4?8U]*** #[&OI1]C7THHH /L:^E'V-?2BB@ ^QKZ
;4?8U]*** %%HH["I$@ [444 3JF*?113 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nxtc-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %- JP# 2(  A$! Q$!_\0
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MJ"*JW_B2UL-:LM*,4\D]RX3<B?)'D$C<Q]=IX'/% &S1110 4444 %8NK_\
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M(TJY!@'(!['_ .L:P[NZAO=3N+II'C4@M&L@YZ=/;O51;.Z^T3)''N W.IW
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M5=6^I:=J<]S)#<)*EG);%3@,,AFZ<#/Z5M&UCBJN:F]_(K7GA76=-T][RYM
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MEW!<# 4 GT&*$Q$1E8?= JU%)A,GBH?*#,#WI9 0, <9Q28$YN&VL%4+D8)
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M6(Y(Z8Z5-),(?N[9).I<=!]*KM,(TW 9;&!['UK0X$B$#!R?K3F7!  '/(J
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M-.P#J***0!1110 4444 %%%% !1110 5BZO_ ,?:?]<Q_,UM5BZO_P ?:?\
M7,?S- F4_&O_ "!V_P!UOY5Y>"0,G->I^,%WZ9M]0W\J\RF'E87:"<9.>U5%
MV/(S%>^B%RIZU#M&>O%2LO&0.#41!Y&"*TN>>*\/!QU]:K2HPX JXYV*I)^^
M,CC\#4#.2V,<>IH3&BH8& )YXIR1=">"/>I9V8(@'1LDGW%1%69&(XXIW*'
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MZ"NAHH C>WADD61XHV=?NLR@D?0T[8OS?*/F^]QUIU% " !0   !P *6BB@
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M110 4444 %%%% !1110 5BZO_P ?:?\ 7,?S-;58NK_\?:?]<Q_,T"9-JO\
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M&2NX'VZ4Z:PEM&C$Z*A=-Z%9@^!GV/!KI7G,GPY@D@TVTD_>,LBK!D)PP,F
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MU_"F^6>Y)_K0 T ]N3[T\#GK_P#7IRKCH.*, GB@8@QG'>@X'H*?CBDP,9-
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M*9(YI8G(VDQR%<C\*HJV*MELC-#,*D$]R%UWR>9(\DLG]Z1RQ'TSTIF^583
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ML<YI2<CJ,^] Q-IS_P#6INW(Z=Z?GG&!2@@\=/:@+D3)P#CZTSRQ@<?2IA@
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2KZ6%K&X98$W#H3SC\ZLT ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nxtc-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ A8# 2(  A$! Q$!_\0
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MV3_XJC_A7OA7_H$I_P!_9/\ XJBT>_X?\$/>.FHKF?\ A7OA7_H$I_W]D_\
MBJ/^%>^%?^@2G_?V3_XJBT>_X?\ !#WCIJ*YG_A7OA7_ *!*?]_9/_BJ/^%>
M^%?^@2G_ ']D_P#BJ+1[_A_P0]XZ:BN9_P"%>^%?^@2G_?V3_P"*H_X5[X5_
MZ!*?]_9/_BJ+1[_A_P $/>.FHKF?^%>^%?\ H$I_W]D_^*H_X5[X5_Z!*?\
M?V3_ .*HM'O^'_!#WCIJ*YG_ (5[X5_Z!*?]_9/_ (JC_A7OA7_H$I_W]D_^
M*HM'O^'_  0]XZ:BN9_X5[X5_P"@2G_?V3_XJC_A7OA7_H$I_P!_9/\ XJBT
M>_X?\$/>.FHKF?\ A7OA7_H$I_W]D_\ BJ/^%>^%?^@2G_?V3_XJBT>_X?\
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M_7.2?^!'G\L4ZE+"T4TW=F%6G0I*R=W_ %\OQ9U2G*@TM(!@8I:\LX@HHHH
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M9D&[\JF+JK*I8 L> 3UH ?14?FQA7?>NU,[CG@8ZYIP8,H(((/((H =1110
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MX0D>3P9HC20O"WV&$%),;AA .WYUMT4 %%%% !1110 4444 %%%% '*^%O\
MD/\ BO\ ["*_^BDHH\+?\A_Q7_V$5_\ 1245<]R8["_#G_DGVC_]<C_Z$:ZF
MN6^'/_)/M'_ZY'_T(UU-%3XV$/A04A (Q2T5!1FC1K,7IN3&"Y.<'IGUQ6B
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M6O6HU&HZG#B,,F[1T/0.HI:S]*N))[;,N"WK6A74M3S)*SL%%%%,05A^,?\
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M444 %%%% !1110 4444 %%%% !1110!RWPY_Y)]H_P#UR/\ Z$:ZFN6^'/\
MR3[1_P#KD?\ T(UU-74^-DP^%!1114%#64,N&&0:RI?#>D2W5O<M91"6W8M$
M57&TYST''7FM:CO3C.4=G8:DUL   Q2T44A!1110 4444 %%%% !2,<*32TV
M3_5G)[4 >3:[<B]UW45#?ZRYBM1]%'/ZM7I.B)LTR+C&X;L?7FO*9+26#Q,E
MD\T<TYN9)Y?+;."QPOT/(X]J]?@,<4"(&&% %>ICK*G"*.[%I*,%'M_P/T+-
M%,$J'C<*>#FO+.$**** (IV"02,75,*?F8\+[UY)HCP[IY)'#R^8VZ3J&.>N
M:[SQRLC^$KP1DC[I;']W<,URND6L7V.,"-2&&>E?-<05-(TK')B7=I&OI4L<
M_B>T:R8.1$PNBF<!<?+N]\]*[38#7&:#;BV\6%+,%8VMBUTH.1G/R?CUKM:]
M/*E;#(WH_")L'I0$ IU%>D:7$P!2T44 %%%% !1110 4444 5+B_MK7_ %TJ
MJ?3/-8.I^-=.L%*L<MCH3@G\.OZ5E>*=.O)=4;R8KZ59 #L@(53ZY;MT'YUF
MVW@?5;DYV6NGHW4\S2?F>*]&CA\.HJ=21UT:5)I2J2_K\7^!R^KZK#/K3WMG
M<2Z?<R_/@JP5CZ] P_#-;>E_$75M,11JMLMW:]!<PD?S''YX-=U!X0T[^QTT
MZ_07RC)WS*,Y/ICI^%<EJOPQGM6>?0+]XB?^6$YR#[;O\<UT/$X:J^2:T6U_
MZN=T,1A:J]G46VU_\]_ON=EHWBW2-<4"TNE,I'^J?Y7'X?X4[Q@<^#-:_P"O
M*7_T$UY5I7A>\G\26UEJ.EW%G)OWFXMOE3"\Y_N_B,'GI7JGBX8\%:R/2RE_
M]!-<6(HTZ4X\CO<\_&T:=*5J;OI_6Q?T?_D"6'_7M'_Z"*O51T?_ ) EA_U[
M1_\ H(J]7&]SE6P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y;X<?\D_T?_KD?_0C745ROP_98?#/]F'B;3;B6TE!
MZY5R0?Q4@UU=74^-DP^%!1114%!1110 4444 %%%% !1110 4444 1R2+&I9
MB !W->9>*O'TUW-)IGAYP2,B6\!^5!WVGI_P+I6S\1K/4KK25-M=B"P0,UX!
MG<RCZ=1[5P7ASPO=^)G6."-[32%;YY"/FE(_F?;[JUZ6$H4E#VU1Z'IX*A14
M'6J/;\/\_0J:+87>I7AL](\QWSNGO3D=>N#V'O\ >-7&%Y:7<D+)J+>4Y0EI
M&&<'KUKV+2-%LM%LEM;.%8T7KZL?4GN:O&)&/*BMEFO+)VC=#GF-YNT=/Q]3
MR*PDN3<Q9BN!M.3YD[;?QYKUBR+-90EMVXH,[AST[U)Y$><[%J0#'%<>+Q2Q
M%K1M8X:U55'=*PM%%%<9B13P1W,#PS('CD4JRGH17-)X0EM&Q8:F\46?E26(
M/M_&NIHK"MAZ5:WM%>Q,HI[F=I.D1:5%)B1YIYFW2S/U<_T'M6C2TE:1BHJR
MV*6@M%%%6 4444 %%%% !1110 4444 (0">E+110 4444 -VCTK%\8_\B9K7
M_7E+_P"@FMNN;\>7/V?P9J$:\S72?984[N\AV@#\_P!*J'Q(F6S-?1_^0)8?
M]>\?_H(J]4%G!]ELH+?.?*C5,_08J>I>XUL%%%% PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** .3UC3M0T?67\0Z) ;GSE"
MZA8J<&=5^ZZ?[8'&.XJ_I?B[1-60^3?Q1S*</;SGRY4/H5;FMSM6=J.@Z1JQ
M!U#3;2Z8#AIH58C\35W36I-FMBS]OL_^?J#_ +^"E^WV?_/U!_W\%8__  @W
MA;_H :?_ -^%H_X0;PM_T -/_P"_"T>X'O&Q]OL_^?J#_OX*/M]G_P _4'_?
MP5C_ /"#>%O^@!I__?A:/^$&\+?] #3_ /OPM'N![QL?;[/_ )^H/^_@H^WV
M?_/U!_W\%8__  @WA;_H :?_ -^%H_X0;PM_T -/_P"_"T>X'O&Q]OL_^?J#
M_OX*/M]G_P _4'_?P5C_ /"#>%O^@!I__?A:/^$&\+?] #3_ /OPM'N![QL?
M;[/_ )^H/^_@H^WV?_/U!_W\%8__  @WA;_H :?_ -^%H_X0;PM_T -/_P"_
M"T>X'O&Q]OL_^?J#_OX*/M]G_P _4'_?P5C_ /"#>%O^@!I__?A:/^$&\+?]
M #3_ /OPM'N![QJO=V,BE'N;=E(P09%YIL-QI\$82*:V1%& JNH %9G_  @W
MA;_H :?_ -^%H_X0;PM_T -/_P"_"T>[M=A>1K_;[/\ Y^H/^_@H^WV?_/U!
M_P!_!61_P@WA;_H :?\ ]^%H_P"$&\+?] #3_P#OPM'N![QL?;[/_GZ@_P"_
M@I/M]G_S]0?]_!61_P (-X6_Z &G_P#?A:/^$&\+?] #3_\ OPM'N![QL?;[
M/_GZ@_[^"C[?9_\ /U!_W\%8_P#P@WA;_H :?_WX6C_A!O"W_0 T_P#[\+1[
M@>\:_P!OL_\ GZ@_[^"C[?9_\_4'_?P5D?\ "#>%O^@!I_\ WX6C_A!O"W_0
M T__ +\+1[@>\;'V^S_Y^H/^_@H^WV?_ #]0?]_!6/\ \(-X6_Z &G_]^%H_
MX0;PM_T -/\ ^_"T>X'O&Q]OL_\ GZ@_[^"C[?9_\_4'_?P5C_\ "#>%O^@!
MI_\ WX6C_A!O"W_0 T__ +\+1[@>\;'V^S_Y^H/^_@H^WV?_ #]0?]_!6/\
M\(-X6_Z &G_]^%H_X0;PM_T -/\ ^_"T>X'O&Q]OL_\ GZ@_[^"C[?9_\_4'
M_?P5C_\ "#>%O^@!I_\ WX6C_A!O"W_0 T__ +\+1[@>\;'V^S_Y^H/^_@H^
MWV?_ #]0?]_!6/\ \(-X6_Z &G_]^%H_X0;PM_T -/\ ^_"T>X'O&Q]OL_\
MGZ@_[^"C[?9_\_4'_?P5C_\ "#>%O^@!I_\ WX6C_A!O"W_0 T__ +\+1[@>
M\;'V^S_Y^H/^_@H^WV?_ #]0?]_!6/\ \(-X6_Z &G_]^%H_X0;PM_T -/\
M^_"T>X'O&Q]OL_\ GZ@_[^"C[?9_\_4'_?P5C_\ "#>%O^@!I_\ WX6C_A!O
M"W_0 T__ +\+1[@>\3:EXJT328]]UJ5N&/"QH^]V/H%7)-96GV=_XEUBWUO5
M;9[.PM"6T^QD^^7/'G2#L<?=7MFMO3_#FBZ5)YEAI5E;2?WXH55OSQFM2E=+
M8+-[A1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nxtc-20211231xex10d24001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231xex10d24001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S 2 # 2(  A$! Q$!_\0
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M[O\ QS<MXG\774R+=_/#:QG#;/X>3]U<= .>]=O/9>'/AEX>U#5;&Q6'Y%!
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M/^0O>_\ 7Q)_Z$:['X;?ZS4?I'_[-7':I_R%[W_KXD_]"-=A\-O]9J/TC_\
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MN'KY36A53O?^FCW:O/\ XDHWFZ>^/EVN,^_%;?@_Q!_;&G^1._\ ID  ?/\
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4ZS;N?_OHY-;U%%2VV[L:26Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nxtc-20211231xex10d25001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231xex10d25001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = %$# 2(  A$! Q$!_\0
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G-,\IL;2@B,@;.,_>7IG^(T =K17"?\)W>_\ /I;_ )G_ !HH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nxtc-20211231xex10d26001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20211231xex10d26001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > %,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W_/.*3(..
M>M'/OUHY]QGGZ4 &0<<]:HZK?265JGV:-9;JXD$-NC'Y2YR<L1_" "Q]@:O9
M^OTQ6-KK?9IM,U!B!#;7)$K-T0.C(&/L&89/H3VH IW&F6<%I+>:K')J<J1/
M)(UT@=3M7)"19PHXZ 9]23S570K.QU70;#4;*V?39IK=) ]E&(&5CU+)T(R#
MPP(Q57QYK]C:^$/$-I;:E%_:\<'DE/-"R[V ("C(/1LX%9_PR\169\#:7:ZK
MJ4:ZE]I>W17E!E+,[%>.O(]>* .WTB_FN$N+:]"K>VCA)2HPK@C*N!V!';L0
M1DXS6ED>M8^E2&ZUK5+M<-$HBM!(O1VC+EB/H9-OU4^E;&?7\>* #(]11D>H
MHSZ_CQ1S^(H 6BBB@!,<^O/Y4@_ ]#SU^M<YI-Y(==\UG9H=5CDDC0_\LC$P
M7UQRK+T[K[YJ30-0BDU?6+$*_FI>/(2<;<80<?G0!O\ ;J>GI22(DJ/%*BO&
MX*LK@$,".1CO7/>&+J&675E13OBNY=^4 _Y:R8P1R>!WZ5#X<N8DU*XC6,^7
M<0?;+;UBB+D&/K_>^;C^\1T44 177@2V\QGL_L3(QSY5_9K<;>,85^' P!P2
M<8P,"FP^!87E#7/]GPH&#%=/L5A<D'C]X26'_ <'DX-7-$NYCJS&20O'JD)O
M(U.?W6TA2.O=3'T[J?6H(TF%[:RI(7M+C4I-T4C',4JF3YDZ_*0IRO8\CN*
M.F@MX;.WCMK>-8H8U"I&@P !T J4\?\ US7):]=6</B-[>Z@:7SM/P@'&UMY
MYSG*GW'-6=;MYAI>BV<\RR7+SK TKKN5G\EP21D<$C- '1].G;@<T<$8&#QQ
MSUKFY;Z.Z\+Z=,J2*OVNVC*LVXY695//?H>>,^E+XCNY1,?(<HVFP_V@X.0)
C I^[P>ZAQR.I% '2T5RUWXTAM;N2#[%(VQL9W@9_2B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>nxtc-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 8:39:11 PM-->
<!--Modified on: 3/3/2022 8:39:11 PM-->
<xsd:schema targetNamespace="http://www.nextcure.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:nxtc="http://www.nextcure.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
        <link:definition>40301 - Disclosure - Marketable Securities - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Property and Equipment, Net - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
        <link:definition>40601 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails">
        <link:definition>40802 - Disclosure - Commitments and Contingencies - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>41401 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>41402 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS - (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>10301 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureTermLoan" id="DisclosureTermLoan">
        <link:definition>10901 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>11001 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>11101 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11401 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11501 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11601 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>30303 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31403 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails">
        <link:definition>40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails">
        <link:definition>40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails">
        <link:definition>40204 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails" id="DisclosureFormerAgreementWithEliLillyAndCompanyDetails">
        <link:definition>40701 - Disclosure - Former Agreement with Eli Lilly and Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" id="DisclosureTermLoanOtherDetails">
        <link:definition>40901 - Disclosure - Term Loan - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePreferredStockDetails" id="DisclosurePreferredStockDetails">
        <link:definition>41001 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>41101 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>41201 - Disclosure - Stock-Based Compensation - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" id="DisclosureStockBasedCompensationRestrictedCommonStockDetails">
        <link:definition>41204 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails">
        <link:definition>41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41501 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41601 - Disclosure - Subsequent Events - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10501 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>10601 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany" id="DisclosureFormerAgreementWithEliLillyAndCompany">
        <link:definition>10701 - Disclosure - Former Agreement with Eli Lilly and Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30503 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>30603 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails" id="DisclosureCommitmentsAndContingenciesOtherDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" name="IncreaseDecreaseInDeferredRevenueFromRelatedParty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ResearchEquipmentMember" name="ResearchEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_AccruedConstructionInProgressCurrent" name="AccruedConstructionInProgressCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_AccruedOperatingExpensesCurrent" name="AccruedOperatingExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_CollaborativeArrangementDisclosureAbstract" name="CollaborativeArrangementDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" name="ResearchAndDevelopmentCollaborativeAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_NumberOfVotesPerShare" name="NumberOfVotesPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_A2015OmnibusIncentivePlanMember" name="A2015OmnibusIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="nxtc_OmnibusIncentive2019PlanMember" name="OmnibusIncentive2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_EmployeeStockPurchase2019PlanMember" name="EmployeeStockPurchase2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" name="ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" name="ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_RequiredReserveRestrictedCashCurrent" name="RequiredReserveRestrictedCashCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_PreferredStockAbstract" name="PreferredStockAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" name="OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_RestrictedCashAndOtherAssetsCurrent" name="RestrictedCashAndOtherAssetsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_MarketableSecuritiesAndCashEquivalents" name="MarketableSecuritiesAndCashEquivalents" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_RestrictedCashOtherAssetsNonCurrent" name="RestrictedCashOtherAssetsNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" name="ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" name="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="AccruedSponsoredResearchExpenseCurrent" id="nxtc_AccruedSponsoredResearchExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DepreciationDepletionAndAmortizationAndOther" id="nxtc_DepreciationDepletionAndAmortizationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>nxtc-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 8:39:11 PM-->
<!--Modified on: 3/3/2022 8:39:11 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementBalanceSheets" roleURI="http://www.nextcure.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637819367498676456" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637819367498676456" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819367498676456" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367498686459" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819367498676456" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_637819367498686459" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819367498676456" xlink:to="us-gaap_RestrictedCashCurrent_637819367498686459" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819367498676456" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819367498686459" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819367498686459" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637819367498686459" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637819367498686459" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819367498686459" xlink:to="us-gaap_PreferredStockValue_637819367498686459" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637819367498686459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819367498686459" xlink:to="us-gaap_CommonStockValue_637819367498686459" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819367498686459" xlink:to="us-gaap_AdditionalPaidInCapital_637819367498696460" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819367498686459" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819367498696460" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819367498686459" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637819367498696460" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637819367498696460" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819367498696460" xlink:to="us-gaap_LiabilitiesCurrent_637819367498696460" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819367498696460" xlink:to="us-gaap_AccountsPayableCurrent_637819367498696460" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819367498696460" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637819367498696460" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637819367498696460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819367498696460" xlink:to="us-gaap_DeferredRentCreditCurrent_637819367498696460" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819367498696460" xlink:to="us-gaap_LongTermDebtCurrent_637819367498706460" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819367498696460" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637819367498706460" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819367498696460" xlink:to="us-gaap_LongTermDebtNoncurrent_637819367498706460" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637819367498706460" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637819367498706460" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637819367498706460" xlink:to="us-gaap_OperatingIncomeLoss_637819367498706460" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367498706460" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637819367498706460" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367498706460" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637819367498706460" xlink:to="us-gaap_OperatingExpenses_637819367498716459" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637819367498716459" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637819367498716459" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637819367498716459" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637819367498716459" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637819367498706460" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637819367498716459" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637819367498716459" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_637819367498716459" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637819367498716459" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637819367498716459" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRent" xlink:label="nxtc_IncreaseDecreaseInDeferredRent_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="nxtc_IncreaseDecreaseInDeferredRent_637819367498726465" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_637819367498726465" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819367498726465" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="us-gaap_ProfitLoss_637819367498726465" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367498716459" xlink:to="us-gaap_ShareBasedCompensation_637819367498726465" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367498726465" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367498726465" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637819367498726465" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367498726465" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819367498726465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637819367498726465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367498726465" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637819367498726465" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367498736465" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367498736465" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367498736465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367498736465" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637819367498736465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367498736465" xlink:to="us-gaap_RepaymentsOfDebt_637819367498736465" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367498736465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RestrictedCashAndOtherAssetsCurrent" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent_637819367498736465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="nxtc_RestrictedCashAndOtherAssetsCurrent_637819367498736465" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367498746465" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819367498746465" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819367498746465" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819367498746465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_637819367498746465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819367498746465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_637819367498746465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_637819367498746465" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)">
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819367498756465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367498756465" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819367498756465" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637819367498756465" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_637819367498756465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedConstructionInProgressCurrent" xlink:label="nxtc_AccruedConstructionInProgressCurrent_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nxtc_AccruedConstructionInProgressCurrent_637819367498756465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent_637819367498756465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nxtc_AccruedOperatingExpensesCurrent_637819367498756465" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_637819367498766463" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819367498766463" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_637819367498766463" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Future Minimum Payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637819367498766463" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637819367498766463" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637819367498766463" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637819367498766463" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637819367498766463" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637819367498766463" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819367498776464" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819367498776464" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637819367498776464" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637819367498776464" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819367498776464" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637819367498776464" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637819367498776464" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637819367498776464" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637819367498776464" xlink:to="us-gaap_DeferredTaxAssetsGross_637819367498786465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819367498786465" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819367498786465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819367498786465" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637819367498786465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819367498786465" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637819367498786465" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819367498786465" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819367498786465" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819367498786465" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637819367498786465" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637819367498776464" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637819367498786465" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637819367498786465" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637819367498786465" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_637819367498786465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_637819367498786465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637819367498786465" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_637819367498786465" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>nxtc-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 8:39:11 PM-->
<!--Modified on: 3/3/2022 8:39:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFormerAgreementWithEliLillyAndCompanyDetails" roleURI="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.nextcure.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="nxtc-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nxtc_ResearchEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Former Agreement with Eli Lilly and Company (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" xlink:label="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_A2015OmnibusIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_OmnibusIncentive2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Subsequent Events - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>nxtc-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 8:39:11 PM-->
<!--Modified on: 3/3/2022 8:39:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover Abstract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2021 and 2020. No shares issued and outstanding at December 31, 2021 and 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2021 and 2020, 27,680,997 and 27,568,802 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from former research and development arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Product and Service [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized (loss) gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF STOCKHOLDERS EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities, net of tax $0</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities, tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation Depletion And Amortization And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRent" xlink:label="nxtc_IncreaseDecreaseInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_IncreaseDecreaseInDeferredRent" xlink:to="nxtc_IncreaseDecreaseInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) of consideration of unpaid rent that provides economic benefits in future periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" xlink:to="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in deferred income from related party and obligation to transfer product and service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue From Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from public offering of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of the term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash - end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash - beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment included in accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_CollaborativeArrangementDisclosureAbstract" xlink:label="nxtc_CollaborativeArrangementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_CollaborativeArrangementDisclosureAbstract" xlink:to="nxtc_CollaborativeArrangementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Agreement with Eli Lilly and Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Agreement with Eli Lilly and Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_CommonStockTextBlock" xlink:label="nxtc_CommonStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_CommonStockTextBlock" xlink:to="nxtc_CommonStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:to="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Separation of Lease and Nonlease Components [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs, Including Clinical Trial Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the tabular disclosure of estimated useful lives for property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of estimated useful lives for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:to="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Available For Sale Securities Maturities Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of available-for-sale maturities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of fair value of the Company's financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock based compensation expense recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assumptions used in the Black Scholes option pricing model for stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of shares excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for payment of underwriting discounts and commissions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Underwriting Discounts And Commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts and commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract" xlink:label="us-gaap_RestrictedCashAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of principal debt balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RequiredReserveRestrictedCashCurrent" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_RequiredReserveRestrictedCashCurrent" xlink:to="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of required reserve of restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Required Reserve Restricted Cash Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash required reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RestrictedCashAndOtherAssetsCurrent" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_RestrictedCashAndOtherAssetsCurrent" xlink:to="nxtc_RestrictedCashAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents restricted cash and other assets current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RestrictedCashOtherAssetsNonCurrent" xlink:label="nxtc_RestrictedCashOtherAssetsNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_RestrictedCashOtherAssetsNonCurrent" xlink:to="nxtc_RestrictedCashOtherAssetsNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_RestrictedCashOtherAssetsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents other assets non-current from restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_RestrictedCashOtherAssetsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash Other Assets Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_RestrictedCashOtherAssetsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PreferredStockAbstract" xlink:label="nxtc_PreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PreferredStockAbstract" xlink:to="nxtc_PreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable preferred stock:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets to be Disposed of</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain income tax benefits, interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProFormaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Excluding Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities other-than-temporarily impaired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Realized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross realized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Maturities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within 1 year</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 to 2 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total investments available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Maturities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within 1 year</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 to 2 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total investments available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds (cash equivalents)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Other Observable Inputs (Level 2)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the Company's financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds (cash equivalents)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred into level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred out of level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred from level 1 to level 2</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ResearchEquipmentMember" xlink:to="nxtc_ResearchEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible research equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedConstructionInProgressCurrent" xlink:label="nxtc_AccruedConstructionInProgressCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedConstructionInProgressCurrent" xlink:to="nxtc_AccruedConstructionInProgressCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedConstructionInProgressCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction in progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedConstructionInProgressCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Construction In Progress, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedConstructionInProgressCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related benefits</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedClinicalTrialCostsCurrent" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Trial Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial costs</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Sponsored Research Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsored research</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedOperatingExpensesCurrent" xlink:to="nxtc_AccruedOperatingExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Operating Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" xlink:label="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" xlink:to="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to research and development collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lilly Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of office space (in square feet)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expenses operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum payments:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding balance</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_NumberOfVotesPerShare" xlink:label="nxtc_NumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_NumberOfVotesPerShare" xlink:to="nxtc_NumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Dividends, Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_A2015OmnibusIncentivePlanMember" xlink:to="nxtc_A2015OmnibusIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 omnibus incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OmnibusIncentive2019PlanMember" xlink:to="nxtc_OmnibusIncentive2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OmnibusIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Omnibus Incentive 2019 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OmnibusIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Omnibus Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 omnibus incentive plan and the information pertaining to 2019 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan and 2019 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_EmployeeStockPurchase2019PlanMember" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which an employee's right to exercise an award is no longer available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved for issuance under the plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Increase In Shares For Issuance As A Percentage Of Number Of Common Stock Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in number of share reserved for issuance (as percent)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold number of shares of the company's common stock available for issuance under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Threshold Number Of Common Stock For Issuance Under The Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual increase in shares available for issuance under the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeitures (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value per share of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Additional Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Expense Not Recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected income tax benefit at the federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit, net (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible items (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior year provision to return adjustments (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal components of the Company's deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charitable contribution carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards that do not expire</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contributions amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>nxtc-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 8:39:11 PM-->
<!--Modified on: 3/3/2022 8:39:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementBalanceSheets" roleURI="http://www.nextcure.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfStockholdersEquityParenthetical" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureMarketableSecurities" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureAccruedLiabilities" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFormerAgreementWithEliLillyAndCompany" roleURI="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureTermLoan" roleURI="http://www.nextcure.com/role/DisclosureTermLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePreferredStock" roleURI="http://www.nextcure.com/role/DisclosurePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommonStock" roleURI="http://www.nextcure.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.nextcure.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureAccruedLiabilitiesTables" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureFormerAgreementWithEliLillyAndCompanyDetails" roleURI="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommitmentsAndContingenciesOtherDetails" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureTermLoanOtherDetails" roleURI="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosurePreferredStockDetails" roleURI="http://www.nextcure.com/role/DisclosurePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureStockBasedCompensationRestrictedCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.nextcure.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637819367499186472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637819367499186472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637819367499186472" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637819367499186472" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637819367499186472" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637819367499186472" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637819367499186472" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637819367499186472" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637819367499186472" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637819367499186472" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637819367499186472" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637819367499186472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637819367499186472" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637819367499196470" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637819367499196470" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637819367499196470" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637819367499196470" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637819367499196470" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637819367499196470" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637819367499196470" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637819367499196470" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637819367499196470" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637819367499196470" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637819367499196470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637819367499196470" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637819367499206470" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637819367499206470" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637819367499206470" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637819367499206470" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637819367499206470" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637819367499206470" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637819367499206470" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637819367499206470" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637819367499206470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637819367499206470" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637819367499216468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637819367499216468" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637819367499216468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637819367499216468" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637819367499216468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637819367499216468" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637819367499216468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637819367499216468" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637819367499216468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637819367499216468" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637819367499226472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819367499226472" xlink:to="us-gaap_AssetsCurrentAbstract_637819367499226472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819367499226472" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367499226472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819367499226472" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_637819367499226472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819367499226472" xlink:to="us-gaap_RestrictedCashCurrent_637819367499226472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819367499226472" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819367499226472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819367499226472" xlink:to="us-gaap_AssetsCurrent_637819367499226472" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819367499226472" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819367499226472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819367499226472" xlink:to="us-gaap_OtherAssetsNoncurrent_637819367499226472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819367499226472" xlink:to="us-gaap_Assets_637819367499226472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" xlink:to="us-gaap_AccountsPayableCurrent_637819367499226472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637819367499226472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637819367499226472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" xlink:to="us-gaap_DeferredRentCreditCurrent_637819367499236470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" xlink:to="us-gaap_LongTermDebtCurrent_637819367499236470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819367499226472" xlink:to="us-gaap_LiabilitiesCurrent_637819367499236470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637819367499236470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" xlink:to="us-gaap_LongTermDebtNoncurrent_637819367499236470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" xlink:to="us-gaap_Liabilities_637819367499236470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819367499226472" xlink:to="us-gaap_StockholdersEquityAbstract_637819367499236470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_PreferredStockValue_637819367499236470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_CommonStockValue_637819367499236470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637819367499236470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_AdditionalPaidInCapital_637819367499236470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819367499246471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637819367499246471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_StockholdersEquity_637819367499246471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819367499236470" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637819367499246471" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS - (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499246471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637819367499246471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637819367499246471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637819367499246471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637819367499246471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637819367499246471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637819367499246471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637819367499256472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637819367499256472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_637819367499256472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637819367499256472" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367499256472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637819367499256472" xlink:to="us-gaap_TypeOfRevenueExtensibleList_637819367499256472" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637819367499256472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819367499256472" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637819367499256472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819367499256472" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637819367499256472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819367499256472" xlink:to="us-gaap_OperatingExpenses_637819367499256472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637819367499256472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637819367499256472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637819367499256472" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637819367499256472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637819367499256472" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637819367499256472" xlink:to="us-gaap_EarningsPerShareBasic_637819367499266472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637819367499256472" xlink:to="us-gaap_EarningsPerShareDiluted_637819367499266472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637819367499266472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637819367499266472" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637819367499266472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637819367499266472" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637819367499266472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637819367499266472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637819367499266472" xlink:to="us-gaap_NetIncomeLoss_637819367499266472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637819367499266472" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637819367499266472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637819367499266472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637819367499266472" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637819367499266472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637819367499276471" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819367499276471" xlink:to="us-gaap_StatementEquityComponentsAxis_637819367499276471" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819367499276471" xlink:to="us-gaap_CommonStockMember_637819367499276471" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819367499276471" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637819367499276471" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819367499276471" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637819367499276471" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819367499276471" xlink:to="us-gaap_RetainedEarningsMember_637819367499276471" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819367499276471" xlink:to="us-gaap_EquityComponentDomain_637819367499276471" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819367499276471" xlink:to="us-gaap_StatementLineItems_637819367499276471" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819367499276471" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_StockholdersEquity_637819367499276471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_CommonStockSharesOutstanding_637819367499276471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637819367499276471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637819367499276471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637819367499276471" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819367499276471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819367499276471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819367499276471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819367499276471" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819367499286474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_637819367499286474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_NetIncomeLoss_637819367499286474" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_StockholdersEquity_637819367499286474" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819367499276471" xlink:to="us-gaap_CommonStockSharesOutstanding_637819367499286474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_637819367499286474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" xlink:to="us-gaap_ProfitLoss_637819367499286474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_637819367499296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" xlink:to="us-gaap_ShareBasedCompensation_637819367499296478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819367499286474" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819367499296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637819367499296478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637819367499296478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRent" xlink:label="nxtc_IncreaseDecreaseInDeferredRent_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="nxtc_IncreaseDecreaseInDeferredRent_637819367499296478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty" xlink:label="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty_637819367499296478" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819367499296478" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819367499296478" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819367499296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637819367499296478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637819367499296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637819367499296478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819367499296478" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819367499306473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367499306473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637819367499306473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" xlink:to="us-gaap_RepaymentsOfDebt_637819367499306473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819367499306473" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819367499306473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637819367499306473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819367499306473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378193674993064731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378193674993064731" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637819367499306473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637819367499306473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637819367499316470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819367499306473" xlink:to="us-gaap_InterestPaidNet_637819367499316470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637819367499316470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637819367499316470" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637819367499316470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637819367499316470" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637819367499316470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the Business and Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637819367499316470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637819367499316470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637819367499316470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637819367499316470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Marketable Securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170090458325" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637819367499326474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170090458325" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637819367499326474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637819367499326474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637819367499326474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment, Net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637819367499326474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637819367499326474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637819367499326474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637819367499326474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany" xlink:type="extended" xlink:title="10701 - Disclosure - Former Agreement with Eli Lilly and Company" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_CollaborativeArrangementDisclosureAbstract" xlink:label="nxtc_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureTermLoan" xlink:type="extended" xlink:title="10901 - Disclosure - Term Loan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePreferredStock" xlink:type="extended" xlink:title="11001 - Disclosure - Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="11101 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_CommonStockTextBlock" xlink:label="nxtc_CommonStockTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="nxtc_CommonStockTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637819367499336473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637819367499336473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="extended" xlink:title="11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637819367499346477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11401 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637819367499346477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11501 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637819367499346477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11601 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637819367499346477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637819367499346477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637819367499346477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637819367499346477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637819367499346477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637819367499356476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637819367499356476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637819367499356476" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637819367499356476" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637819367499356476" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_637819367499356476" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637819367499356476" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637819367499356476" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_637819367499356476" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637819367499356476" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637819367499356476" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637819367499356476" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637819367499356476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637819367499356476" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637819367499366478" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637819367499366478" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637819367499366478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_637819367499366478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Marketable Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637819367499366478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_637819367499366478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" xlink:to="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_637819367499366478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_637819367499376471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_637819367499376471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment, Net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637819367499376471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637819367499376471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637819367499376471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637819367499376471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637819367499376471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637819367499376471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637819367499386474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637819367499386474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637819367499386474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" xlink:title="31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637819367499386474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31403 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637819367499386474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637819367499386474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637819367499386474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventTable_637819367499386474" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637819367499486478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637819367499386474" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637819367499486478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637819367499486478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637819367499486478" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637819367499486478" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637819367499486478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637819367499486478" xlink:to="us-gaap_IPOMember_637819367499486478" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637819367499386474" xlink:to="us-gaap_SubsequentEventLineItems_637819367499496453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637819367499496453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819367499496453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_SharePrice_637819367499496453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637819367499496453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819367499496453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_637819367499496453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637819367499496453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_CommonStockSharesOutstanding_637819367499496453" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_PreferredStockSharesOutstanding_637819367499496453" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_CommonStockSharesAuthorized_637819367499496453" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637819367499496453" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637819367499496453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_PreferredStockSharesAuthorized_637819367499496453" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499496453" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499506475" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637819367499506475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract" xlink:label="us-gaap_RestrictedCashAbstract_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAbstract_637819367499506475" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_637819367499506475" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_637819367499506475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_637819367499506475" xlink:to="us-gaap_DebtInstrumentFaceAmount_637819367499506475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RequiredReserveRestrictedCashCurrent" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_637819367499506475" xlink:to="nxtc_RequiredReserveRestrictedCashCurrent_637819367499506475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819367499506475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RestrictedCashAndOtherAssetsCurrent" xlink:label="nxtc_RestrictedCashAndOtherAssetsCurrent_637819367499506475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" xlink:to="nxtc_RestrictedCashAndOtherAssetsCurrent_637819367499506475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819367499516476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_RestrictedCashOtherAssetsNonCurrent" xlink:label="nxtc_RestrictedCashOtherAssetsNonCurrent_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637819367499506475" xlink:to="nxtc_RestrictedCashOtherAssetsNonCurrent_637819367499516476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499516476" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499516476" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499516476" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499516476" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499516476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499516476" xlink:to="us-gaap_ComputerEquipmentMember_637819367499516476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499516476" xlink:to="us-gaap_EquipmentMember_637819367499516476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499516476" xlink:to="us-gaap_FurnitureAndFixturesMember_637819367499516476" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499516476" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499516476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_637819367499516476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499516476" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_637819367499516476" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_PreferredStockAbstract" xlink:label="nxtc_PreferredStockAbstract_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nxtc_PreferredStockAbstract_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_PreferredStockAbstract_637819367499526477" xlink:to="us-gaap_PreferredStockSharesOutstanding_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_637819367499526477" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_637819367499526477" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_637819367499526477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_637819367499526477" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819367499526477" xlink:to="us-gaap_TypeOfAdoptionMember_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637819367499526477" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_637819367499526477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_637819367499526477" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_637819367499526477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_637819367499526477" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_637819367499526477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" xlink:to="srt_StatementScenarioAxis_637819367499536477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637819367499536477" xlink:to="srt_ScenarioUnspecifiedDomain_637819367499536477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637819367499536477" xlink:to="srt_ProFormaMember_637819367499536477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637819367499526477" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637819367499536477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637819367499536477" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637819367499536477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637819367499536477" xlink:to="us-gaap_OperatingLeaseLiability_637819367499536477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_637819367499536477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637819367499536477" xlink:to="us-gaap_FinancialInstrumentAxis_637819367499536477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637819367499536477" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819367499536477" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819367499536477" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637819367499536477" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819367499536477" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637819367499536477" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637819367499536477" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_637819367499546469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819367499546469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819367499546469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367499546469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_637819367499546469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_637819367499546469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_637819367499546469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_637819367499546469" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819367499546469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_637819367499546469" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_637819367499546469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_637819367499546469" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_637819367499546469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637819367499536477" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819367499546469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819367499546469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819367499546469" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819367499546469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819367499546469" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_637819367499556471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819367499546469" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_637819367499556471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637082166474633472" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637082166474633472" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637819367499556471" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637819367499556471" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819367499556471" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819367499556471" xlink:to="us-gaap_MoneyMarketFundsMember_637819367499556471" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819367499556471" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637819367499556471" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819367499556471" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637819367499556471" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637819367499556471" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637819367499556471" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637819367499556471" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637819367499556471" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637819367499556471" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819367499556471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819367499556471" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819367499556471" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819367499566473" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819367499566473" xlink:to="us-gaap_FairValueInputsLevel1Member_637819367499566473" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819367499566473" xlink:to="us-gaap_FairValueInputsLevel2Member_637819367499566473" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637819367499556471" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637819367499566473" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637819367499566473" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819367499566473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_637819367499566473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents_637819367499566473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637819367499566473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637819367499566473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637819367499566473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_637819367499566473" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637819367499566473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499576470" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499576470" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" xlink:to="nxtc_ResearchEquipmentMember_637819367499576470" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" xlink:to="us-gaap_LeaseholdImprovementsMember_637819367499576470" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" xlink:to="us-gaap_ComputerEquipmentMember_637819367499576470" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" xlink:to="us-gaap_FurnitureAndFixturesMember_637819367499576470" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819367499576470" xlink:to="us-gaap_ConstructionInProgressMember_637819367499576470" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499576470" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637819367499576470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819367499576470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819367499576470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819367499586469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_637819367499576470" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637819367499586469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedConstructionInProgressCurrent" xlink:label="nxtc_AccruedConstructionInProgressCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedConstructionInProgressCurrent_637819367499586469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819367499586469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_637819367499586469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_637819367499586469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedOperatingExpensesCurrent_637819367499586469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_637819367499586469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637819367499586469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Former Agreement with Eli Lilly and Company (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_CollaborativeArrangementDisclosureAbstract" xlink:label="nxtc_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819367499586469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819367499586469" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819367499586469" xlink:to="us-gaap_TypeOfArrangementAxis_637819367499596470" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637819367499596470" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819367499596470" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ResearchAndDevelopmentCollaborativeAgreementMember" xlink:label="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819367499596470" xlink:to="nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_637819367499596470" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819367499586469" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819367499596470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819367499596470" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637819367499596470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty_637819367499596470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_637819367499596470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Future Minimum Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637819367499596470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637819367499596470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637819367499596470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637819367499606484" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637819367499606484" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637819367499606484" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637819367499596470" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637819367499606484" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount_637819367499606484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_637819367499606484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePreferredStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637819367499606484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637819367499606484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637819367499606484" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637819367499606484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637819367499606484" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637819367499616480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637819367499616480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637819367499616480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637819367499616480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_NumberOfVotesPerShare" xlink:label="nxtc_NumberOfVotesPerShare_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="nxtc_NumberOfVotesPerShare_637819367499616480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_637819367499616480" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915319547421245" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915319547421245" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819367499616480" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819367499616480" xlink:to="us-gaap_PlanNameAxis_637819367499616480" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637819367499616480" xlink:to="us-gaap_PlanNameDomain_637819367499616480" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819367499616480" xlink:to="nxtc_A2015OmnibusIncentivePlanMember_637819367499616480" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember_637819367499616480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819367499616480" xlink:to="nxtc_OmnibusIncentive2019PlanMember_637819367499616480" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819367499616480" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_637819367499626473" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819367499616480" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember_637819367499626473" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819367499616480" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637819367499626473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819367499626473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_637819367499626473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637819367499626473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_637819367499626473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_637819367499626473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819367499626473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819367499626473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819367499626473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819367499626473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637819367499636471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819367499636471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637819367499636471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819367499636471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637819367499636471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637819367499636471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637819367499636471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637819367499636471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378193674996364711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378193674996364711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819367499636471" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637819367499646594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819367499626473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819367499646594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637819367499646594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637819367499646594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378193674996465941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378193674996465941" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637819367499646594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819367499646594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819367499646594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637819367499656472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637819367499656472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637819367499656472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637819367499656472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637819367499656472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819367499646594" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637819367499656472" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637819367499656472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637819367499656472" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637819367499656472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637819367499656472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637819367499656472" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637819367499656472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637819367499666472" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637819367499666472" xlink:to="us-gaap_IncomeStatementLocationAxis_637819367499666472" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637819367499666472" xlink:to="us-gaap_IncomeStatementLocationDomain_637819367499666472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637819367499666472" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637819367499666472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637819367499666472" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637819367499666472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637819367499666472" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637819367499666472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637819367499666472" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637819367499666472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637819367499666472" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819367499666472" xlink:to="srt_RangeAxis_637819367499666472" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637819367499666472" xlink:to="srt_RangeMember_637819367499666472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819367499666472" xlink:to="srt_MinimumMember_637819367499666472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819367499666472" xlink:to="srt_MaximumMember_637819367499666472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819367499666472" xlink:to="us-gaap_StatementLineItems_637819367499666472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819367499666472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819367499666472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819367499666472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819367499666472" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637819367499676477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819367499666472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637819367499676477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819367499666472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637819367499676477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637819367499676477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819367499676477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819367499676477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819367499676477" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819367499676477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819367499676477" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637819367499676477" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637819367499676477" xlink:to="us-gaap_EmployeeStockOptionMember_637819367499676477" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819367499676477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819367499676477" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819367499676477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819367499676477" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637819367499686470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819367499686470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819367499686470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637819367499686470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637819367499686470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637819367499686470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819367499686470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637819367499686470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637819367499686470" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637819367499686470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819367499696472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637819367499696472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637819367499696472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819367499696472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637819367499696472" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsGross_637819367499696472" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637819367499696472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsNet_637819367499696472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_637819367499696472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637819367499696472" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_637819367499696472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_637819367499696472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637819367499696472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637819367499696472" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637819367499696472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637819367499706475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637819367499706475" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637819367499706475" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_637819367499706475" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637819367499706475" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_637819367499706475" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20211231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_637819367499706475" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637819367499706475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637819367499696472" xlink:to="us-gaap_UnrecognizedTaxBenefits_637819367499706475" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637819367499716478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Subsequent Events - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637819367499716478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637819367499716478" xlink:to="us-gaap_SubsequentEventTypeAxis_637819367499716478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637819367499716478" xlink:to="us-gaap_SubsequentEventTypeDomain_637819367499716478" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637819367499716478" xlink:to="us-gaap_SubsequentEventMember_637819367499716478" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637819367499716478" xlink:to="us-gaap_SubsequentEventLineItems_637819367499716478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637819367499716478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637819367499716478" xlink:to="us-gaap_AreaOfRealEstateProperty_637819367499716478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097824584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NextCure, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5231247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9000 Virginia Manor Road, Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Beltsville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">399-4900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,724,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Baltimore, MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099121816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,337<span></span>
</td>
<td class="nump">$ 32,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">207,254<span></span>
</td>
<td class="nump">250,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,187<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">227,817<span></span>
</td>
<td class="nump">287,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,992<span></span>
</td>
<td class="nump">15,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">242,386<span></span>
</td>
<td class="nump">306,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="nump">3,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,449<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current portion</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,608<span></span>
</td>
<td class="nump">10,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">12,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2021 and 2020. No shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2021 and 2020, 27,680,997 and 27,568,802 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">421,047<span></span>
</td>
<td class="nump">410,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(663)<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(187,026)<span></span>
</td>
<td class="num">(117,637)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">233,386<span></span>
</td>
<td class="nump">293,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 242,386<span></span>
</td>
<td class="nump">$ 306,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099086600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097671096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from former research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:TechnologyServiceMember<span></span>
</td>
<td class="text">us-gaap:TechnologyServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 50,192<span></span>
</td>
<td class="nump">$ 46,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,573<span></span>
</td>
<td class="nump">17,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">70,765<span></span>
</td>
<td class="nump">63,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(70,765)<span></span>
</td>
<td class="num">(41,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">4,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (69,389)<span></span>
</td>
<td class="num">$ (36,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">27,615,977<span></span>
</td>
<td class="nump">27,532,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">27,615,977<span></span>
</td>
<td class="nump">27,532,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (69,389)<span></span>
</td>
<td class="num">$ (36,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(1,442)<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (70,831)<span></span>
</td>
<td class="num">$ (35,824)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096505208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 402,529<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (81,034)<span></span>
</td>
<td class="nump">$ 321,484<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">27,499,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">69,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted', window );">Unrealized gain (loss) on marketable securities, net of tax $0</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,603)<span></span>
</td>
<td class="num">(36,603)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2020</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">410,551<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="num">(117,637)<span></span>
</td>
<td class="nump">$ 293,721<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2020</a></td>
<td class="nump">27,568,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">112,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted', window );">Unrealized gain (loss) on marketable securities, net of tax $0</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,389)<span></span>
</td>
<td class="num">(69,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 421,047<span></span>
</td>
<td class="num">$ (663)<span></span>
</td>
<td class="num">$ (187,026)<span></span>
</td>
<td class="nump">$ 233,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647181208472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>STATEMENTS OF STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gain (loss) on marketable securities, tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097629368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (69,389)<span></span>
</td>
<td class="num">$ (36,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_DepreciationDepletionAndAmortizationAndOther', window );">Depreciation, amortization and other</a></td>
<td class="nump">7,196<span></span>
</td>
<td class="nump">3,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,288<span></span>
</td>
<td class="nump">7,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,889)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,959)<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,244)<span></span>
</td>
<td class="num">(44,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">195,438<span></span>
</td>
<td class="nump">187,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(156,477)<span></span>
</td>
<td class="num">(137,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,360)<span></span>
</td>
<td class="num">(7,132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">36,601<span></span>
</td>
<td class="nump">43,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments of the term loan</a></td>
<td class="num">(3,473)<span></span>
</td>
<td class="num">(1,527)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,265)<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(23,908)<span></span>
</td>
<td class="num">(2,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">36,284<span></span>
</td>
<td class="nump">39,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">12,376<span></span>
</td>
<td class="nump">36,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DepreciationDepletionAndAmortizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DepreciationDepletionAndAmortizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration of unpaid rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income from related party and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101526152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the Business and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NextCure,&#160;Inc. (&#8220;NextCure&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#8220;FIND-IO&#8221;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#8217;s product candidates, building and optimizing the Company&#8217;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#8217;s product candidates, discovery programs and its FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public Offerings of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, the Company closed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net proceeds to the Company of approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparation for the IPO, on May 3, 2019, the Company effected a <span style="-sec-ix-hidden:Hidden_sDmryUZLgEqm_48xdkZO4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s convertible preferred stock automatically converted into 15,560,569 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. Additionally, the Company&#8217;s certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to the Company of $160.9 million after deducting underwriting discounts and commissions of $10.3 million and offering expenses of $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#8217;s former agreement with Eli Lilly and Company (Note 7). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the issuance date of the financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#8217;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#8217;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#8217;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#8217;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#8217;s planned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in one operating segment that operates exclusively in the United States.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101403896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December&#160;31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,772</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,512</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,284</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-02 (Topic 842), Leases (&#8220;ASC 842&#8221;). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. &#160;The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101401016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 249,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,676</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, no marketable securities are considered to be other-than-temporarily impaired. The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2021 and 2020, respectively, the Company recorded $57 thousand and $70 thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturities of the Company&#8217;s investments available-for-sale as of December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,775</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,479</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total investments available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,254</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099138376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy as of December 31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101516840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,359</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,391</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,010</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,496</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,369</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,737)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,560)</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,809</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress at December&#160;31, 2021 and 2020 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $4.3 million and $3.4 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099169080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 973</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,744</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,627</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101437624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Former Agreement with Eli Lilly and Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_CollaborativeArrangementDisclosureAbstract', window );"><strong>Former Agreement with Eli Lilly and Company</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Former Agreement with Eli Lilly and Company</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Former Agreement with Eli Lilly and Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the &#8220;Lilly Agreement&#8221;) with Eli Lilly and Company (&#8220;Lilly&#8221;), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly, terminated the Lilly Agreement without cause. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized revenue under the Lilly Agreement of $0 and $22.4 million for the years ended December 31, 2021 and December 31, 2020, respectively. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101526984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s leases primarily comprise real estate for office and manufacturing space. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company&#8217;s minimum obligations under non-cancelable operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,231</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,537</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,427</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense incurred under operating leases was $1 million and $0.9 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#8217;s management, are likely to have a material adverse effect on the Company&#8217;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#8217; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#8217;s motion to dismiss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#8217;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101406776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a $1.0&#160;million term loan, or the &#8220;Term Loan&#8221;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, which amount remains secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101526984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of $0.001 par value preferred stock, and there were no shares of preferred stock <span style="-sec-ix-hidden:Hidden_Q1KEPjTqhk6GA6gnGmG3gQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101526984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.001 par value common stock, of which 27,680,997 were issued and <span style="-sec-ix-hidden:Hidden_cpk3pttepkCkflUjT07eqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. No dividends have been declared or paid by the Company through December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101520424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#8220;2019 Plan&#8221;), which became effective on May 8, 2019, the date on which the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#8220;Effective Date&#8221;). The Company&#8217;s board of directors (the &#8220;Board&#8221;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company&#8217;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> during the term of the 2019 Plan by 4% of the number of shares of the Company&#8217;s common stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year or such lesser number of shares determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, 2,313,433 shares were reserved for future issuance under the 2019 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options granted under the 2015 Plan and 2019 Plan (together, the &#8220;Plans&#8221;) to employees generally vest over four years and expire after 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity for awards under the Plans is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,170,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,295</p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,115,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (104,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,112,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,810</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,020,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (481,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,860</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,915,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,783</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $7.47 and $23.25, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $469,000 and $633,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2021 and 2020 was approximately $13,398,000 and $2,389,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the Internal Revenue Code. A total of 240,000 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> until expiration of the ESPP, in an amount equal to the lesser of (i) 1% of the number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, (ii) 480,000 shares of common stock and (iii) a number of shares of common stock determined by the administrator </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the ESPP. As of December 31, 2021, 6,464 shares of common stock had been issued pursuant to the ESPP and 784,216 shares were reserved for future issuance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $10.3 million and $7.9 million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $23.3 million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of three years as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">69.7 - 81.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.8 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.3 - 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101495336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,376</p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,376</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101423032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,511</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,874</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charitable contribution carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,783</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,109</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,552)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 557</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (342)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021. The Company increased its valuation allowance by approximately $20.2 million for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company had federal and state net operating loss carryforwards of $160.9&#160;million and $163.4&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $138.2 million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $8.7 million and $0.1&#160;million, respectively, as of December&#160;31, 2021. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#8220;IRC&#8221;), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2017 to 2020 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Coronavirus Aid, Relief, and Economic Security Act, or &#8220;CARES Act&#8221;, and the Consolidated Appropriations Act, 2021, or &#8220;Stimulus Bill&#8221;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099169640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the years ended December 31, 2021 and 2020 the Company did not provide any contributions to this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647181477096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">16. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 4, 2022, the Company entered into a Third Amendment to its original Lease Agreement, dated January 30, 2019, whereby the Company has expanded its leased property by approximately 5,700 square feet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096579224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December&#160;31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,772</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,512</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,284</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs, Including Clinical Trial Accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-02 (Topic 842), Leases (&#8220;ASC 842&#8221;). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. &#160;The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election of practical expedient not to separate lease component from nonlease component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918707-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467743&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101515720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,772</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,512</p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,284</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Summary of estimated useful lives for property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure of estimated useful lives for property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101452456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td></tr><tr><td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td></tr><tr><td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 249,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,676</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock', window );">Schedule of available-for-sale maturities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,775</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,479</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total investments available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,254</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647099154632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair value of the Company's financial assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101437624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,359</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,391</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,010</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,496</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,369</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,737)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,560)</p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,809</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101403176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 973</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,744</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,627</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101475752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company&#8217;s minimum obligations under non-cancelable operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,231</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,537</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,427</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096468888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,170,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,295</p></td></tr><tr><td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,115,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (104,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,112,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,810</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,020,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (481,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,860</p></td></tr><tr><td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,915,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,783</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock based compensation expense recorded</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used in the Black Scholes option pricing model for stock options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">69.7 - 81.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.8 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.3 - 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101455608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of shares excluded from the computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,376</p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,376</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101464456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,511</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,874</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charitable contribution carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,783</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,109</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,552)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 557</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (342)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557)</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097284120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 02, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 19, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">611,578<span></span>
</td>
<td class="nump">4,077,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs | $</a></td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of shares, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101514600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Liquidity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097257624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of principal debt balance</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_RequiredReserveRestrictedCashCurrent', window );">Restricted cash required reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,337,000<span></span>
</td>
<td class="nump">32,772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_RestrictedCashAndOtherAssetsCurrent', window );">Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">3,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376,000<span></span>
</td>
<td class="nump">36,284,000<span></span>
</td>
<td class="nump">$ 39,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_RestrictedCashOtherAssetsNonCurrent', window );">Other assets, restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_RequiredReserveRestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required reserve of restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_RequiredReserveRestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_RestrictedCashAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents restricted cash and other assets current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_RestrictedCashAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_RestrictedCashOtherAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents other assets non-current from restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_RestrictedCashOtherAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097771240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P3Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P7Y<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097871032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_PreferredStockAbstract', window );"><strong>Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Uncertain income tax benefits, interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Not available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647181208472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) - Accounting Standards Update 2016-02 - Cumulative Effect Adjustment - Expected<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647095624296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 207,917,000<span></span>
</td>
<td class="nump">$ 249,897,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">854,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(666,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">207,254,000<span></span>
</td>
<td class="nump">250,676,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Marketable securities other-than-temporarily impaired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Cost Maturities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within 1 year</a></td>
<td class="nump">104,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost', window );">Between 1 to 2 years</a></td>
<td class="nump">102,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total investments available for sale</a></td>
<td class="nump">207,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value Maturities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within 1 year</a></td>
<td class="nump">104,775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Between 1 to 2 years</a></td>
<td class="nump">102,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total investments available for sale</a></td>
<td class="nump">207,254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">207,917,000<span></span>
</td>
<td class="nump">242,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">854,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(666,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 207,254,000<span></span>
</td>
<td class="nump">243,679,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,997,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,997,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097440824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">$ 207,254,000<span></span>
</td>
<td class="nump">$ 250,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Assets transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Assets transferred out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Assets transferred from level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">209,934,000<span></span>
</td>
<td class="nump">261,831,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">2,680,000<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">207,254,000<span></span>
</td>
<td class="nump">250,676,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">2,680,000<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Fair Value | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">2,680,000<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">207,254,000<span></span>
</td>
<td class="nump">243,679,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">$ 207,254,000<span></span>
</td>
<td class="nump">243,679,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,997,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper | Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,997,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_MarketableSecuritiesAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_MarketableSecuritiesAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097569288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 26,729<span></span>
</td>
<td class="nump">$ 24,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(12,737)<span></span>
</td>
<td class="num">(8,560)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,992<span></span>
</td>
<td class="nump">15,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,482<span></span>
</td>
<td class="nump">13,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,566<span></span>
</td>
<td class="nump">8,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 1,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647098982200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AccruedConstructionInProgressCurrent', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">$ 1,751<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AccruedClinicalTrialCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AccruedSponsoredResearchExpenseCurrent', window );">Sponsored research</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_AccruedOperatingExpensesCurrent', window );">Operating expenses</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,449<span></span>
</td>
<td class="nump">$ 4,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction in progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedOperatingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedOperatingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedSponsoredResearchExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedSponsoredResearchExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647102288344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Former Agreement with Eli Lilly and Company (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from former research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,378,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nxtc_ResearchAndDevelopmentCollaborativeAgreementMember', window );">Lilly Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from former research and development arrangement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nxtc_ResearchAndDevelopmentCollaborativeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nxtc_ResearchAndDevelopmentCollaborativeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647098878536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Other (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expenses operating leases</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647102293816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 1,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">6,537<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">$ 11,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647102402696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Other (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097746808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647098895048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">27,568,802<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647095124680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share Based Compensation Expense Not Recognized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
<td class="nump">2,170,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,020,718<span></span>
</td>
<td class="nump">1,115,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,731)<span></span>
</td>
<td class="num">(69,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481,569)<span></span>
</td>
<td class="num">(104,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,545,794<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
<td class="nump">2,170,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable at the end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,915,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.95<span></span>
</td>
<td class="nump">$ 6.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.89<span></span>
</td>
<td class="nump">37.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
<td class="nump">1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.33<span></span>
</td>
<td class="nump">25.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.15<span></span>
</td>
<td class="nump">$ 16.95<span></span>
</td>
<td class="nump">$ 6.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,810,000<span></span>
</td>
<td class="nump">$ 113,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860,000<span></span>
</td>
<td class="nump">$ 10,810,000<span></span>
</td>
<td class="nump">$ 113,295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.47<span></span>
</td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="nump">$ 633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,398,000<span></span>
</td>
<td class="nump">$ 2,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember', window );">Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding', window );">Annual increase in number of share reserved for issuance (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember', window );">2015 Plan and 2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,313,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">784,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding', window );">Annual increase in number of share reserved for issuance (as percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan', window );">Maximum annual increase in shares available for issuance under the plan</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold number of shares of the company's common stock available for issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096531336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,288<span></span>
</td>
<td class="nump">$ 7,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,081<span></span>
</td>
<td class="nump">3,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,207<span></span>
</td>
<td class="nump">$ 4,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096659176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647097705384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">4,545,794<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">4,545,794<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647096524472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, net (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items (as a percent)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year provision to return adjustments (as a percent)</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as a percent)</a></td>
<td class="num">(28.50%)<span></span>
</td>
<td class="num">(32.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647095060248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 44,451,000<span></span>
</td>
<td class="nump">$ 28,511,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">8,862,000<span></span>
</td>
<td class="nump">6,874,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">306,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">3,184,000<span></span>
</td>
<td class="nump">1,783,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther', window );">Accruals and other</a></td>
<td class="nump">1,121,000<span></span>
</td>
<td class="nump">635,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">57,788,000<span></span>
</td>
<td class="nump">38,109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(57,705,000)<span></span>
</td>
<td class="num">(37,552,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">557,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(83,000)<span></span>
</td>
<td class="num">(342,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(83,000)<span></span>
</td>
<td class="num">$ (557,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">160,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">163,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards that do not expire</a></td>
<td class="nump">138,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal', window );">Federal research and development tax credit carryforwards</a></td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState', window );">State research and development tax credit carryforwards</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101456440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140647101480280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 04, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in square feet)</a></td>
<td class="nump">5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>nxtc-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nxtc="http://www.nextcure.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nxtc-20211231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y7GXva2dbkWtJbsUzFBadQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2019_To_11_19_2019_YzRMsCVKvkGV2jcw4HTlxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-11-19</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_UUzyonDaOUCSPT8lhBhUag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8gqQyeXsEa2baPiReBeLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wIP__71uMkOD1PkXsn-N0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ROd0_OVRAUibMHBnTwZzJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZINGtOppMEOQvolyBs2r2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3BA4U7O4vEq4IVDY7BQ4fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QqInZr8FSEKmnGZDc0UpLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g2SurcQldU2PCyhEWEYFNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7hwDq_hUlUOMlE_Q8n38kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qNbbMd7Kt06bhH7DHJgopQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_2_2019_WWMv6pgpRk2zjvig2oOTzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-12-02</instant>
        </period>
    </context>
    <context id="As_Of_11_19_2019_qoi0IG6E5ES_Szx_7icP0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-11-19</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRkd_wQNpE-PlILTjaNCPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_G_yj8-kGZEqKlKj7UfkTfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_G53rdmX140OTQJmbyiS6Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_w5P21kf0c0WRJYhRcmUNfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nxtc:ResearchAndDevelopmentCollaborativeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_GZR3kGJhT0eFCCICgDlBxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nxtc:ResearchAndDevelopmentCollaborativeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JJOGCiB-VUKIQzM08BXQzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_couFI7dtvE-qXjH-EmZFUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jUzYlFOGn0CwHbmMVEGKpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_oYnlwjc7HUGb5iWfCmq0fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_BSsHwW_jjUWkVvqBCbt48Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LFp27XQr4Uid6yEPdONaFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q2ALKasRH02YKQvydmMALQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_HwvSSMcY6EWFFgNhar4zeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xZ8jUscG3U-QIINlDwJ2ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_Qq_WJ4vpZkiMhOxoPOoNuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ytC6nbqJ5kebhS3ZyEI15A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_FRWWKvwUu0m7aWpFF9Q6iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qr9RYIPNZUOJJAf5Pj-l0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mtHwI-ED1USEa2VQIR0lwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_w26PQYiKDUS0odivM7VviQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Yan-j4dWbkS2KGt5iU5VRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_B9L06CbX5EGrB1JXLY5xsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E7waEgPyPkSn9Zcc1udIPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_hW36vSQqcEKgeJbxONrVSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qdi16EmCNUKD0BX_L5w1VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2019_ML94Z-Zsg0C5Id5hiZnfiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2016_dCCJWmRM8USlY0UQ6_FnFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-05-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_POQwOZH2fkaMcb9h4V0jNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_33XxS2bj4katgp19dilw6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_eNVV54RhUEqTl5x1mLRsMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_1Jdd-_wpikG_weZqBMb3Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oYhMcGirCE25Vip1ZFlDcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_kmwB305biUWLo3UjsSooUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_zGOjNpmC6EGr7pG_-L0KzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3BxpsJ2iNECPTNPjm8MqUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-04</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_e_s4q5Pn_Uu6ZKwpy8z4Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aAofUk9dFUCw9X561F27_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_ypDyfJrUqjGxvpjHQzEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aiYI6v5UyEeVRnXYUS5XLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HC8YQx8WSE68y6ph75dG7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eiLn54zwfEaRz2KZJSxGgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_pWUZUIh3IU2JNJgRAHr9Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-12-02</startDate>
            <endDate>2019-12-02</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-13</startDate>
            <endDate>2019-05-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1bJ_AHosZkOR2oPN_YnoLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vrV78_WLHUylRfRKRtNrFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mNncfD8YUC8da9cv5QKbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_SpiKMzSntkeJHGELywtLIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_JO8kC4Wv30ykMH8DL_H1Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_woD1OcCVU0i7W0uEaTV-eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NPmdibs4nkishMWIdyp4yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FJ9ZE9uoI0-WmaYGYBzHyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_XJYS-dihHU6jsGASXI2Dqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_2_2022_KjFy2haETEOXfvQdXHC5IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2022-03-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Vote_w0Gf5YJwbUupsjwI1CCnAw">
        <measure>nxtc:Vote</measure>
    </unit>
    <unit id="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_y2qUci353EOOoH7IWozW8A">
        <measure>nxtc:segment</measure>
    </unit>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      id="Hidden_tTt21ZgtBk-W0pJEfxQKVQ">http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Hidden_UtQtRmGb0EuPJna7GdernA">http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="2"
      id="Hidden_oyydoO0AdkylL5JPTmIRgg"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="2"
      id="Hidden_k3SONQVP20aoC7_plLOxow"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">-1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Hidden_BHSA1K7qf0y_675z_dMI4Q"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27615977</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Hidden_-_keUW7NyU-mmVNN33QaCA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27532177</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      id="Hidden_wTg-hQItxUW1i-lAprnTXA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      id="Hidden_iUdxlbiBN0aOd-krv8nVQA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Hidden_DN8xdD6MRE6MMojBwaImsw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27680997</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_7KcVcMJBiU69M_MlhSgwBA">0001661059</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_nReG94DGwUmK5NIO-e3MYg">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_PKcQKiqbP0ahpUmPOG-2Tg">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_xla-VDeQNk2D_qJeMnwTPg">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_Bir83qcYQE6XN50l4JUimg">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Hidden_hkoQ8GJUGEyIHnTAb-r26w"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Hidden_NpCa8uFUzkmtHk3QJCc9mQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Hidden_E4lkwXOE3EWjcwZxsH94jw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27568802</us-gaap:CommonStockSharesIssued>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="0"
      id="Hidden_VR5dWCt3C0Sh1B77yMPuHw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Hidden_uWLkBdDsz0GtDJO97s-CzA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Hidden_cpk3pttepkCkflUjT07eqQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27680997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_3_2019_To_5_3_2019_UUzyonDaOUCSPT8lhBhUag"
      decimals="4"
      id="Hidden_sDmryUZLgEqm_48xdkZO4w"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.1245</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Hidden_X3VsFAQ5NEiHq5ECzPm1fA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Hidden_-cFdHJxdp0affo3bQWS-jg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Hidden_jNhHuhQk_UyO-tEfYC_Y8g"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Hidden_-hqGGvF5CEGm7P86VQb_dw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Hidden_Q1KEPjTqhk6GA6gnGmG3gQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesIssued>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_zrqGWf8NSkSMy6CKDsPjOw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_rbpRueyt6UmCR2s7xQwiSA_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_G4_iZqKvw0iFDqIeC-zlKA">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_LwNs8WpbQEOUcPBbQXNi7w_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_Vjy9xtNjAE-erdirKxoOHw">001-38905</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_St7Kx_UdOUialkei9DTWtw">NextCure, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_r0vAyNHnekip1U0EGNAsHQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_3TBw89D-1EKKQ9xUQ2-zcg_0_1">47-5231247</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_OLmWhBATu0yD3dUSKahCvQ">9000 Virginia Manor Road, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_N-TE6qrITUCXDTQbXKJaNw">Beltsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_QW7LhqDa1EW4LtCtgTWSEg">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_U2NBL_owJkOCQkC2nIczqQ_3_1">20705</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_DGxBSD4_hk6Jz9a0LNER4Q">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_-eeFLttoQkSEMOMP4VsjhQ">399-4900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_Rdjk9W0nak22qpDqRK_MFg_1_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_pJFZueOvwUGTNtT0NpA_ZA_1_1">NXTC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tc_MbpyGBYS-0GKgXrDeBmNTw_1_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_IE2hrjNbi0OA8Ihu0LLB0w">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_wa32Sz4HREyWSiv8kHybtw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_CajEhy9w6U24s03qwC9nhg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_FVHfsRNeFkOQKsOLdnBJBw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_bgL_vhTi3066CjwhIfz7Vg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_bDG7hl2N-0qp9aaY-C317g">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_foNhY7jfDk2vxPwWDY15Fg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_F_4vXQpUJkaKopNKvYf_Yg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_FZFprHNPx0-YwzOcimLVew">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_x4N-hJlOJ0G8-WIiGF_tgw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_XJYS-dihHU6jsGASXI2Dqg"
      decimals="-5"
      id="Narr_K4FAKrcEHE2Zmw-BoxjsmQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">209000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_2_2022_KjFy2haETEOXfvQdXHC5IQ"
      decimals="INF"
      id="Narr_wKCaYvVe_kehH2eU8f2oGw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27724303</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_mjV2hEL9MUuqHsIUCt2YAA">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_tcZ1siYIlU-Yq6SbWrM1pw">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_2IFDkryPW0GhGc0swy-PXg">Baltimore, MD</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_RYWJsm4ZkEuvouvtoVy36Q_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12337000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_rjvQPcf_BkeqMJ3KFo8z1Q_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">32772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_-yKUpc1ZBUioMZwNwboLGg_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_L4NlIsWlREmKehnYaAcjUw_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">250676000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_dl6Evgz8RkGF1VQpQ24TIg_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">39000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_0um09vOXhEOTQ-0ra0gAJQ_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1706000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_rTx5S5plgEqeUOyfjARgOA_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8187000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_01Mfs-nZL0GipE5hQZoMLg_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2824000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_D7HrXUt6akeHNfEtedDRug_9_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">227817000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_k0fiHthUmEG2DPOfybVxSg_9_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">287978000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_MKcyBHKJ806tpxgEq5EZJw_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">13992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_P5bvhJtiJ0y4QQgA1JKvjg_10_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">15809000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_sMF0opA4mkeHr1X-v9JKJg_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">577000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_2hGsnZzYPUeEu2jd1GrKbA_11_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2857000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_XhUQZ6OX1ECk8dNmBLyBog_12_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">242386000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_OwhrkQTv3U-w55lQofC9KA_12_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">306644000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_wUfHPYlUrkio2wRp9aOQZQ_15_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1942000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_Zw39KuS7k0KezPgdyvTj1Q_15_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3901000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_6Zti3kTsPU2n3fvtWGxZ6A_16_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_YLj9AoDHMEWd5pLB8hq5OQ_16_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_tjmAiqzZu0OPmfPY0Nrvgg_17_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">217000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_GxOgnhB0zEao11LWyIm8Wg_17_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">130000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_wz5ztxF7YUe8M6DSWHX4AA_18_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1667000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_keq6tfcvrUukD2ZphXD8ew_19_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6608000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_SQEuYS94K0mHbm5vbleOhA_19_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10325000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_0rq8s40wyEOplWQKumBOJg_20_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2392000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_lckJOanckkGGhwRk2fYoKg_20_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">792000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_ZlNAu_yuW0mp7NT5bPi3fw_21_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1806000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_m1HXzzVUEUmjV4fObydI9w_22_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">9000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_upydhDMQqk2hD4A48A_SWg_22_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12923000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_hApKvNcjAkuP7H0czp1SrA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_JtT4KP5yz0eTkdz_v09I5w"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_OqBOERsaDkKdE7GXxtN92Q"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_SK47j7HMe0K43kWLxBR4wA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_-Mj5ReiVnky2aHZ-djwR3g"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_ME3jicgyiEuWiJ6Q7JnUWA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_drTeyeHY20KtixJdf77A0Q"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_bXIvEggYSEyU6I1xp3BhrA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_vKByLr6zIkCDQ-5M7EFTlA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_E7g-125TvEqmJliWKaVlWw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_0zNhKlf3L0mkCEEI1DeuoA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27680997</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_vKX98nVho0KzwJg4b6rFQw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27568802</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_CRCmduRSGUOEb-Qu-zf3Ig_25_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_GrWsWuhi6Uiq_0s2-qGC3A_25_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_BWgY7QpVK0ahqdaHqYmAFg_26_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">421047000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_MJ20h10qj06wxE-cWSGJFA_26_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">410551000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_xaqq0eaqRku4dqhVxkDHkw_27_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-663000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_AqLhD8w8dEe5RPZ52fOEIA_27_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">779000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc__j9lLRj_UUqBy0A8SgX1wQ_28_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-187026000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_KOVDrTC3-UGCgwP-LmHG5A_28_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-117637000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_0-S47vs5sUinhkIaBYrtQg_29_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">233386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_FzsoMx6uskmSsYjpZ5Zlig_29_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">293721000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_nAd6pDHqNU6xwD02V6XgvQ_30_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">242386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_Rhdl9_u0PEyHe2mOl18c1w_30_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">306644000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_zRJUignyv0WEi42suKvh2g_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">22378000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_ndkIa5uz1kCb54j7Z3d7ag_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">50192000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_n96MgJP8uEOROO-L1blFDg_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">46554000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_dDx_9x0F70q0pYFSIv9A7g_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">20573000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_Pzuvyy2UEkawQS3K_9OVjA_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">17049000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_s866e0MZfkqv63Lc6eFl6A_9_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">70765000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_jPC16Cjg502-WrqnlUvwfQ_9_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">63603000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_fGNXBPyruEyG6CQIMM3wrQ_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-70765000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_-xEu1kXC606pZpgCXbq0zw_10_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-41225000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_3YQ6Pr-DJEawqLjBSPnVNg_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1376000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_f5rzpbdv6kSIha6bOuB3IQ_11_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4622000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_2I8JVjQpt0SGTCOz2Nq6sQ_12_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_mMxGYsi6HECkooXbLUGxIg_12_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="2"
      id="Tc_DOuvgo1eSEawirQnsKhwSg_14_3"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="2"
      id="Tc_fBtU6RmMq0CqG8zOIzAIoA_14_6"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">-1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Tc_Ieg9O3TzDUSNHWbYGOMQHA_15_3"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27615977</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Tc_boOSB-aM0kaYBW2D5xaw3w_15_6"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27532177</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_dIyBc56qukCPOk7tGhiaVw_17_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_XZUnfycio0Orqa1tWHyOHg_17_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Gbn5HrZHIEG7twuz80-WOw_18_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-1442000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_Pm2VaBWNGkukYJyvse3fNw_18_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">779000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Dw9PL9AMX0izUuhJ8p4u9Q_19_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-70831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_fIFBsTvdzEGuCyaGuT5_Rg_19_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-35824000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw"
      decimals="0"
      id="Tc_p_FxqYQNMUiNv2dd02JVqg_5_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27499260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw"
      decimals="-3"
      id="Tc_0tuliEgXz06zjL7kDQE1DA_5_5"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7hwDq_hUlUOMlE_Q8n38kQ"
      decimals="-3"
      id="Tc_9T-YtzIPNUuDs2W_D2wcQA_5_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">402529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qNbbMd7Kt06bhH7DHJgopQ"
      decimals="-3"
      id="Tc_gQDIEGXSS06zBPJ7vIT5gQ_5_11"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g2SurcQldU2PCyhEWEYFNA"
      decimals="-3"
      id="Tc_84ZLguxhR0G-8f2IWdSHOw_5_14"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-81034000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw"
      decimals="-3"
      id="Tc_o5DK1VR-yUyfyGdIQgWlbQ_5_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">321484000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ"
      decimals="-3"
      id="Tc_kxHLG-I0106mY9WC9-FhLQ_6_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_ROuYzX5SbE64mvJwXm65hQ_6_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog"
      decimals="0"
      id="Tc_Q5sARRX4N0axbwwH2CiaKw_7_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">69542</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ac0FdGnWL02fYeL47Ulfog"
      decimals="-3"
      id="Tc_geKUkmYAbkeKVQDmUZfK9A_7_5"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fpcjWzYqg0WL_F3LJqZIvQ"
      decimals="-3"
      id="Tc_KAHGzf7iAUCT11njv2aizg_7_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">111000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_NJzJcX2bZUi2aKP1fGNTGQ_7_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">112000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Narr_3RG216plPU-5i9AeajCfow"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vrV78_WLHUylRfRKRtNrFQ"
      decimals="-3"
      id="Tc_Hd2z0f3Bm0GWJ5MyLshMew_8_11"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">817000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_jbj7ZKsH7ECCMBkGTM_fnA_8_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">817000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mtHwI-ED1USEa2VQIR0lwQ"
      decimals="-3"
      id="Tc_ADyzzHoj4U6ACV_Nww6M1w_9_14"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_b6OBWs4I80CfRmYYMmg6tQ_9_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg"
      decimals="0"
      id="Tc_ZbNyHXXUFES1xEW_ha-6RQ_10_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27568802</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7oKSYcyWE6CJN4ieUcuHg"
      decimals="-3"
      id="Tc__8hiYY1thkqywguas813Yw_10_5"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3BA4U7O4vEq4IVDY7BQ4fw"
      decimals="-3"
      id="Tc_am-VIeeSX0-XiGgpOwhV8Q_10_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">410551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QqInZr8FSEKmnGZDc0UpLA"
      decimals="-3"
      id="Tc_60c5AdLU70uy0EmkEjNd1g_10_11"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZINGtOppMEOQvolyBs2r2Q"
      decimals="-3"
      id="Tc_0Y3kiqRJRUK_X0SYm51mvg_10_14"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-117637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_m3M4LS5_JES8L9Ydsg0kVA_10_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">293721000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA"
      decimals="-3"
      id="Tc_0VL_E4m3q0aQjXxL1cRGsQ_11_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10288000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_n60bsALA8UOxSVhIRHwh3w_11_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10288000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y7GXva2dbkWtJbsUzFBadQ"
      decimals="0"
      id="Tc_Nfzgk7bVgE6a7b-ULo1DWA_12_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">112195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aq5qcAyLykqF3nYUCXRRwA"
      decimals="-3"
      id="Tc_SAQ9_b3qm0aqdmx-tT9iXA_12_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Q0h3XJ0zi06iO1nkyd_Ejw_12_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Narr_c5BCK8tfpkO-vPBEExoWng"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1bJ_AHosZkOR2oPN_YnoLQ"
      decimals="-3"
      id="Tc_M7F3qpCVXki2evkxUKVE9w_13_11"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-1442000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_tzGtDPTtu0mWkaj1Xz5gWA_13_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-1442000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qr9RYIPNZUOJJAf5Pj-l0g"
      decimals="-3"
      id="Tc_bHCQ2Ku_eUuEdeggH0V1jA_14_14"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Gg1IMxdoZEGTy3da4pW0-Q_14_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w"
      decimals="0"
      id="Tc_scCTlqQ_lk6vsPNP2vxIvA_15_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27680997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1s_2LYUdiEylDCwLsOHp7w"
      decimals="-3"
      id="Tc_hAxBNVZ34k2eT-1sdMnvng_15_5"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wIP__71uMkOD1PkXsn-N0w"
      decimals="-3"
      id="Tc_1BKf-v_x2Eu6jUYYduU-Iw_15_8"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">421047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ROd0_OVRAUibMHBnTwZzJQ"
      decimals="-3"
      id="Tc_jjbdFbi1LUeKLecU-esUkA_15_11"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8gqQyeXsEa2baPiReBeLg"
      decimals="-3"
      id="Tc_kqyLOvzogkWYfCkRkLqRVQ_15_14"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-187026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_Bk_v4Lgy4Ue7zcHHimQh7Q_15_17"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">233386000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_3kc3d2Fje0qtpkHIBHyRPA_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-69389000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_31826NnUjUuq3A_dX5qv_g_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-36603000</us-gaap:ProfitLoss>
    <nxtc:DepreciationDepletionAndAmortizationAndOther
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_KM7vRZY5s0GQxM6zNo81SA_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7196000</nxtc:DepreciationDepletionAndAmortizationAndOther>
    <nxtc:DepreciationDepletionAndAmortizationAndOther
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_3Y-evtYTLUq1V-VkaxIpOg_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3413000</nxtc:DepreciationDepletionAndAmortizationAndOther>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_hO3R0pYChkmiwjaDwgO9iw_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10288000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_vVMnO-49V0-1KT4Fm0MsoQ_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7911000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_WMiWZQGaJEaGzwcxup0YWw_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4889000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_M7VWVFGSNUKBM8rTFU58sg_10_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-559000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_EXTev06UCEKJ_8UmKwK_lA_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-1959000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_LvqfEDowXUW2fReDg3HWpg_11_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2040000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_HQkLhaKTvkanC43tNblZTQ_12_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-178000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_SQzeY86M30GopeBBQfS36w_12_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-244000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <nxtc:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Vmr-82K0UU2ZOCTRfdO6Zw_13_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1687000</nxtc:IncreaseDecreaseInDeferredRent>
    <nxtc:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_C6p9U4A6lkyRXENaQMFEQA_13_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">348000</nxtc:IncreaseDecreaseInDeferredRent>
    <nxtc:IncreaseDecreaseInDeferredRevenueFromRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_YGaRRcg_nEi4moc-ndpP_A_14_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-22378000</nxtc:IncreaseDecreaseInDeferredRevenueFromRelatedParty>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_Aa9veJy91EyoMvNiovpckA_15_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-57244000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_Mz4rMJnWuUeoV0lr5D2Wpw_15_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-44954000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_xgdEj60caUerMhKh8YtPOA_17_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">195438000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_ZLMiBkRdg0mG6tFZGS1H4w_17_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">187784000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc__O7c36skFk2LHhuPHsTwHA_18_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">156477000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_hMt6ej88O0C2xtsbZ_8X6w_18_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">137129000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_vqlWPyBdh0eB4t5Xi4Hahw_19_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2360000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_xbdq0TJqd0uDr-70oKGbwQ_19_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_KisAOQUozk-LWlVD56MvYw_20_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">36601000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_IKXglhNvyE-_LuNLNC8EVg_20_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">43523000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_MOo1XDD4x0KOkC9d0-Y4Iw_22_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">208000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_pwMvQV3xzU-9CNUj7owi-w_22_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">112000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_4MMH1DM2ekSMQQPmXRnIuA_23_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3473000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_AGeZRHNa3UCk44H-xsFVZw_23_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1527000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_fECcZP8DFEeIArAjreEZyQ_24_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-3265000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_ZOm7XgIMVUCX9P5EqET6_Q_24_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-1415000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_nOYqhB4lUES74xiYqYvOsw_25_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-23908000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_IV3UMCCu7kK2dW8Iow4IXw_25_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-2846000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_g6i1UIP6-UiAnzoeIVclDw_26_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">36284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_rmNEW6bF6E-IBU56dJ5aLw"
      decimals="-3"
      id="Tc_4bzlzUOH1EKlpNro4M0GdA_26_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">39130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_aQrJids3hEqyEeIetcjWvw_27_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_3aOhrIEeSUyJp-Jcj-tUeQ_27_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">36284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_EkEmzk3-rUCulTwz7q48Hw_30_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">162000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_VBJJsNPQOki3HV86F2qIvg_30_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">130000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_g-Qwc5REdUWbC0nw4wgEBA_34_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">109000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_syUFkIqMeEOeYXhop5-Mig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"&gt;NEXTCURE,&#160;INC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"&gt;NOTES&#160;TO FINANCIAL STATEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Nature of the Business and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Organization&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;NextCure,&#160;Inc. (&#x201c;NextCure&#x201d; or the &#x201c;Company&#x201d;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#x201c;FIND-IO&#x201d;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#x2019;s product candidates, building and optimizing the Company&#x2019;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#x2019;s product candidates, discovery programs and its FIND-IO platform.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Public Offerings of Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 13, 2019, the Company closed its initial public offering (&#x201c;IPO&#x201d;), in which the Company issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net proceeds to the Company of approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparation for the IPO, on May 3, 2019, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_sDmryUZLgEqm_48xdkZO4w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the closing of the IPO, all of the outstanding shares of the Company&#x2019;s convertible preferred stock automatically converted into 15,560,569 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. Additionally, the Company&#x2019;s certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to the Company of $160.9 million after deducting underwriting discounts and commissions of $10.3 million and offering expenses of $1.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#x2019;s former agreement with Eli Lilly and Company (Note 7). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the issuance date of the financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#x2019;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#x2019;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#x2019;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;"&gt;COVID-19&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#x2019;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#x201c;lockdown,&#x201d; &#x201c;social distancing&#x201d; and &#x201c;shelter in place&#x201d; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#x2019;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#x2019;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#x2019;s planned activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment and Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in one operating segment that operates exclusively in the United States.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg"
      decimals="0"
      id="Narr_g8krM8N_5USM6691c0jolg"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRkd_wQNpE-PlILTjaNCPQ"
      decimals="2"
      id="Narr_xpawgYt3C0-jX8qgkF1BOQ"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">15.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg"
      decimals="-5"
      id="Narr_4uYI4vUpQkimPJsYIjWlBw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">77000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <nxtc:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg"
      decimals="-5"
      id="Narr_hZd4nnIJ0ECUVDBMcc8HHg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6000000.0</nxtc:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Vmjy-ejZvUG1bE8eLFxSAg"
      decimals="-5"
      id="Narr_X0gfwbKyNEGGWnCp8JRTfg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="0"
      id="Narr_LkU-fd422ki69ghRU1oEDw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">15560569</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="0"
      id="Narr_yepjZJat-Ey_FyHvgA5ZLQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="0"
      id="Narr_JJEA5hw9EU2jJdrZf7C8OA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="INF"
      id="Narr_XyWMeT04y0qghKLrwuWYgA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="0"
      id="Narr_C8Oky10Dcku5qKbA8lCnGw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg"
      decimals="INF"
      id="Narr_rdXyQUUE30KPkdxBuOREJA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_19_2019_To_11_19_2019_YzRMsCVKvkGV2jcw4HTlxg"
      decimals="0"
      id="Narr_cwted_7ol0-0BEL2vsKcIQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">4077192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_11_19_2019_qoi0IG6E5ES_Szx_7icP0A"
      decimals="2"
      id="Narr_OTIiTJBmEUKGXeCGMk9FKA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">36.75</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA"
      decimals="0"
      id="Narr_4iXtvlqCUU-rvXA6eny2Tg"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">611578</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_2_2019_WWMv6pgpRk2zjvig2oOTzw"
      decimals="2"
      id="Narr__lbo_d0O90SEF1A_J7NagQ"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">36.75</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA"
      decimals="-5"
      id="Narr_VgAkSDVlWUG8_MciuyMu_g"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">160900000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <nxtc:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA"
      decimals="-5"
      id="Narr_UpGy1d24wESt0zGWJSsBiQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10300000</nxtc:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA"
      decimals="-5"
      id="Narr_Te4DrcShSECPWvVPgWsIgw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="INF"
      id="Narr_NLNpsInQf0GHDpo2dQkTqA"
      unitRef="Unit_Standard_segment_y2qUci353EOOoH7IWozW8A">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_gDgAQDPUo06XOkLwwm-UFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements include the accounts of the Company. The Company&#x2019;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x2018;&#x2018;GAAP&#x2019;&#x2019;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Update (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#x201c;Term Loan&#x201d;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December&#160;31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#x2019;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#x2019;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#x2019;s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs, Including Clinical Trial Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#x201c;CROs&#x201d;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, &lt;i style="font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; (&#x201c;ASU&#160;2016-09&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#x2019;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;) as defined under the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-02 (Topic 842), Leases (&#x201c;ASC 842&#x201d;). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. &#160;The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#x2019;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#x2019;s financial position or results of operations.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_6kr33IK5D0yB83VJeQZpcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements include the accounts of the Company. The Company&#x2019;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x2018;&#x2018;GAAP&#x2019;&#x2019;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Update (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_XjmbwBAOhkymiVATF7K7-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_SHfNwqwJlkuelhz_VV8iZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_vdAHLd2EN0i3Ea5sjdLThw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#x201c;Term Loan&#x201d;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December&#160;31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q"
      decimals="-5"
      id="Narr_QS2v41IwKkam_GVZx6v-XA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">-2400000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_O4xoeqJMI02sxslJymX3UA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <nxtc:RequiredReserveRestrictedCashCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_vi7nO8UYBE6Gw_LEDbqrBg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</nxtc:RequiredReserveRestrictedCashCurrent>
    <nxtc:RequiredReserveRestrictedCashCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Narr_9h4hUezve0KXnxByuMQS5w"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</nxtc:RequiredReserveRestrictedCashCurrent>
    <nxtc:RequiredReserveRestrictedCashCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-5"
      id="Narr_pWFMtRlcAEykOScQok28iA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3500000</nxtc:RequiredReserveRestrictedCashCurrent>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_Mr1RYPUQX02LLXHCfLVfrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash (including $0 and $1,806 in other assets as of December&#160;31,&#160;2021 and 2020, respectively)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_HjJD777x30uhx-9uOl8DNA_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12337000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_c_MiorMZAECsKXlrUIpNFw_4_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">32772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <nxtc:RestrictedCashOtherAssetsNonCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Narr_ktDXHuzmuE-Zr0ZJBs-dnQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</nxtc:RestrictedCashOtherAssetsNonCurrent>
    <nxtc:RestrictedCashOtherAssetsNonCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Narr_a1_1H3WNQ0K0WvzEDp5lGg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1806000</nxtc:RestrictedCashOtherAssetsNonCurrent>
    <nxtc:RestrictedCashAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_3wU3IaV_IEGsAgDzKVJV_A_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">39000</nxtc:RestrictedCashAndOtherAssetsCurrent>
    <nxtc:RestrictedCashAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_3_oOuz11zUGdiCPd6ajEuA_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3512000</nxtc:RestrictedCashAndOtherAssetsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_BV8C2NjXA0KxwWNZZoC6ew_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_tWr1rj9E5Euy4HlH70UAuw_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">36284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_Urqyqcap80-MmyBdjXtARw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#x2019;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#x2019;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_pB8b9-aVPky1zFZXb0MfVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_aL76DiFXm02K9ximrqQj1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_rwdxTbsVqkSi1W0rnpxsSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_BVw7ve1sDk6zF5bStVj8jA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg"
      id="Tc_JyGMiATq_0O2kc4XUS_1Ww_2_2">P3Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_FRWWKvwUu0m7aWpFF9Q6iQ"
      id="Tc_i_4wX9gY00u8KDgfQxU6iQ_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ytC6nbqJ5kebhS3ZyEI15A"
      id="Tc_AMXJTCAzDUqjY3Me1BkpQA_4_2">P7Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Narr_QX33rRJqVEijVckpuYhgHQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Narr_XxmWNTK_uUWWcaVdqy5cZg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_zKXZQgOkEEaSOeD1thaNqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#x2019;s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.&lt;/p&gt;</us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_i6rlyzjcekeP9PgoSTNqhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="INF"
      id="Narr_EwrjcVqlxEyPGvd0HMVx_g"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_zHJLPBIChESAxtcZNUv9tQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_6rRszFsc7Eysv6Gn6qIiSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs, Including Clinical Trial Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#x201c;CROs&#x201d;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_iFoxBDAg6EeNl0smIsu_AQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_tltV-F9nZkC-TPk4IcGT_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, &lt;i style="font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; (&#x201c;ASU&#160;2016-09&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_jnMcWsovKEGSJYgSEhOGBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#x2019;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Narr_TIFWTuRGXkGAqKG8hQZSHQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_IEkYBWbQE06uEa2gxfpUsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_lCPSqmSOy0mzcHs-zP7lHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_EmmKTsU6pEyz8iCIYJ0w8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_A9SIW9znT0GNwImI1XfNGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;) as defined under the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-02 (Topic 842), Leases (&#x201c;ASC 842&#x201d;). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. &#160;The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#x2019;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#x2019;s financial position or results of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw"
      decimals="-5"
      id="Narr_Tx03DgTslkmw9u8AH7LmjQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">5800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw"
      decimals="-5"
      id="Narr_Go0OzEDsxk-KJCd21sqkHw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_b1oMqMbk70-Nr2gOZlZRDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 249,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, no marketable securities are considered to be other-than-temporarily impaired. The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2021 and 2020, respectively, the Company recorded $57 thousand and $70 thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes maturities of the Company&#x2019;s investments available-for-sale as of December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Maturities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Within 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Between 1 to 2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total investments available for sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_5PrE-6176EKxLjlRByrJKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 249,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog"
      decimals="-3"
      id="Tc_r5cjIRr3zUexRW7DcMAK0Q_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207917000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog"
      decimals="-3"
      id="Tc_8yS6RFF7cUWnBpcdFfUiUg_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog"
      decimals="-3"
      id="Tc_wlOHj6NMXkO1ixllLImS8g_5_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">666000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Dmx_-ggz30CAdmvaEjPhog"
      decimals="-3"
      id="Tc_oWwsVd5LyEWkFkq28cs-Fg_5_12"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_f6FcGHiKmUS5vLvuRFhYxg_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207917000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_ZYnlxToLXkCKRSFwebaQrg_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_bpibasfy_Ue3fZ_9_ewtSQ_6_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">666000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_LGJYrAt-o0q0_WvZ8lqYPg_6_12"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg"
      decimals="-3"
      id="Tc_uqmO2Ebp3EOSDYgHArSGpA_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">242900000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg"
      decimals="-3"
      id="Tc_XZA0X6STW0qwZXBTrQHDlw_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">854000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg"
      decimals="-3"
      id="Tc_Sduq1JzU6kqbhSX2CzkPbQ_5_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ax1OPAW6WkyixU7PPqsDlg"
      decimals="-3"
      id="Tc_fb0lu5FkRESx-Br0VDgoOw_5_12"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">243679000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ"
      decimals="-3"
      id="Tc_0QUjgYKmSkaYPag94pWyMQ_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6997000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_SjiEcEjCsEG-vce7-oR3zQ"
      decimals="-3"
      id="Tc_IkpfXt9qmk6EYcUI5yy2Zw_6_12"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6997000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_mRVoza8bNkG0xeG1TghynA_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">249897000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_iteW9b8bIEqtcGeOzr0bmg_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">854000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_N0zhhenFM0ufyJkwk6al6A_7_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_xUwL3QQScU-LeD7yelb-cQ_7_12"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">250676000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Narr_wwBHzKcx50idQyu-bEGVjw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Narr_bueko-QyWkKIUMqIGZAV1w"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">57000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Narr_3WtjcmjpsUOYPqs_2I8aiQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">70000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_zf46_FJWpkC5A0C1tuIWJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Maturities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Within 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Between 1 to 2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total investments available for sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_IPdoIfofwUK4yoPiv28nyQ_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">104959000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_7mvWCl6J30OlMtVJyM1vKw_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">104775000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_EuZT8PyoLUCZU7en4HsySg_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">102958000</nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost>
    <nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_IJT_88W1TUaPhBkmEHqDxw_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">102479000</nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_m6NRgXV6DU6AOQthVaeJ-Q_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207917000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_UP3P7jn_hkuI9Q1gU12YEw_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_lR80szm2C0WAed6H5lvHug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy as of December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 261,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_ZgqV2bxlA0CzWJb910J57g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 261,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_kmwB305biUWLo3UjsSooUQ"
      decimals="-3"
      id="Tc_4dcnmquowUOjl8J7pQYD3g_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oYhMcGirCE25Vip1ZFlDcg"
      decimals="-3"
      id="Tc_8dYFTdzUbE6KyRW4jqCkfw_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Yan-j4dWbkS2KGt5iU5VRQ"
      decimals="-3"
      id="Tc_2QHogolw6kWWBmO-226dqg_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_w26PQYiKDUS0odivM7VviQ"
      decimals="-3"
      id="Tc_Tz9X8QP-S0ay56DHKRAdxQ_10_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_JO8kC4Wv30ykMH8DL_H1Ww"
      decimals="-3"
      id="Tc_qmNfIuY9YU2P8LBWfTJgeQ_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">209934000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_SpiKMzSntkeJHGELywtLIQ"
      decimals="-3"
      id="Tc_sHsOpOyumEybceEkAv86nw_11_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2680000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mNncfD8YUC8da9cv5QKbA"
      decimals="-3"
      id="Tc_z4omeXM25UakmfYiSybrjw_11_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">207254000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3BxpsJ2iNECPTNPjm8MqUw"
      decimals="-3"
      id="Tc_xLHaFMTP_E231P0w3fcjKw_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">11155000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_zGOjNpmC6EGr7pG_-L0KzQ"
      decimals="-3"
      id="Tc_HhCh6sqibEefqqasnM0qtA_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">11155000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_hW36vSQqcEKgeJbxONrVSA"
      decimals="-3"
      id="Tc_KhbGquBOSkmcO5fj-7rmsA_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">243679000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_B9L06CbX5EGrB1JXLY5xsg"
      decimals="-3"
      id="Tc_8VQPrsv7UU6w8KjAWQJmrQ_10_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">243679000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qdi16EmCNUKD0BX_L5w1VQ"
      decimals="-3"
      id="Tc_tRZL9PAVaEKYfEzfA7s07w_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6997000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E7waEgPyPkSn9Zcc1udIPw"
      decimals="-3"
      id="Tc_k1RKHKtHKk-tOYMQFQswlg_11_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6997000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FJ9ZE9uoI0-WmaYGYBzHyg"
      decimals="-3"
      id="Tc_BY2JOvRCJUOS8Zbosc54VA_12_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">261831000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NPmdibs4nkishMWIdyp4yw"
      decimals="-3"
      id="Tc_GRQKLSdXCkmGFq7-jiI65g_12_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">11155000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_woD1OcCVU0i7W0uEaTV-eA"
      decimals="-3"
      id="Tc_nb5HsTjN406PQzhyX8r2qQ_12_9"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">250676000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_75Hht7571Ee3UmJMUUsRAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,737)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,560)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,992&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress at December&#160;31, 2021 and 2020 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense was $4.3 million and $3.4 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_pOCMR_lzi0mrnzkJvjpGFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,737)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,560)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,992&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_BSsHwW_jjUWkVvqBCbt48Q"
      decimals="-3"
      id="Tc_j1nSlmovrkKJgUJhdYEOtg_3_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">16482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_Qq_WJ4vpZkiMhOxoPOoNuw"
      decimals="-3"
      id="Tc_9UYZFgnkd0CQtLNZu06N9Q_3_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">13359000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JJOGCiB-VUKIQzM08BXQzA"
      decimals="-3"
      id="Tc_uJ-oW1t4tUSH5ztOKr4ntQ_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LFp27XQr4Uid6yEPdONaFg"
      decimals="-3"
      id="Tc_Yt8avdDwcUm_KIK_yVAG0A_4_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8391000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_oYnlwjc7HUGb5iWfCmq0fQ"
      decimals="-3"
      id="Tc_mLAnM5_MhkWA9jmQJI1WtQ_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xZ8jUscG3U-QIINlDwJ2ww"
      decimals="-3"
      id="Tc_ao28GxI4_EiZPj6vJv8C7g_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1010000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_couFI7dtvE-qXjH-EmZFUg"
      decimals="-3"
      id="Tc_ZoUtcuuv7EO2cBxI7QPBIg_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q2ALKasRH02YKQvydmMALQ"
      decimals="-3"
      id="Tc_Pz1a8dEAmEOLIRB8ngSk5A_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jUzYlFOGn0CwHbmMVEGKpQ"
      decimals="-3"
      id="Tc_M41p3sjqLU2i6hJQo8Ratg_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">371000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_HwvSSMcY6EWFFgNhar4zeA"
      decimals="-3"
      id="Tc_wc2uZSSlZ0qXsIKvt2icJQ_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1496000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_d7zLTP82uUWVMfN_FwI-zA_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">26729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_cN0BSvUIdUmDYPe2qWxPqw_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">24369000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_hrk9HhkbmUaT_z0mi4jBBw_9_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">12737000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_QNwqpXxiOECW5jumu2Wi0A_9_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8560000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_CemFNOvtUE2fVqh10afyMw_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">13992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_tmDw2rhGwUOzC6PtvXq1wQ_10_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">15809000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-5"
      id="Narr_2Ym-1sDxz0Oo7juXDs_4vw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-5"
      id="Narr_AfLsCbvNHUeMohYyejiM3w"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_Z4hXJIGNHkONwL0ME6MJXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Accrued Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 973&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sponsored research&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_jjjBhlrdL0CFSyUUxUvy6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 973&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sponsored research&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nxtc:AccruedConstructionInProgressCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_cKcV_W-Io0-194p_HTacKg_3_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">109000</nxtc:AccruedConstructionInProgressCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_MdudHo5Yak2aL9yE9MfN4w_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1751000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_U9vjW_VLj0KZ7DkcHoR9QQ_4_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">973000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nxtc:AccruedClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_kCVQXO_YxECV3NZurBWPbg_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">727000</nxtc:AccruedClinicalTrialCostsCurrent>
    <nxtc:AccruedClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_FDiqVn6K9E2Em3oe_X1pAA_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1744000</nxtc:AccruedClinicalTrialCostsCurrent>
    <nxtc:AccruedSponsoredResearchExpenseCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_rKiMJ6p0kUW7io06Jg5xmw_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1315000</nxtc:AccruedSponsoredResearchExpenseCurrent>
    <nxtc:AccruedSponsoredResearchExpenseCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_2F2DbmQeb0SLA-HekBHxRA_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">472000</nxtc:AccruedSponsoredResearchExpenseCurrent>
    <nxtc:AccruedOperatingExpensesCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_D4FkrPpjkEGOP8q4K4F68A_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">656000</nxtc:AccruedOperatingExpensesCurrent>
    <nxtc:AccruedOperatingExpensesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_TmZFbaP1F0yFnQPT-9co5Q_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1316000</nxtc:AccruedOperatingExpensesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_vCOgig9KqU6NbttODv2WJg_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">13000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_kZ7Axq-FwkG52z42SP0ApQ_9_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_1eak_EfxxEGneJeH--Nurw_9_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_doG9nBhP0kqczIbVtQO-dg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Former Agreement with Eli Lilly and Company&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the &#x201c;Lilly Agreement&#x201d;) with Eli Lilly and Company (&#x201c;Lilly&#x201d;), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly, terminated the Lilly Agreement without cause. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized revenue under the Lilly Agreement of $0 and $22.4 million for the years ended December 31, 2021 and December 31, 2020, respectively. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_w5P21kf0c0WRJYhRcmUNfw"
      decimals="0"
      id="Narr_GwMVG96FdUG2WUhKnhvngQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_GZR3kGJhT0eFCCICgDlBxA"
      decimals="-5"
      id="Narr_9LU-GZeyCUu-RRZOc0SCuw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">22400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_eR3epGnM7EeFT4zOzoN68w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s leases primarily comprise real estate for office and manufacturing space. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2021, the Company&#x2019;s minimum obligations under non-cancelable operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,427&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense incurred under operating leases was $1 million and $0.9 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#x2019;s management, are likely to have a material adverse effect on the Company&#x2019;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#x2019; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#x2019; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#x2019;s motion to dismiss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#x2019;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_upN1zaYMCk6v7vAyOTT3gg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2021, the Company&#x2019;s minimum obligations under non-cancelable operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,427&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_mspO-HFqRUCApxgYYMqoyw_3_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1172000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_8eSWNjRTCEKugKatPZ9SKw_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1171000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_vsPPO_5dHkau1yKcC-F27A_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1231000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_emfO8CAg9EKgTOR4kj8e7A_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1316000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_eTCgMzbV9kSCm2Mn0CN2gA_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6537000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_tDoeoqAjeke9_UyqFsI7QQ_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">11427000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-6"
      id="Narr_r9xPdIWQuUOyDD0hFXGD-A"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1000000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-5"
      id="Narr_R6fpHEE7rEeAQZ---9Q65A"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">900000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_f6ruOnqxVEKzfOfccViKcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Term Loan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2016, we entered into a $1.0&#160;million term loan, or the &#x201c;Term Loan&#x201d;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, which amount remains secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2016_dCCJWmRM8USlY0UQ6_FnFg"
      decimals="-5"
      id="Narr_TQ83WWOvoUObW9mLPCbsNg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2019_ML94Z-Zsg0C5Id5hiZnfiA"
      decimals="-5"
      id="Narr_mB9QpLf5iEeQGXswMQ6KXg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Narr_DRjMmv6B8ka9_AYazrR8kA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:LongTermDebt>
    <us-gaap:PreferredStockTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_MrmZaHLxfUSL65t4kigbWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of $0.001 par value preferred stock, and there were no shares of preferred stock &lt;span style="-sec-ix-hidden:Hidden_Q1KEPjTqhk6GA6gnGmG3gQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_a7zRTz_TY0G44I86TksWBA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_K8jZ8z478keRGqe470Suhw"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_7r2CSHviJUeYHbYhA1kS7w"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">0</us-gaap:PreferredStockSharesOutstanding>
    <nxtc:CommonStockTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_u9pKnr5J0kKB6VbwA9-qsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the Company&#x2019;s Certificate of Incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.001 par value common stock, of which 27,680,997 were issued and &lt;span style="-sec-ix-hidden:Hidden_cpk3pttepkCkflUjT07eqQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. No dividends have been declared or paid by the Company through December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.&lt;/p&gt;</nxtc:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Narr_nSAeDaZlt0-GtUJN41Xqdw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="INF"
      id="Narr_TQhlReRec0KzzYommSSN1w"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Narr_nTE20PZJAEqIOpUXdH0Xiw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">27680997</us-gaap:CommonStockSharesIssued>
    <nxtc:NumberOfVotesPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="INF"
      id="Narr_S9lk7sEHf0e6tlOtbHMKuw"
      unitRef="Unit_Standard_Vote_w0Gf5YJwbUupsjwI1CCnAw">1</nxtc:NumberOfVotesPerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="INF"
      id="Narr_rzHRgMLW1E2Z4LOXOkWiSQ"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_RyBTQBhCdUuoZr3TD5y-Qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Equity Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 3, 2019, the Company&#x2019;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#x201c;2019 Plan&#x201d;), which became effective on May 8, 2019, the date on which the Company&#x2019;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#x201c;Effective Date&#x201d;). The Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company&#x2019;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; during the term of the 2019 Plan by 4% of the number of shares of the Company&#x2019;s common stock outstanding on December 31&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; of the preceding calendar year or such lesser number of shares determined by the Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, 2,313,433 shares were reserved for future issuance under the 2019 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options granted under the 2015 Plan and 2019 Plan (together, the &#x201c;Plans&#x201d;) to employees generally vest over four years and expire after 10 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;A summary of stock option activity for awards under the Plans is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,170,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,115,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,542)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (104,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,020,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,731)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (481,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,915,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $7.47 and $23.25, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $469,000 and $633,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2021 and 2020 was approximately $13,398,000 and $2,389,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On May 3, 2019, the Company&#x2019;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section 423(b) of the Internal Revenue Code. A total of 240,000 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; until expiration of the ESPP, in an amount equal to the lesser of (i) 1% of the number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year, (ii) 480,000 shares of common stock and (iii) a number of shares of common stock determined by the administrator &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of the ESPP. As of December 31, 2021, 6,464 shares of common stock had been issued pursuant to the ESPP and 784,216 shares were reserved for future issuance thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense of $10.3 million and $7.9 million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $23.3 million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of three years as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;69.7 - 81.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.8 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.3 - 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_eNVV54RhUEqTl5x1mLRsMA"
      decimals="0"
      id="Narr_RYihVZiJtEqnYOqy1fhYiw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">2900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_pWUZUIh3IU2JNJgRAHr9Ig"
      decimals="2"
      id="Narr_vfWR6wtpNECXozPYsNKPNg"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.04</nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_POQwOZH2fkaMcb9h4V0jNQ"
      decimals="0"
      id="Narr_wnCjeeL0FEaRAiJaQtp2zA"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">2313433</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw"
      id="Narr_Cz0-jmFaUEuCMMJbTQQLQg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_oU_lZTNqoki2RqxUAGYpYw"
      id="Narr_jyghYh75g0qOTVZ0G2fs_g">P10Y</nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_VwM1iBcLHk-yX20Wi7gjfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,170,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,115,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,542)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (104,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,020,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,731)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (481,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,915,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g"
      decimals="INF"
      id="Tc_6WKZ69gc50i5PREOsI_e_A_7_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">2170212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g"
      decimals="2"
      id="Tc_FTR7NpF-wEW42mZhfjA1SA_7_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">6.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_G53rdmX140OTQJmbyiS6Jw"
      id="Tc_xgvIFAtRtk69_n492cHuZA_7_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OI7AIThGBEyQOlrExyb14g"
      decimals="-3"
      id="Tc_aIazqnpYm0CeF1b8y7K2-A_7_10"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">113295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="INF"
      id="Tc_8H62AbLQBkOC8AlqON61CQ_8_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">1115720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="2"
      id="Tc_8D0dVaBKLEGdRcmFk2pU4g_8_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">37.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="INF"
      id="Tc_L_K068e050OUubMn2V23nQ_9_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">69542</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="2"
      id="Tc_SUU0VcOFfkG1-Dxm_e4OuQ_9_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">1.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="INF"
      id="Tc_VPieaV0rdEafcLBrcf6IMw_10_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">104014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="2"
      id="Tc_0mQ3n1FeRkGLhZl4aU4Wmw_10_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">25.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ"
      decimals="INF"
      id="Tc__suFsxaOa0aObafqdOrnzQ_11_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">3112376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ"
      decimals="2"
      id="Tc_yGi6vDCjS0WcNevIep743Q_11_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      id="Tc_4A4mnIoPuEG9LWTUOXe8nw_11_7">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_X0C8vI9DFkK972dhwfQegQ"
      decimals="-3"
      id="Tc_16f_hnCmckK7vwVMID4KTw_11_10"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="INF"
      id="Tc_BUh-C-DwYEuPIMzXFtdL2A_12_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">2020718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="2"
      id="Tc_uB1dCGhleEiMUuVrdO0ZVg_12_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">10.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="INF"
      id="Tc_LSP5RckOVkSu9YBrht_dhQ_13_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">105731</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="2"
      id="Tc_DWTAFHZ-RU6uzeQ1aWqP2A_13_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="INF"
      id="Tc_ZYnHHAJmrka25xq5XZ_g9A_14_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">481569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="2"
      id="Tc_oY1KWVwYXE2ITVfZxmwatQ_14_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">21.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="INF"
      id="Tc_HJcOGaqIo0yQdemDBjpEmQ_15_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">4545794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="2"
      id="Tc_FS2votmF6kuBmEjCBAfXCQ_15_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">14.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      id="Tc_cXg3HahHrEi4JR29ea92nw_15_7">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="-3"
      id="Tc_QCRTy-a05k6Eo0BHRXEciQ_15_10"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="INF"
      id="Tc_kJ_bjFUZEky-_YaX3XFyHQ_16_2"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">1915494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="2"
      id="Tc_zwzFXX_i5E21KQVm5fZmyQ_16_5"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      id="Tc_Mzk8XhWkckmZ4BakCkAWGg_16_7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_OOyLOcalhkyFa7sxBRi87w"
      decimals="-3"
      id="Tc_cHCINdAM8U-QjSPmSxeLEQ_16_10"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2783000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="2"
      id="Narr_LW0FH5CFrUWOpbOIEEWNSg"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">7.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="2"
      id="Narr_6e9Z2k1KBU2L7WBkCv0ToA"
      unitRef="Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg">23.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="0"
      id="Narr_3ehMVWt-jkiNvDIcv_DTPA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="0"
      id="Narr_WCreSwh_B0SkOouRlmyAVw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">633000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u1smb-705kCVKNnPZg1_Tw"
      decimals="0"
      id="Narr_VdtP6BVgdUCi5PnxXFx7vw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">13398000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_u9xFpG_kkEu5Q0o0WttKkA"
      decimals="0"
      id="Narr_83lITadgH0mA3-it8usA2A"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">2389000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_1Jdd-_wpikG_weZqBMb3Bw"
      decimals="INF"
      id="Narr_EmwaNgNzL0OSBQmxEei7Xw"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">240000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ"
      decimals="2"
      id="Narr_5gRQzC0AFEetAzST9ZJF9g"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.01</nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding>
    <nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_42Tpiq25NUOdihv0IAy8xQ"
      decimals="0"
      id="Narr_xwoyfveQeUOkPoaT5d52uQ"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">480000</nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_G_yj8-kGZEqKlKj7UfkTfA"
      decimals="0"
      id="Narr_9ojBYBwiH0iTV9yg9QrU0Q"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">6464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_33XxS2bj4katgp19dilw6A"
      decimals="0"
      id="Narr_IE6kLDLFdku-nLohQ2jzrg"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">784216</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-5"
      id="Narr_IKDxg_Uy00SPXe-IbK6XwQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-5"
      id="Narr_fc0uSizHbUebyk8MFI2X3g"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_TcVHblcGuEe2b70AUgRwKQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">23300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Narr_9R_fCOnFX0ynbTlku3ncSw">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_qkJ48ZEOFkGpX3Mmiw0AFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_ypDyfJrUqjGxvpjHQzEA"
      decimals="-3"
      id="Tc_HANgt6MtnkWLFhKVeRHKXQ_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HC8YQx8WSE68y6ph75dG7g"
      decimals="-3"
      id="Tc_HBXTeLvaqUubPep8fxcbkw_4_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aiYI6v5UyEeVRnXYUS5XLQ"
      decimals="-3"
      id="Tc_Jj4ir4tK-EKAaEGO9_tSjA_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eiLn54zwfEaRz2KZJSxGgg"
      decimals="-3"
      id="Tc_tzpq66seukejEZ_UuN6M9A_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">4859000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-3"
      id="Tc_5HeMB_3KaEi7vRRliJ47gQ_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">10288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="-3"
      id="Tc_O8BxxaI5-USmAEJ6FX1fpQ_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">7911000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_ocdp-WXrZEmYFnv1rzUSUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;69.7 - 81.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.8 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.3 - 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg"
      id="Narr_EVrIdedkiEaxDueScGxyoA">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA"
      id="Narr_WZxifzsQjESjxsQy3nPF1A">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw"
      id="Narr_JVn9hR-AtkKEjJmLWRpFXg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="4"
      id="Tc_fhw5-OuHwUaYFHOcUbkPxA_5_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.7969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw"
      decimals="3"
      id="Narr_yL9NnkYYNkivsjq4F79mIg"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA"
      decimals="3"
      id="Narr_2CydXJWG1kmX2YFSY_hTEQ"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_o8b8Fp07_0O33CO7ZqQKBg"
      decimals="3"
      id="Narr_fPnH8ZC3Vkaz3b6v1I__fg"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_cnJb3kMczE6Ml0orbBjvcA"
      decimals="3"
      id="Narr_VflD86XATEOnDkLEC9wuyg"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_KHqYaZALPUSmH2gCIUIPkw"
      decimals="3"
      id="Narr_Dq_cLRPxfkC6B42Tv5-U9A"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_jhyaiG5MXkqFEXFMn0pYVA"
      decimals="3"
      id="Narr_07Kg4VxzF06Z-3j-jQuq6w"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_iog4UuCtWE6GAxrrbFks2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;13. Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_iXbW33CWcUK0lPjI-SNsYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_e_s4q5Pn_Uu6ZKwpy8z4Pg"
      decimals="0"
      id="Tc_dzuRxnRkLEK4xhb1_7zP8Q_3_3"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">4545794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aAofUk9dFUCw9X561F27_Q"
      decimals="0"
      id="Tc_LP5NbPlGIUC5p5in9zt-7g_3_5"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">3112376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Tc_PxbC6Sobx0SQASMU3Oz7ug_4_3"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">4545794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Tc_KcHwAQQmDEGiZVtw89qvlA_4_5"
      unitRef="Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w">3112376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_77sBmoxUOkiCKiNkPKEL7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;14. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior year provision to return adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Charitable contribution carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,552)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (342)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021. The Company increased its valuation allowance by approximately $20.2 million for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the Company had federal and state net operating loss carryforwards of $160.9&#160;million and $163.4&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $138.2 million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $8.7 million and $0.1&#160;million, respectively, as of December&#160;31, 2021. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#x201c;IRC&#x201d;), certain substantial changes in the Company&#x2019;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2017 to 2020 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Coronavirus Aid, Relief, and Economic Security Act, or &#x201c;CARES Act&#x201d;, and the Consolidated Appropriations Act, 2021, or &#x201c;Stimulus Bill&#x201d;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_ppU4t1gBWEir_pz9g4X8ZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior year provision to return adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_dxS6cXI4MEupRiW9MWYegg_3_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_HktW3HhafUCbYssQD4nETA_3_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_G-zE5Dj0LEeKDrwi5qzQQQ_4_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_4joGK_hDYEGMA6WlWxGvYw_4_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_T_4U7EHQX0qyNEI88iM2_g_5_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_BUIlBiul_kaLneuI6rUAAQ_5_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_gZzM2_hUh0CHmQUN8p06_w_6_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_HWDDLZrLNEy4utvAIuXa7g_6_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_25QFCgmz1kyr_ooeIOHVvg_7_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_nlYQnKTC00WCpjrn1hEjwQ_7_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="3"
      id="Tc_DayPibu_mEOH8KlvaHft9Q_8_2"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">-0.285</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="3"
      id="Tc_gZtYYJ9ekEiFe8o4L0FBgg_8_4"
      unitRef="Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw">-0.329</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_Bm6CfzZPNkyt0S8Xx7NkUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Charitable contribution carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,552)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (342)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_qlKIagCKRUiKhHR-VT-eQA_4_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">44451000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_KTMK2KtMDk2RPpKpkhEZcg_4_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">28511000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_DHwFV1In_0CV1GZ-qvEmJg_5_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8862000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_lI-AOlA2i0Kd2PIhM7fiHQ_5_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">6874000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_lk7OAC0gzkqgmkVI_EqSTg_6_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">170000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_n8MUDZyW6kKjA6BHegqIDw_6_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">306000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_doy5M20-PEC1ztJ8sBi67g_7_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">3184000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_2yN9acVGS026tTmHZzcoeA_7_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1783000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_mn0krQyEbkyJXXDoe17eVw_8_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">1121000</nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_AnXmVyj9Dk6JOE4S5NVnew_8_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">635000</nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_eB44cyE_PkGfzmhGbeYiKQ_9_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">57788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_78KQEXZC-Ee4Tvaw6aVmmQ_9_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">38109000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_Vkh01yjtGE-IDbPIc2fLqA_10_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">57705000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_YeGvuyB4sUCRfijvNT8VAw_10_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">37552000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_XgInd3HopUSrCSczAlcCgw_11_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">83000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_2elx-MUV3E6Mp-Qj2lI1Ug_11_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">557000</us-gaap:DeferredTaxAssetsNet>
    <nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_y3fYBkD4-USGGf_94g1STg_13_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">83000</nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_sRD9meFTTE-QIjcWgb5hUA_13_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">342000</nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_olP6YLajfUSVTQXQCb6baA_14_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">215000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-3"
      id="Tc_lW3D5oF0J0SIsoipN72EUg_15_3"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">83000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw"
      decimals="-3"
      id="Tc_FdnbMJT18U-AFcOw-4oKrA_15_6"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">557000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="-5"
      id="Narr_Lf7_bEnw30um-wDIZSYX3A"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">20200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_sKVImdQFiU-VtcBZKjk20Q"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">160900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_se03hqRzk0eJpMD7U1kUgA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">163400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_hqk5DU_YiUCgS7KttJFTjQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">138200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_Om4kYNF1WkiK-IPHMYxg4A"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">8700000</nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal>
    <nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="-5"
      id="Narr_ngAYFsm2I0qpruY4V-zoNg"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">100000</nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ"
      decimals="0"
      id="Narr_59f7dYum3ESxAYEm3pnTlQ"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_ZQMQTVB8JEmc7Ebh4s0_eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;15. Employee Benefit Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the years ended December 31, 2021 and 2020 the Company did not provide any contributions to this plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA"
      decimals="0"
      id="Narr_lxqL8wlvJ0q8NzLxZv2vxA"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      decimals="0"
      id="Narr_REm_x9uud0axiL3do5AFLw"
      unitRef="Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ"
      id="Tb_Vg1UCy50dUyjDCvyT0MDlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;16. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 4, 2022, the Company entered into a Third Amendment to its original Lease Agreement, dated January 30, 2019, whereby the Company has expanded its leased property by approximately 5,700 square feet.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ"
      decimals="0"
      id="Narr_QQrBjKt75UO2BbWan09Khg"
      unitRef="Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ">5700</us-gaap:AreaOfRealEstateProperty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M,(AC5$]QB&<X!@  DQH  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
MF5USVC@4AJ^[OT+#=G;:F1!LV4!HD\P0"+MLDY0-:;O9.V$+T,2V6$DFR;_?
M(_-AFA''GMF;Q#8^KQ[KR.^1Y/-GJ9[TDG-#7M(DTQ>-I3&K3ZV6CI8\9?I4
MKG@&O\RE2IF!4[5HZ97B+"Z"TJ1%/:_32IG(&I?GQ;6)NCR7N4E$QB>*Z#Q-
MF7J]XHE\OFCXC=V%>[%8&GNA=7F^8@L^Y>;;:J+@K+57B47*,RUD1A2?7S3Z
M_J=AZ-F XH[O@C_K@V-B'V4FY9,]&<<7#<\2\81'QDHP^+?F YXD5@DX_MV*
M-O9MVL##XYWZJ'AX>)@9TWP@DQ\B-LN+QEF#Q'S.\L3<R^<_^/:!VE8ODHDN
M_I+GS;WM3H-$N38RW08#02JRS7_VLNV(@X#0/Q) MP'T38 ?'@D(M@%!W8!P
M&Q 6/;-YE*(?ALRPRW,EGXFR=X.:/2@ZLXB&QQ>9S?O4*/A50)RY',HHAS0:
MPK*87&=&F%<RSC;CR>:E2;Y-A^3#^X_D/1$9N15) I?U><M XU:B%6T;NMHT
M1(\TY%-R*S.SU-!*S..?!5I O4>G._0KBBH.>71* O^$4(_Z#J !'G[+U"GQ
M:!%.'>%#//S//(/6/5?K/SU-L$]$4.@%1_0&<LT5Z<^T4? N((+A7C L!,.J
MS#Z\KK@K7WBX[S6_(!3M/46['D4_RW*6D'N^DLJX<' =HW*.X'3V.)UZ.!.N
MA+0C/B;PWCC[IT)I._I^>?>N8@1T]VS=F@E3#'RU>/V.=Q>N-6>)QOKK;,]T
MANIL'6$D$D[N\G3&E8L%U_ \OQF<];PVPM/;\_3J\-SSA; O"G36'4N=V<-U
M[OB+&>2*GX#91:<(F.^51NK501M !A4,]#&XW OYPE^=5HE+>=!EG8[OM7L8
MV8'%^W7(X$FE@N%4&/L)F1H8]T0J,I Y( .YC)T]6:$^O,8@:0E)ZT ^L!<R
MCJ$/Q5Q$FQ)T?-Q52(;=9IL&/@V[&&%IT'Y0A[ ?QXIK?;([(#=P'_F:N?L.
ME^Q!ILEWH18B$XS<L@S2<2]9#-G)!60'9F\8>ED*?-S,WZ(/[!FT]2"?,R<V
M+@?31:/7,!7 +,8O2X2/>_M;NOW(G"BY%EGD[EE<\W:(H97EPL==_BW:1&H#
M+_<_8G7\=<$5J==%G= ORX6/>WR1Q#Y,]H^CX (T1$=762-\W.!O9 1],EG*
M#"L2%2)!K]<,>_AX+ZN$C]O[@S!0L.2<^/3#[".9\BA7T%M.+%QI(-,4/&AJ
M9/1T0MY[IV#-9,446;,DYV0%<S:]9 I[$6A90BCN^U#X8Y$MR/0UG<G$15LA
M</?WPP C*4L&Q4U]UV/D^B5:LFS!C];9"J&[_G38_PMC*BL$K54A?L :L?F4
M@7-!7IF&01>3L=:Y>]15:-Y)#*TL#;16:?@N$RBEL'PN)DS*N4JJ4,*!2L.G
MM0P?ICC*SB@WT\AB:(&WYFXP7/&1:XRL-'M:R^S'F>%JL^BW$W"V0W62X8H5
M9*77TUI>7Z2.#* $+:1R6D:%SIW,FBR*.,B 2+P1Q A+QZ>X86\)IRE+$G*5
M:_A9NW.)ZU0LIFCI_+36\N ZY78*LR"_@X)90CU*5RQS]QTN6$565@!::Z%P
M_7*XFMHL^IQ8N%K5<BHH+3[ '7H\&-V3?AX+ _.;OC$<YA,%VRAA"Q=9A5XE
M66GY0:U5PG0)_HIEL$*F$JCT^Z"6WT_R62(BZ!_)7.XPW*JT"Q6[S;F&.18L
MG-:NQ@]V8VHY^L_E?VHKO29?<P-9RVRI=FT[;94[AT#=+@T#+SA"5=IZ@)OP
MSL]'0MLIUR.'B0BVA5$AUVSZM!F@NU>EKP<U-WH.V49PT6E0%6)5>VJEIP<U
M]WNV5-MMG^-<N-SH$:,J?3S _;</2/$&Z]A;__^V=X+2P0/<<'=6=&QZ5Q%^
MK3)M?OO5[WB??V/IZC-YE#G4@9N;"497NGB ^^Z.;B142L9#)R"N$%($)"QM
M.\1M=@=BESK6KIW[J;C$%4N,2*7=<W(O3EL'N_BVH!9?0S2)[/;,9D-_?W7_
MQ:5??&=HE;=O/M?<,EN/-4GX'$*]TRZ\;FKS!61S8N2J^"8PD\;(M#A<<A9S
M96^ W^=2FMV);6#_'>KR/U!+ P04    "  PB&-4V4^Q)EP%  #D%   &
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M1;(W?+DSC$<,7['D%'AH#C#$R*&^/EX=OE=?&!<;/W'C)Z[M>2/VUI64K-"
M*L6T.INPZ#46O=JB/V:1JA28V(#$7K"?%7^BF5G"&:N=J: V9;^LIQ7"GD>6
MBZ=N2(92'B8$-U+O</H-3G\2YS<J'YFF]QD#BB65Y)HS)\:=F;"S.H8$!WX/
MI$,L@"$)W2B#!F4PB?*&*2UYHMDNGBY\P6!A+^YA&XH@ D>0A0VR<!+9M60E
MY1O 7DSI5$S5.1<Z9=)\G]U-Y<(<#@!%*.JG?2B$(^R[49,&-9E$?2<TS8X
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MLO.#'CT^%3D'@Q>>R5?E/"J1S*90U=Q2/ZUGWNMRTCMZ?H.S<#6Y-C#5(/W
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M9P2.V\30+>VY _:65.[05A>$1%O!,Z1K3%#%\H=JDS+%0%Z.K.,UZWCE.M[
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MP-_:,/R:/D BO+83IS_( :>CR?GY:/KB^+_D@)/GX_.SG2.@@$YUU/ $G;(
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M"8B7;YXN3\,U@'"7U2U0Z"$.AQKF_/3E![SZ%J[2[S/2V[ NX44F'2CE?7Y
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M[V_;FI3 !NRF>'RM]\+C83 A#:CS83?49.Y92:!Z[]P6LR0W3B%\B$,\(K$
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M@XZRP>PJO*X/P3)04?H)^1$(BU;C)\(B81CDI9[19R07C*O;M!UYSL#>PJ<
MRFR$'9S>FIZ3 &OD0X>0>V+:P85&&/AE9&L"&W =#)IE-G$/S<B[J$R6V;L.
MXQ!QB3#%O6>=_2OP>7+/Z3U1EO7 V0QR2#A=;2)$,)@@_A71;9G]:'Z-8MB6
M/$Q0UUC"/B&'E%UP5*[,<<%I!RE;#S7HK!L7ZGYDX CKGA*+;V%Q;DL>$42G
M,$@,P6-@>?^D?HO!;Z>SA)G7Q+:4*I9;-4X(PK^G3H&^$BW=HC[TX#7D]2+Z
MYQRE"\1'T"71]PY@*;6Z,4[SQ"H+9J$UAB>%+G$;HK@KV=D4?Y;#X1(YVY-]
MO'&Q"E/-)&V3U&D,5\7,VN ?9UUF[UL,+V104"M#)ZDL<MQ<0PN01 6P(U-%
M(""Y@3 (TR#@?_TT3W0<;'^<*ZGB67]=>C?.])%G>HM$1G4P]%340<_#==5^
MBSCTV04EB'R4E>RI7'D]0!!(F2)\9UU]9@0\E]M'./,M!O3$:#.,SNP6*QO$
M;,Q^"K]UD#MW@ZTC0(YF<X(84[E0JS;K?<\C=,%*+D:RF&UR*!]8Q6/O 8+;
M9L/,4U0=L#/Z.^R E!APB.$D]L^[CI@JAM1HLBA>@Y$V73OL3<UREQ_$998R
MC\1%9"@2;5A@4 Y&CS-!L9:L946S B.3.-4$2QPW&S?LXAFX8:H%X:]:K7<@
M?JC1WH\37))V,.2)BB:#4[4Q%A-9(_^=2IX+.^P*71M4N. 0HXN:3IHW[)M0
MV#,0.\:J!V=ND@2%D II[;7V<RRW&HC 4?3J(%D(35S,$)F4"F.7:0SZ2, "
M;(M7(BG+"&>,W=DE8@W61W-MA\2*')<K8%"ZPI9I8BN1)5@.T%\EBZ[1,?&5
MF3\Z+9B^H0 /=#1H-1>791Y/X#,E% :'T8ZO4.5.WP]K3! QH1F"&3,F]Z%Y
M,2*OM0=B<E4R8O4;4-S?8F9FY"EP="V3Q=0>8]NX+4*&UZFS%'IETA)'XI*;
MA5LN_2 ="K0\2B$/7OISFCC"T0%B,9^,)#X:DB^D)D(]Q83 J!&J3XY"ZV7V
M:SO&(B9]7.<L)LLAL#[K>&20<J9@!G-BO8S2+N@%<EL@%E"[%IQ*(-'#7R$B
MRIX^0LR96E'P&D1?<X).<CN<>; <S$&7Q-CR0R(=-I(R4@ !Q_>:[F#U9^\O
M^ 'EL&@I1CGPXMBR4!G7Z;N5YTB>:^#@_$/PM\"UBFAB+I%GQ5G 46D\L*G)
M=-HXYY@S(.T,(:^Z *W9DT6A% <-MF!S.C7)F$LD&>9P-71 D 5/FS^P4$[Y
M6X"-C7..L0:/0P:4L ?$8FFJ\Q7J^;8[8"06FFN:,C:TB7CNYAJ43(;@"9@F
M!DAM4,W@30N4T9S4\L)[4Q/Z:H=\XOTB_ N!U81=T2O!&_Z8SB&QI=J7-%'8
M)B("2\UB9Z&FM'WIA#7HEB8SL$!!22#R&3? 0:)E90&3]L!("4;0PB3D<_0G
MV8*3Z4(BSK(-UWD#1$335%WDWL3EGK.]#1H$7=/_ /<8P>F4UUA92[N JI*8
MGGH=\0)XZ)J30F,O+U))[MYJ/W7G.(Q)Z=*/1J]<H;PN$.N"M2L GE)-'SKI
M\>L&])[#""SAQ@MUNWW='IP[T?BHX#&U8 Q2H<'*PHH1=M'4*D1"R8.^O";O
MV0!ME2&[OB5H+>!!0$G)6:>C,8E=L(P?V:30!?>XX+"("+*.PQY,U969)!]C
M5BR,$4!NNTW>2$U2FDK/3U]>O?_-:SO28@(P!YN,-$SGM-TGTKE<0N'DMN.*
MM/;\[;#IIL><>11!Y.7!L<XUT(H8'44JF"YT144B*)\S'CQK5W6UT5C20D\%
M[?0=[?GCSJ1VQ9FC-6@/$LYBBQEU7E.CGJK:Y+P$BY 7A^ @23?:I!DRU'B:
MO#[\23TE8K^TAM4#E5.]0#:-VO%:+H77H<K,P<""DG\5IZP+QW$&VU^EC5C?
MJX1W8DQ.(6T2*22%]*,TB$RGBE07B.+?#AW"E Y,>4:&GO.7+)]CZJ.I@9\G
M^/,PXGF;2^ HAYTK)#5F'!VQ>M6S(80 I3*"!"RM?S*.O%A"SN775N(Q \<I
MSQ)+Y+EI]EQJ)SEJ&WI_?D(%T6N24D4P<4[U%==T;5US4!R&.12UB]IA$9'!
M,V)J5VL(.#T[%'LPRR?]MJ.N5J'^!YLO9HL1ZX0KF_\2><P!&1OT#IBM K=S
M4TV HVIXWPR25=)("27?J:B+P^$%ZMCED,39:'F"/*!S>5.5.%\J\.S#8:B;
MMN>B\/<P1,/=QD("05TTE91SCW.F78-L\JFUNRICZD"E.K:X,$9[PZG&*:,@
M,80F5&.ON3AADW/1 0V)-.Z"O%OB4H/Q:]N (4"7@;167M[0:@*%]I8"F[8M
MR?44EUAB4"T>4_Q#UJSA+B)\1V+%X\HXI:==RAB1O'CKJAA'RR9:&4YV=3!Y
MTC%<]I&P E+:B=WY8AT===C_ P5M-[7$:@V%'$%?(,]K\6941+#K"B5E25 X
MU V<PX_5'FZ%QTK&O7WO+@&AE"Z!+3A5;4=,%KA-M6)\GKQ"SK*Y)O2]UX?@
MI?=Q%M4NC)!W>1_<ONRR1E;&"ZGO%ET>CA ;V0U'D<P:#+#H<* EEIEXY3RP
M;'V9<1&,@$7_!$-7*5*CL*_:03=%Q&8*S;A(8AJ0*SW/8;AIX/3O2IR3XW[R
MBM0MLCK<C/NB N_; !'#2O+:3UA)%_:M.P/'YV<O%LDD)QPV3.9]!4'ZIY/K
M @(=-(=4-Z52+:Z0JGRQ B?6*Q@,[1@P54Y3?+52^K!ZE";#.!:ADK#IV,'.
MZ/&3-A;*;_.NI(?D*<SBG*RQ[)=4E8D$#ZN;1W$8LF2.^GY_C R%B^<^MOT
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M?"GX98Y/,S#$@/^OM':[#1W0/O86?P%02P,$%     @ ,(AC5-$YK</'!0
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M1C8JK4K(,79]<YOU&E&E %#)1FNL:25CI957U"%'#?+KHJR8"%):B"J+]F3
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M:J= YY52=A"<@_$O8/LO4$L#!!0    ( #"(8U12J[\KH@(  (D&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*U5VV[;, S]%<(;A@THXFN27I(
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MELK2Z/+;BOX5J%T O2^5LCO#)>C^/K,_4$L#!!0    ( #"(8U2:D$-U2P,
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M:?\W8A)9AH_&;6A-2=="A,$.Y:75 VG K"5G?'X!&(-E=!"@N#%P7A=LWN"
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M,9,(0P>P7VB\;;0/I*#_3GGZ;U!+ P04    "  PB&-4]V'SY<@"  #\!0
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MD^GY601V:-!APM2&IM@22XN%825W&EKO(/:2B \3'V"\)5>_ %!+ P04
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MIGI6\1TV2[@H%U 55?F,WL44WT74N_@/\2V?T5M->JNHM_J?^7J>799+F"O
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M3^]HFS&@;M-  :/.'3@>X%VKM&^#Z8W4M-,_#M@GWF@R.L;2BA,V%67+#TQ
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MT$^/$FH1S?=]1L/+=SSVPZQNU6O[R:\X=-A-#L' 7^>58 K_C(H(!=*-;6S
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MTS3%;47/%]I@0.<;8_Q1" 'Z!W'V"U!+ P04    "  PB&-4Q@9>G"XG  "
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MB9E)E'49/\]$.( '>V"#,OONDGCFNR?+I^$4.>DC\!3=?@TZ1+U%>A#^<;G
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MF@97$4R"#7W%-5U;UYSD",L<B]I%[;"(R. =L7B@!33<GAW$ W@Z%_VNH_$
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M.^174DH:P&XJC]D$;C5=.Q!-;A3<8*XN&-*KIVA(<5C.]!VBCU/M15&:6[[
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M<A3 9,I.8K_2"YPC!$ \+BZ%G^PP3=R<]I?CW-$-:GP'RR"_FA&:2G"8F29
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M#0X.!QZH9J1O"",K-T8OI*&AW&US>@6AL@)TGDEJ&6O"&FC?5;,O4$L#!!0
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MY:JP.[35L']!=_+^H2;/,=]W?(D"5]P ,R[,?CY<$J+0"^#GW>/6N,38^DQ
M4#O:2^0.[\1+W&]G^P8U,I45P$1.=_&>>DQ-'<- IC#GIL6)O0AF7MPI?9;B
M#7&TH703VX$;K(CZH9>.X3CR@G$G>*VX5/!(%J!6\IZ[1D254V@:10TE_YON
MIS5'ZH$W'4/@A9WR9<'$VE83[EG9M-1@)?5 )C(D0ZF7D+TX\M[^,'@G#05K
M=V'TCE+2K0X0-ND(F[R6L%2F6@KG-^VHA:&B=+G",:W1Z"'.'4;_OS@WR+UC
M2J(I9*.IRGJ\1\&KONNG/:@/6PY9BFC',4>NF@X-%VLHI=:0,:4>Z1.W82K7
M< 33Z62:A+2(TDD2AB\3S5INR:9[EM-)>A+U3D\FZ6QJZ:&XL>V6RB&,XLO&
M4>2I(\]UPUG0.XN#$[@E-'QCOTZYJRY]-%O&]80G83KMPTYF:0SG6:8:5FH7
MHZ1[JP8$PRCL1Q0G\)NR:1S@4D\ZF9&UM.]9.@F#M_ ':JKAT)5YKG!L@8)D
MW'\1SR9)$HVWUVG(IR.@>(\@269/.40]?$F-W' <(-*_<Y;&HFS[%; Y9)54
MAG]O#X[@.(W']A%/R;<O@D:HDG\GPVL:G?IIVMW]7G112#$/I'O/]SUC%.(8
M/A/AA].PL]*MACJ-OS=>5*C6;HBB.R,;8=I)HSOMYK3S=CSY(=X.>9^86MMH
M2UR1:N#-J*VH=G!J-T;6;EA92D.CCUL6-&NBL@+T?B6EV6VL@6YZ7?P#4$L#
M!!0    ( #"(8U3;W?"^CP0  *\2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;*U876^C.!3]*Q::AU;J!AL"A%$::5NVV3YT)FK5F6>7.(U5P%G;
M))W5_/BU@0))P"$SFX>$CWN/S[$O/I=,=XR_B34A$KRG22:NK;64F\^V+>(U
M2;$8L0W)U)T5XRF6ZI2_VF+#"5X626EB.Q#Z=HII9LVFQ;4%GTU9+A.:D04'
M(D]3S'_<D(3MKBUD?5QXI*]KJ2_8L^D&OY(G(I\W"Z[.[!IE25.2"<HRP,GJ
MVOH3?9X[14(1\8V2G6@= RWEA;$W?7*_O+:@9D02$DL-@=7/EMR2)-%(BL<_
M%:A5CZD3V\<?Z'>%>"7F!0MRRY+O="G7U];$ DNRPGDB']GN;U()\C1>S!)1
M?(-=%0LM$.="LK1*5@Q2FI6_^+V:B%:"&_0D.%6"<YC0-X););B'"7Y/PKA*
M&!\D(+<GP:L2O*&4_"K!'YH05 E!L5CE[!9+$V&)9U/.=H#K:(6F#XKU+;+5
MBM!,E^*3Y.HN57ER]@7+G!/ 5D"N";C)A;HO!,#9$MQ@086^L^!$D$SBHG;^
M (O\):$Q^+I:$4ZSUS+XEJ6INOLD6?P&+B(B,4W$)?@$;"#66 $ FH'GC$IQ
MI2ZJXP>:) I/3&VI9&@R=EQ1OBDI.SV4(Q*/ '2N@ -1^/P4@8M/E\TXY7<'
MZJT9]0O;C@ *2]0!<)$9[@'_ ,@]E^-?IT%A!=J1?3=@WERDTQTT@,Q\.!PT
MP]FJ*.O*=.K*= I\]ZS*- "[-;!; (][@!_)EG!!@"AJ56P2*@'7Q=VU("54
M6$#I;7T[@R/DC+VIO>V@,*XIC(T4[H7(<187ZN+RR2G97*@GHYS!2_ 3]"[-
M30GOMVCY"'G!I*95EOQQV!@& 0J=;OI>3=\STG_2O,"&4Z7@9^L9[V):(DU:
M%%Q_%'@'1$]%[='T:YJ^D>:"LYB0I0 KSE) 6W.N7%MM7IPLRVF_ IDR?76]
MCHF9D$)KZY)4CHI@BRWRX2CL9AO4; ,CV^=L2?B.4ZGV5+"D(F9Y)LO-59>(
MHJ:WRSY.)39";4YPY'93FM24)D9*'UL\(.^J]1&D=_02QFL/WCUR6(\<&D>^
M;3T45Q\.HCHI(=5\:$:&AR,*CZH>>9X//3_<K[J[XT G\"<P#(/]P'E7H.=/
M)K#G04*PL5]XHD8/*O%,K15\FQH\4'DZ9&X,V5?6:BS0&4N8Y>D+X?H9JP3B
M7*X9I_\JY49]Z'@Q8?4YU#DX=#XH=%]W8UO(.4/W!G.PQ4FNMDLEO]!Y:LN,
MJ@&"/=.!$!WJ'10V/QFVK[-Q462VT:/*_>4E=GL7XU#QT,CYD,A]W8UU([-W
M'^G^I24>#UOB06'SDV'[4AN;1V:?OU]\-?1;J/%AY/^_K1QJ3!.97?-W.ZFH
MPF]7BA=XAD)IS!.9W?.,+BE"'0[:T_V@QD.1V43[^Y^22-GV=%MZ5&&W&05!
M-R.G<3O'[':_U>-$SK%+^3V,&I=RS"XUM,6)*IR]KL\=C0_&MUMOXOJOG ?,
M7ZE2E)"5RH*JI;4 +_\=*4\DVQ0OYR],JE?]XG!-L)HE':#NKQB3'R?Z?;_^
MCVKV'U!+ P04    "  PB&-4O^Z<>PT"  "*!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6RM5-MNVS ,_17!3QNP5;&3MD/A&*B;#1NP%D&+;<^*
M3=M"=7$E.F[_?KHX7@8L>=J++8H\YY TZ7S4YMEV $A>I5!VG72(_0VEMNI
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M4E0TOKX,=I+W!NK63_U&(]TAOZSIT0+C'.B\U!KWAKM(PS.8_0902P,$%
M  @ ,(AC5(YO#K L!   \!   !D   !X;"]W;W)K<VAE971S+W-H965T-# N
M>&ULK5AM;^(X$/XK5G0?=J5K$YN\D J0"MW=6^DJ5=OK[F=#!K":Q)QMRG9_
M_=E)&D.3N-Q=OX#MS#Q^QI-Y&#,Y</$HMP *_2SR4DZ]K5*[*]^7JRT45%[R
M'93ZR9J+@BH]%1M?[@30K'(J<I\$0>P7E)7>;%*MW8G9A.]5SDJX$TCNBX**
MYSGD_##UL/>R\(UMMLHL^+/)CF[@'M3#[D[HF=^B9*R 4C)>(@'KJ7>-KQ8D
M,0Z5Q7<&!WDT1B:4)>>/9O(UFWJ!800YK)2!H/KK"1:0YP9)\_B[ ?7:/8WC
M\?@%_7,5O YF224L>/Z#96H[]<8>RF!-][GZQ@]_0!-09/!6/)?5)SK4ME'H
MH=5>*EXTSII!P<KZF_YL#N+( <<##J1Q(*\=AG88-0ZC*M":6176#55T-A'\
M@(2QUFAF4)U-Y:VC8:5)X[T2^BG3?FIV2\4C*+K, =W#:B^88B#1!?IPHU=9
M+C_J\</]#?KPV\>)K_2&QLU?->#S&IP,@&.";GFIMA)]*C/(3@%\S;2E2U[H
MSHD3\096EVB$?T<D(+B'T.)\]\!!9]2>WJC"&PW@?2V?0"K]5BOI0 M;M+!"
M"P?0K@LN%/L%&5IPJ?J.N_:/*G]3H$\S$B0I3H) 1_-T? X]EF$Z3D\L3TA&
M+<G(2?*+X%*BAU)K1EYQ_:*UHH]K#1,?,1AU:7:-QE$XR#%N.<;_CN.?>M['
M,>YL?Q''<9=FCUT2#=),6IJ)D^8GJ9@6(LWO,V4"?:?Y'OI8)IW===;)Z3G5
M/'LLHR!.XD&JXY;JV$GU2":DE0FNMB NU):6%PJ*'1=4L/P9L6*GXWE=[W4L
MXP[# 69IRRP](]=MIC?Z;>Q-==K9..HIFZZ5,1J@B ,KLH%3)TP]HUNJFH.[
M<H@%/E)N[(S\!U-;5B*,GH&*7G'&G6AP$*91.AP1L9L3Y^9S4 < L[OBB%04
M>H^]@3GE0-)H/,S!BB\>.3G\Q17-$;,:C.B3_LVJWE+=X"!)\]YZ:F!CIXR>
M<K(2CD-GIFTEGYMO*[S8K;QOY[NKICK?B4.IL%54[);4L_/=E4J=[S!QO'-6
M+K%;+_]SOL\1T%-.5A>Q6Q@77!C=4X"6O,Q<70"VBH;3=^@JB%4?$OS/OJ(!
M<%=$TV#UF(;$I'?H,(E5-.)6M+-["])5MI[FHL?*U5T0*W[$+7YG]Q>DJW[]
M#4:?H:-NB=5(XM;(<WN,!B9RUDC#M4<^PU'L*'%BY9.X6^ %+PH0*Z;K_([N
M0+C>?RN<)'J/>K):2-Q:^&8]+4A7!>/4T7P3JX'D77K&10,3O<G /[H[ZJ/?
M5%=JB59\7ZKZ7M:NMM?VZ^JR^FI]KJ_S]>7;PM3_!>CF<:.[,I3#6D,&EXEF
M)>KK=3U1?%?=4)=<Z?MN-=P"S4 8 _U\S;EZF9@-VC\Y9O\ 4$L#!!0    (
M #"(8U26EQ?R6 0  $@5   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;+U876_B.!3]*Q9::5IIMXEM"%!1I);N:$?::CK3G=EG$V[ :A(SM@-3:7_\
M.DX:0PDN:%E>(!_W'A_?$Y\X=[06\EDM #3ZF:6YNNDLM%Y>!X&*%Y Q=266
MD)L[B9 9T^94S@.UE,!F-BE+ Q*&49 QGG?&(WOM48Y'HM IS^%1(E5D&9,O
M=Y"*]4T'=UXO?.7SA2XO!./1DLWA"?2WY:,T9T&#,N,9Y(J+'$E(;CJW^'I"
MNV6"C?C.8:TVCE$YE:D0S^7)I]E-)RP900JQ+B&8^5O!!-*T1#(\?M2@G6;,
M,G'S^!7]HYV\F<R4*9B(]&\^TXN;SJ"#9I"P(M5?Q?H/J"?4*_%BD2K[B]9U
M;-A!<:&TR.IDPR#C>?7/?M:%V$C T9X$4B>0MPG=/0FT3J!VHA4S.ZU[IMEX
M),4:R3+:H)4'MC8VV\R&YZ6,3UJ:N]SDZ?%'QB7ZSM("T ,P54@P&FF%?D,7
M]Z 93]6E.?[V=(\N?KD<!=H,628&<0U_5\&3/?"8H >1ZX5"O^<SF&T#!(9K
M0YB\$KXC7L1[B*\0Q;\B$A+<0FAR>'KHH4.;^E&+1WWU6]GZB03I!:")R)8L
M?_F@4,)SEL><I8@I!5IYANLVPW7M<-T]PSTP^6QDF:: GB N)-<<5)LL%4S/
MPI1+>34F89_TNF%H9KW:K%=+9"^,^M%FY!;77L.UY^5Z:R>-M&2Y2D!*F"&>
M:X%26$&*:!OK"C#:X/*6K2]BBV74L(R.96G<KA33PS-ZEZ<O8HMGO^'9/Y9G
M(D56L\2H*2QI(]Q_E[ O8HOPH"$\\!)VSN)Y[H<-V/ <RPR'SA9#+_N_A#:
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M86^;.!C^*Q;:ATW:"K:!A"J)M":;[J3M5+6WN\\N.,$:V,PV37>__FQ#(:7
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MY0ZA(DAMHFF3-BUJVNW9@9-@U=C,-DW[[V<#15D@J"_@R_DNY_B6'KEXEB6
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MFFN,=5D#)WHB&Q!V92T5)\:&:H-UHX!4'N(,QV%XA3FA(L@S/[=0>29;PZB
MA4*ZY9RHO[? 9#<+HF W\4 WM7$3.,\:LH$EF,=FH6R$1Y6*<A":2H$4K&?!
M371=I"[?)_RBT.F],7).5E(^N>!K-0M"=R!@4!JG0.QK"W-@S G98_P9-(-Q
M2P?NCW?J=]Z[];(B&N:2_::5J6?!IP!5L"8M,P^R^P*#GZG3*R73_HFZ/C>Q
MR66KC>0#;$_ J>C?Y'FHPQX0I4> > #B<X%D ))S@70 ?*EQ;\77H2"&Y)F2
M'5(NVZJY@2^FIZU]*MS?OC3*KE++F?PG*(Z^2R+0!W1O:E#HH@!#*-.7=N9Q
M6:"+=Y<9-G8K!^!RD+WM9>,CL@64$Y1$[U$<QM$!?'X:_T;$#H\^'\"+T_A-
MHRP>>OSJ)8YM?<8BQ6.18J^7_*]()[2242OQ6ND1K3M2 B)<ML(<*FL/3SWL
M6G:;3T/_R_!VOWYGYA5O\Z)7>2]<I*.+]*2+^]9H0T1%Q<:V'2.BA$-NTC>[
MO]X7[WVZ[I[Y0=2&"HT8K"T33CY:6/6]VP=&-OYK7DEC>\,/:WO=@7()=GTM
MI=D%KD'&"S3_!U!+ P04    "  PB&-47XP5$5L"  !)!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T."YX;6R=5=N.FS 4_!4+]:&5MC&WL.V*('6#JO9A
MI6BCML\.G 0K!E/;A-U^?6U#$$ESV^8A^-@SPYFQL..6BZTL !1Z*5DE9TZA
M5/V L<P**(F<\!HJO;+FHB1*EV*#92V Y)94,NR[;H1+0BLGB>W<0B0Q;Q2C
M%2P$DDU9$O'Z"(RW,\=S]A//=%,H,X&3N"8;6(+Z42^$KO"@DM,2*DEYA02L
M9\X7[R&-#-X"?E)HY6B,C),5YUM3?,]GCFL: @:9,@I$/W8P!\:,D&[C=Z_I
M#*\TQ/%XK_[5>M=>5D3"G+-?-%?%S/GDH!S6I&'JF;??H/<S-7H99]+^H[;#
MAE,'98U4O.S)NH.25MV3O/0YC A>>(;@]P3_5D+0$X)C0G"&$/:$T";36;$Y
MI$21)!:\1<*@M9H9V# M6]NGE=GVI1)ZE6J>2A8Z9A "<K14/-NB]RDH0IG\
M@#ZB=P@C61 !,L9*O\LP<-;K/G:Z_AG=%+()"KP[Y+N^=X(^OYWNGJ"GE^E/
MY!5Y@6%[GP_96.<SA.0/(?E6+K@MI,D%R6"0#*QD>%52&LD[5#7E"@3BZSYR
M1!I5<$'_0'XJ_4X]LNKFT]XEGMO]8KP;YWPK,+T!>. T')R&;W-:$X%VA#6
M:FW8NCWEL%.]'_7C3ES7.[)W$RJ]ACHP-AV,3=]FK-\X*F5S>M.F_T1\O%N7
M$ =-1D.3T7\UJ6\ J4B5TVISJM/H:J=7$>DE1.<%C\XM<\D\$;&AE40,UIKC
M3NYU'*([N+M"\=H>92NN],%HAX6^ZT 8@%Y?<Z[VA3D=A]LS^0M02P,$%
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ML%0G&> Z0#U?,97*?J(W&,Y&Z7]02P,$%     @ ,(AC5 &G) R#!@  JQX
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MMZ!;N%JZ>AWDJ(\%00_C4\PVN\!#> "T42SHEBP':YV906RI)O%@;VC'Y\R
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M*J9>[*$<5F13JGN^^P5M04/#E_%2VD^T:V.QA[*-5+QJP5I!15GS)"^M$1U
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M38_AADO3!H*T+YCG<R'T?F(W:!K+R3]02P,$%     @ ,(AC5,^LG\69 @
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MI,%FZ(8-/E>@K 'NUU*:_<0>X!_ X@]02P,$%     @ ,(AC5,>M4.TE P
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M^1UQ1EQ!=HD"_"<B/L$C0,NWN_L.G* O9&#B!9/QK,I=.\*&?=C0A TGPGZ
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MDS^(QD"_WW"NCC?- /W_$A8_ %!+ P04    "  PB&-44C](@!4"  #W!
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MH5O3O07K$VB^,@9/@3]+TY\@>P%02P,$%     @ ,(AC5-@B$!\T P  \!,
M  T   !X;"]S='EL97,N>&ULW5A1;]HP$/XKD3M-K30U0-:4K("T(56:M$Z5
MVH>]588X8,FQ,\=TT%\_7QQ"H#[$^K#!@B#V?;[O/OLNV# HS4JPASEC)ECF
M0I9#,C>F^!2&Y73.<EI>JH))BV1*Y]38KIZ%9:$934MPRD78ZW3B,*=<DM%
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M5HTBJT:15:/(JE%DU?\IZY.UZ[_^I:"_YZVIN_=\-ORW<?4*4$L! A0#%
M  @ ,(AC5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  PB&-42WJMK.T    K @  $0
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M=#(N>&UL4$L! A0#%     @ ,(AC5*JUJGW; @  H@H  !@
M ("!#!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #"(
M8U0L4?.%HP0  "T0   8              " @1T7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  PB&-44X?6LIP$   >$@  &
M        @('V&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ ,(AC5*2/4MY; @  304  !@              ("!R"   'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #"(8U0H06=>I04  +,5   8
M              " @5DC  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  PB&-42-$?Q1D.  !<)0  &               @($T*0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ,(AC5,J8V@O")0
MS7D  !@              ("!@S<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( #"(8U1V<WO6>P0  /@-   9              " @7M=
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ,(AC5-$Y
MK</'!0  210  !D              ("!+6(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  PB&-4N& JZT$#   1"   &0
M    @($K:   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M #"(8U12J[\KH@(  (D&   9              " @:-K  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ ,(AC5)J00W5+ P  P@<  !D
M             ("!?&X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  PB&-4O)'HP) (  "S%   &0              @('^<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( #"(8U3W8?/ER (
M /P%   9              " @<5Z  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ ,(AC5.VDS$9/ @  ,04  !D              ("!
MQ'T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  PB&-4
M%#?UNF #  "F!P  &0              @(%*@   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( #"(8U3]XIA$DPD  'L=   9
M      " @>&#  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ ,(AC5$QRQX5! P  70@  !D              ("!JXT  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  PB&-4_@EXQ-8(  !G%P
M&0              @($CD0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( #"(8U32XS:XF (  ,0%   9              " @3":  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ,(AC5*0&A!-/
M @  ' 4  !D              ("!_YP  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  PB&-4Q@9>G"XG  " @P  &0
M@(&%GP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #"(
M8U24IC S) ,  /X'   9              " @>K&  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ ,(AC5 K@'8\= P  Q H  !D
M         ("!1<H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  PB&-4 >/GKBL#  !C#0  &0              @(&9S0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( #"(8U1FR5]8R (  )L&
M   9              " @?O0  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ ,(AC5%:,(#:= @  2 8  !D              ("!^M,
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  PB&-4('M$
M#I0"  #I!0  &0              @('.U@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( #"(8U2N@4#R]00  !L/   9
M  " @9G9  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M,(AC5-M2NY5I @  I04  !D              ("!Q=X  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  PB&-44X>E0" $  #)"@  &0
M            @(%EX0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( #"(8U3;W?"^CP0  *\2   9              " @;SE  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ,(AC5+_NG'L- @
MB@0  !D              ("!@NH  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  PB&-40-3A/I4#  #/"P  &0              @('&
M[   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( #"(8U0#
M/ORC=@(  +X'   9              " @9+P  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ ,(AC5'O)0^K2 @  H0<  !D
M     ("!/_,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"(8U0A)BP L0(  ,T'   9              "
M@:4% 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ ,(AC
M5,P6H;IS @  AP8  !D              ("!C0@! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  PB&-4>S\\T38"   A!0  &0
M        @($W"P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( #"(8U2]-WWX2@(  !<&   9              " @:0- 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ,(AC5-7V=VL3 @  3 4
M !D              ("!)1 ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  PB&-47XP5$5L"  !)!P  &0              @(%O$@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( #"(8U2>TD7>
MX0(  "<)   9              " @0$5 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ ,(AC5 &G) R#!@  JQX  !D
M ("!&1@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  P
MB&-48&9_!ZH"   P"   &0              @('3'@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #"(8U0VZ\&4V0(  &0*   9
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M970U-BYX;6Q02P$"% ,4    "  PB&-4D&],7>,!   5!   &0
M    @('%,0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M #"(8U38(A ?- ,  / 3   -              "  =\S 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ ,(AC5)>*NQS     $P(   L              ( !
M/C<! %]R96QS+RYR96QS4$L! A0#%     @ ,(AC5/G@\:_0!   Z"4   \
M             ( !)S@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #"(
M8U3S((MYZ0$  !(B   :              "  20] 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #"(8U2R:$G8U0$  +\A   3
M          "  44_ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !! $$
*OA$  $M! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>98</ContextCount>
  <ElementCount>349</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS - (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS - (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Former Agreement with Eli Lilly and Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany</Role>
      <ShortName>Former Agreement with Eli Lilly and Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Marketable Securities - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment, Net - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Former Agreement with Eli Lilly and Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails</Role>
      <ShortName>Former Agreement with Eli Lilly and Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails</Role>
      <ShortName>Commitments and Contingencies - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Term Loan - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureTermLoanOtherDetails</Role>
      <ShortName>Term Loan - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePreferredStock</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureCommonStock</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stock-Based Compensation - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="nxtc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Subsequent Events - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="nxtc-20211231x10k.htm">nxtc-20211231x10k.htm</File>
    <File>nxtc-20211231.xsd</File>
    <File>nxtc-20211231_cal.xml</File>
    <File>nxtc-20211231_def.xml</File>
    <File>nxtc-20211231_lab.xml</File>
    <File>nxtc-20211231_pre.xml</File>
    <File>nxtc-20211231xex10d23.htm</File>
    <File>nxtc-20211231xex10d24.htm</File>
    <File>nxtc-20211231xex10d25.htm</File>
    <File>nxtc-20211231xex10d26.htm</File>
    <File>nxtc-20211231xex23d1.htm</File>
    <File>nxtc-20211231xex31d1.htm</File>
    <File>nxtc-20211231xex31d2.htm</File>
    <File>nxtc-20211231xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nxtc-20211231x10k005.jpg</File>
    <File>nxtc-20211231x10k006.jpg</File>
    <File>nxtc-20211231x10k007.jpg</File>
    <File>nxtc-20211231x10k008.jpg</File>
    <File>nxtc-20211231x10k009.jpg</File>
    <File>nxtc-20211231x10k010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="425">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nxtc-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 98,
   "dts": {
    "calculationLink": {
     "local": [
      "nxtc-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nxtc-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nxtc-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nxtc-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nxtc-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nxtc-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 408,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 21,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 26
   },
   "keyCustom": 26,
   "keyStandard": 323,
   "memberCustom": 6,
   "memberStandard": 25,
   "nsprefix": "nxtc",
   "nsuri": "http://www.nextcure.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Marketable Securities",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property and Equipment, Net",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Liabilities",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Former Agreement with Eli Lilly and Company",
     "role": "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany",
     "shortName": "Former Agreement with Eli Lilly and Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Term Loan",
     "role": "http://www.nextcure.com/role/DisclosureTermLoan",
     "shortName": "Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Preferred Stock",
     "role": "http://www.nextcure.com/role/DisclosurePreferredStock",
     "shortName": "Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Common Stock",
     "role": "http://www.nextcure.com/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "role": "http://www.nextcure.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income Taxes",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Employee Benefit Plan",
     "role": "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Subsequent Events",
     "role": "http://www.nextcure.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_EPfvmjikOEaoJLlrb7x-dg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEETS - (Parenthetical)",
     "role": "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS - (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_12_2_2019_To_12_2_2019_fl0kH0gO60SvzizL0TFpiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_y2qUci353EOOoH7IWozW8A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_y2qUci353EOOoH7IWozW8A",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_8_1_2021_To_8_31_2021_d9SIdBaYEUiqKV-wVtR-7Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DTf55tn5nEuURiAawx_EMg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_5_13_2019_x0DQ1W4mNkKV2y9Mvy2ULg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementScenarioAxis_srt_ProFormaMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_JrefgPykdkmCSNrZNEgolw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Marketable Securities - (Details)",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements - (Details)",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_JO8kC4Wv30ykMH8DL_H1Ww",
      "decimals": "-3",
      "lang": null,
      "name": "nxtc:MarketableSecuritiesAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property and Equipment, Net - (Details)",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nxtc:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_IxP1CiGtak-xpjhTmHM1iw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nxtc:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_Y84E7pX-Ak-4O0b7X7G9kA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Former Agreement with Eli Lilly and Company (Details)",
     "role": "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails",
     "shortName": "Former Agreement with Eli Lilly and Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_nxtc_ResearchAndDevelopmentCollaborativeAgreementMember_w5P21kf0c0WRJYhRcmUNfw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies - Other (Details)",
     "role": "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails",
     "shortName": "Commitments and Contingencies - Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Commitments and Contingencies - Future Minimum Payments (Details)",
     "role": "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails",
     "shortName": "Commitments and Contingencies - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Term Loan - Other (Details)",
     "role": "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails",
     "shortName": "Term Loan - Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Preferred Stock (Details)",
     "role": "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
     "shortName": "Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Common Stock (Details)",
     "role": "http://www.nextcure.com/role/DisclosureCommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "nxtc:CommonStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "INF",
      "lang": null,
      "name": "nxtc:NumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_w0Gf5YJwbUupsjwI1CCnAw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY",
     "role": "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_joMAb9BeCEOJpZEtKoF5Jw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Stock-Based Compensation - Stock options (Details)",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_xYB9Qda7IESO7hV6-Ncu-w",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income Taxes - Reconciliation (Details)",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_52mQmGK6UkKuqvM52V7uKw",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Income Taxes - Deferred tax assets (Details)",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tGzyUNMpjkyvnHssxF3eMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Subsequent Events - (Details)",
     "role": "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "As_Of_2_4_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_up_d33X3NEC30-3eQDeyDQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_G0rrRJua7EmsuJJOnMjSOQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)",
     "role": "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://www.nextcure.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_A2hxQt0I9EiG043xR3mozQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_IcPH8ipjgE-CorwBlHRypQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 33,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover Abstract"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nxtc_A2015OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 omnibus incentive plan.",
        "label": "2015 Plan"
       }
      }
     },
     "localname": "A2015OmnibusIncentivePlanMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_AccruedClinicalTrialCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Trial Costs, Current",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "AccruedClinicalTrialCostsCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction in progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Construction In Progress, Current",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedOperatingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Operating Expenses, Current",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "AccruedOperatingExpensesCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedSponsoredResearchExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sponsored Research Expense, Current",
        "terseLabel": "Sponsored research"
       }
      }
     },
     "localname": "AccruedSponsoredResearchExpenseCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost",
        "terseLabel": "Between 1 to 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "terseLabel": "Between 1 to 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Former Agreement with Eli Lilly and Company"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.nextcure.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nxtc_CommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockTextBlock",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, Federal",
        "terseLabel": "Federal research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, State",
        "terseLabel": "State research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.",
        "label": "Deferred Tax Liabilities, Depreciation and Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DepreciationDepletionAndAmortizationAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.",
        "label": "Depreciation Depletion And Amortization And Other",
        "terseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationAndOther",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_EmployeeStockPurchase2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Employee Stock Purchase Plan.",
        "label": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchase2019PlanMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration of unpaid rent that provides economic benefits in future periods.",
        "label": "Increase Decrease In Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_IncreaseDecreaseInDeferredRevenueFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income from related party and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue From Related Party",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParty",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_MarketableSecuritiesAndCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1",
        "label": "Marketable Securities And Cash Equivalents",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "MarketableSecuritiesAndCashEquivalents",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes per share.",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 omnibus incentive plan and the information pertaining to 2019 Employee Stock Purchase Plan.",
        "label": "2015 Plan and 2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_OmnibusIncentive2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Omnibus Incentive 2019 Plan.",
        "label": "Omnibus Incentive Plan"
       }
      }
     },
     "localname": "OmnibusIncentive2019PlanMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted",
        "verboseLabel": "Unrealized gain (loss) on marketable securities, net of tax $0"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not available.",
        "label": "Preferred Stock Abstract",
        "terseLabel": "Redeemable preferred stock:",
        "verboseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tabular disclosure of estimated useful lives for property and equipment.",
        "label": "Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Summary of estimated useful lives for property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_RequiredReserveRestrictedCashCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required reserve of restricted cash.",
        "label": "Required Reserve Restricted Cash Current",
        "terseLabel": "Restricted cash required reserve"
       }
      }
     },
     "localname": "RequiredReserveRestrictedCashCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_ResearchAndDevelopmentCollaborativeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to research and development collaboration agreement.",
        "label": "Lilly Agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCollaborativeAgreementMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible research equipment.",
        "label": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_RestrictedCashAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents restricted cash and other assets current.",
        "label": "Restricted Cash And Other Assets Current",
        "terseLabel": "Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively)"
       }
      }
     },
     "localname": "RestrictedCashAndOtherAssetsCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_RestrictedCashOtherAssetsNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other assets non-current from restricted cash.",
        "label": "Restricted Cash Other Assets Non Current",
        "terseLabel": "Other assets, restricted cash"
       }
      }
     },
     "localname": "RestrictedCashOtherAssetsNonCurrent",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Maturities Table Text Block",
        "terseLabel": "Schedule of available-for-sale maturities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer available.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.",
        "label": "Share Based Compensation Arrangement, Increase In Shares For Issuance As A Percentage Of Number Of Common Stock Outstanding",
        "terseLabel": "Annual increase in number of share reserved for issuance (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold number of shares of the company's common stock available for issuance under the plan.",
        "label": "Share Based Compensation Arrangement, Threshold Number Of Common Stock For Issuance Under The Plan",
        "terseLabel": "Maximum annual increase in shares available for issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan",
     "nsuri": "http://www.nextcure.com/20211231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r97",
      "r105",
      "r111",
      "r172",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r362",
      "r365",
      "r367",
      "r368",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r97",
      "r105",
      "r111",
      "r172",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r362",
      "r365",
      "r367",
      "r368",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r97",
      "r105",
      "r111",
      "r172",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r362",
      "r365",
      "r367",
      "r368",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r212",
      "r233",
      "r269",
      "r271",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r483",
      "r484",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r212",
      "r233",
      "r269",
      "r271",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r483",
      "r484",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r111",
      "r197",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r233",
      "r250",
      "r269",
      "r271",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r483",
      "r484",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r233",
      "r250",
      "r269",
      "r271",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r483",
      "r484",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r106",
      "r111",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r106",
      "r111",
      "r197",
      "r270",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r189"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r50",
      "r52",
      "r53",
      "r476",
      "r492",
      "r496"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r53",
      "r60",
      "r61",
      "r62",
      "r94",
      "r95",
      "r96",
      "r352",
      "r487",
      "r488",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r307",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r304",
      "r305",
      "r306",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r98",
      "r99",
      "r100",
      "r101",
      "r111",
      "r153",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r199",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r333",
      "r334",
      "r335",
      "r336",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r412",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r273",
      "r274",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r274",
      "r296",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails",
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long Lived Assets"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r138",
      "r141",
      "r147",
      "r168",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r348",
      "r353",
      "r382",
      "r413",
      "r415",
      "r458",
      "r474"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r46",
      "r91",
      "r168",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r348",
      "r353",
      "r382",
      "r413",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Cost Maturities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r158",
      "r160",
      "r468"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total investments available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value Maturities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r158",
      "r160",
      "r466"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total investments available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Within 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r158",
      "r159",
      "r467"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Within 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r32",
      "r81"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "nxtc_MarketableSecuritiesAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r12",
      "r82",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r87"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r391"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r343",
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Former Agreement with Eli Lilly and Company"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r251",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r198",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance under the plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, number of shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2021 and 2020, 27,680,997 and 27,568,802 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Principal components of the Company's deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r64",
      "r463",
      "r481"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r251",
      "r265",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r224",
      "r226",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r211",
      "r228",
      "r229",
      "r399",
      "r400",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "nxtc_MarketableSecuritiesAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r17",
      "r18",
      "r323",
      "r459",
      "r473"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r15",
      "r403",
      "r411"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent, current portion"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r19",
      "r403",
      "r411"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Charitable contribution carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards that do not expire"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r329",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "negatedLabel": "Unrealized gains"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r112",
      "r114",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r368",
      "r369",
      "r464",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "verboseLabel": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r114",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r368",
      "r369",
      "r464",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of federal statutory income tax rate to the Company's effective income tax rate",
        "terseLabel": "Reconciliation of federal statutory income tax rate to the Company's effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r92",
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Expected income tax benefit at the federal statutory rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible items (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Prior year provision to return adjustments (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r317",
      "r338"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit, net (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Share Based Compensation Expense Not Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Option to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r60",
      "r61",
      "r62",
      "r94",
      "r95",
      "r96",
      "r99",
      "r108",
      "r110",
      "r125",
      "r172",
      "r235",
      "r236",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r367",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r487",
      "r488",
      "r489",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Assets transferred from level 1 to level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r370",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r370",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of fair value of the Company's financial assets"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r265",
      "r371",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r251",
      "r253",
      "r258",
      "r265",
      "r371",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r251",
      "r253",
      "r258",
      "r265",
      "r371",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Assets transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Assets transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r265",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r225",
      "r234",
      "r358",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Fair value of the Company's financial assets"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r79",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment loss recognized"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r318",
      "r321",
      "r328",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r315",
      "r316",
      "r321",
      "r322",
      "r327",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Deficit"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r456",
      "r470",
      "r498",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r91",
      "r142",
      "r168",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r349",
      "r353",
      "r354",
      "r382",
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r91",
      "r168",
      "r382",
      "r415",
      "r461",
      "r478"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r91",
      "r168",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r349",
      "r353",
      "r354",
      "r382",
      "r413",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r220",
      "r227",
      "r228",
      "r229",
      "r460",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balance"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Term loan, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss",
        "verboseLabel": "Marketable securities other-than-temporarily impaired"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r54",
      "r56",
      "r62",
      "r63",
      "r80",
      "r91",
      "r98",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r115",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r168",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r369",
      "r382",
      "r462",
      "r480"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r111",
      "r122",
      "r153",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r199",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r333",
      "r334",
      "r335",
      "r336",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r412",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r140",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total future minimum payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum payments:"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expenses operating leases"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r41",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r252",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r275",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock."
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, number of shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2021 and 2020. No shares issued and outstanding at December 31, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of shares, net",
        "verboseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "negatedLabel": "Repayment of principal debt balance"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r299"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r54",
      "r56",
      "r62",
      "r74",
      "r91",
      "r98",
      "r109",
      "r110",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r168",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r347",
      "r350",
      "r351",
      "r355",
      "r356",
      "r369",
      "r382",
      "r465"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r188"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r190",
      "r415",
      "r471",
      "r479"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r190",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Payments of the term loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r313",
      "r451",
      "r505"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs, Including Clinical Trial Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r12",
      "r87"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r236",
      "r307",
      "r415",
      "r477",
      "r491",
      "r496"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r94",
      "r95",
      "r96",
      "r99",
      "r108",
      "r110",
      "r172",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r367",
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r247",
      "r248",
      "r452"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from former research and development arrangement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails",
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of shares excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of marketable securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r274",
      "r295",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r274",
      "r295",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Summary of stock based compensation expense recorded"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r275",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r279",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of assumptions used in the Black Scholes option pricing model for stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election of practical expedient not to separate lease component from nonlease component.",
        "label": "Separation of Lease and Nonlease Components [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Restricted Common Stock",
        "verboseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end (in dollars)",
        "periodStartLabel": "Outstanding at the beginning (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r281",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Exercisable at the end (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Exercisable at the end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r275",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r291",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r60",
      "r61",
      "r62",
      "r94",
      "r95",
      "r96",
      "r99",
      "r108",
      "r110",
      "r125",
      "r172",
      "r235",
      "r236",
      "r304",
      "r305",
      "r306",
      "r335",
      "r336",
      "r367",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r487",
      "r488",
      "r489",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r125",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r236",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r91",
      "r152",
      "r168",
      "r382",
      "r415"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r20",
      "r21",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r398",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r398",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r398",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r398",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r225",
      "r234",
      "r358",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r98",
      "r99",
      "r100",
      "r101",
      "r111",
      "r153",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r199",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r333",
      "r334",
      "r335",
      "r336",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r412",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r314",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized income tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Uncertain income tax benefits, interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r113",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918707-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r509": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r510": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r511": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r512": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r515": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r516": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r517": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r518": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r519": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r521": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r522": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r523": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001558370-22-002824-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-002824-xbrl.zip
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MO+ "5X!9Z+? <E7A8"T72V-L$622P;R47X(46\6]#$Y]MH2"SGK=7Q[NITK
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M0@L_20HU_G"XG?1%.S?WVD^O8ZCWDG[>2QKMJB_>-&J<Y9"?7=A@$G=SQWF
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M/A2OO)2>H&0 VWM;TUZA8ZT0LK_GAJ7OXB<S]ML;[I(/$9KDU4$]."N:?F\
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M1MK>5)DCXP_A1K1P3\H/_P-02P,$%     @ ,(AC5##AT[CW#@  /=8  !4
M  !N>'1C+3(P,C$Q,C,Q7V-A;"YX;6SM75MO(CD6?E]I_T-MYF576D* =#J)
MNF=%")F.E 04F,L^C9S"@#6%B[6K<IE?O\=% 574S76ARX:16IU [./SG>_8
M/KY_^<_[PC)>,>/$IE]/6J=G)P:FICTA=/;UQ.4-Q$U"3O[SX]__]N4?C<9O
M-\\/QL0VW06FCF$RC!P\,=Z(,S?&]G*)J/&(&2.69=PP,IEAP[@ZO3B]/#MO
MGW8N+EMG1J/A2[I!''+:U/!$MD];F[_T?*DVO38ZS4ZS?=9N&Y?7G:OK5LL8
M/F[2/8*24Y*5T"+TCVOQWPL4: !8RK^>S!UG>=ULOKV]G;Z_,.O49C/(?=9I
MKA.>K%)>OW,22OW66:=M-7][?!B9<[Q #4*Y@ZBYS27$Q.5K75U=-;V_0E).
MKKF7_\$VD>.9/U,O(S&%^-18)VN(KQJM=J/3.GWGD[5>$;4RP,-?24KZ#6RP
MLV%\8;:%G_'4\/!=.Q]+_/6$D\72$@*][^8,3[^>T'?'! 7;K59[I=X/(P<(
M%QYU@RPA<#3'V.$GAI#X\_-]2 6*(;O+\*EI+YHB03,I=[,RM3:_\,%TL,3,
M8XMWZ:1G+Y8,SS'EY!4_V#R_SGE$[P=0#_'YG66_E=,](*6TFK>$FY;-H="1
MNU@@]C&8CLB,0F4W$76ZIFF[U('V:6A;Q"28/V/N,&)"FR&TN,4.(I8TFHH*
MJQ#T(V)_@-@7"X\PZ$H<*+4PJ%1A%2I]APC[!5DN?L1(?/;<HK#6Z=(J5'O(
M;*ATS@=4N/[_7+(4!3UAI[#B6?(J5!U<D[EX\D#0"['*.4F*J H5AA9M01R/
M2J]]\ZH5Q!I0W)WK"%\EE"S<Q1!]E/.>P@55"/8>8J@%'J-WT6*8-A1N$:]M
M+XPJ6^)^U+_%4PCI\ 0^=#G')7B1$NJ#,)%ENI:'[P%4]A47 @M& T%K0"9,
M)WBR^98X0BX$=6<0H1H;$?#[3?>A^]3K&Z-O_?YXM(IT0#W+-D,2+1'"V2QL
M8*$G!T6]J&F*^(L7.D%,/4-H*:+55A-;#E]_XW'1.&OY0=L/_M>_KPRT%FVA
M%VQYD7GHC\WZ-.NYP"1U4A7TT_Q^T?E\V;KJ7'P^O[J\^'QQ_NDBH'J \RX+
MHT#,7,N'7R-N$(Y+_11-+CIT(:U!@,]U_BFS%U'[^879>12WV00S&#.=&"X'
M?>RE* M9)\8;)K.YX_UER8@-O>['UY-V322),$4T@_!#=$FOR/(:1J>'&/N
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M:0:</A(!YAWM1Y8O=T;[ZP(,![T;R"NB]DNJ=B '5J:3]\QGYJKI+,R.5CD
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M,9JO[,:LQ+6!['X!UR&55^.*R #3VNW'7P)$&,GFJUOT@D(SY55T-M%A37<
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M/)S*/8<3&5<K#P/AM*,2WRMC"&ZS\/Z"#))CA\I\[32N8+.BW ,)/*FSFVL
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M.M9G.F>TI4DAW#ANPVJT3;<_A72.DW@\[5P\"[-"N.\\%/DL$ ZN@&84RV)
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MK+<)J6W<(S&8$$+\KD-]MI+/8T!6F$)KB\:E1-)?<<A&"QFZ$V8UNC"=&@!
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MG TYV/RP$]93FH *)@FW0<1MX-:V1K#L3:KL#N$/Z<[@G4N8FO7&2<(N2IU
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MFWU(8 Y\34T&I#WF_+**.S6.1+ D[X#IM[S" (S'C+.ME8=- V7E>&H&>A>
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MV2SQ4YJ55!8GG_?4C9Y#3H6_>"J=AX_.%CEX367X^JIM7)Z(X7$RU?77CH6
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M=)H52,AD-XP'.1N2\<$RZS"M?J'GMEE/VW$=[Q@^EA.>/G8Z[CK'Z)88H#/
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M%=O@)1_^V.QO#+T-#\3QK*'$A!L<J/9.Q[))+<>T:3O#(ER '>#_X63IU0D
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MGB7IR@;MT1]Y!/<V1>TH1+4SXJCOKX/V[H[@5,D6AVE]>?[!N5D?OJ>S1]L
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MAMQ07QQ=/,^.- JFY!?.UCYL(;#8PVZS<>(]Y-[&%.+"#WR1C>OF]_CY'_3
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M2&?M\Z5,,I*)1F03RP4IY!,32#9QK $(B,?18T_;$ 01T%HQ^)<P+H@1MVI
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M&?^6]T8L;+5,:["*69Z!!P+P*6[ 5BS1839)EYF 2)O"34#1U'X&8- JMOF
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MY$2%S__0@?3XX+J._<-10YY[N8<M"Y/[J-,_8'#R2"VIU66O:MWYL&%D4/]
MTHAC:NDOJ9#9U5OGIUC*"Q!"9[.[K7WX?,9\^(Q_\>\%NO_QZ? 46K=/ RMD
MC.+13N.C7%:]GLO-0>MLH$EH%B38@MV^/*DNBB#);S:,P@6V3']MC  3)MN=
M>@H/+C;[$CE:Q7I<3T $$DF'7L.!P:("1X@Q4*"G@.3LU6M0U/&IX#VB;H>Y
MX#Z#HV=O$-*45P7>"MTHX=Q>,'KT$14B&XO6+@OCT,#<55!:%R5TIC^47!H*
M&/S)\D 8AX#ZS01_!N8^8:&.26IA\[: 4.B%6O\0C&?C%4C*N!,W7.$JB%P"
M<7JECDOI^%XFP\GHV^AQ\F*-[ZSQT^AY.+D?/[Y8P\=;ZV;\[>EY].OH\>7^
M'R/K8?QB>KZ^Y%9LS5^-7XK:6M.=UAOP(G"'I\>-[\4C^0V&BYLH"/$H2YDF
M2Q=;7+V-F_\U&BO>8S5GL9<O$&L$LDD@%00 _]^4?M?>@))Q2&H##V&P<4ND
ME\";X"^,9ZF(1F2Q">"K"QY@0#-/C!X]!Y(HYPR?:*;V8TUJ3[<@WCS-*567
M0I;:WCB5"ZQ"8DSU,N[O&>L'RY8DRKS%N';].']0*@_J"L/H8QP>Q)1<M7J(
M<MO+=>(K\+ <72R%X70)/4AD2$J4LJ%2TZMW8&G";R_M2DF0O.M*[R#!QZ&L
M.S.C K/6K&\B7.M@L&EI'!":;"QJV%&J]0N=^?@>?<\O"H&]4+ [=1H+XIPI
M3=NJ*YW.(PAKS4"A39>57L^(TOP&YYITG(6E9]>[UW8 ';)QAFX4@FG-&9.S
M=Y=QT89%!1>A^K<(E0(1P4=15.?ZT=!&Q9R J>19\=M47<O&M@!2,7)")&V]
M9R!A<2WIM&DZ3+8$&F_";F'@N'X0H5IO9T-JQL%,WLHDQ+*D@ T:QG3M;GX#
M<+X@LQ,/S)Z#QVCY"M!X5HI98*UA0C2,PY-,D)0AV%XVBM= 7<E=*())I<X;
M2R1(Y0 ^8>DH7EMUP8_GQ?J3CV(HA"&"KU%($@9/_.117-W-HASJQL%5U$6D
M2 0*8N7TGQI;^I(,0(=*E0NYH^2NG&;!A";D[QX"MDLBSG_U76+-O]K0(Z(9
M>[D:?@@&^$^W^)_>'*\YT)_69#E1];D]!^].Q:KT,E;7C4R%\&J@S.BQYV@4
ME<QN+G9W%+A.SZU1$ZQ^4A.L_C(9W_S]U_'#[>CYQ1K]W^_WD]\-#T_//79H
MD'N3JZ^FK#KIV"9DDM0Q$#<JXO["J*=I];HI9M&IY8NQ4=(=T[D>?<(HL52^
M1R;N\!W2=LG,/N8JEJX?AE*Y6318Q[FW4M\ <5'4/QQ+VIFK2VZU5"[&'%Q2
MU6E2IDVF-IE]>JE9<8ZI.W=3\V:R-<[;OY_:;\4]=<MM1'Y+IMJK&_=2QP*L
M4N/A]%PU%WF^]9>8#]I%<E7;7JJ3GU-JY)O>33,^'H-[_&/M3GG=T%P]-MH>
ML_DR^"T;7A 0L -P"Y+_WGOE4]^S[[IW/OIA(UKHD" 5<Y7/UF,9 #(8[^7U
M@;0$PP:@0X:2JVP'%^.2T+&*W?<8YR@TYFY<:4Z7WN)&6 22KF58"-(553:<
M_BL*PMC!/O$IQ]Y82,35'6>+P<>@& +/ (L_@"%X >@-.B"YWGH&CC_W8BJL
M8BZJ/[LG2-8B1J651G1%\,;:2+* Y6]K8RG$?QO'; :C=X <&%!#P(7I[ E2
MY<A%Z=,TK1N]LFB2I4D"]AB$C .?')APPT]4-#V-\&5)_1'\B/]"=TQP]#4.
M9[LW<FQ9*"V18]B:FDRZAKC:ZEP4YB46YJFY!HP- 4&CQ1:!61X1[SUT8I ,
MCE.(D-\H"ZU+=L6E97(GWS0.D'(MG3X92GI_;-K2VS*6O'< X^=905YF0\X"
M,IR^O04&)^.2'IXD+KN1-S7&8"AU^?86-<(B2/%SI0P_:X>OMN#I)L7H3DK%
MZ&HCJ;M;G:Y7D=6R-VV[>XA4>MM@@)5J'..]*^$HJY.W(W-U8P>+.]?_P5N/
MX+3FB<?-\.57Z^YA_)OIA0=RR%K+@-_L5'31=:PA0WE"_AO$ZKK^^!Z Z;VW
MSDPX=$+XEF":S9LX(9-M!56C6T<?&2PK=0'IVOUBH<Q@R#@K;QH8AP-)>BT#
MIH9GLWR!*N(6R+6UYT 7%+P&$U^."5+QJ?T!Y\ZDI_3MM/ 5"L7E?0OP:!P8
M:Q;_[()8Q=YTN"1/A/^RTW_&N\0J][5(_Z*4KK"4+O5B;&=0V/)7MQ::4@LZ
MT.5J3+,8%>.":%O,RL8'A#62D%F62ED8_%JF:2!:?0TU3@+&P4[9XME2)DHC
M]73M_,HR>4)@9</I;<I3FML\L^BDKE9(.RXT(V8< %OBA =XC>72=O&\2D#H
M@3EYD&FPO1LZCA_AE>?)_F DKZCMMX_@XA%!+PO55(H"19@7:+]"-UXS1("T
MU75/L<0C!;/61LIQL<Q=9G^?L:"K#HCL'OW%0U/FS2IVT@ &ZPJ3SR#.6/!D
MHU+02#,B>PP6?GDH#=S5E;&/_SS3^M:FOR"3) M9=5>,*LU&D<F]]P8"&=>#
M#$+& 4[2]: HR[W<3F.A. !, V*Z7VR7'$^_V2&)GO@8S[[9Z \0)]_<1%30
M;Q'%Z!B'*DDHJ;QLE"":7MY)XM-K]A37^3.""(@@CJ?O'J&LL3C:VC5#W4TE
M@6"9XQU$^/'DVEZ()R$)/8MK0_,"C$I@CU$F)I.V+@1#H<8O[M:;LH)83XZP
M6$]Z"K66,I'EINC"*> .>K;G2#@%, @9!SQ)IP!1ELWR@BHX!9 WLE@B^!B/
MA6&[3]&K"YWQ#/-&?R_#W=\X%$E"!7O7+RX2Q6D33,"92)Z.VG[[B2M^4?32
M=_$,5NEV=#R[!:^TM6Z[V?Y@A8OS_=J35PBU]19I?P#54B:]W),3@9#_3TZ^
M;[9+9MLS/J$@Z.#I0/Z 3\7%7^1:)D_2RC<HCAN1)VVC=V=A>W/PC*?6".\7
MJ/OYW0[".,"+G@4,$-=A+FS+506T]QNI+."UO7]GI6;55C>O _#3GBY0+_X&
MTN[GZ8DB=,'O)5JMW%BXMIL)]]Z;^6B9:+CF33)?[\Y;M#9\]C*#T;V'QX.G
M$,E!C#?8U.#50JNB> 98/$>:8=!"K55!JO7<]O)&_-'W'"R]S2V'-UV?KN(B
M$76.?=[^Y@%(U)_?BM->EEE/P^WBER93&$98B?A8$A%NKJ/PT0]_!_&,HFYU
M^+H;!YUV4*C:]+00Q&[,DORD,K<P<%P_P+][)-%)8#R[C@+H@2# XKRV QB,
M9T\YZI\*FJ6DF1D<X?]G?;8VQ/$_$OJ6/[/"!;"RKUBV-[7B[Y"_;'W)Y/PS
M8S2WO?11](WO!;X+I]D+Z3P;XUD*2MO=Y.VI,>>2:.O)G]5F[!O 3#"TKO$X
M_U AHHK/&&?=I.*KD%EK%Y)3:@ZO=F$.7Z+ETD8?X]D+G'MP!AT2Z90\OR-)
MQ;#4G-PM0HTY/"Z;PY0^L7JY+UB;3UBY;YAL",M"J<L3P^B@YP3/TG"=(>+K
M;)QYJ==:X?3>G,G=I-=2:0E8T<DU\_ZD/.\WU*P".9.G>++%3A8 \)H%?(8?
MN8R+=3DK> D0#!U='@\NCHZNCD[/+D^.]3U<7X^9/'F+1[U17FG\WO0&(%(K
M=X)L<B&4O/3GW]"H^EQQ4A[KSZ#5$@M57J,=2DY)B)9Z&W9G0Q37UO@&;/+O
M9?[NH\:(G9:-&"%GQ?2L+8(FF[&U$#:\U!DN=A<M=JEJ2'7&A=G'. O!HZ>\
M 1#G3NFFY&(7$SI[@9%_?)&[1JB9TF?E*9T1C!TR:Y+_:25$39[6U,<H-7.;
MHY^N<-GJ<?%O)D1(&#?]N?6Y%2#;CN/NGU/H&7%JK,%YV1JDM*PB,9.M0)G[
M&^*ZK[4"'/WT).XMIGHB:3A+(^4W" VI&6<;N+5<2*TKD?GNFXD['RT!&LX1
MB#?MO\%P,7+A W1=LID@23EM[X/3<EQ4' UB\M::OO4#?\#"7[#B3\3;B\U'
ME%@42G:@&]_%L\(GV43>P! A$JY97"$HID*XMZ:"1W4#K#,2 A2*<^-$7SQ2
M0\T6:QZU8[O[APE2]0DF'I38!,3N7> )7'!<E@U!CF@ZZ8MD3=Y,, 12:RT:
MTM!6)*UVC/5F0X2(,9:CE:ZW:Z:UY+_[NXH)0,L'W^:-#[DJVPM"P4I)F&P;
MB(>9VPC0&FN9[<7!U$UK2FOCYB];'_F)*L)1A^J"Y9V"Z=CB)\)\4W%P5.4+
M3.E8&2&3)V21Z\=H^0K0>):4KWRR$\]PEG^;W_/?FJHFWV%^U/5NPLK6QDUQ
M21HN^@OY6>^D+<A5<N4T!!4QFPF13EB!'+^R3$ [DE(R&N>&0)O,U';&36,9
M*EJG)>;FN).S-^:+6G2H9B)711L2>I]C@M8619,G]8:'\2P_[#3=](T?A$$,
M(3+":9:FKFY/WI*HGKT[[Z"O\X.NW>.WHVJ<A9&#E\*908&$.FF1'D%<.?,)
MH)C=81@B^!K%(583/V>,TPK/G*:J(D 2?\@B7[)6 %GQMZS\QZS0+VQ+-M\S
MV9"-;.1!;[X1']M$T9MK,3[;PZDS*]3VQ>EPBJ?#A5Z#4:>7O"D0XZJ3DSPI
M_S>QWWD=_X.*X,"$B)51,7E:KOGE=N@Q>^@JC;0]HOI88WH7XZ8HAXZV"AV)
M\=;)B3I:KES_ X!KX($9#$G4$^>$K0C]RXA9*34K)6?RS,WOQ>)D)"%$?+?Y
MC2CH<>;AX<%-R=TGO-=$ZU&FNA*XIVM*SCB+T$#W!=>?3#ETTGJ\1*\!^#/"
M9$9O_ \!!A5Q@AM*UIJ4R69CF_/:[#RTYII2#16'4_LVD=;>N"E=IY=B*B$1
MKCHZ07D>'PL]0L:0.CIN_@C9^O?LI_\P?(IW_SURFG9C:UP?R?_6S7F^SL89
M +'WR"V85)QC_4H39KX'8#P;!2%<VB$UN7&Q4<<QP,&,TOSGNMXEI^D7M]/3
M<AD'KKX=QT5S'GM9Y*-:'*5LGI7B$D(1'\FBX,^PX,^[#ZX6K"NMJZP+<U49
M,YB(HG?H.%X$&5-:)5F;!?(]!PL5)?>F,/CC!O,!0_(3U35'[=%Q/(AR)JNJ
ML5& 6+_7SZ48N_>PT*)E[=K#U;?C(&G.8R\S)5.?=O/M>7F[=QPTK=CL95[<
M%X!EG*8R?"#%.K!4'GW/)3^2*P3?XS\X-:+5<43)XSF%UU6_X)6+/DJ23#WZ
M(7@&4P"69,-7C# GQ0 !<V5K3*_K,)/*=^;>.^H5UO !$V#YDZ/E+7@#KA];
M]CA3=<!&%4?/CN.G*8<94OI52>"K[T]_0-?%TKC'6O/FD&2\B%/<;?^;B1MA
M.AU'D1Q^,TSUJ^+F)KXY'WF15""-Y46.M/ -D*TG&U4-*'4<5[(XSI#5+^?T
M.EB/;Q=.:]YQC BQE0&A7Q[C9[QR>Q$@Y8U) @4B*9*8Z"8*0BP:Q </,2(=
M!XT$9C,HJ7$W:RL'B.TL @L2Y/>6!K2+Q$_P=N\X?%JQF0&G7V[I[?<=?'BI
MZ564WSF6WV678-*$NPP=_?)"/X(?.=$AW\,_.B#GD.>#BRB9CN-'"KL9H!2[
MI_4'=$Z(OXLOG//DZ/CHI$TX9_*M0S"G\L.SLP#3R 5)?<.MP!!\ GQ9^"@D
MN:]R90QBW=1>2;0FW'';HD@ 9A48I>0%H=[V90&1T^\!F$7N ][=L>'4EEQ'
M0:2$;:7QIMIJ'0FM2B?E5:FRXE%7%B MI8_.CD^/CB\OKLZUKUG#-QNZ1%%W
M/GJQ\ZAX!H[O.="%,=X$5ZQF9(TS-2UURUK2)$I(V0NHEFL8#[/?2-'8C15B
M+F)MZ/476FI$HV"ETU0$2VAU.RVO;I126%U9WWI6$^OZX]K&FSD'O"P "+\B
M/UKAC2!W>:R:[L6I<(&GPJ"CE;*:,-K])-64HEE")N"L; (8I;.Z8@;VIH96
MXVAA<XV W'I9?;<!Y=(_0M/_O#S]*VIE=67:]ZUH5FZ?6ZUF@2-J#0'CS$"C
MTE@M^>V^.6 4[Q"R"Y=EN\ L@-,5"[$OE7 V$^$N"HDC%'IP&2V?";[<+*TK
M/C./\:IID_''+R)$C4H+VL;9F]9U<]2)I?MFJ3K_MXA%&E3=#U.R@'?%&!W2
M@9?G3G6 <:SI),HX&#HA?,/0%;1530D79^2E_IJA\I."*Q*2=D>]='!FF45?
M 'J#Q-E4):VA&P\F?F=(+C?F'OP+ZP%@BYLHAQ^SDK^W5U#>A>R471L88'Y3
M:0]_V&B:-P#$WYK(+@BB9?*[QJ:X^4?V"LO*!*8@191QI1N$=ID5\1[-"CAT
M90_:[4H..7\//J]-H1N1QV>;2^#1N^-&6,_)LY+E*@I38R]: D+^AXPS8"*U
M(W8DCDXFN\T5G1 R/167\?G2$UTQ*'VH09';1<YF@)QX-EI]MDDVAQ;!8N(D
MC3,5@C4LI//>OY/E;3IN+)'D5?[0:W'9(T2M/^AJSW8GX\ >2:0;9O\Z"J '
M L)UFE#Z*4?]*7IUH3/&$Q"1!3CV<:^WRK<@M*'+MU*='E545DW&0%[JA M@
M92.)[XGBL9"_Y$=#PDSB 5GK$:672IN=M/7OZ;!,7_+&:&Y[\*^8L1M\\/)=
M.,VJ>>29SN6_>\&_ 3SN7$FT3:CO$,\_FNVJ:&J<89*J9T8)"#KWC(4ON\\Y
MUJAL?!*PT0>)PQW/XBD\?(>TY.W4]@7&3R_UQRYS:Z=:L?Q,FJS=S? ?[27^
M<8)L+\!PQB.\]9<V]&AJKNUHI+[YE5:A]&8L4[6O)Y7-T_@;($6M:8>V[._F
MJ:^9^,MZ9+-HEKJV;!3>2H)[O/"PC&]5\R*G5^>G9YHK(+>TO=P\2MKXT\JH
M:#/;E<DHX]^^K/"I".]B\)!)^;AGHM4!#2Z"9$R'$1L+%5"2P?]NHGAT "Q.
M8CJ]C<@Q+KD[C7V[P2/X$?^):H6X.O<23,VX5OH@6VLZQB<$'>K9<-V@=U!@
M<R;I=I:V*&E,@.\ , W(Y1 !.WFW%?NJ<GF1DQ,U_@4@C[I"Y@.7!L3Z!B2)
M4NAE!9\J^=Q[,(2V6_2+"J"LLO\^ (N?<:7U?X0+UM%RSZ2A../9=P\/]P>Y
MP?;FQ+M-\JYDCG(8D.W=]DY&G$!? "*)\UX6!-J(9;W7(_,F#@&C&1A&E[Y
MIC&OO2P#E+M]2[;^XR@,0MN;TE<A5I>^@4285Z4U?W051RWNX'AQ4M.K;U!I
MPJ[2$C[:2NENSYEA%"[PF/[:W.'7691-C[ZA1)15M95W#(#(DXW&*+Z?GL8Y
M5+*0S'JHT'KV&#)"+*LMQ6/26E1K8-B=^@:8!MRJ+;%C!E8$+0U?YX(TSX[.
M3R_.>H0=(:[5%M-9BU5_#.,#_#."4SPJT7C%8PGQBNN/'^(2.QZ7^!B1J([Q
M;)V)X07,XW%1>*6V-\X&*8M0%!-!)]_M\-4T> 982- A+SKM8"%FAX[+<=,"
M)0X^6YMO6^3CG;%#W:]Z4-1ZS>BK&QMG*X3+DO(R97 8:_XZZQFLUHYHDI.8
MX^IONXMQ.A70$ONNCXO3MF;^*C'!'IB3?6YIXSG0!!+"[[V'11<1 =S9#A@N
MR4RA (36O%_@$.)2:9R2,"PH][[/^+ &\5!(P67T!HK227,-5EWW\O3KA^[;
ML:L@MX3^!:2B-,^6:+UI\1?Y(CXU>05ET#8.>8)U')7)@&&33  5B978XB:\
ML1'ZP(*+/4 ,T-3V-0X4ZM1<#:EF$I)TC*7%7PJ7PZ$N9%N2&X<+@)(7T,QU
MK+;;7N*FE7!Z&:'=2NHJ%KNBZ ?ZBQ7OVI[)E9RLG9H?VJZR$H%%EG+3\='W
MN*U<9;>]1%,KX>PF1ER_L[>JP(JHR[=T]23D\JVNQ7+P_.Z,@TUV&7J)$59>
M"\[NQMF@IK5K&[!IMK^XFIOKCPG^.".]!4=/XW3>2HN5_N1&(N@B'@A#S#P8
M'#V-PT-3!0I H89[LY(L))DL 5J/GIDA@]*Z.UJNT4W%R42 8[,TRZ?1_=&D
M@ ;+K@X])3,CY$$2TX7YOH/OY*> J4QZAQ[K59!IJF/ K,7WH2;;37U'XU2^
MJZT86P*]]&9293$*0K@DD0C? S"+W ?X1LU<(D3#.' U1(, K+C%(++7U^\/
M&DZG,!G@O3?ST3+^I*A#J%S&2L0AM!F"E1O#P2'4V*^\E22C>C2,ED58'V-8
M7W3!<R/*D>*[4'V+@>H'MCHA(:KD*@LOSFDO$YW%]R+WRY4-$5G@;K DYO7&
MB]G)&)@T\_DV8,[@&)P-(^/9@^_-R99EFER&3?QK@!?L%;9;T_&,HFKN_N9I
M75R/93"T8[^7%F-=QN"[Y^!-,CZDA_7;'78G\[ C9#$:,*<TB%37IN.[A]:U
M!K$TKH$'9C ,UN)Y IC%6#3>]-[#8P=!.'HG%>5HUXPM*!J'J08H*4--MD!Z
M4(*9\WF;@S_D?B3Y27-_1[Z'?W22EX*B1][3EL_>DC%9R: *K0K#VL=3\#]U
MO9)Y!#]H\!@CO(GPYN#>R[> G@-7+F!%2[2B:9PA8RNM;+/D<R_):KD:2V0-
MI_^*@C 6PIV/&")BQ&((T3 .1O)A47&6:RVA'D"-W*:-9\-I,G;FY6%54^.
MTUZI9:!P,]X#/&S$]4+<73::!M]74SL$QT>#\Z-C)D"X^AJ'&&[M5EB0Q@R;
MAY0 A3F4X']M(P3_ZI\WT3)R;5++,BEJF63QWTBO8CWB[68<+E0N0:V$(NF"
MVC3L5$82\G<T!C^M="L&$0;G?34PZ^6]<B5J0J)3P&%H7-"Z\$BAHR!:9W=Z
M<8!G8[XIRU)ENZ(@3OJ_#O%+09)?>N=P2/GZ[@4KX, 9!%/J6D-M:PPLQ%2V
MI6HA[CHZ^_$4N2,A0M0%HMC +,4**:BH7 ZVS-/HSCRP#S7ALJWI&H.C7;K0
MU$A-P4M;+5A=YXU\ '8 GN%\$8YGWP,0APA0<,CLTQN,L?5?QIFX5)3>7>JZ
M?BJ*X0':K]#% ^*"TKKU 40<\MA-,C>55]_?;/0'"(DM?P&X#23W_F)7V"?E
MS*T;HM:&*OY]5^Z@[[TWD-X.D-Q^:?1^^+%AIC94B9^ MCR.N<&\8:T0=>&=
M(2D1SKJ'YNAIG.D0U^=V>L<F'!O\5GN=X7J3MI)Q1TQI;9R:FRJJK'(1C@U6
M\P397H#7(1+)]0+0&W3PLI;+;[[A+B#76T'UGYAO]V5^PCA B<"@XCY8M6C,
M>B=^XZ.5CW=.H#@-:_( ,/H8!P?E"BUC2%Q IH%BN02(2.#)QOOJ1S^\]QPW
MPOO(WV"XJ$X_69<YHB'! YRD2\^L- >;=^';2_]FXM3Y]X1H&(<H>1N@]G)0
M>C36M:%B"WBX]%%(HNI)N=[1.YE8>$8/'0=%8!U)?PUF/@)#U_5_D,J^N.L-
ME@4,'_R !DK%7RVJ[_3\]/S*E 0/3<$G>HA3(T-9SL7*W*&ZG(O;HML2K.,D
M$05@^A5AN9"W)K9+)/L5KU*)!"?V.RTR4 ;MO8"S.DGU,J])4W&1J:T*M 7:
M!]"VDE3;D).::CNZ8,M>M&CK5*-=!(W87@!3HFB4IG_6M>9771*1E81,S+5T
MXA39DX7M3<"2^"S0Q^;A.VUGVY[P7N!3D9A2K)[U+&\->S8_YW9"C2QEGL!>
MH*^E.%*4G??*(M*E2Z3UC510YKDG%B6S%WB3(I04=1>]/L;0)$.<N= ;>^!W
M8*.";Z,E#NF$C4.F%!0U!Z>@I)3&H<DJ,\,MTAD>!V9]LD!^-%],?OA$" $+
MB-+I]QV/NQ&86<5*=VQ%7_"FV@7IOS]N[;#H)KZV WI6!8F?Z#N2=R8SLTIY
MZ0>SG*TIG;!QP-6Y61444XK52S/V SJWKW<V1*PBK^V(&H=117B2M)%ERVT?
M-K$T.$JE793N&;8]@YZC4KWX#EO9@EZDK_K[AUE%,MO--E7EFZ+U1/P&;/+O
M!GDQ3\N/B@A5*R9KY>EVZ%G16BX;ONH<Q*PN!#U'E\>#<XR;T_.3D],+;<])
MLE%>?US;+@F.>ED $'[%YGF%0<]Z3L33U3C3(JR5LM%HS+?!STVJXX<9#XOH
M'<Q5N:B^*H*PQ;@V6.&ERMM;/#6([V]#TCC0"&JZ#!7ITC#K=<@WWP,?27##
M7>1-V<BH;FR<SJ6KK"(<A%\29NE;\1.Q_="^N$#,>J9C[).P?8&/5&F9508U
MMTO+G1'C*R'6^W9V+^-0(G$OVH1U@RM5/9&+0*R'<,U7Q5&-:4P$*)B,"VYE
MEB'15@)F;3FR:JOC66-(B) P#A-MM5G&1VMQF 60W*19__@K! B+>/'Q -Z
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MB3]Z7T%4Y0^11O> TI:RDA7NOBOW&T_D$A;S+7@#KK\B"873K "\E]*B=/<
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M>%F-8V31#\O:\ZHOA&3-_@H);+0P2H2C*!J$4B%0R&CH? 3C]K3[RX-5-4R
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MI'RN8<)0%O5XBH<7"-D'3/T6HP7.WB#=V;1#VFS8<>N7N(9@9:)Y@ZZP'8D
MO^"<"AG1"F&[;''6& M49=Y119^MTCN[(L>BT\;R/,S,;Y.]]V5]&9)PAP1S
M\0P1#OZ*38='SLV3#-8 0D,&QT2.V32@FR=9B#&8OBTPWG]VSINP?#(*Q'W%
M'NY=:'MHCK1O)"!%LPA687,$P%5$V[',N[H.),QR>[H*UJG)E@?S, -LST:(
M1?G!BR(& FAH9RI9_:F#"1Q#]I304 XB"=L6 0([E+CDB'R4(2CMU  [''H&
M6)X,!#9K"$"<#7)BM:^"=!"^%M."8#]X&8<J7R^NC.W+E<RRO4>@+X] ,\$N
M\Z07DJ@ ##O8X-X1\*8P(=!/T*4Q=:9#JQ7Q6L'"M1!B*C0R=@]S7Q[F[A /
M=0 [.92C#N6#!]'-+E+[HNG1U''14#CL#$:DO7""&7]"5. 5N6T\ZIO0/!OT
M;@!4".J$]W@9;&X3@FI<ML<];T*765W<V%H%XCI<%G8OYW\A)#N#0JT4?I?&
M5Q\LJ!P<.-<.%KG& 0$9 YA[D_Q%?6<'X!H0 @8$/"LL+/6)QUP/P:IKZ6CF
M=9[I32O%BG BAHBAD%;:/4XEN,S3KZG?FBZ*&0L<S[+TZ2M*RW(4WJ=>SJ9>
MIO:IE_O4RX^E7NZ9S==@-HN,2I%:S5"Q'L4\:X;H+S?X@$4WJ,A'<SE=%M]%
M_H;:#=-H-,><8=GC_A9N?N8A6P?46,#3B XB)BA1V/!=7&,/X%\#P,'6*30'
M )+%U?B8B]IV#>I+I$YOW_DMOO_O?Y+Y'P>^!D.3T(8@M%"Q*E2F(ZPXAPII
MTN@\4T@Z41P!O*!A(VXX2T<@CRB2 2".511.W#G@6!2JAL&K$N\3&/98L9HB
M'T8)"IT8L #LD0,4U%D!"Q%S6L]K$#Q>-[!P"HSCOO*%$[!@56Q'PU4Y>G@\
M^%?$WX:6\0<I^>5P7<<:K^NX5_:_%B)2WWR75B: @F 0\\UX2;1 O0X%#Q99
M>:%W,^1:LW<ANGR*("S7@?)HO.888&%X5%KPB;='F/,F1CIX\F&#ZJ&B_%-0
M;E24AIA],HA Q*QH2L#S"(;;)L%<7A4J7&%2Y5)AT&<T&K#KYY2+GM>P'-KK
MD0;0T)*5HM!>-"[XW3U(A&@\RTWW_I<]YO[D]C'&U<!S(A'L@L+JD@(^1^J7
M652=GY<5\0NA*RJOA4/-&@XK:+"HW*\=\ T_(6:YCY_A-[.>LX*'?I$@AR^!
M%A[Q%\LBWH*UJZ)N(.2*@PL)U*XWP_ C127)NJ#8RSY]9(\N-*!M,5S[(.>(
M@CVAVNN"!(?,T!IV0J_0K@)^&7:8P;9LY/(DU[ UVE!LVQQ'^1;MI^'C'0OY
M)-J68KA+%@M":^#>8BE@@54[Z'+JNZ?":,?K*3,Z07C='BV^/%IP^YLHU\$%
M,5$'?GGM=P&T+%5<Y!N.35O?RR9[J JLNB&ZJ>H*YD5?QN)W2*<5Z;@\('WL
M>)B10Q\*[;>;$41);0<%R;P'-)TN!@&]WE#DWWI&((S_> 7,_>&ZX*B"E9*[
MHEE+GL'7]$:B^=;J_O50R<@F97DUQO+V^O_7PE0;1&A 2E8-"CX8,T(0 9<^
MTBW:.]WC?,$T6+E+*FCKB@%Z]HH50ZAV$#+-^?-H)M?3PXHR$9NF$N<P.)"U
M $\UC]5E#!O"7[%^#Q$2->MI&49%TT%9.!#T:(8+<G/$@NHFPB:R]_CL46H9
M\POLVR+D,3!"1_(9_3*!HJ_C]&!!!88%$>\S6OA*Q7U8I?5(2B6K&<&[+@2H
MMPPK>(\V:K4RPN'$H?0:@=WOPH]5..4>A[X4#CD(#6AZKP.'CIU^M/1(%(*Y
MCYY;E0%J!<@&KQ.P'$JT *[ )[ $$_W9-,)U"3GD4\LX;7H F<6 -6_C);#"
MG?0%@8'DF%O/]B+@U\(U0)@^^5:?SI>2 Q\L488(AAA(9WZ-*)8%+(/6!G*I
M=$;V<R -31>/6. HZZT$[(J%D=*Y6*%UZ',1FF QUXF(A'[UI*C)UW&A)&YO
MNI?!]C!-.\>@2&ZO</(!E:9N22:7=; 9LJA2;09\^^1MSQ495F3U&(6<>D%
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M0"[AV'2SQWH'D&&!:A_PIA8$,!25.9MI](6N.W["H6T2"D-S'4+/@3.8==:
MKK1L$63G%M06A2J(K,T2#R0B@@!RH7K;*3\#L)1!@E[/9KD/%0(31=#@@J9S
MT *67D>L:JC4@4'#*__[GUPB(?\X+5=.8N4J_13_<0"K<:%*$MT^A&?13O;8
M])SP"3EAJ.#!DN* ^.FR;3NN#48(FT,6.7&#=3F+#,8/"-O^W=+;MEBTO$1Y
M8*A-R"QX^75@Z'4A&D_CU_(>]TVA3;!C9<DI/ XF5&,L_(:#!*32I@NLHY!&
M7L=@OP1(]KW[P6L06,;? @!BZ62AWBR$U]*1H*-TJ.FAOP1_&ZOBWNM()Q1T
M&'$.'\$$"S(F],:F>A%^]J!>H$K0 SM#)M.JHELWPUTE5$_08!$6ZVP"_#$*
M5UV:?7@@ZFC35M&OGIFD]!1L.+!52M?$SV1$;I^FX<9@@2:$A=Q/ _=TI,;B
MZ3!*->)ICD[0&4&JJJX)VD!"AD6,@4A MP2X7F5I_6^__+>$C1D0XQU(-!:L
MZ"K0/YS0+\>$H&/7&T+.!D!2T#^!5;@71?B $O%I)="D>: 8=07QY@N&5/!Z
MY Y@S?FU=B7_,!OKH!ZADXMK]@<[2T1WAE8[Y]!-Y>G5T3/A(]&K$S&LM)L
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M%E-<:_BE&BE^JG2TH$GSK3?&2D@?I]DZ#0S]=)MC,]:@<A]O.J+X7AHQ'AN
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MR7!SL.9DEJ8[A\:5,CR$[Z+(,#5"TQE-97W&<56')R^*5F$VBN[SA!%F.T:
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M5WN4L3B/NH,/I;5"5'-)3KA>ENT*":/TG.$6#EZ'\H;&HL5V)8;Y; 2 1/Q
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MEA9+>Y*(X014B7P&Y:)C0$I&DFY@+@R:= Q"M!<B]:L;!J-5-K$]2I6X@+.
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M> =Y]%V%IL\/A:9#H>GCP-A//O^H^NCC9?P!'LM=*)>P&GZ9$CD_X"Z(RWL
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MZ.%ZZWPN6+1'%#V&8V3#0B\1(:PC7$5UJ.%H^#ZL,V8(8\1BDU/#] RHTA&
M0K1B)-NN\+APYY_Z<DYBD%9IN[TND(7*'6B*=.<,YT\$2J:SK/!DN2_BYI3V
M/I[K5/_0FDPCF2[R:BA'0[V1M3C7$)L2[[]L12A8G "#:?E&?Q+?#7<-+BL
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MPIX9N0,>]QE+@8I88-T. 5,"?F!1"T,IL5083F*RG5Q$U2UR1\W0E3>*CUQ
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MRVE\T9*Q]@?PLFF3.79#V9^HZ%L;I#JK(),IWJT),;U(B 'LR60_N,F'.V6
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M;_Y/08Z[/4!O/O/O_W\1QJF'__K%S?]AGTZ,F E0 DT2_3AE"$T#.7E*^GS
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M_[=D[IO AS,+N,W6>K["J2JNS&"C"J_4V=\2RVC/T-B](Q<HNC@\,$)JK_\
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M..,KJKFQE,/BQZ^_>XLSGII\E)U_Y]2Z%K_O69KVL.66F'(SQNI0DBB!EHA
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M,M+>#$*S](8C5?AWS8+G_NLF5_HZ0N?BKF6J\]"MXH&RP=5$]HQ^YNVS3[E
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M($097'(2%)2M2Y8;Q!#U49!0A/4&1%!#Y*2BP?]43+5/4XS?2$GAL1@_OLP
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M&P^[L(S'BA.'7P]P$$-UIF #W4"M10>$-*F",EI.MF82.GQ:CY*).@*$+K'
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M+%NDC9K(W[KY\YOV<G;IZX0YMB>'ZZ[>6:U!J@A'5>BAZ)8\\53TPF4)1#I
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M[G1/NL2F=X<\(A+%:*=[2,G4U5LV=<^X)DO$1UJQLBGE;:-0J!X$=:>D[V0
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M#^'_OGXV^='7AQ#OAR,CG-SKMTSV_>_E_O""?WS57L5'K$[';MBPNL?X#7Y
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M^'P0FY_$-]BU]P!XE(TD*F[+C6O>8"%%_TJFHI35N\ZE8%-NWM%[C]\TW,$
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M7'W)[ZP\2CWSDQ<IH>VF*XDX:2UV.F.W92[<E3 X/31$%T/'_=5V$BTB:D]
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MB+V$NV**R5LUE)RA7^ JR]HZN[;J_8%3&^6T90P'0?FVXH-?4YJ6-'=JR]3
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M4)R106Z\EA.*5+$"53!PC "Y9'P8ZLWP+]BE@JO'I?AMZP/A=#O#0J3-D(*
M-V:<%+I.1-]-UU_&1Y;'(Y?BD8T\'IG'(S<A'OFK H T&]!@9^1?):GO>EXB
M[8-^3;8JTCJOHT*%L1O?T/98P[:3\E-FC*1*'K/,=F"Q&*$PTS70]\)^PSEK
M/Z[-RA'F3R-D-\C1WE[>NM8E%<2UHL4#, I&UTR*4J![=:YJ&LAF(>^6M<HZ
MD<KSZK.S/#&D/IY:WXT53\X:U/U#I(:D L!*.#JN(W6&/A5Y4D0 4YI56\T%
M.SR4(V1+.T)8)]P-'&=K+[3]2^L"8\VGTU" 9GHB*%,07PP4%\U@@]9QB-U%
M22[IVSW9X"OM<3":DO+"Y11X*J&*LX78#<.N$%)'.3@YGE W.9L2=E+/]C/T
MO[B<%@U4:EFG*W=)Q12^BBC%*B:F8():3PJB]C*XL2:KLHPS4HDG(899^J@N
M'RW7"LN!]FKRN"(<.Z.A&0EX2413W0LU@XRL#Z M\!Q@C9[RCFP8HMZ1* 6.
M6S%1CO]0>FW,;>LWQPD'9+I>"G;.XZ:O^.#($4XK[Q-Z*%\-WNDM4M%;<\7V
MS<M&6XM>N.QLI\/$K^+$2-3!9I$1 U'.=3X'SHHW\KGB# Q)YS(2:;(Y2:-+
M26FF$1_-!FQ93G4J![>T9'\0*' .F2"AGJ#+JIT\\Q A1PIFHGLEOT>NBI=!
M1AC&!IP80TQRD!%AV>-UD'&%:1NM &P,11PT9<MT8*EPLS<&PX^,T(Q9V ).
MF2-9D8WX>S16, S)[A9*:TSW'C"1^R;<L$/5>=CLPV2'"W:  7.>X*+I8NHI
M,)9J.^;+S!2-@3+MV=@V96#)C.6^RILLF(*S("^6C$NE<BK2IT,26#LJ^TL0
M,<#]* N',]=A$HZ4 \WA %QL<\/F8O=S+W#(^);%^<D$R40[,YF;3MU058&"
M0;EFGXH1*!U80D9HY0NT@5V5JP&'-PR8<:MPFAPV;K#$3(ZW*>;RT:KT%9F(
MX@B4LXKTN.( ]<<1[B?439RI(,.L/%!]7LY]LLKH]^@^I0N63$H1UR"4%)N:
MC>D>75FPF)@9^X97G"M,E,^2N).4 W$T-9G&9": D2VY=(TJG3'<AI)?VE;<
M^/@;2% 2!/%RT0*<X?9E[%KU\5TQKDG()H(;I/7=AB7*O8WPQF(IZ@T^%SIG
M F"$:12RZ@.=X![YNZ;Z7 OWQR]*.U0\C"D6H!^ZD2/;&3%#&2ER9FQP&:W4
M?<B_,&M>I@O!KZ@V4C-WB7=>7&TK"SFP=%FY('\>O]$X*"AWQ6#F>1C-@R.A
M9H#HIIU*7/4PUT*FR$>!)Z0[9IDL7KI_<A8',FRC)$_NC=O[2]K ]NHS;%&B
MQ(\8V=Z FQK&#Y%W<B&I;#6!I1<4#:-:.J*^="U=,)=MH7R="J-2 K#=*:C$
M(AO[:6<*_0O<[O .JP$--TI',?$&G>5P]YP66NM-F7NJ!S<A/B[Q:GF%24B3
M-B3%:H%3/0J6\"E3E5I6*Z^\<C&ZCI%#=-MB\!Y)A8@"&:M9AI<BA'1BD/9"
MJSX]3M 'Q$77.>;NV%0_'B7\YBNHUF3^O*#[4PCK$=K@H8$+<K9 1)I>-K%C
M.^0(55MBQV1ZPGNY$,R.S")A\A^Z?BI!AA"'7D$=Y-CGS@E,R<X#?94&A'<0
MZ)""J1&J/CW#2(M&-GL#'($! 00>6<V@ZLKPA;04Z%O).95#4VE "0<LG;HL
M:1L%\B',#N*+G0!WC[Y9RC&2E*$%IJ2<E:WE@N6P]FUOI$ /25#;E)]QU4DL
M/WNAB98D25/RDU%UB@86>HNUF/T5N6HF..M.%(+E@)H[9E3+:\_.K1R+,[AD
M6IKMZZQVDE-QF1KWAN*TK64U8YM;N&I/]RA [_H2I.Y >#\CE5@!&F#JE6%3
M)>J.4 ]&%1Z9K4)_@AVM+>7M44W#9(  2 3U!)=8EX\9^K@2DY!54?/:=X:G
M+6-;R,C0<!,DD@#CAF,U7$=%=P'O?)F<QXX()?1C)PE_@^6)H4BBNL[.8_ H
M1BP542_HJTDOQ@N(IP!1!3Q-@,^;@Z.*+SD,YLSURF>331I3"0W/YKUDY.Y3
M#J52PU H8>XA;XN3#+$3MTL)6UG\YR:%T/4-3]4TD%.(I-"C+UU?]U((!H6L
M61!Q)>R2GI\0L%$A:>VG?0%)W?[V?I+)6249.0 FW!-9 -MFD\F!4VXU^M5^
MMUP1]6ZU)JI=6Q2KW7ZK9S>$+9QBN2>[3_(=^U,Q+KT^]['N%.QAYQ03=79H
M]L8TZI9+]4J]M/YVE;>9B;*Q$2[.*KW>MN+U6;1 2ZWP,>M(#X&UM#7"K<EN
MJJ;?DHBXQ$,Z7HU<!]9%S9::Y6(E[KJ6AQFSPHS-/,R8AQE_+<RH6&RQ6*WV
MG$:W*42S6RU61-=NE.UNU2DVBX-6:="T2TLLMGQ,Z=2HX79+S6*]V'Q<IEK>
MMN(5/283/:*D&!6G&0G;^3ZCBD+V&2NU!03W:P&B[\KUT"A3[7IDW +TGHC%
M(A6O7*LF!^5FH8;E8_A(]*1PG3^KT=@KI5!?_M6S>T$8^WEATS,<7S?37:2J
MA>KR77-J2X3U,=0A+V7=Z;RWQ.I*M4)S^4ET/Y>2@AJ5'-;"*Z=5&,N4;SR3
M8R_@9K#L(QZ:02J/;*A4K!0ITA'7K>B #NP0I0K-:Z-\7ARF,17QR#'I2,&4
M8E5X9.-,!9<[*QK:C^ICBQUZ)#0R9C4D6\F!"HA/%LXF"5%)[K5!451+0-_]
M5K_<K39K]:[MU$5WT*C6JD[5M@?-UA*Y5PXP2'<<:XO=5KG9>%R2KVQ;M"K+
M6-9C4CY%OXRF31'GZJ-1K?T"R ^0[F0F\=+Z50HQH!.U<6H62#-TIW$I\@Y%
M8(:<&EQ05U+()*NU$UYP# S(VM^W"&Q-M@S %FGS7)P3RHJD"3J)(CCVZW"H
M2!:8;B Z.X.^+<IVL]ML]6K=:@GD6*\Y:'8!E_NVW>P/FK7!$CI7/X!=<FH/
MQ'2QJ\-,$=S3JFCD?R2LKFY;N#B+5V<9R\M-@QO0H"$&];I=;'5KK1IP-;O1
MZK;J@TJW4:]4F\U^JV4/*@DT.&Z?G.WO=RNU>KWZP+K+2KT^JRP>E@6D:FP-
ML:+V@?*#]X)0C;8 RN9111T:;O:X.%O;MC[$LQ7C)6IGI9RJQ&LMP!7<@LQP
MT<$#XF#Q/M;VAGKP%RE"?*_A6/U]Y)"AZ1LG]I]>8@TFW%[\(\&R;X@%W.#;
M>*C*B0"6Z_SGK]X_&Q6G3,[JPV9KD2JPD>E4;[R@AY*&!@;(\S=;S_%ENNU<
M+ .CQ1B@HR_[?+:SK<1>.Y*]*U&]H^9_9=8U':O<*#3*U4*E6#%'TH0$O:RJ
M!=8?Y4CEU*0O]0 ,WLA"9?;NH52,KY4/-\O392U\E'P.>I=Y<'AZ0$5O-L5?
MX^DS>-E(>&0 1)S>AD$5E+*],+A4[V%OJ8]#9X3.Q8A7M@P!\LGJ*(4JV4^O
M,EZ']'2JI4Q#*C!4/6-H/(_[  D6)G4DS/]:5:&MQ-&M6O5&)-U5R>\;0S8J
M9=;'*BF9N<\.ZHGM.NF4?54_(0M 9 &%3 5;+@18G?NO+(^,U/]$,4-<R"&S
MJ3"09@R;F_E./.<C7=I &7P37=)EE&R919&X#IEU2N4,<1U$NMQA@Q'KG/O1
M2J5<MBW<EUV8CSG=\T@V4]X8W*,NPV"!5PK4"YIG(6.=&,?<]H^/$F%]=N7/
MA9JE2E$1 )U5*S1JZ18UR18KTSAS6?>BUJ5C?Y1JVW OUMG3_=Q 0$W2D:U]
M)PJR>$.SOEVQ &*>#EIQTP9:D9PF,XT'<6$K5VH3G4A26#%?T1BO6+)>[KD>
M=V:M5"I;Y4JQ66G\&;=?Q7(T3;)Q7F[ <&TQ6"DY<&CC>$C;Q\SE_[7'D[]!
MN]GFOJL?<+ (4-7!PL>1TL<NCN<J6'O"]S%RBP%\ON-TC+'6?=/:P@T?NPBY
M=_9@$-KFPVUJ7P%;_X:=&*Q>$%QNA3/?YUGJF.\;-V2 HY;#5\G]HD](PIQC
M61272CIO_FC4MUN\1GD<,L?<$=A\6X>W5082AWR544J9E9'NAO)'?;MHZ<=P
M^BLO1.>,+_FV_JAL5V-,V)WIT!UVAPP<ID-N6QI$,F%5X7:01'^XC/)REH?/
M%:P_BMLUO32)7#Z5/YKTKAX<=YC4KBO9&10A^041]-S'[I"1;%G9QS1KV2%?
M5< O+SCN7!X*3.1%U0C[1]&;..=>MOP68T20<"&_99,>:U7I@22LL>'N!C4\
M/Z0@) ,VX]C#)+0)$TD^JBYR:ABW_"13+23LXA9 @=%O_R5'K-TP[I07_4F"
M5Z8)R\R34C$Q+(R$*<TTD$^7@Z*-=!,N$XV;Z9DC^LXH9*V/S0_B<&C<28P0
MV+-]S ^2G<ZS,4VB-ZIH,O,U;OJ.\M7#^RC2.Y,9F6A24(F%'6KYFIA\>)K-
M".&:[30CI"PA[I&MT199HLEF:4!LM5Q]V?OS9?7/&Y)=LMK^IQGIYGD0!LZ@
MU.HW&MUJOVIWJ[5^O]NLMIK=5K7F.*6ZW2C7EQU)=39_A*-=;[OVU.[66ZU:
MY9'#S/5MZ_\[D0/2__\- G<>RUV*Y;;R6&X>RUU++!=85:M8;/2ZM6JEUJU6
M2]4N!G#1+UZT&[5JL5:N+3&QQ@==,Q:AOWE&BAPPL4J]\L@QG@9Z%I<Z;L>+
M)#VJ#=)Q$5&O>B,$LJ,3C?":DSC3Z$@;KP]:/O)K6M278 8VCRR^L1UIXGM>
M,%?*MP$ VP# BHXK*K\LH^F*FD(:2_[,_F6QQLK.6Y^B3J##"VY0(+Q(<!:?
MZV?$EZ0/RU@YEA)A=B@J,G,[=+8\L&NX;:%^*4]@0M<:5113^M\2.JA@+M?U
MJ9HK5>TFAZR ]O1-J'S='O:(7&J_$,-$=:[GDBILW*/: *N2)U?56TH/HP*M
M&@)&1JS2![$E7%*] Q!H]2X2-T  >Z#(GI<("GX\-ZZD=H[^-'1[&)@F#XV1
MD=FGOD'D!BR0&Y(+A:=&BX?"B@6A LR TF.ZI;/V!%L8R04IGRW"1?Y\BKF&
M  P*79[HDK ]N;L#N;LX.&D^XP[X<Q<2<".)!ZI_-16MV'B;T4:'1F< <4]'
MNC19#<M;0B\T(N3DX =U6Z6902R CD!OP>5NC(TG9^EA(K7KDT(%& L&3\\-
M)CC0P.Z+&2E:&KBJ]-)1I7U8:: R4*2C$#_Z\+V'^:)AA(O98OO,Q3$V ?:9
MZU/?)<SF1\<]%KGVI;>(#32Z4FPI)@5O$A1!HB@VGCV_!,6RO!8]GS)G&K:E
ML4+^R#U_T.&.Q>5]'F2,U9G *48Z;B!';O@ZW;:O[D>UDS)OR24W"/HS<OV2
M\:3;M0+8O&!(\)K 8U%/*\2E)#I==T!/,S@QEC%1&K9Q'5J;BX@+*-0B9$M/
MRJEAQPCR/AXRQ,-Q]B0,L/Y_'QXV)*=408\W(I'+,X+@R315*-@Z\E$1'2[,
MJ(^<Q*;#/FJ&$&T_FLZ<A2ZE-R 4F5@1-UPG $GH\K;!MIUA[I+$K,!7-?Z)
MA]EZZ/= [TL5)E/2O,.3LB3>I=&+$(&]E_V9%#MP+BZ]2U82R#1\50VM1!#B
MA#VAQ SSCD@H3 6@#T/N^.; [2YR;L1D7; ?WX;26-[%J=L4$I"93(B&CD-/
MXB(Q[<C72]#;N"OMW4QT*@&<FB6GZ1%E$\HD+#BF)'7W^PR[5:(CQ(W&1MIY
M3+LX+=>13$+WA9/%!]A<5P)BL^HWLP<2\CQ"E#WVS5#4!3$V<SKU,SQ/UF)/
ML+$%.A)QJI9CG;I#3_2W2C63R$Y+-4E@E)=W!/)83H%L$IW%1;JV=3RBD9E_
ME36O!O!3A'*@5NVGD,YVKFR:QH.^,N /U&>Q;]&D3&LZ&P<AXY;J,>?@1#\0
MS"K0@[Q)OM:BAFO*TXI5H_1N>&5[-L20(T<K6$$3J)KX/*MK:L<.W_2SV&>(
MX2XJ[5(>_*#O8L8,8A S**8$\AWN*#E!&L58B+@+'-RJP+I_MF-]X-\T Z/\
M*F/,YK9U/N%YH;3(U%I<8WP=SE*U4F,ZP:3='$\MI4YB.(./C^($"A&D)LB@
M+R>/4=P-J0RT;!&><@$,/XGP5#E&<8 4+4%/2BBF4)*P3K+!>'(4CWX:!7-?
M5_P)3UQQ;DFIAHH@<DBN'M,51W[@;T5CFF6"PMF;8142X4<B?>%TYV!'8T&
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M<IQ*.3B0.*?$&7K'@K/^3.'$7-&4&(HUH<O8YRH>5>N$"W1!=KUUJ=VN3++
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M/D'I)53;".P2,^BI8S7=PMDG*RHK,UXM6S-(8!<,M1S+PSDFMV2[^$MS&V^
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M[=4?LP/C&272>5XP)WV D6\V1G3](2*5N:< ;W2Y448BFG>!$ZGXEL Q(Y0
M-XM@?]&?K]:SNVIZX0D&>>5&+@<57HU<![9*CJ!FN5B)O;_WRZUAD"*XI%1
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M@O&5%H 5(KPBP/G_6,;?")6E4\/ARP;@$O.7Y6W)$<SJRUM&7LE#GP:35V5
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M)+C&AH>NX&#$E=5>W2F:!+R26+JF#A24]/X4%\$ I14[ E8(+ +@;5V!DB!
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M.<@[#=6ZY/M*4N&]K=4*Q[NKVY4;N^(8"ICQ?)0C S@R!33UF1J;O.+H^AS
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MLT2 ]B08C'ZG6VA6+_2]@'5#VY>C>-@!D.K=66"--&N(U)0]"(74_*JXXS+
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MAH-DPH;$2']&CW.;AVLK,<R,4D[9UO)>L2<>Z2$EGZDI]MVP/QNCYM9'=&2
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MI>6!J0$7(+2SSPN73($F>S!PJ7(!ZVVXGA)T^ZN@3\438"ZAE:W>= .(=+<
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M'T+*WYD<OQQ\:[6#W;<?.A=.;7+PNCGZ7COZB.181W*LE]>?K;1!/H1=,1
M&<<*J1I+57E/@A!WFELDS\DB><Y1FB>N/R@R/ 'BVX%_W1L:;DZ_C=ON]Q]?
M9\6CX_'@^$OQ,+P:#KLE:FE7SNN]<RK.J?BQ6NO>G8K?7!\-_='KXH^.'91*
M!Q>+_7'S@J@82\ JQ6?C73@3X=CR MM_..WBW\B$GG%)QY.IWZ!\O'(>TL[Q
M^&GC\1,3LP>!/T2I@IWL;PC _:C]F%[O-;Z<B^:'^N[IQ=O/U7:[6VIRY]AZ
M_7G9]7^G&[4]A#<_-P!R ^ 9<::UF_%W<CA>BN_UZ:!_%9[/+G?+7R>CS[M-
M,>^6J&=;O5 OWM3T*2?@G(!S GXXU>(N!'SZL3/[<MJJOB^.W_;&M:N>)XY&
M;21@U"R*A4JY]FRL]U1\P!=3*QCDAGP>GOP7A2=_@[?_QGX*Q?![,ZH6YXO.
MT<2[^/A^-GY]]&X(*R.'?Z&2]V_+*?+?19&_P7-_(T5Z_<MW1[;?O[Q\\V8T
M/[DL#[X$[XDB00-HW$B/3\^SL-J?_\#:0&ZLY/V<'G^WCQ@/R D@)X#'W^WS
ME?IF(.%&>?_5.VS/NHO917$\:1R>U7K';F4P[Y9+'$MH/N4I=#IPD*?_YQ'-
M/*+YV'&##.XS+KW]_./'I_/.^?C;I^K@J+=P]EO ?:B]6:L D,_M_YR <P+>
MC+A!!@'/)@MGM/OAX_?+\FBWVJXVV]W3BR$2,*H/Y4*K7'E6'@-X9%;;,D%M
MR];7@28WC_)@YH,R);V]O&=9CKC/ G$WW!9=GH@NH\\1BI."-;%#Z\KV9@+=
MSG_<K"/LNE>N(TA#B$9V**)NYWAP-?[F7AYU[.#=@1?V&M=;SO"7%87]P[W[
M#9WE/9&$/+;#HQ"TF:EP/N&^CD5XBHO52D21E8A#.PR[H_;D_=5A_UO[<G;<
M>%OL_YB43L,VG,+#P^$N%L]O@\.[Z5GU_7%M\:,HSBZ=']VK8FN_-G_Q3W&[
MF-F5(?6%-1&A1:#X^ZYJI@3<]9?7K8^.W=COG!XU1I_J6X?]V=;\41&(H!2U
M9]-1$ (].9D ._K^^JAS$MF[E^^=3N/-Y^OI8:O\\3;$6</N'QIM[K3[T_?5
MQK?&VP^B^+Y:N;PXN'Y]4IVW*5,';)X5YG,:9Q@&EJU?9=E3:U?TQ;@G0N:R
ME5*!_\"-4^]>//_MS<2QK4CT$=)SL @CX=\%S/M1-%L!XJT/WVHGPOWD7R[*
M]MNO6\ZW^4EEN*$(MMZM?^A4OKG]X<+MS"[<=_6/C7?^^05@UV%P=ZQRZ?&$
M,L%L&B%80,::&&9E(U?NYMG(-(_-V_*#IX?0EN_NWTG  PERR[W>XNV_>DO_
M=.=GPZW1Q_WI]?E%R=WRVI/0/_O<SH3E3^J=_ F? \ "]N#Q-[(?N_S*#.O*
MTUC7H>2D]V_8\A,D/??<N?9Z[NO#HGWD;%V&5TW_T\=-)+VGX!I-863*Q+T!
M.U_\LQ.,QX&?:?PJ4-QT^],TD'G3][<*G?!,+,3;+^7B^ZE[_<X9-!KMXJU&
MSH9:QS\+A-[G_:O.</CEM+,XK^^7KB>5UR-T$=S1-+X+5B7,YSM<OY'FSYVA
M?R<+\^K]Z\5!6/^Q?[FS^W&K]J'1V3OS;G7,;*1]?=^M=QK#K5*Y=G;5^3Y^
MY[D7[^U/WL4<C>M[6-=W0KL;+? 5]M'V9F#H;SBF&RS4XH_#T7MO4#DHCB]W
M.IW]TJZ8!8"=Y4:AWBP66JVL0N@[' @">2/ ^QL8P%%LEJ_@ )];H"2-@N+[
M'_-WPVJO'NY]G!.,:_5FH5G,2@F_.])G79NMNG6JWN7\\U&GTKGXUI]_O8[>
MMJK?YH^@NK%/(Z6X_10^96]T][!Y[?Q?]JZL.7%E2;]/Q/P'HF=NQ#D1R%<;
M KKOG @6L9A]$=N+0D@%" D)M+#]^JDJ"8PM[+;=8,#HQCW=;EQ(5;E\E9F5
MF97E*DV>JU3,:7HE%6?V)19Z$+'YT&I_"U[1"&3]'$!I60)]<VJW,SR##,\@
MOU%&S\E3\@ZV &QV'TGKR30S,\5MMO)"C1\2#9?8CICB6*1QBW\ZK.(/=3?4
MW8MDX[U#=_-6U^ZZ$Y43U(5(VC2QR&>8%-)=[C>Z>ULI%"GX+K0 28_,)54A
M5",B2W/5D?0P@'V5 >RP1/A*#8(G3:I#12H:&4^-CF!+NCONQQOS3HF4)@M%
M*BSZLU0.V@5>@W^:BI+L&9OTANH8JN/UJ>/I6_R_6QTKCS0YH<C%E.16:YZ0
MNZW\8RZ%U!$U^*?(:"QV^KM\KJA@/R7+[LS5T0%"Q'0FP()\FLTM, &&K2Y!
MY"_=M.V_(ZH!/P[O$+QE'^7ZJ'"%O@W"NK]NS?9X4N$:TN#,H0(7L>*6H1)7
M@5,;M:4U!$&X<OB.(VBXEA8+$DB+IN:RRF+266O9@K82:7Q[ ,<%"Y'^#B$A
MA(3O#0FW;@I]&!U>@D)J49YD$ZN$PH-8LSZ(T:,:7TPA4$#]C.)O74AV8^&0
M UM( 2-55IW0\0I+I6^J5/H6#9@F<"35  HO608DE7V@AUE/#=^R6<1I4B\W
MIZ(@+-(;,I5HC7O4JB'2"7R7<B(>)>E@ Y;3V2VA8H>*_4T4^^2VQY\I=JG6
MR5KM#$,(^<QX52?*LT(^ED**C1HC4/$HQP0CI7_?<FSFUZ[;DOUJ@X30WPK;
MQYW2K[I>P+OQ$Z'#'B<\5MUCS9N)%AM?VC%;4(V)5I32?<MIC$4:W_9 ,TR4
M2;S5/"Z$@! "0@BX6O/G71"0V]IF9<VYMC9KV?WI?! ;0%H@"$"Y)DDF&J=/
M?P!UT?Z1.(?U"RR<>\2R9ZK,0%563'>H@XL@U_^>R2O[^F5=#42=L[=DRE#>
M!5A&2N'FV<*B*G#K59:D.UQOO&R(C'?A!$N?UV8)E3I4ZF^FU.?L-_E>I6Y.
M%#TINF2=WQ0 /:OI5$*F5DBIH17"D%R48]G?62'_=B3(OA-PAWU3#]^I>2>O
MG)<!Y*#E?:(:\+W.S^> @26&HO=BTYZ B"2C=!K)V*"6+8;I(.O'@A\;$14^
M;6SAS%L+7Y3A3( -(B/5D Q9Q3$@R0$S^!K[X3P+FKJVHXXVSU;$<&\NZ3.,
M^+>B+O_Y#_QC]SU9!Y*%0&+R2U'MN2YM?F+)\=^[0P0Z_L#$T&S@1Q.OK K/
MSH=&DOP7FM#!<Y\]C)"!KO]ZRQ3>/>%<@N)3D68/SAD]*J(K8/:$.?CSO__K
M<#E/GAHAF[II_=SAX@']?+K0&"+'@!A: &*(-(+O_RGI*VEC[^S^Y .S@]R?
M>VAE,'M)2.=_10Y^1E0)<&TFK8D#POF(3.A@Y/STO[;[#,/I_D/3QJEX/RV@
M2ZA:[077?*8[YOPG33UPSQG.4@_Q6(#G9^FZP#SQYS]29&(AH/Z?=BUSU KX
M;=U?&\D@TNH,PGVHPWN-D'ZO%2])?8R"$D9N<30$4B+&C42&'4DB.V0Y49+B
M0 2 489T/#8<QI4?WEM/0[7#U0[AIO*ZX'NTK/*]=D9H\GX-8[&:\=#,FW^K
MG6KS%;[:;M5RM3K?3+6+M6HK5<UF:I5ZDR_PU5:QPY=K%UW"TR0CM5SD:9H1
M.,_(LXE&RK56ZX1@_:&9OL3JOU0#[BFF:T/KQ(Y&P%H&\'>X9AA[X/M.#1%I
M!E'&L?\^8(P(DG2"30QE$<39F,AR%"D.XW%:!+$A"12&&@XIQN>*M#,BZIEV
MERT9;EO+C%PP[HG%9,YMB-#(>3ERSJ5<S=#('.DZCZUB>IZL5&MCD0Z.=-E)
M?+YVMH(P<ZF5U96G5)N$ADEP9$YW1ZWJEDH)8+WIUPJ]M)KA4G!D[.7(RCCI
M+K-#4M5F[$H;)-:#;#[9$%F1?#F2X<A4L9E=TV1M[I1S15TH@4E*C 7?3K9H
MHK_0'4$ VUH[G7+HQ)I!(P-4*LA)61A2W8S@5B6U.K<KG<1Z!4<&YFFLZ^58
M.[X9:%*S4Q33;M+DE93(!>?94[860V<S8PW09,KM]4U6GS;$>'!D8EPCF.*
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MZK4G$2#!6WP^O%3L^05CPU?TA/ZLGE"Q!X:^:+7.GRH%2N8*$"84@P^* ?O
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M?II8I):+H*E%\-Q.N*5\=$I_J0;<[$S7AI:2_?>%-NN7N\9SH$9[RWLW U^
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M<0CO>Q^-+/A__E&TE?Y-><*9&>8;TOC% =[=,U^HA]B;#2%"OER&+\D'^I(
M%_(EQ+&;XDN(8]?)EQ#'SLJ7W]>(/3N1^:W=?#$B)(Y%;K\DX^%WB'Y1DGR0
M M"I0Q_^WX_8C\]2@WT@SWO!3>*ML[SC]!D^>^>AA/SXIP\D*\(;"E B__GW
M\&420*@:WU8U_I0D)].5"U9;GUB7=A6[WIGBOFPWU*M;TZO$[RCREA1X3 _^
M^5P,#C6(_JP&4>1#@OE.&N15N ]#(0F%Y$TA(3^*J<?"WQ?-50ZN.2/9DPCR
MTNS(R#)G$7,.4&,.8QQ!"9I+W"KWY\D4X\H6?[)V$%X@X\I6]YE,RU/$#2Y
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M3#0BS4PXW2W^5P0:0Q$3M3(*[?@;M>-/O+M=4DF9@#%_FUXWOLSP4.G@SSI
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MMQ].N(C7R?M16BJJ/=>E#9(=\$M7#4!, -+#GR]H-75M1QUMWB(6AB[$T&,
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MYR&:ZM+0/VN#G\+A\$5C^%H)>@AH8X,?PEG [1D_\^ 1:&+>0V; F9B*_=P
M0QLJ,GOA_H_U'^5S#QT)Q<;V?9],W$ #S!UO!+!F:&(6CDWJ>G27IO[6,[$J
M>2;!D;D_S?'YS.$DI"5<];'7>LO G^)T!?C>IQFC&4@*3H9 9B@^2\93G)@X
MU]O>%6SX:>.O) 5@RQA]!3[H(5(<O0AX0\OX)<T\V7@967=U!1'#-X^\2@NH
M+S@W'/H1 ,T&Z"K<19#XO)HOODOWCN[]#Y0R/S*ACXC,,"BO2'Y,:V=6(5<
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MA6<.):[[A4_P2?&<'Y""[I-U@D-')K(>U*=:_=>JT:%+:J!CRGT=^-6<]+;
M>&^LY $*.\PG$)&+3P4L5[.3U/8ND^U-VMOC%0!!R2O=>=YA =J4B#NH7^P0
M&NA^*,3VRJT\J\T"SO-B'=128RFING>@B*(U*!?6^QW$!6S;3Q#$/OEO*&$
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M;]G@,29RO$7*X0\\<Q>?:FB4PUE<=^^I',RASNKS/)?FK'VJHE2RS*!@@7(
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MSH2R,0,^]OI''+<S<8A[M#FM&7OH3\>Z"<JR(HZU2(=CR=S"R=^+FN[8#?0
M+O(F'_M+&P,4(3X9R.K*,HV_3Q;D!C^,M\._+#7X]'6L=?@==1[BC[1V.1X
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M<N1(Y]CICOEH%T8!%QV,!EQ$SB6V _+!XPQ'DA!B^W.<5B=\=L[8#!SRH.,
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ML>L@X1[U@:'7/>Q.QPJ(]C3LZ<C=I"B-3>^M)#8;/5><9&RP<++A\J]_)"Z
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MX^.%-L;(8O[NBN'/MX5S^PW_=%,HV"'IT<;P36W"@9/T$!F&W],P?'<.B)3
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MDH2N?!DTN]-EUM@_*K,6B=(7%Z4P;ZZ?C"8?8W5^+J)\;>%Y!ZS=S'4Z$3)
MV5=A4T.^HX0/=/[L4A!:U& V>>E$R/#"SG]CKB!:[^MPQ6_A2!]3BR&+A'7]
M_C_?C>%#-L5+!/MFHYAGQU[^]G2(I"*2BH#3]JO0(72'@U>G"L +Z S XBC;
MSV#EA9&)+W[W\BX)LA_NT+EXG@D[,LO/^T&SL9HO]ANU8AB[4E)J_'Z ]NF0
M$HA!=LU+(G4M57I$4N?+LC\&,=(6M>I$FVP']=1>:\N;1$[==TB! I9)7>73
M+Z%Z1I+\_23Y8VY"(TD^E&3P%N*S\1$ISBXWPZ*2J269EM(P[VO[!KNIT](
M(,79(RFG7^QX?2.96TD"8\/48@F2UQ.=*,Y^HK@T5MF'P+*=/EY?>OI?4DWB
M4-I?U9$%R'I!*K(_0RLSG?6W&BA+XS6[A[.>^KGV7KL;%)\&64E-58Q];TI@
M=UDF@>R>W/GLGDB=?&]U<M(O<>GI1^KDA#IYR?BJUOJC7&[(]@=\>W:S6'*5
M]>T.4!HS1)6D_K P0MB\.AB6\7@.!BQ&#'(PHB/BG^C%2\-U?) WZ.+S_)+J
M[JV'S!XBJR+1O_>WO.E'9KSA#?DHU&*FV9T^W&=N!YE"JV/.[GFI%N]0J$4F
M>Y5GSP*U&&F%KZL5J%ETZ7E&6N&H5CBB P;M9#L[5T>SA57-=]CI@$T\<EL"
MDP@Z(/$B5&*$5_3+V;(VULR,-V*"PAN&/)$E,<8K"F2ZRN9K*;%7%/4#Y]O.
M-$.*;65SYLVT'4M[315CFDH@<:X@B19QAHXZ1!\-R31L?!!>$,AHH+,QKP N
M;\R82=!DS!N2:#><(>%1]C%%7EOH"*/"NR2:T8L&X [8!Q:$QC"6!-Y"+5YL
MYP<5\AN@%G[,&;X+87+M0)5X,Z?#PFPD]7N43PM,-L=,1LEL+CM*9=/L*)_)
M)4>"D$^DDSPCL#GV,%G\J=09]Q^J67$PS-6>N[R>G*RDZ3&0@!J?3(@Y\[&Z
MD&^SU6PAMRS--0 )R!VV'-=FM<)#.U]E]E*J(L][##/?=8XE].\W]\G;=2&>
M&^S;B5MT;*I/NLH6M0ST^5C6]@^=9DICI'S[)OO$J<,-,QVE@GW>&;G'3?LN
M=\.T2GPUFW^:#*>=#FH9Z'.XM>X,=IBZ662D;AKM")E-O0)P FR 3$PY\[R_
M?9*,Q;!37O9'=PJ3?3B:^Y_J:>-F1VQ4.6NH+K.LU98?.+@6"[P^?I/AQK-A
MO\?(J5V<317R?:8(%;Z#KY>KLC6:EZ9(_R^F\9(^K@Q$;7H,4,#,)]/C7D?<
M+_;;G+&VA(>[. /0 X'UY!H/]8XV[S06Y1XO%NYKS[V4".6C E-*/VXSJ=Q:
M; RD:KDV?=3FS.,&^@Q,2;MM[/*5V>V&Z^E&.[_;)(7A#OH,3LD<3.X2_6[[
MGAEV>[/>FALPM6SA&/)!?K=L/W4&CYU!KU>1BI7";%#?%D:Y8,O)3) 7S=N1
MN-BG)X5NKUJ\&Z#7YX*3K]?3B31_VVT.XE+N)E^]:;6736@9F/RHM<T^K"I,
MB=OOV*>F5FFU4XCTN>#D%XG!T]-X]5@=%)=W3[?W.69W)\(X\P&ANU^UGXW)
MQ.#J[=MD+]G-+<P*]!DDTV)Z5]6?FB6-D^5%;==):E5Q#9VR@3D]K]NMRJ[:
MT1=RCQ].=T_S5>UQ.LH'Z3102X:06]UT.8M;SE?WC=URU-F.6.8(23EE,M0'
M2I'CE[?%DO:XK$_NI] T<]ATMGE>&8EQ2AZLI_5NG&M7*G=)W&MPK$*Q4&3Y
M_O-PD7@J6L6GS6W;0LS'LL$1*-HJ7U:TX6*0&.O);7+&RF,!-PVJJ!6?EQ?=
M*C,HSR;/=XVM),Q[N&D0HN/YIC'<[HV[1:(0?Y [:GWYK$RA:6!=G^5QFINM
MV/1@WVBGA/*ZPQG3+30-+M=J7VSD*]D>.RA6^'BIM"N5'FMX! <T&*6S L/G
M,Y,1(^02H]0D)8WRK#0>L;R$_I]CA/'8IO"Y@"=LR\YQ4=W*AJ!H!MIMC2"X
MA-+-,<;S,E%DA@5)S%32RJ9B38D-BC9$22R8+[2C,"+O#D5Q'$?(!_B03MF6
M%#6;XNG4BW93ZCH&)(EAFL0:$@\461)0IK":=NC Q"/+96*7NK%-+P=CD#=C
M$YC4!B9E@[K-^(V$K"8 /_38AD;L3MI(2@S03V+(*DIBFT\FMIG;"3+3D'FD
M"[,]/"*BE=7E,4&'LZT]2\5HB@8]RQC8R/+TL/30]CV!I?Z,N'3VM/96Q]),
M-"L"41E;(1&4P&B.\1C3D7Y/9D; )067^N@[1>:Q!2=+-N!=>*:8H%.LJBL+
M1HLQ_0!:TV8 -$_\"_K.Q):S).,VHHSXRD0F.DQ:=?\:H[%NP)J^BAD6XB_$
M%^LCY(-#!<&RC4$U8V*\[V5)$<'TWH204DE*J8'JSM$FC@@MT%%!1,<'X'8T
M+71^-@D($6($:[DB,(ANP_'>BTYD2Z,N311$2'K.(C1W",>#1T1&S<W85K,4
M>)D4'I'I:WA"Z $X-\%'$' *+^4YW2TU45(,PC9^SE(DP_ P$#2Q_,3&W1)R
M$!Q544),M$0:#[\&$=O5+*#XT.%1!U H#?4^M\0I:)GK6$$ A0@^BKW=RU27
M\/'2;H2F >7 C,!"P2#LE\)*>S09FB3J!E;=)*K *36&E#/Z>JKI&'334:Y)
M-!2/NG;;.UA5"F[WFNJ5#\[.BK:%,9"'@0'QL!&M":E1<P.M,4; A972#GOV
MJ.00L5<0]PO-0\*D-F>'4SB!_178&]'B_AJ-3\"".2"_Y\4'"YAI-_L;XCSI
M@>^DK&O6"I$E:+$]3=?WB?%.*3#%YV%MG&>96CI[Q&([WNY<%EL$'G:ZF!Y[
MG7HQ0M*#"NGI7$,=3I!LV!2S_XZ#B_PG@7@%[.]7H56=W_FQH2F6*?T#**ON
M#,^%IWHZ'?PM&#5>=-P_O"EB7KPI.O,JT/L+_.+ @GRKA6"O$[EH(4*P$/GK
M;+0085B(2#6%9"'8Z^R+B"'10GS40J2N$_EH)4*P$I%N"LE"1&932!8B,IM"
MLA"1:@K)0K#7F<AL"L5",*] WD4K\;:5>&,VQJNNOH^;=>[8#?H'@>Z\K)8_
M%PT<1#:6_5U(MG3F.I4/-20;O.02$,B1O'PY>3G/X>8[T."U<\7Y\7S#2)5(
M.EYW2WX+&KSF$?P.1/A:PO .8+?L-7->#*4_M9QZ;EC.NT$;?R4>.(_#X5O0
MX+6S_B<B0G1LB/1 =&R(C@V1=)RQ& ISV6(HKUE*-".C[:1B1/;2-[696S@;
M)5K^R%R.S.7(7(X,@LA<CLSE2#HB<]EG)!5(HG*#)BIK>F0O?5=SV4FGC5C@
M/"R0N&;/:S^=[98ALA2_._M'EF)D*4;2\9TMQ:J#7U/ " F1E?!-#44""!0M
M_S<U$KTH1R&W$G.!I;] 7?DS\_?;YGBZ>OCX3(KL$X>KXXH4$1^\CV7SB?G@
M+PIX%^F$2"=07DA$O/!.EL[GYX7DWV\U@P*@7A>MW(;Z+/+&+ :8B!M> 53"
MG^_&V9>>V27*JH#/Z_O-F_BYOM^\OR^?0S;1-YPWR2#Z?A/_OHP>*?3O-._O
MR^>9[ZG024CGIYWX;YPW/FYB,?N_#.Z_H:G2WH:MGR!:&Y_A#!T*+OWXJ_3W
MJ+[XX;??QVLK?EQA10K(/H(C=4$5X7^<>[ N[&3#:8*%@43>E4 4&A@<Q?G9
M ^GN*3.#"Z?ZNN%H28G6Q'GB2-$>VOEBN;U),NFQ/!C>:<G!W.AIVN#WZSX>
MG^61UQ\I\Y@2!76YMK3MH#57<K7LJO-XFX1"5U#J]2J38\Y3Z/5;Z(H/!WIX
MITJM'X'-\-65A?.Q8M>HP'Y*7V].&W*9CQNP'Z%_M,=90RC+>I%+I._E%?M4
M4FZ%Z47T3TY\+/7%Y\&8R]3WW6%JOBXN)END?S*1_HELE3"H'UI7*F*[T.8G
MOLNV]S$IA7_"=Y_P2HMLE:02D%/@.;K7BMR@G\8-^H+ 1G[1Z*+K"U]T19P?
M$@Z(5'[$^-^1 :*KL"_"^9_I;JRHZ2L-2E['QEIT,?;63>IR8:1A( +=L2Y,
MA,_I67?D[E8:FSW'5_ 1WO!'7HW/4^)PO.@EZF4S+0_2]]W?OXWS3Z"PX64%
M'" E3>^A>7,[0;%@T0N"H%N26(5P9\DPC[C&$YV*-M64;68Q'-XL6_%$(B.N
MIR.6P7=S3/8JD4Y%WO$_.T]^;X5E'RX_C\:*G/'1MAQMRR'>EG_WWCOQ$3O]
M-I%I=Q[E^NV@QVBBO&ED[S=R"';Z_G/^(==IQWL,OT]G;BOU;D'<=6"GST<[
M_3NY$;ZW#K1]"I]'"7[ZZT_'L< F\ MH(GOD#GQO/[B?J9.(J47-@BOGB\CV
M^\7 A'&J(;1BSF(IU%JY13$UW"29_:)1R=W>C2KL</MF2T'=F<)/-PC"8RP$
MS*XC9L%ZV9Q4K<?\XR#1SMW=#"?]VE1"9@%+' #YJWSRC&;!=]0P)^Z8+RYV
MYXKR#>-<PZUB0AW7VUO)]<9S3S474JU2YN[V6_.N^O;SS9]I+:-BM%:MO;7D
M]F-!XA:%32ZC;D%KG3^D]SOJK,@JNOA4OZ;*^A"73&[95(7);>YQ4,R)?%[8
MI#OU<>&#5=9S2EM*#XU$>L OEI-'N;<?ZW.LLC["__(=E=:)R(Z+2_*YXLK#
M.-<_=L;\!\O:.PPG]1XL2</,R3.4N(*F*/S*D'[:'[PT@("/&<&26O*[.%:K
MJCV0N")-S)^\96KV%YA&Y!NZ'*2-9WUH&_B&K'Z.^1^8C:G;XZ+O8\DL?\V3
ME7PQ'4^4-T<ZUU"'$T7;VA2S_XX#:_X<ZQ*_B&\1C?Y9:88,ZNRG+BD\5*$X
MZ-/YG1\;FF*9TC]H;)X9L@R9XGF\9]=,VF'"$XBQ,-M?55IH7LZ_9W6<GWE1
MJ,[ +PZLSW=>E]=RWJ)UN<RZO);4%ZU+I,>B=?EU[(!H72ZT+J^!(T0+$RFR
M:%TB@RSLZY*_CI8EA,L2J;%PKLMKH!;1NEQH79CK="0PYUL8GYN77H TK24:
MFG#D;_R<ASJ"(O$ZK.'L'U$V5@J__XF[LCVJE'J)['4R#7-#7]%%2F8"#D9/
MO[[.XH*D*/^\5.+H?5?@9*V"1,H3\T=6A&720;K"O__W__BXR+D< (>UIO^T
M;P \!*2$26 6GTIQPJ3\! W@)Z]L^;U!9YO-7R?M0,^?SB5"$@:%I"69_I^8
MYS.0);!LX SW4,[G[*:/^?W=]I>O" M==? ?)Y!"]:]X"AUYTQ_C589X3%MD
M^-A,AWO4_^JWBD<E"#XC+M>7O.(K3$:_^O%O'U\[:)-8D=P?&(Y \42HWF<.
MWG?CRA>OU,QH<@_]XJ#+79'2(=5F\?J2HVGUN1X92;\5*U6;A6:Q6KB+]?J%
M/M?@FOW>.P[.,Y:Y99CR9$^^DE4HGDATR^G;)K]NPK&[;]*>Q_7?H4P=$Q7>
MOHYNWZ2,LM1IJXL]UYSF[\?KG-C;CMA1X@=A*Z?E=EVH-.,UH3F0TWNS,)GJ
MY6)_.DJ,<H<MTZM-?9)J[5J#8N>YGA4WO-%.3D?)4?JPY<32QF+EH;E:%)?Y
M=KXWNL^RE0)J&>AS(+9'L^YBO>42JWSQ)I[-3Y[0VU/!/N]'XK T,_M%IMPQ
MDP6ETTXP]0)J&>BSS(^XPMWV45GPUKK#I>]7\QQNR;*'316U=-\KY>LEKBCF
MXL;M*-%.Z]M1.OAZ8VGIF>?[^6ZQ;SR(P]XTKNT8:!EX_5A:W[86Y:3%K0N#
MD=#=<4]*=HI:!E^_,A)/M>&X-F5ZB0'7LT0]O>EV1ID1<]BR\=QHE)[XXGBP
M3^57Z_VL*E<*4]0RL)Y/F_)XL4CFJ@R_>QI+VHJ?#4O0,C EH3@?U)?W@_FB
MN)XQ55W?-)1) ;4,3&FZV,?EGESO#WKR7K-,;FSI.K0,3LDJ=HV[76UY,Y#O
MAJOG2J_WD&X51MG@E!1=6J]7.UT9K.\G["JY6_6ZB$ERP99J;YMCTMJ\R:V?
M6_5=O&L).P$ 9@.3CV]%Q'#+4F$1'TVWDUJGUQEVH<_ Y*6[^TTM_]0U%F5V
MI60S3.=1Z@%H9)#MZ\W6<UDPRPN)O^73'>M^GYW!V_.'+6?-XJ*7F0OK@<0/
M$^GUZDD:,- R2*;Y<ZJOU^?2S4+FA\,V5U[(NR<8*!N8T[Y;7$CYS4V1X\N#
MQ9VVE6YV1F>4#]+I^5YD%IOA0AS(R\QV*<V5^&-V"SE @:;<_KG^D+A14DPY
M]9BK+V59W*(514TS 7%:MS1Q/*SG%@DU>7M331?CVSS.+ J.=2Z9^_Y]I?W,
M9,J)S)V2+VRM<@&B8 (CZ-^TQ'IS7K,&Y?[B85CEGQ^*BP*-\?,W[=UE!'.:
M6>2Y8H+/%S/KKBED<!!S< 2R.N)VUH-J#A)[)<X5UP\#WMA">%-@!+NZSCS+
M.V;(R=6;)[Y7+)?X:@&:!GH5GQO-ZF,^GN7*!8UMMW9R8:A/H6F L::[VVU#
M7M^UN'V:V5:JG;5U8^&F <Z:/VZZ2[X\S@PL;3(2%Y-=@><ZT#3(,-EENQS/
MK-.+07$_;SZOU?MB\A%W>T"#$9],Y])C-C5*H;/.*,4DLZ,<D\F.I$F&327Y
MG""F<F]_8O0;;X$8<\\S35[71]-59]T=,SMST!-G2;TG,JLL7PBV2^Q2HYV<
MS"<&O6G)B&?O-=FJ;/UC2(GI3'HLBB,VS29'*2$]&>42: PI*2],F#0KY:74
MVY\XG.DO/>.?Z2@K2.-<-H76G)UD4 \L4JJ,*(P2^;0T81.\R&1S;W_B<&2_
M](P],G32@O 46;5X'#6(^6H\4KHYQGA>)HK,L"")F4I:V500NT)3X,$33SU-
MU_>)\4XI,,7G86V<9YE:.NL^%>HXFC>4M7TY;.9BQ_'O4^W]0TGBE$)$VO<W
MZ9/.7*?3H:Z%>(2B+Y5&O)4$'&1+#EY)EIX%$TR"^=.:T9%P?2?A.L_=WS<D
MR8>#F_^*"@D;D2)1NG@MD<] DH^I4_*I:/*E)>=]"I^?5_V^LP'70YW($S1#
MU?PLE<X_G]!\=,&*ST"2UZ[5/R]-HJ-.I$.BHTYTU D'D;ZT*+V#P9:Y9LZ[
M-[^SP=:Q-%,28VU=%M (9#46F6V187^$3UKF3-(CYHAL^LBFCVSZ,'!'I$,B
MFSZRZ2-1BFSZ@*U6$"! -T; I8R8ID=F6V33'[/IQ^@-&PB>BACD0Q@D<<U^
M*@8Y>9L3V:^1K$3V:V2_AH-(7UJ4OJ']6H6L-YA@K& 8$N0G1M9)9+X&V00#
M_T;,$9FN1YACH&HG3C>ALUUSKS'&2_/\2U9CYDRS#%X5C;\_BS#\T91)3D#P
MW\#DWT<G9K]2@@4MZ11QR1D,K*_#)7]A-/T8&^F3\]A87XY3$A&GG,?@^G*<
MDOS[K=98 %D^!#42O;.&8ATQR:W6\?-KE-EXY8!RV5)!WXL,)\L(?2\R1$+Q
M<LV_;T:&D_4 OQ<=(JF(MHH#E.1O3X5()EXN6O;-R$#BB+\*'7[CQ'29>6;P
M*QJ:*NUC2QR+%IL@ZAN?P4T01C:^>'3$^Y5$_<" AN.% KW3.G.%4\8I,PJ>
M@F!U3U\E4BPM)'"S!++R$05-DS>[E5%+R$VNV.XWV_-EKK$>O+UR/'WWS^.S
M//+Z(V5-=W<5OM3HMT=<(LFVF6UR(LSK ).9_/$ORUZQZ?3YBII^-VUR:7R6
M=RP*'ZF3/U8GH:X2_UQNS9NK93'#E?7LJCR*WS'UY[=7B7\/#569%6<98RV/
M.6FR7O.&VF#6)B#I9B(-%=D[;RY;= G]%"B-'+'EITK4?:\BWQ^P='_(F)__
M<I#LO02?6!(L739E*;HAC-R^7^6&\"4!#P%=(BF)K@S#<&48B<FGX(]H,[GD
M'6(D))^!.Z)+Q0M?*GZ,F'RR6\:BIJ\TG3>EV%B+KA@_K\OM4D>G<#E"0G2#
MX C6K30V>XX+XR.\_K-A,K/I==8"5Y]*M?&NU=3O>X7?]OK[)U#8\+("?IF2
MIO?0O+F=H%BP[@5!T"U)K$*TNV281ZX ZK-Q>6W=M'J+I=!*3^;QK+XT<#&[
MY(]_$ZGD52:;CRX!OLHUY<6.J>%22=&E0;2Q?OJ;K\^\K_[N!7WB([;JF_P=
MDRF.'])<6;]A:P]WC^F=,;W\5IV[[[1U8Y,=##+;7'U>&'9J2QT7D\U'6_67
MNQB]F!<@7%KN2UVCVL?[Y5+2!9E78BM^)>F1.^_L/N\+9AZ'D$PG+U@O3:9/
M; #9(MT&B6YJ9E6%?5T2A[(Y.][!1Y@R:U%F,]RRV!S4;YF;A]%=>LO>_WZL
MX;N9,F;WZ2[?+MSS7/UQPCU/"EF#R6ZA*GWRQ[^9JWP^>SY#)M*2IR[0+RW^
M(2/3R0OV2]/ILLZ.2'XB*^-/;MXO3:7(R B_"X;+;GENVMZW%STU_R0(K"56
MV[^?Q?5N=LN"[=8K=;-27\3-UF.C4^H86V4*=DL^LELN%JQQ:8T2,C*=#.:X
M-)T^WO-SF95G$_@=%)XR\K_^OHWE8]@D8EA1LR#]( R2_7X)Y!>?9CA-HK-8
M%J5:_HG+6UJ5B0^7_&/Y\>:YLG_[Y8ZZ,X6?;CZ,Q[@(F&!'S(B;QT2MM>D6
M:X-6+_<TU@PAG;HO8!K\^#>18:]R23:ZR7E7;\>E1>R#DL<O/L_0JY)0YX8W
MVTM1'ALI=2$;L\:P*NY7J?W;SSU_IIW*W4[]KB<^%!?+<FF=C<_E:B8]!;)&
M:>&1F?/[KJ!+S_++JJ8/<<ELM5NV)13O!XR<'3(6Q_?OX]+; UC_3#6IXW3%
MZ,^;*2;3[CS/]@\Y/;'N %DA!";-7&6RF4@WO:N[Y=)2^T'@ 1>?YWLX1_Z#
M9>I?+ &@?&35XHD(_/$84[ZE^$V&?'=*S2VDPB9[\I6L0JFMG\E,D&O (T-)
MUY])L:*V1&/:QT19C*F:&3-U7C4FDAZ#+WE<IBNV))I3C/%F;(*T8FP#:C&&
M=@(^IH/6TA$+Q,:@5&-CR=Q*DAI30!L;,='"OYDSB2#J[R5>-V(2&IX8NY4$
MK$_)+TGV*H9V Q:]6(0/S'6HZ"3PNKZ'J="Y3V(36>55'+HDJX:I6["Q&%?H
M#^I"!U**$A!(DG&Y(O0C+PB:A9K%5OP>@T? 9'GB:X\I,H\9!^T ,7ZUTK4=
MWI*\)!]+ F\9^/6(I#%CINEFW)3T90RUA-UC3W]";9"0+XWK& Q>HKN;Z.D+
M+2N_QTNN2RL=/:"::"2FA>9#?Z<O.3I/] MB!C09142#0ET@XCX#ASB/C7D%
M/09CE"0S)L)$-)T\MI45Q?<4KG6$WF2A.4ADW<,JM[R]_Y:X6;V[SBL&$Y]H
M9E+HI1)]'AT-1@G4\7]X;\LG4[H;*-J06Q=ZN?(J-U@_5K>CQ(@Y;-EI)8>M
MG16/#_C9_;P^JRW4SAY:!OK,W]Y,5:FP+0WB4ZW;&];RXNV\@%JF#UN:H_O!
M;BEE"X.BD6O?J9*DS>/;43+X]OBH-]GF^UMU(3V*]7JN+-9W[!2U#+R=&PQ+
MLT953'.)=7I;0$T78@?Z#+S]8<^:#]*V7>%:R^2D)]W-'G-F9Y0*OMTLUMM+
MLU%]9-8/(K>5Z[/B=MX9I8,ML^5AJ9'8K.:#]4.]NZT6>*O8G(XRP99WDZ$2
MK\X?A@M^F$@G'\OU:NMV.\H&6XZ2TX<"FX_GN40ON<C$VS>U3*4SR@5;9L;]
M.<OJC,JM6[F%LLY6A-3S=I0/MJP^R%9V=CL5!O6JRDVJ)3V_O<7Y1(&F]X_R
M[8:M[C9,7#6:Y>9THMRGMM T0'MQ+B[CNU+_@>L]W%B;3F_4:[.XJ4U\8O,U
MD:#JLN"SO&\M'0L3XE)L>K.CON8:XNRH*K0K.7DUGW+QHJ9O;Y1*=[_J'%XA
MMG5MA0R+?1L)N(EL5;!35Z 57$.YC]YXHVC"@IJKXU$V79F9V726Y:3D8%EK
M# 9&MS#]@523P*]0YTBQ2.]F0. _O65*J)D25Z2)^3.=LG<$JO[CZ=2+^C]]
M';/GC!6V,^$K-"8S--N4;XR2/49@ +0QFXXZUQ1%VX+-A@=^,68)LLBJ56QT
M1\JSS"QU]7E1V\Q7Y5+G_5GD7?8!BOU$GJ$6LX!(RZ\,Z:?]P;N^L'8SPI)+
M?A?'E%;M@1#&Y"U3L[_ AB_YQL>\'J.;MH%OB/V>8_X'9F/J]KCH^U@RRU^K
MBYAEKO,O)OB(\N9(_QKJ<X(8RR::_7<<SA<_QVBK7\2WB$S_K#1#!K;ZJ4L*
MXJ^-=- G/7;@%]M-^;&A*98I.><4,M'W/E4=LH*G(?KQ5T^::"[.OW]XTDYG
MHX4(P4*PUZE((D*Q$,QU.EJ),*Q$XCH9K4,(UB%236%9B$@UO>]*O+&<]ZMF
MZX?,^@]JN9_'1@S[K)V"JNG?+:B:R%RGDJ$NJ HO>:F":L /?JSX;.C$(1?@
MBPN4L_]XY@]/&6$F<%7WJ;@>?$COQ@<O&J,?S.H1%[R-"YCW4'07S0A!?78E
M0X(P%=?O^F[Z[=)3NT2X12H$2_I>$17A ]U-V@$DJP\([V*=&*N35P$W^_Y^
M)>%X+(B)&MG"Y#2PT8AZ1F4[',WG@^'B?K.^*8[-5.[W4_A/CJ>L:\:QD*LY
MJ_:4I;;1%_7:=%";B8]<RX0+4JABEKE*Y1+G";A*7EX8(B40*8%WB?'\8R70
M68^&M=1F];20&[/63FNWM*;U^_FP;U8"^<'C4VFJ+D2FV#'OFD\6DVGF.T@)
M0$1X\BJ9?@EX+'2GN"#'WTF\(<V0=1:3ERM=V^" V?<!7KZLJ^(#M=:'3M(^
M7;R7GOHV2NEMEHG=UI&/JD<\J&ZJU5KEHGP3OQ_4JYWG!I.[>>@\_SZR\9MU
MDU6+___L?6EOZLBV]O<KW?]@]3U'ZI: XP$P[#YO2P;,/(.9OEC&&# >\8"!
M7_]6E0V!F&0G>T,@B:5S=B>DL&M8<ZWU+&-(.$F'ZY53>Z=5LY(ZRK8"!DHF
MEDK?*"'\MMYWQ-816]_.UG@+6]>+)DF/.E:2DV?I'=N>M9I"\==14-_-UF,G
M(VQF!4_D-+Y6J?&[ 5/"&<#6:<C65/:U MG/&4Z!6>FN(UE1..7+>%+7EF??
MV9WZ-<OEP%3//2ICK*O>2J3+7&F:DH?SO+;&YQ\85M'JC-Y(\8VE,F2R*ZU3
MK1!#!V9^P[!*C$A2450ED@61++BJN?.2+-A.,BO.%DL4%^]4*DVUX%5)[P.C
M*X)!9DK;2I)GY4E[E=Y4-YD\O0"R $978CB!?^[@2M&UP)F[EE_X-0?[!WZ.
M@BN1%_;EQ-*OF2A'_@#CB@%W!)))--QBA9XY&S:^'JW*<5:;%+D/=,(F!N>(
MKKNAV18IYK85NM/.56#5&;K\N1'88119B7CZ<7CZUTR-5WAZ33+UFF!WRS@Y
MKG4VNYG68.H?Z'FT]X20F;&,QK;JE6XNHR]Z2HH!/(W0?5[S.SYK6 55</NT
M(>N8:1D+<!K7,T#NO< '<JCNC3#ZT0[7O=?[,%+R5X,S3ZQ9T=L!8P9R<L7M
MQVJQ5=+QO%>>:HT!6ZJ9'R@G&TG"I.S5NLZ1<GI9[1B9KN L>!K:/A1](WS&
M*#[S2.P5B9-/972]*D[*WJ;7:XCC-#LL%A?-I6 E][^ 7_;+XL0327?2ZZD3
M?#VR*[6-0\IBM0/$"0KR)+.O75,_>I#G0!A!@[/+F PQ; &W)HK[1#[B5Q-7
M!.^4]CNNV3!7RFZCEVU[6Z2DQ@<:*S-Z7^^W,Z3+#0>->9,O>I7XGN$S/J!T
MC"9OU!DTBM5$?/@X?(CSE6V;R,LE1U#B6W.U[&OE!B%_X%6.V,1SO0U7F7%:
M8=R6R/5PVUY[@ _3L$5OC$I?/U'VWOY"'=A8/R">GZNY*L+;FT%L/5%&0$H^
MV)]F@&7LT0=1V"7RD[ZPGP2%W)^?S-I@GGBW<,*ZX&=5@C\ P<><</"+0O&"
M/%Q:2K:\5*8:)_3Y/:[)R54N!X$#X042&:.I\!W27U$@)1(0D8!X)#/HA@*B
MT_36YF@KM]C\,+4";R&',LX  9'VL_?#N2]_?;FXB"Y=+]/W>TBX>X.UWZQ<
M\MX+>QA7[N-"*DWIDES*2UJQV=HX'$O.!^LE@0OS70,A#E.HY#&;O5W=<\3#
M$0]_!1[^N'#,91YVM()'6LN2Q[7V^73;V8S6A->!/ SO7%*Q#/[3:,QI1XTG
MR.A'P6-^! #NE])K8-^,GS2[.*!T']LGB ;\1=9A=PW8M\&P,"N$,>-G$:.V
M"A(V=65U%C=<A/0-F0E.0U Q59BB<<9\+L-^#)!;'Z>W1N&U !DF;4U)MR7,
M$VSL7U?FT%_%-S]AV-2[&F__W%LX,F[:9]RF8%D\.=;BA%W8[O&60:_<4<'F
MDQOOCW^2B7""&@:.4#WLY*TW##_;,)P?9Y(L;8[BC!)/MO I/:)+687Y^ UC
MYG4[/]TTRYS4,);CG;22&Q38,"J1?'G# BYZ=Y>:&&1+4Q(A)*>Z>^I=\G@2
M\MA!0J#'GK',DQM<,OL#A^57J779N]2Y9) BEPM:UEMLSVMZGNYZ^]QN<:ES
M2:DBX@/-WNWP76.^*XH;O=6)7^Q<0I9Q>4.Q$XM-UYJKL5+:S57U8N>2C;(?
MK^;DA =6K[EJ4_'AIMN^V+G$V<MMLT&G]FQMI_92\WW7K(XO=B[IVF1E["[,
M!B?L6DPY6=_T6V;'A_ Y'UFC%BF3R.YS>*W2IM.MG8 W!IU+/4[Z[;H\WZ2F
M0[:UZF>:UF9:(G?,I1XG) <V/C/J,APIU7<*N=O4M*QWJ<?)*%FD"XO:8,3M
ME :5U,S%NJ%U+O4X&1O&=%#=U#S<U=5Q=DR8A"DQEWJ<$,GQKB'MJC;7,NI=
MMV\J/*5=['&RDJ=MME^9RMRP+$ST>%44Q%%PA7H^<NZ9=,6LL3R^MI2=U"YW
MF(Z^N-0-95FL#BF#G8PYB7,MMS#*"D82AC]#9Z16]"&]W!63['JZGU<KZ;Z6
M'\%G?E2#$R;HTM3VFS1!F>.W:*H_=6AZK=?))+D<52NE9EEI-;TZWF#3C>KH
MD_0Z22>P8+'8R6KO9BZ &3$7VF/=MZ=)3UQ*,U>56O,P7?0AQ81)8K5:Y9:J
M-:OC^6)OQW%;;K-+>U%ODP_N;4(D<"("Z3X^]J[] Y+103S 01")5,01#W$0
M.&HR&YW$W4\BDDT/<A"1;'J4@P"R*>KW<\63>.]M_<_LUH];=>:2R_E!K4Y>
M%\N?:P^NTO@DG?S4X/\W:7QR<U9YB,8G7Y(5?J</!O&Y6>&ZW5 BXGA&'*G/
M3AR_V23%%XKWS@*^*?P$)/I[+_ >"42I!SC8*Z4,P?C'8T/YP?,CR&LD;$<$
M^Q4(]CZE%5\OJPUV_/@17*9=AB[(PSRHBVGS8DT<\,-XQ<#C1#9I\N6^(-86
M04..GZ>U/9)K$2;4MK"S#%5%Z28H."+-L*FD2W/Y2CTY[FLK?J#(^;1U/:_?
M"GPQB7+U7'=6,U5C)TE=GWE.;NI?EBB-F3LK&ZFQH)!"/;MCLXUY,^GY;32(
M&)VZ%>!1Q(J/SHH?4)'P,*QX]93U7V%%+KM9#?E!?877)G1!$<M&-]OI^*TO
MLO0U$1H?Q$5691U.$7,L&?R+LL C;^.3>QMW6/=G<*8_B25QYIL$[-F'W)F'
MS/FRZ%+R@\ZHQ8^W;'Y -2>NE1NVIPN_K05-W@HP.F+S[[3N* 1QFQ#$.]B\
M6)#7 SU=R[(DJU&&Q(\(DV$.'2OH9+CFY%,%('JFH=L&+$$[E)]%OL[W\'6B
ML,-O&@M'UCFV,O:K&5^6)59-;E33)JYP0UHV\'1UD=IJ7M!C(D81J2CP\$V9
M,0H\_*9*?S\SDD6R,-4ZTA3OU9EX65)RY6TW: Z1I%^#O/B<H8>6*<'B*'UQ
MJ+J. @^?W2.YMCWPG1V-FY@(1YX+I-$K?D8A652L-G@Y6VJU,^MD+5E,9QB_
M!T,Z=:O.WA'S?@WFC:($US<IWL&\?6U2G IMHHCOBGJGW8]G12-U['A $=?L
M>'"'($'+64H6%ODB[Q(OCX1#>K\;BL=%)[UU[M]7/^"(RI]4[^>A\D^BAP\Y
M!4CSO"F38)-O+>1%MK;FTLVIX[0*&W)87?CM"*[:ZO$!O/EG8+M]PQ%4V);@
M.8Y*Y"-<WT>X.^;E!V;FWWVM#R/8;M&(X!FRT"N9!A.:V:[C14\II<A]DNRU
M<<;L^)T%DK%D\E8-CR+&?RAF^, *A[NO]6$8_Q8-!M[,^(0D*#P[WV[9DBY5
MI7(\WG0MS^\8D(RE7TTR^@Z8OE>9Q6/NC0\F<8*1(:J28$&67OX]DVU3%78_
MT.$&KSKP*DDGJ!2< /@H@.I D'OG*!HGSSU[6%R45/7OU\S?Z^)PO%@U2R9/
MK%Q_%PD\'0;;@/_^[_^<88D<I1G$M#.L'P>1=;*!P<:02'HMI+@/52+,P01^
M"*HG[.R#L9]-'-V['T>I1\%) >%)I?Z-G?P,MR5T;! O[V3GSO#P@J^=0^(=
M/OP)9$IPZHYA_B")1/K\Q)-$@DZ%#OTF7L@)M.1_!6QI01'Z?_U6_F+1./P9
M\!J0E.I9X7CP$?!D$#*A,<?R!H(8M(\L(5Q)9%S&U/Q)]7:3'?7S7)<- "PJ
MS?PU ;;?/9M6G^WY,^FWL&*ER33S%::.]?I,GVVPS7[OGG">9\=^+IL@K;P/
M4N>R_'O.4Y=8Y=88H7D(DPD$ WHA8UF"OI @9/MKN+$SHY35<\LVKJS%?64Z
M<#JM^.R3X,;2":P(N%2R,&9A26BIF"<[2XQ59:PNJZK?ZB=O:. (=P\#/]_2
ML::Q02@T& FAO8E,#$'*!A/%$']),TS6'0,3,,U5'3D.\<&?X/CANF;21E(-
M'Y1??#IZB,1^W(X_X7,A*9/XW_Z.'+<*?4K\_=<K6X;]>?K5PQ=BF.E:MBN
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MYRX]F).#XQ?RETS!PF " O*$ DY#U]FG&LB3WJZ"/I;:?J*'+I%;ZTF=7-Q
MVB+SO?)&KG+2N#P=+QE"Z='>9=7T1&?/=@\[TQ5PEG%Y&_<5Q8\R^@_?(6IL
M>]5?+Y5TB4DO]))6HA:=BS@C5\AL>NVZ (F3V5%MH?]  ^=$\Y[G=@ _&)O+
MV\"#ED4IAJ%;%^ N^QLA <\;_0+XRX_*'$0;#%F=ADN?;]RA]P!\S0$6?&-
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M4?U":A?O+,(M;BZ/^TPM;@@RX3M8<?_&_'37'J4JBM5,U=A)$L8"/G!VL*I
M?ZS*J/-T&'@QE\):F@[8VX:?0(D!A"R<]UEJ/AH'/WUJ, G=P9EA.G[6SC$D
MC$9"LQ/5!<PD^YBY@Y*ID)3S@&Y%PL<75> A,#02.P9*CE$1?R3,8WOA3V?Q
ME>/?H#)%:1E2<!ZP'@.\P54=X= >Z:C7GPE!/^)S7"\J%YO!&GS;OQU^T3X
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M ;YJ7B/A[#>TC:?G5Y)4QXNLT&7DJM!Q3'+/0&U#$50L25$OICBBA+0SN1Q
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MCX/.*YY(@U?Y#R93"?S@^<+MD([4C FN8V XAL/W_@>\^/ OVICC+'R?&,Q
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M0P-+^55_ +BS%YYO@&?. 2,>]NWP>QQ:?#^FEB0H<0_LU-^F8<N0*'Y8DHH
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M_43-31T',\;MDJAX*>';>0C,Q[RF8MU+B5].ZZP7U OY92Y6W?W"#R.PI9V
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MDDGU7D"9WE*0N*_GB'CL%9J,[U!JZ,J&81.'_<33&&*0CC" P6%=GIF&?B*
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M/!J&Z;CV9,.L[(8-QQLVE:(%4NPRQMPD12-%I?R6OF-/*V4[^5<\3J>;U.*
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M(+=;(*?GG>#^=RM)*"_P]GS;;FV8=@:[T8@#6N!&3<NS2LQ2D\X'GM.)0[P
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MA-S(G?E3]SQ4E8.>2*+;<N-'9,<)DR=?>DM6MA2D4V'2"-5D2U;T&E63G3I
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MC#X>LJ>CW]64:S0S!B^OBTM<3,$0YK>UJ%0<%>*B$B*_1:5U9*1P;W5<_N5
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MP# 0AN%#S;8!F0J79<+3- P;H%.&N@8Z8[G6FE,Z3PF>FFBHD\RR]"LOK*
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M#?1OC9.IT09RG"=BR7N6&15J59P%;5-%-HG;5+SH(J6TO=@A77KW(-IT;K?
M1\HH3]M6,Z0T92P];GJZE<%_??@Z!DN(/TU4(GS,2):"\C",6WB2_CIS*[7[
MGHZ:']^V]NK)\<HPB!!7:</0>NI^/F];I)) ]"&V3"/X1HPE@KF\_P7%HYIK
MN(QZ'(/+XA2E'AY/'2.?6B.'.6:47WC<PU,YH!T1-Z)X[N:#Z#H&'ZLZKO#W
METV>G*& 7*($>=9I[TFQ.59]?+.RY[(<>.3(&;4V6M6QHJ57]2+AI)>4 ^<=
M^3YIK3J'Z^CD3,;9D7J.!)G"D'R^;@RJ!@H,MXKXC=2]SDNZJJC-S=85Q!R?
M7)-3IQJ+;N)5EK1+P) D?O1CP9'\-=(7_[4RB#;ZS1UD92(-YU$_.CFLNOSX
M[^UH_OX%94K@O$VU>H'VFL:).8*NK_TF?,]Z>DP&,V>?:>%SR"#&L+(:U(EL
M,5#"UNCEZB1)_GLB_UU<<B!\8RI7WS7I7I',U)IFL9]ID#RY&S#AGTJ@?)=B
M4 ,,>^4(&I\U!N7H*#EJN@;>N<]-;2]JV0<:>S 69UEHI5'@64U&>M=P)50'
M^)2"-K]9AC[\OE(DO&2OWM9X#UO"L";IX>/];,=)!SFX2._ZY+VIK<Y3I.H2
M&#!,*2ZEALCT,X902ZN4E49(O-$VQ IY=Z+L-8=/JW#!QDE8UVMED>G==<J8
M0?= H"\E2R'?DO_$Q#U^++A(JPU#WO?ZR.B*[U2NJXM!:!,_3)/K%>)MO@'9
M%/\$@_KR($;A5PT_Z&\)2IZ7%%SN.D\R/R78O\$7&F@W;BC5WQ KXW1W_;W
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M(+[X/19XX8<RG>V?P(OT$M_$[+-)C.7<FG)NNA!41DWK>UO87&I\?N=6I%'
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MU2;+IZ(HH0D?K6 4].+\+DD^@9F"%GY6":?RC&5TTMT>2T1X0<F8'8-&D6"
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MN<N5S?R]DHMVL)HBD_@+:HKK.>CZU>Q=FM+"XCX5SQ[J%X)GSA6PN1F>4.-
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MH$L#2.4Z6XD/);N@\7F2!(J*JA[$@9T?W[+V*J4NSY2CY243 ]FS]]>_TTU
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ML8#;^O]I[SN#FFK7M8,HV"@BO:J@T@7I4@(B M)!6D(1 2% Z+T%44% "*"
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M"#A3[--L(31<9Y4EA'WKE!!LBITX&93*P!\41Q%(@>%;X>NIOY6:_/LE!RL
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M6QOC4/<WJSTFA9R+MY((M)]$A<2KA##UE?<<WB$36? -0^Z&,3*4Y'OIU,^
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M!RH5I^HIGJGK!!H^-=<:S=D?T?Z2[']-L)#_7Y+]LV#_(M<\  ,>#K9X\-@
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M'FKMSH11MMT4EJ-&T0<3H#Y=3^?6YP7/@"P8J/,'G]0&*!+!L/D#49#HVC,
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M'?#<Q8[J&/TN=MWC6:]B//W]=#;DDAREF]+ZFA(_X<F\JF<SJ)Q\2^\V#X1
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MPZ !%_%W_WX7AA!YI2V'T3ZQP(@;"V]7)N4.//S'N5U$R1)_X*EE(5Z]VQX
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MX^I(# GF<NBPRI\!LZ!G $/"NE/HU9Z03,%MN=2W" WHJ"KUMT0K*OY^TF<
MIJV!\MH-:"RR\(PV8EV!4;"T<I((([GG7.P'WP\2\'C+Z<TO<=)Z2!9[W<.'
M&(N?BC:I&3NA'Y"13W/013$?M?)OBT;/%5X";;PF9!&/FI)Q3Z[ZX46_CG@V
M5TE^[T0-0BV\&CEZ!BQ<*4HH\VP[IQ.(@(09JXO"34!_:Q!]?#]E^";56W'N
MG29#IGA%)=G-EGB*XC=F?#U\/4-FNNI6&O-T>>N1FK01Y=P#^!?-7E2N(NS-
M?@^0)5HPI8J+?\4?+0R1_)=]-SL*#X9N!FD4X1Z?KN1EPC,S,3G\NNS$![+L
M)%\-UT[^2>CO0O3^V9O&/NKH-K\I@Z\I'N/+]2D4;KK6KHS1I[V%UTL\/'0[
MRG'0O-9F<@I-!YTY&+I*+BG K0_]]\?2_@.%)J?N@ #5@JO$FT(:)4\)[U/L
M3.5$/;MBC"9;[5K8BMIO=+ J;[-F%2(SRW[H+0C5/"*JX_W&(\US7T:9$NG.
M9>ZNHFD5,7D&>-W*7#W:%?9@]]9(U^3\I$#+'\=,/-3@=56M_;:H O($]L"_
M ;$K]<"YNLBBZ>;;?_-GQ_"%6YEO%DRE ZMU-+&MQGN3S2S9SB:?B7]K'G&+
MIS;!2, +Y1!HNJQJ97>D*_\2E5L:@YD8!=0I'!4-]J[L=]@00^*#QXOR\"O0
MB6$WL9$590>KC37WR8\9$=OP5, U9-L(X]WB;H65,JL*J*:\\]CZ4&W*B*X;
M\CLWJ%DPPQ?BG\4W2:?_;K(<_GO"1P9TA39FQ4T"M7IY7[F8Q.P@:(,% QY^
M(ZU68TD/= I.Y]U'@,M'0<W9T'8YEJ22,D&GNL0CZJO'@+W6JB@GTLX''<K8
M539LXYV+[99^G]2HM30E7NS9 [5R32OJC0"BD]@1TE^,3"S5;S!"D;)!%S'H
M=FXV7@,V+B.% XL%0>A:!9I.DB$N6Z:FD6HUTD!J1V"/(*[IQ[^FC# ':?VO
MIW#-^;B'*B" (^.;#P9-#L=PE>V:2F7-:6]F;'-;,J6.TV[S<>LU^X0_P\!\
MWL=OJ;#:!_S7N*;)H!<_35M1"!S:S9[BM(&\ C%J!H2$ %^TT7SN@B98@TP0
MNTYZ5 ]AL6GD!W@7:?JY?%S WXL&X/WKK=A+6)?4P $*+%\I"Y,D8YF:'/B_
M7V"X8T86YQ)RKR\S3+UY/PM67G65$6DX2JUZO<Z23%=#(-_%1A)WI*4X+Z.)
M5EU7UC[,C*Z2X*Z'-9S-\:!5,C_:I%DSW$'J9OBF0$'H@K!R4SND:L?S$/FJ
M6O*TJI/,XMN%T/0H+UXO*C2I4/M*QM!$)NVBKVC'!L:P;V_U4U:GOOC[ BOF
M"9G2"F:Z7DJ[8M"Z"N4Y'.JG;/$#[?,V_8LDHN:6PMRY]4@MO'+O:._:225C
MY;L=(J)'13*\,T1(80G7N_[QRZ$,*&4V5<,(&7Z!R2@DS.ZO:2_E[UU/9U+@
M4GX3F1]2(1PE!Q,WAFN2USH0V#)ESB=C2G"OE3,_$,L8?7:4H+<X;SL>R?:6
M)$9ELO4EY9ECI4F:,F;.9+9ST9%W)AH)*$#\M;GZ>L[T_^R4Y4MQ1F/U7S,*
M8=^YX!)*%RM>#5!E)^'6/#*FG>*5&]JFS-?G4_N#E&_2$^Z#!-)[M4))F7HQ
M,88)3O?M@GYJDAN?;I7%A27ZC%TY9A<QRNZ]21W2*9Q;^.-II/Z1*/:?X>>Y
M/^"]<ZX=^BY\IKMJ/IM^NWTO=\6'0]L/"(Y>A-2;C5#EOT0?/<G9:6?7&2I?
MMI@47?K9D=GU74M8)->G#+=EN@!_HF2558NL^4@77+G4K@D.2/R<V!3A5UU.
MO'9%*J%PT B79H+\!1ET5=*GD+4$?&AB7MKW]</7D+$8(SI1U=:SOM!+'SB:
ME]#.>T=2LC<]*S14Y\8[L@?V%_@D4<3>G,N_$!TVWUB[;SVYKS?]=BJ39L'1
M@?J 2(NIX/Z5'<N4%KA?-O+0Q&0P(0[L?E$0TR(9CQEH.]!*949RJLR=J>#.
MEJU6.>DQY GFB5=>JD&?/6ZRCU%VT=,"6W]]DYO-HIS.N/@,B/)Y5^L_^'T5
M;K[5"-,;[!5G?UQ@AF&7R.*-O-Q\0#TS,;@UD;E4E7LMW!8[A J('A;NZ_!M
M#/-LFI=JWW\(UK?:,U1*7O9791-M2SV.O-\H(;N:\D;6L/:@OPQSZ._VM_I&
MV4Q6ML-#21 UL>L-R]557?YULAX)\\!_9_",O)I&\3R7?)4,Q:55#JB7%%,1
MTVG,&+K O,:6,>,\$+!9&Z8;+/AHP+R(+^&56@'39D]EN^S:8-?C=B-C10>(
MFV^ZFNZ?OM6)_\,(9;.SY&:UR?[F>9MH=8KQ7,D\4=,<WWX@=P!\1/+7BUI8
M6,R31@]];)WSRB77@RB0OJ;[!WE$>>I6?V0Z01=NN[/W(S^K>JU]*I);F/G0
M+;,@NLZ8QX+USO?2UJ2@Q<&L9N+1@3I8<\U_$WI^*N4!T2TLO+=$E?;+=^X^
MK7X]1?A;22%9VA"E*HJU\K%&4%[$$2ZN,::[ S/I&FT.I</XT!</VF%2+$L)
M5ITD7Q./9TP^PZ][JGG5V!@%84.EZ>74@4SUO/&IBO/OWDPE';J[GUZWMF!F
M3XUF0V<A.+TJ1A-8JE'Y 6R@/3&+G^2Z)F@J;4=$(8C>KO9V3T?OLZ0VJ;LC
MGJF9Q#!=UZ%>/O:JF@A!M*"VH/&B#LXPOX>TEQ9YCM"7OELYXYYHORC^F(QC
M0J5/TF#NH[E,4G=!_73TF,\_RN.')0\>TTI>%JTUE$]/^$+C(Y(!P2^@;NNR
MLNHG:T#CT:1-(M,&NK]#LF$M<E@]IHO,V)PM]6:5P1?PS@P;[@9DRV\(T><,
ME.XS,K)0QN22AE7Z+KI4J%18LY6Q(5KI:MZH=*=J;0>.4L&<?-XWH>]_Y07#
M9X@?I]T%R_TM&AV-2K9;6!&7DQO\M$2Y%+^+A':\:)\P@_:<_8)L;($L^>[)
MI(2GW@E3I^U>G\0RS%4,R?3CY86!AA<#8-J%^-\0AEG/AU9_^O):$K3!CD"4
M',S71IHS0@H61;ECPV4NT(F=R^KWZBBYZB;JQEBV%UUH=-<Q48[5LH,_2<,V
MSF,F.XCK?74(NS7G$E4G9&OH";^H#CL#!F@S=5H?*S'#78=BY8\V%M>+E 9J
M<\EL@#?\"T>F-]HMWDSZW?9AB'V(99%@DEPOU!O>?+2&W!)%(;*MVB"&"19D
MW8N6C*?M,=_!E!9%ZVATS<G"^,WAX9_&[ UC@RMK^MR_P<O[LI9??^W[LAT=
M&,YZ(?"R)]E;U5Q6F:E/Y(%%6=;QP.PW<OM=DM-:N:'#^RHWMGX3CXIY=\E@
MSI'WZ37-EWN*R1[H]5B]K3[MC.8[-VZ+?4?G3;?J9C]>.+7Y.+L] ]Z+0QOV
MG@&V:_,KI\8;W.-;-$EXP0C&]Y=EK-MC;""^H;8,AI(!VC;&[+"+"IFA3L$'
MU%P&K'74'I>: ;?<@Q/$?2Y.2C:B&Y)7?C&^5)&%6K*<X'*7)K:';$Q;;%H,
MB*%ET QJ[]H38UIS\CH1]9?::$P(<H/=4*E/$[#LS[\G=03J3MI9])C4'4>D
M]/26K! M.P>.R=#;%15^\@0ZCI^&8$V[<WMU'ZKU74L 1V<'/,>:"MT, <VR
M0HS;')LA8OH;W&VK0\U5[;ZSYD&ED27(D375HN"1Q<FB^KC#2W4799+N+3Z1
ML$H%=;#M[H6NG30-;KT:'!"6-^" =(%_%W+:#2#Q6/8S(/N(5CJRG/'/H[8@
M 1<I.S=T1%S+!"Y])F;<M/R_;I8PW\3%E30\NARA.Y-=P'J\Z:0&FJC8:JG7
M#%%1D*+\G)?\YXB?=0["7P6@I_9T72RN!VW-"3=/ GMWDM+1XE2D'G&$17F'
M%,6@3&C")5X48_VAKEIS5DO1A $V*+S=-*['CL=0,[>1O4%[(S@+2[Y[^G#9
M\W,NG_I"C(0 Z(#;!_L*?Z O&5 A]9M[0ZQ":W@8Y(=TS*@]/Y_52*;\N^@>
MWQT>]T/#E_XEDB6W<8V'(<%;Y@7'@;<DX7BGLI<4EV4V!<,)C(/[)>W'8WA(
M-95\7_4D[L1<AP6SQ17+;:.2:]OES^P(7LFZ:B?1 ;)FI"]4!T:7BRG4L=]/
M?M$R781JN#)RQWEEYKI%)Z$IFP5JM%@S">1$2]+V+41B:QR#"H?9<FRHJ1QG
M-F>U"G7G#Q<><NO]?Y,BBIP_ Y0FQX4S,_S"^>U-2Y<X40=6DH%3$Q[4D_:F
M30]"\CO)DD#,(+0#9I;\]F#+KX_%)<+BE]6(R?M^$2=\G$ZL;7-NA@UK;Q(X
M9#F<5;2?[,#.M2U;ZZ>@#)\I 5MZZXH8H;]FO@I]';$FY+Q/5;Q?D#!&I;_J
M_IN0E<UUUTM]8XN\7Y].BTG[P>UR[FW!PNVNI6O3Q M?S_2U/K.T'U'2C+''
M-\Q]=T64U+2L\=)B5I&EM_DO_U8)% 86<,%A%'_2WVYQN_9#3^MJ(1*-L5W)
M.+6+.(N$&L91[B#):$"[)L%:Y@._>>1.MV<M,[T\93@&7Y%;D*_;-52((NL%
MI/^$2!)RT,="Z1[9]9)4?>,0K7/R0%CP=,&R.158^ 9, BIAHD+% #^-])57
M<_-(&D$"XH_T4Q=5$N?K&^IMG*/>4+Q#1#>M2CP"O#9A#'Q\1UM73=DZ<ZA&
MCJ[?^V';,O)$9ED=,XEA9T07Y@K?>-W%V#:X#YT[!^I;G7&C5&^T9CO$=\:R
MKZ+>RXXK6&@N?1F;K"R(1.(,/NHQI]G<FPZ]!S6\W)<[_S:W4DA@YGMLX$HJ
MWT1Q/YO^*#..<R/'&U?%8M_IW%T:TPQMV$VKZ-!%!/-$]6IJ +OG(M4^+YH7
MT"'R-8L4CQ:M;:CZUU/?0)O+HBLVLW3&5'U*G:CBY\^M21XGZM["-V(RROR$
MF#X##!O"GP$S3H@7*^!KRS&B_4-?K-#+7*LU;K_8K<VWR6R!9GN7>)/>1K+X
MADR-[]<50W4 _#ND##W3C25#S752KQ;5KU7F&X2P3)C.#>QF@1K'<MH:;31N
MT_'J"P&*^]25K^L0/L4ZVR[R#G<Q=;%=G6C0,X)P7'R)!AGTTJT/*(^E$?S4
MRG'X#6D7(\4K45@G3FO]*P_F9O49Z5K&&!SL]?*BZS6+_AP\A/M#LM:T^58]
M +>IEW4"]^PE$6@&TF(I\0%N.B>NR+Z3VYXL:8"B-"GSD5))@I4D@GW;A -(
MF7>*UT,.&#%/@)7/=S+\BQOY::R>547VS8@L^*I4]$#VOK2XI*HM$QA+[&RB
M';OO/'1#*WU/W)Q"<5/H,G? 51/!%B#'[<>=9@+$C\.X+A^\*[&?L5>0HN"J
M__A/NLF GEYRI,;B(XSKP:U[H:I=1\)G=>R'UN=E0U)78RD\8D-HY+J!?JS@
MYD4S93%*4!L=4CXY;F>16ZN) Z)/D(^5GI3]#BPC&EJAA\YE4U'L<(_R['(C
M&FL[.+(O:BEFUX\)=_OGWENV/.SJ+R)]Q2?:A)\L$R3K))#5 ;OM8YS9N_?#
M?SK0]N(5#T=ZE9_37XGM(-08_4.,<3;+SDKI])#C'49-. >O^27N@M^;)L+\
MF/K@]YTF:S);6E9ILE_??4_:@"]TM-7%B)<8LJ:<:X^-2KB=I:(<L>.D_BI^
M73I72'W->[@3J]<Y*=G<RZXJ*,B:0FU1U]]C6GAQ2&0IP7?#G>O$'V.?-G!)
MVQ".TR5!$ +GLK7CGO8,4,]F1UZ\Q,NUJ32T&=U?UY9!P^?M1;ZJ2*TF4&YF
MJ?#B3#8#S21=IM]^KE.@5/+EX.&\=:_8JHH,5U.]G1G1%E(B$R-<W'P&$&2X
M,M:=7I?3G+=S-)Y_Q O<])L%%\42(C>T?]THC36&FK9UH>O/ZTHWCKH(!E]\
M2A+Y#N$VC9\@"^3(Y.M;C"[6D<+5XM_Z(ND%:*D#O^"@ENA*+2W)P>(^M0]%
M+Q_BV8_*'@)=,EH.@B[ZM0[)A%O#\MIX1,GL.NOM2XJ%CQF,7D;1%!:QR@>(
MY_Q76]-J>H4"X&DXI<U3NS%_)WJ+AH\>EI;03W>S0>[>W#M9;\GMSG@R;6:9
M/I%KEH?]LM):$Z;LA7,H7A!#0G!A@$H4%Y[ HEF548]NY$2])UN-$9M%_V55
M40LYP0*',N(J.0M/4X/)5P<U3X%3!I;6;?J>8DD$X^S,_@$Z2'XLP+NT\ABR
MCCTVC"A))ZDOH"<YJZ1U\Y62R$SC)",%^YH$W/*JCSO3\W=KT&#\&\I5-&M'
MGV(R-D5I9U>;8 K^ HL>])\@XH\L<Z/ZA'.;U<J% M>B'$R8#:ICE'OL*Z")
M1'/B]RZ>5IEV*UCU3Y8VCBJ%=6UNR?'L+83W2:+C$,?TM?PU&KGM!3=!'DIW
MA%S'WR?9ME<*UMWL_>MY6;BA'GR#[&^^V"EC W>OI#6<3Q,<&89WW+%0;7T;
M5CMFJ),9)0>BFEEO/?'V:GIC>VMZ<U6D :1?L&,GWL(#@GL$RCQ(EHLS[1QI
MD$#RB10%A05E$G2AQ[)\R*[/ '=((H'**%OQRZ<I2(T-W(_^ ST)!R)YU$P\
MO!2G4@$3R[N4V>9*X):<FBN;B5XIK>GZ^+X-7R%M^1#+A#I%O$&#M-^WG L-
M;E(E1EDRG0*4B&GP^O*!^IGB[\8:Z>@Y\K3P[WWEY'N*4K4TW#B];=7?F^S?
M.G'7?*H_Q8*4ZMGX0FO_!V-O'==6N+2+IJ4M+5*@Q;44]U((+@6*%PGN%"DN
MQ8,&ER!!6IS@+BGN4)S24MS=78*F2#AT[^_L\WW[WGWO^6.MWV])UCM)WGGF
MF7EG9F'06Y!2H.;W[RT,8N2&Q23_<5RL@<$=8$@>$V-;6.N03=K<_$]^8\\L
MZ@E!:$MKO-2"J6'NJ2"PE"3H3">,KT!JCS[*%D)HFM$S$.6(DN$U,+L6HIFZ
ML6'QH<U1X+X0#9N@-[FU]28T_=KUE=)^RM\^+4WQAZEHL/^;FUY<L_GM)G0,
M-FM:N#8J5[A7+$/:2XNY1SB,RRQBU$??D;'?02)0HE?^C\K:;-.<]_=E_.]!
MP]"AB1N>PMT!W5S\>?=4[B!4S/D/[@D?!F>ZAB>V?.)L>$U^894714YM/271
M/K(%LIPKZD&I6[SE>A3;Q#K&SO#<!K'0NM4O;XJ \[72K]/'^;7C]!"_G+?N
M@?IY=Y50=\A"8-&A+?FIFF=5W">Z0^_4<B<WAI^'+GV?J!Y+Z<F(#M)1/"94
MTPK_E@,UGVL)F[FL2]?$&6R9P!*6=2#\>OU[X;&+AU[]+'9+=36]F2!&H"^@
MI"ED_1L&=F V[)>O;+X%Z:35J+!+.],F:+)<5A&>@2-"Z)EB@;V7]D,',9 !
M$,%*H6U(]#$C$\FXT7!'+=95!IX^+WXZW[7KA349B/?M)X5AMV3[Y3'X"CHF
ME]KR_N7&!YU$;T]S4U!LP2C/T)IVK:'BK^.-QGK3O/AXLPI9FZEKW+Q^,I!$
MWSWUA7F;77Q$R]"'_ %7"5W!O)(LN*SRQO:=A0P7QH7B6^S6-M>#QK4.ZTJ]
MG8F!6.\>H[920VFJ\U#O9V?VN+%R]_2.]6?V.?ARL9NI?FF<9TLS&A1ZN."Z
M)D^*O$V_BJG9J+L6$&>VNP0.(V:T-\)X(,V#;^5-C+]F/Q5%IHZE&$MX2\4U
M5LNO+\3<G(Z64@G_2O@9*CWOQ29 M" %S*EXP3M4O%FJ@O.2I &KA([L-[<Z
MPSKER;:3O671C ,'Y31U&'1TV+%"ZY:H^I0R8)[\Z,Q02FZ2EG@JKI?A.D?Z
MC_S56JN#'DK[0VTCR3,R"\KHZ0I+$ >Y0(D9N?++F(*6QZF+?(XM&B_5U$8,
MMA(9_@8#1=9ZK"]4R&?GGS\*D$=KSLS4O:M07V7WYJS9BQ7ZY'(F6)&@Y(ND
M>[Z+*V@7'AIO-:?\E4&:;#6_"/@?V_.8G16..X[Z\R#P!FR#01>P\ O;<3K$
M=F/%YME-04,&J6?[B^3SIP9H>>WG!6Y"7O $:0XBAF>:1V5K;=7QBQ(G#7O;
MOC:#A**N9DJ%KIZ\BWYQQ:)E,X]5,,>U2I2KNQJH;8ZB#LR20/4"#P9.KR8U
MM,I?^!2T-,K&.S!?R6EH6LLXNNM&(34XDTCLX6&IWV+Z4;Q[R3[K..V^7MZC
M+V6\3WM>@:""N$$=A*OO"'\ 6"BA2IUI\7]+A+*P^5B:?!>^:/Y1)LZM@_V
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M14>*D&W3--_*Q99)<9(;Y82>*I25U,I2O2P@/8$RC2_3YQQA,6>D:R>^1HN
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M%T$+)Y91'R(=0I%W6-%''45E%B&4Y15U4HMU&B^@MBJ:8B/,U]OE5^IZ/G>
MGS0W7E5.2::-$;,V(>N'?0]SE^@^EV#N*>M@\^G$6S/S-QA8OH4G@_2%...<
M2A9Z;!W)+./\5_-'?$0]2^?SB(>KB47#]"YA3\%B2UV)T$/H5)28Q5[]M(96
M*3FH:CY"H><(>YL ["VG^*DCI<U:QT,L4T)? V2D;M]<_2H'RO*OQ@_]-^\3
M',,TQ5O?CH*M^:SY2M'?2]I?Y/=F6C[='4VXTBJ(I/Y)X=8GUW=2"L'B,>ZV
M.#-D=5+M&2THXOV/M,]6O1@7H-I$27Z*(+H#Y-IJD= 5O4(KI9Y%!G148/3A
M6TP^>[=!SZHR#CDO64&23:!T=SZ&JLI*]>>7" '[FT?L*L3;L5Z>]P&]LFJ+
M[H7\SPNX_[6Q)#PT^?Q$7ETEQU\D<J4OM*#E& )UC5;[K:-U>.(VQ_M)'C.;
M#.V6<%S=I7>&9N%!09]I\C(K921_Q0HZI4FV1%"AOQZ"<PD?;,!?C!UQH-G!
M ZO>NKFA+F1064EBB1I7T;W,X_K0(RX1MM5;SMU%?6O.(R:"/_W:KQ*"AAR]
M+I]03TCNB@3U ,#B_CYF1>"W\J[Z"#P;?J%P8X97(4^F/H*%F_'\;.N0#'6Y
MODC^#KT$Z],\6YQ0YQ)=4U/, ?U\QC9$'A@ZIA'^T>%Q6^X=H-PHVU'$0VO$
MX+V4[.M0]7V;O#J+SUXUGXV)?$2+;5+=TTJLB3<W3^6;].,<\-XR[V*VNL"9
MD/EW@)B:)\>3T2L9IM@_!ROG?W@[;L@^W-K\4SWHS<'XQ"5 S0I\%"WR4@S>
M1CIA,G('J+.O2?8;\C O(H.+X"6S[,KFZP_7<F$:[[E_WC'&.\I*;N!PX4O]
M5D:]#K_W(\ZA2EF4RZJ8*=/6EW$W'N-<U).?:GU%B1B9W;F'WGE99$!,W/V$
M=8PB=:,1%YXJPB8SS4Q19X->1LSWOPP)[$:\8AH\!*H<V2_PY>\N)87+K3&8
M?>QREULVAPCMH1FM>*2/JW"YE&H2S1[%/J!DUEE^\^,[0OF[J%46'A/R,,/;
MA2D CBV_H<,9.Z#V]KV9H]991>0J)!3AH[B\&::D>EDWFM_-G1"]H>R.!LY]
M] *]HQ8MOGD_7@O#;@LP6Q&U$758I:EN@"^9<U-^K+LY8<5[B5*^ED-!5D0Y
M*:P=&&K;H@M.8NN6U)QF6S,Q!+_GWULH1V1HYZGJ,4.+EGNU@5S]9VZ=V$K
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MNQG2I&8?_GX'@)W_4_PCE**K^)_[\:\O_G;I!4ES[5_Y3M^;?#;WO]\6<2^
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M9T&1"%*?5QF,\9==X'BZ1%M^N[=W@ 85T+[GU53UB!&54%7!T<N]_,<,Q2?
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MN>;SQ926C-S<F*C$)284U_0P2I2F6XPOLTL-!;VM<?_&YRAB36A'/\\3!?L
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MJ?^"82)]#1X  'B%K_MK&;-.J>HC*A-;.AO<4(2A_/^@=_X]'27M?6VOQ/H
MUD5D7\*5+0'3 )N_ML7\,OE>S"8P01S0?HX,O]Y)2^ZZ#$\3SLI?:&K8:[;X
M$$C@;R1#9 ]_7BQ1^B6542-:_)O9D5#3>RF?PFWOI8OH^F&VNG8U K_A0.S2
M7SM!1<:&T.YBG4"W'E^RX19$,I_1]S#FS^#JS&Z0-[EB8:PP-0[EBY]D+FB.
M6WFNE[?->!VP2^Z"F]@RP^T'+X7[ Z^$+7Q634A T0IKH4J*->58OF"D_F@^
M_8*AL;*'I;H6)G! RV&:=UN2YW ]_5J>*Z.I0=QM#D1'7B6!:/%R<%L?VDP)
MV:2WW*0;K[W7"HVGK?Z+>F ,.\Y'.0\0NT\\,D.JU^*3PF^GN5\=7 (#MK.L
MC["@QN@L19/GS+R2:56(,HO/#3\A5QN5)Z>(28$@XBWR,%.1]/F?61I%]<LZ
M^^+RN6;?D<EMU$3OKQMCCN)97+2R@Y@,FL@;4"\:FB#>VUM)! ]WV;2O13?B
M0Q&HZPCVD@&3K>-M;ZHPR%,TF6=DWO >A'BA"JAV//)+]BUZ( EYQ2\72U&-
M,$'3_1Z[$##T'51V(3-V>&E=+?_JB\,[-+5;,'_,S$D9E]:MJK9.8]L7\TUW
M] ^W7VQ=3]7-MA*T\HT]%UWB!5HH[P!,X<EW ),>M9)BQ5583D%OK-]9"IX?
M&*^")2%3Y+0,3JUUVS_-Y7)=(=SO^I>&!G&*RW-GK2C6^>Z-??JQOFR]!/.B
MO*US5]LK[Y;37%=L*S*G-C7[1;7>!B^?V1XFJTIDBJJOY28RWL/\+9CE4C;W
M*XMPEZ7Z4;*6B4*TJ(8A;XSWYG1-<H^A5T'&37E*#E>UJ8R%3T XM#<0EP9C
MRT![YT40 6J+5DYRA%]Y8__J)Y#7H-2E='RCNC2I9,=%<M/"XJ;=8]G!J)50
M$[C7\ZUU+BU>.&%TO:EB/$$[1?S-ZC"'6E.ST5?&/TC8*WDO@JV"&>-%RD<^
M"7C6CKY%QL&2_!A?KCW]L(22IOMLY1LN(BX5D+^H;UB>4>)T;%,+XF:D/T)"
MLY2^E%^?<JN-@6:5T[9@[#LD\B6^>8K)2L_S @"?ZYYE QP[F'8,;JFG7SI>
M2ZQ0[+KDZW.!O*H [QN=\Y@:3LL"/@?)-$/W"P]'A:LM$;-]Q.029Q8GPSJC
M7K].PEO *SW.90<DEI4'K&[I$-HITY'YV=],J*LATYMA=?P=^W/_+\E-63\%
MQ1HZ(C02,686T#0VTS4MNH1U9+M2L_SP(8H[@(?[)[[!S)S@S:-"HVU#*F/C
MZ,]8 TY,F$_A$YQ0"\2N1VJL\70O_$S?O,[(2$SANH&!T+AXV[VO!*;Y_EQA
M>$#$H'WDB.^>GDQVG-"%&PXGQ: @R<@'S%8F>5A)DAT@S< C&GZ*DV8<:"S&
MQNH= $B#%%LFPNEQ*RC8VQY(B='C<14Z8VGUT3.4J,M=>?14RLLT2+)N8_J+
M\:P$1/Q%24%5_]"SJ.L_/ )<1XWJ#^F@00?0@6L'=;5#I\0V*EUAHMO%QQ<@
M V VL'3P-8Y]SW!:J9W]*?]2]5_TOR?@+5XSL.'^72^V.)=B#E4OM@)YQI\A
MEO^%DQO_%< %R]1NLSY@HA#<E'KRGOCY[9Z9*J2N@ZXM3)X;YXC(_Z1)1;?+
MF?#7CP*1R5C.V*2?2E5Z6$]<I?,K H]P@FL# U.M(;,F]0;+JU('A!$72)S
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M%0  ]?(#/,\#/@+@7[^&>PT+#P<'AX  CXB,\089"0D9%PT=!8,0CYB($(^
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M:OQ)/%M_N5_V[BJO^Y88G445K.*)N-SG%3")YZV"S6/<L.3T@N.0,[ Y:9D
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M"RR8,ZW<7K[?$*YZP7%7UJCC^*XC[I'HL>-K7T8%SHL=)PGAK,Q,_]V7K5T
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M-,_"O"M2)$@)@3Z"Q#:_%A&5IJTX.JO&#(()(!A]GM2%1+"6X<+?3Z[*W=R
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M4/AH1INS]R3?!#W>HPA$<AYTPDXJR[#6J"A?JQ5@<%B7*8L'A/&:<)]%K!!
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M&O8IMQ5S][]MS_]_7$]S_PM02P,$%     @ ,(AC5!BRF<8[?0  L(@  !@
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M#/KR-3CDVW=P5'1,;%Q\0F)25G9.;EY^06%1575-;5U]0V-31V=7=T]O7_\
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MJPXQ8R!,KRXF'E'W7XU%(-I8=5VKKIUZNRR:2ZS.E$6(=]]FL^.SJY5Y1B=
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MME#.*%/KQE@4>P?O=XTG@#L)@V=G9Y4EP_:> &2]013O0+_\*KQ0)%<_OH/
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M$&.:>?KQ,G^\0/+?=N]D_N/PAM&)5S)[/GSJ?7;+];I%L[!\ 9R_ -R>-UX
M?'P_Q*W#:$LHMP1L\E+#5;Q>59R8P&:D\^SUQ(LGD<KWLXR1=9UTRW@$L2^
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MB%QFZTY\V',,J!>N]M+>TPFSH]X5NB;_VF+=BDHN#HXNI.RPADH1&A",++T
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M98O*#:/;[ WJFY,WHS;[+-KYAN#XD_M,_LC?+4 [&^9 U1,IW_)Y-R"=\4B
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MRUURJ)GFTU)AC*-38VW$9N&V@5_BND4]3J*6AU/:FVU7;:YFHP 8TLW*+.!
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M"B\%,@LAB?[J N24\1<5N(?-:N:XXB+\._F'>JD]+H;)M9RI\(NA)47QJV=
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MUI=E[;2+6<J"E_>SX=0'EB8!GF<:6E+:?>MF16OC$=+":07I*X31NKJH=R'
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MQ0@,*UM75?++9 *JS;S?A]]FRX!C'Q_N(8.-.[O:T9-'C\E5+R8]<@=?,L(
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MCVLY[MV/4-OLQO)GP ]%PNRO!0PI5M\"^@P^TKA$;?41VI>*L"_QW51/QZH
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M0BGAQB)'ODFJ"LPXV1\4*5(HTO-%!I#@Z:C%%(J^RYW,6BO@K<OM0HVRN34
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M,$U86(Y1RD];<DIY%HWEM-X0)7*Q8>"BGS:5C2^)QI>DMI4=#S+RD\D/KE.
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M;AN'?Q^K:$@ ('(;=+8 0NF+*GTGM$(?&SH3;,UP<>S))$/V?<CL/!' 5>C
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MVJ9P9\E,#Y.B;57N$=NX9KXM'U4],SA(#M[!RJ6?9V9N]G4^>DS_>U'PX+K
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MRE9I6FAFM@'^ZF^;P_* B9F71W8S9-395$F#4(:C+<HG0BJ"&&Z9622Q'Z4
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MD<ZKRA)*2.Y"EB!7Z6A*EL8Q2R1\:WMRAN#'6B'<;::1+U3LKN7F*C? SVU
MC1\/'RE;%@R^)GCZ54PV$E [G<Q'<W]/;(D 1X3X3N/'[K[(_<N2=:?[B\P9
M'2P0?#,DZM?E[M*W['2##_.%RX/*PD]S:+TFN4%R %>R 7U/J2#&))+@XQ.^
MTC" +Y;-I@*4 WBK0J68/F'S*F[EU$;*9?A>/3FN #S!GR1*X%0Y[QUH_3!H
ME'DNG!*V28GW"V?7<85W4U2DV*YR"6CDYYLQ>/8Z?]*DOUHN+/L7"*ZAQ*LT
MF+QKPY1YO*[A)=:C'BP4*;?K6+_KC"5-.5MK.+%-["5JQ';&A)=O[2R=5HE
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MH"L,M^W$M2A-'-1\YJOY[1?"F#3*&>I9KH4<U'B)Z?IQL6FSK_'V\\^OY:3
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M37;KRNFY$"'!KZW:W>G A_G.T)'9\-.^FX3W78LH:02=22\+D/R;9?W<&/(
M^-CZ  AUZ_G0(O?3T+!/6"Z;['F I']8U>#W+<,+OGQO>98O'J-W&9OO(Q*4
MC6 Y]NH/ !CA4DLSJ12PM@^K@H2DU._]DH#A4.D[NL/8I(!MOO3#"1T;Q7G+
MIAH2Q\>M=0&BSP2;,&_O9'=Q[>?MXNWXU<=>!%-8U<VW/8]46PN!L[%>=JV_
M+FJ;= 0V!G\V6'^I\;7H<!"?D1;5.)4O4/G4$59XV/  ('?UY\I2:#&T3JOJ
MON?DN6>9V$GULJ&^2F OQO@LOKA;J+OX1=(?)SEA)^#UXY4E\V=M;5S5D0?
M7GG! :_SNNV@5G;\S,^"ULR_(:5'RI@)E5.2T1^IW51FV/YY9>"+,[* _?J
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M$J*]O#'9+FQU*&Y+_X>4$&VQX^N@>:R5BB"^GR4&LR>+^W^?+4JAZ7N&]\[
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M&/5>?PWVDI']:IUU,V<\-T5YH+R\"Q*]X([EKN4)YZY=;XD9GNQ77E=(+7D
M<(%?]_F;77M>5DTZD?8ZK:6-;O ,A@'P:SK%T,WD;CVUVXUCO*](?MR0+3$^
MZ:"W8!$A05U1G6T(H6'</8YQS(QHI\''O6ZNHR\V#<ZH>7)J?S:R[QA4M#A,
M"IK@-B69I=K5J,->X1>+MBN[DUZ='MV*7EN'<?&"H8JDM\74SXL7<^PR/T[P
MALJOMP;SB\--?0 +9,Z_:00? &)V6WRMN UM67I'AO*=VBMM<- -Q&V17*-8
M)V$I;=HE."$%>G#WVL/#X[(../"VB:VF]26:>BVG^V3$?<3'@7H(6YDBZ7Z:
M0X NMXI)Z>1I4>2?$J4TGEHK4NQ@&52P'_[>CCX5STBIO<N0>S5EBO$!T'6T
M>^O);KO8FRB7TL%\FM\S5%EE7,OP[[]%IU>N!L8,L+!DB%V"H.>Y69<W<Q+C
MS(ZH0A$M_HF]CO7\IS WN"O+$,LHY)GO.$_@A+ 3^U_88?U>9BBL3WS A@+P
MA,W4XF((8-_PZV>($B+A]%([>-F' TD7)I3CB-A<83F6/C92%-8Y5;0QAH--
MC4>>,0D9RPI;AU%2[$5MT<[N;FJP.&ZVR(7WQ[(XY&_[D*_4G._^[IW?N*S[
M-B6;'] U-_YQ0C;LQ&S['3.GWPF<K73RHEW(L.%6)=N+IL>\5.J,Y1Q84DV4
M,AS*>H*"K6>OK9)*_&&W.MS:8FNL25;Z<.F^1-KT)N)RJZJ*F/!5V,94CV(V
MRQ??13E?SZU2(Q6R%]N@BAB!/EJZ67-U\S+QT=73@;&4!T"B^<UT(P\JT/O
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M 9+Y.W?JAS?KX&AV8:[9YV3O.E"#3QS!;')(;K3X_E6/XT<0FT 6X/U_C@G
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M(>:1&X6?:*[N-!@V[3^B*/YW%$%&_* @[+4JSL[VKHQ>RO4!/\9L!Q-UD]G
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MUWFQQ;=%7"T^99T;7RE2 [+Z_@502P,$%     @ ,(AC5%/4,]"_0@  1DX
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MH6;^G8[5[Q%F=S6O6Y>O!3O*[=W30M[P56'F$_[5\?ZM+\EU+GU+ [TWO5K
M9-'9PMSMF!T]>T> J'Z<AIY$0>V45X3VAP?@RTH?7!]KSR91RHJL&DTY[SC2
ML#6:&Z*+_\@>-1@$_25[I$L8CK,_,/=GJ9+[5QU3[!\\RT[?17/*LO=/'IVJ
MT($9RX!REWX%H]5_7,6";]#?CM9A51'^BSR'_R#/=" "[P<9XO&$^7-K\!-7
M-NIB!A [^C5XF[7/,'A6^13TQ<1G1OF?0"9385#!<AV"$I*U*&(VB4:$F::
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M^"#3ZQ+W=.%]GW.H6Y&"F.MW64RNK M^]4"Y\6=F'%@6P0K*#E=3<1O4^M;
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M7Q2+"]H!M62@8DS]X1Q.P3DFB=%<GEZ-111/2_8W+\CI/W-76 5-#5]/?76
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M!]&)B VJ]-"\Z9\ =)(:346I/T]PQ1Y<-4X!C0M;9AC 5Z#)G=MS44X&5-8
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M"9NK6T4"@[!5.O@PX_^; %!+ P04    "  PB&-4C^@K^*P5  "]U   &0
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M0IZ9X_D4!T,J"# ]9  Z!VHR<!O'9$ MZF@F3(]+1SUS(B>)DCHWN26;UO5
M]<'K=6Y9.)VZ[Y'S'0_FE]K#9@,G":P%G%?W':"OIJ7G<;36'B/LI:F-W;#'
M43<;H'6,-8?NO(\!1V_6SSR16@4.D.A&6 K!)E)-'Q*']D%]A5YZG R! YF5
M QX$58L9OF::$\%\6DC^-M#!)"@="\S!D)FF9-/@V02SX-.,NOG@A5>!TY/
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M%)*!56',RII<&O',BT7B8L]$J;A8'7^U$RDR_CE8_OGWBT*W5FGEJ&()NT#
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MG,6G:8=I-$]T3%\BX X C3-GT:ZP_9DS8Q6T%WK<F,"?H3<R;_\'4$L#!!0
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MC4A((Q6)['4?MY\]M;2Z"H#\6N:%[D_6_^267NBC%V_D1'2[+8$GNEYK>S!
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M$^G[<GM\J1<7C'?->="8V$A$"1MVC,33<JO!=AS_&V"(+_"JS<O4"O1V?TI
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MR]["Z![W@VNJW07U(:6.5QS'R'B6'_E*?&MNYS/TSC1K^85/9W[N/W(\L^9
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M;MIWTD#VF2]"OD=%9[U<QS0E-4A)IFX:_HHH4GF.KG'GL.OAH!,SP,#/N#3
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M2K_8N+MJ5?PS<_ \M*E"318*@(6)=#$(ORE]HR51'6Z.G\,,F5VP >5ZAU4
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MCX^KQU1WR>S"P=J-ST).BJGC(05GO'$5U^NG.U>@>,XB/$>F1*\8@/FB_5Y
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M_7N*_AJ:</.=W+]BWOMV3D6.H>?SF7V&$-A!!?"/&?8]GY7O4.V2$S^"I7:
MOCVR_DYDC>A'0,\"6M<:C*!]N'.R\ZF \;;?CGS7@*N>5/BBX:F(5ZMCIJL3
MF)@G-Q.MBBRE\R.EHRIOUG[=U;Q1UH@$47?L4%Y7F;;^J[+&85*C:?5SM9Q/
M(/#5)!];T!&?*U$]XSPYZ?2/5HG.MW7=,8;_&9S[7=W9_P%02P,$%     @
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MRP<F+*Z/ 5S\ Z\)E&=(D^_\?>?O#_?W]*G[^YEWI=LN26>FU=F!N[/1[Q_
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MK];&SK[_O'UWEGLLRU4<L<H[O>*:N>?0[%G7_3Q%SPU->/O-W*^S\EV[IWK
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MY/M]LWNTK7/*-ENK;Y47QHL;Z*=_ E!+ 0(4 Q0    ( #"(8U3QO.16TPX
M ,^:   1              "  0    !N>'1C+3(P,C$Q,C,Q+GAS9%!+ 0(4
M Q0    ( #"(8U0PX=.X]PX  #W6   5              "  0(/  !N>'1C
M+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  PB&-4 G*^E.T>  "=UP$
M%0              @ $L'@  ;GAT8RTR,#(Q,3(S,5]D968N>&UL4$L! A0#
M%     @ ,(AC5 RE"YA080  /F\& !4              ( !3#T  &YX=&,M
M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #"(8U1L^-&VH3\  &N#!  5
M              "  <^>  !N>'1C+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4
M    "  PB&-4T>Z&%7![ P  /QP %0              @ &CW@  ;GAT8RTR
M,#(Q,3(S,7@Q,&LN:'1M4$L! A0#%     @ ,(AC5-]G'S?AGP  :/H  !@
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M.2YJ<&=02P$"% ,4    "  PB&-44]0ST+]"  !&3@  &
M@ %3(P< ;GAT8RTR,#(Q,3(S,7@Q,&LP,3 N:G!G4$L! A0#%     @ ,(AC
M5(_H*_BL%0  O=0  !D              ( !2&8' &YX=&,M,C R,3$R,S%X
M97@Q,&0R,RYH=&U02P$"% ,4    "  PB&-4!ON FB4E  "B\@  &0
M        @ $K? < ;GAT8RTR,#(Q,3(S,7AE>#$P9#(T+FAT;5!+ 0(4 Q0
M   ( #"(8U1)U_YM91(  (:I   9              "  8>A!P!N>'1C+3(P
M,C$Q,C,Q>&5X,3!D,C4N:'1M4$L! A0#%     @ ,(AC5%S\/UM#*@  J^8!
M !D              ( !([0' &YX=&,M,C R,3$R,S%X97@Q,&0R-BYH=&U0
M2P$"% ,4    "  PB&-4?Z=; %T%   >)@  &               @ &=W@<
M;GAT8RTR,#(Q,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ ,(AC5.-?X+A\
M"0  *C@  !@              ( !,.0' &YX=&,M,C R,3$R,S%X97@S,60Q
M+FAT;5!+ 0(4 Q0    ( #"(8U1T#@I66PD  "PX   8              "
M >+M!P!N>'1C+3(P,C$Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    "  PB&-4
M90<@J=$%  !4+P  &               @ %S]P< ;GAT8RTR,#(Q,3(S,7AE
?>#,R9#$N:'1M4$L%!@     4 !0 9@4  'K]!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
